UN	10027919_C051883_0_0_16_22-oxacalcitriol_D001851_0_75_92_low bone turnover	22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
UN	10027919_C051883_14_1924_1927_OCT_D005355_14_1988_1996_fibrosis	In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.
CID	10027919_C051883_16_2237_2240_OCT_D006934_16_2287_2300_hypercalcemia	CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.
UN	10027919_C051883_0_0_16_22-oxacalcitriol_D006962_0_28_57_secondary hyperparathyroidism	22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
UN	10027919_C051883_3_526_529_OCT_D007674_3_591_614_impaired renal function	This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.
UN	10027919_C051883_0_0_16_22-oxacalcitriol_D051437_0_106_119_renal failure	22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
UN	10027919_C051883_16_2237_2240_OCT_D051437_16_2327_2346_renal insufficiency	CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.
UN	10027919_C051883_9_1317_1320_OCT_D051437_9_1390_1409_renal insufficiency	RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.
CID	10027919_D002117_1_133_143_Calcitriol_D001851_1_301_329_suppression of bone turnover	BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.
CID	10027919_D002117_1_133_143_Calcitriol_D006934_1_273_286_hypercalcemia	BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.
UN	10027919_D002117_1_133_143_Calcitriol_D051437_1_222_235_renal failure	BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.
CID	10074612_D008775_0_67_85_methylprednisolone_D001919_0_13_24_bradycardia	Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.
UN	10074612_D008775_6_849_867_methylprednisolone_D003645_6_803_815_sudden death	This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).
CID	10074612_D008775_0_67_85_methylprednisolone_D006323_0_30_38_asystole	Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.
CID	10074612_D008775_1_215_233_methylprednisolone_D006323_1_160_168_asystole	We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.
CID	10074612_D008775_0_67_85_methylprednisolone_D007022_0_0_11_Hypotension	Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.
CID	10074612_D008775_1_215_233_methylprednisolone_D007022_1_130_141_hypotension	We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.
CID	10091616_D001058_1_448_459_apomorphine_D004409_1_381_391_dyskinesia	Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.
UN	10091616_D001058_1_448_459_apomorphine_D010300_1_90_109_Parkinson's disease	Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.
CID	10091616_D007980_0_13_21_levodopa_D004409_0_30_41_dyskinesias	Worsening of levodopa-induced dyskinesias by motor and mental tasks.
UN	10091617_D007980_2_423_429_L-dopa_D007024_2_460_492_systolic orthostatic hypotension	Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.
UN	10091617_D007980_10_1743_1749_L-dopa_D007024_10_1779_1802_orthostatic hypotension	CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.
UN	10091617_D007980_1_323_329_L-dopa_D010300_1_247_266_Parkinson's disease	OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.
CID	10091617_D012642_0_0_10_Selegiline_D007024_0_19_39_postural hypotension	Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.
CID	10091617_D012642_2_530_540_selegiline_D007024_2_460_492_systolic orthostatic hypotension	Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.
CID	10091617_D012642_9_1502_1512_selegiline_D007024_9_1532_1589_reduced the supine systolic and diastolic blood pressures	Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.
CID	10091617_D012642_8_1418_1428_selegiline_D007024_8_1351_1374_Orthostatic hypotension	Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug.
UN	10091617_D012642_1_300_310_selegiline_D010300_1_268_270_PD	OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.
UN	10091617_D012642_0_0_10_Selegiline_D010300_0_43_62_Parkinson's disease	Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.
UN	10091617_D012642_5_1057_1067_selegiline_D010300_5_1035_1037_PD	METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn.
UN	10091617_D012642_6_1206_1216_selegiline_D010300_6_1191_1193_PD	RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.
UN	1009330_C004658_2_226_242_p-choloroaniline_D003556_2_319_327_cystitis	The results have shown that the degradation product p-choloroaniline is not a significant factor in chlorhexidine-digluconate associated erosive cystitis.
UN	1009330_C005253_4_495_506_Picloxydine_D003556_4_565_573_cystitis	Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures.
CID	1009330_C010882_2_274_299_chlorhexidine-digluconate_D003556_2_319_327_cystitis	The results have shown that the degradation product p-choloroaniline is not a significant factor in chlorhexidine-digluconate associated erosive cystitis.
CID	1009330_D003091_3_360_368_colistin_D003556_3_430_438_cystitis	A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.
CID	1009330_D007612_3_350_359_kanamycin_D003556_3_430_438_cystitis	A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.
CID	1009330_D011206_3_373_388_povidone-iodine_D003556_3_430_438_cystitis	A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.
UN	10193204_C009438_2_291_294_TET_D001778_2_414_431_blood coagulation	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.
UN	10193204_C009438_0_11_22_tetrandrine_D001791_0_86_106_platelet aggregation	Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.
UN	10193204_C009438_2_291_294_TET_D013927_2_323_333_thrombosis	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.
UN	10193204_C009438_3_503_506_TET_D013927_3_548_558_thrombosis	In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.
UN	10193204_C009438_0_11_22_tetrandrine_D013927_0_57_67_thrombosis	Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.
UN	10193204_C060802_2_299_302_FAN_D001778_2_414_431_blood coagulation	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.
UN	10193204_C060802_0_27_40_fangchinoline_D001791_0_86_106_platelet aggregation	Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.
UN	10193204_C060802_2_299_302_FAN_D013927_2_323_333_thrombosis	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.
UN	10193204_C060802_3_511_514_FAN_D013927_3_548_558_thrombosis	In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.
UN	10193204_C060802_0_27_40_fangchinoline_D013927_0_57_67_thrombosis	Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.
UN	10193204_D001241_3_595_615_acetylsalicylic acid_D013927_3_548_558_thrombosis	In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.
UN	10193204_D004837_2_372_374_EP_D001778_2_414_431_blood coagulation	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.
UN	10193204_D004837_2_372_374_EP_D001791_2_389_409_platelet aggregation	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.
CID	10193204_D004837_2_359_370_epinephrine_D013927_2_323_333_thrombosis	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.
CID	10193809_D011692_2_302_305_PAN_D011507_2_357_368_proteinuria	METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.
CID	10225068_D008012_0_66_76_lignocaine_D011128_0_0_21_Cauda equina syndrome	Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.
UN	10225068_D008012_5_672_682_lignocaine_D020258_5_641_654_neurotoxicity	Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.
UN	10328196_D003907_4_842_855_dexamethasone_D011565_4_791_800_psoriasis	Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.
UN	10328196_D020123_5_981_990_sirolimus_D000740_5_1006_1012_anemia	CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.
UN	10328196_D020123_5_981_990_sirolimus_D005334_5_999_1004_fever	CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.
UN	10328196_D020123_0_66_75_rapamycin_D011565_0_81_90_psoriasis	Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.
UN	10328196_D020123_2_385_394_sirolimus_D011565_2_309_318_psoriasis	After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.
UN	10328196_D020123_3_689_698_sirolimus_D011565_3_720_729_psoriasis	OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).
CID	10328196_D020123_2_385_394_sirolimus_D019559_2_331_354_capillary leak syndrome	After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.
CID	10328196_D020123_3_553_562_sirolimus_D019559_3_571_594_capillary leak syndrome	OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).
CID	10342929_D000806_0_18_32_ACE inhibitors_D000799_0_0_10_Angioedema	Angioedema due to ACE inhibitors: common and inadequately diagnosed.
CID	10342929_D000806_1_114_159_angiotensin-converting enzyme (ACE) inhibitor_D000799_1_96_106_angioedema	The estimated incidence of angioedema during angiotensin-converting enzyme (ACE) inhibitor treatment is between 1 and 7 per thousand patients.
UN	10354657_D008094_5_574_581_lithium_D001714_5_547_563_bipolar disorder	PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.
UN	10354657_D008094_14_1809_1816_lithium_D006934_14_1788_1801_hypercalcemia	CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.
CID	10354657_D008094_9_1192_1199_lithium_D007037_9_1151_1165_hypothyroidism	All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).
CID	10354657_D008094_14_1809_1816_lithium_D007037_14_1769_1783_hypothyroidism	CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.
CID	10365197_D003042_1_252_259_cocaine_D019964_1_232_246_mood disorders	This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders. 243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.
CID	10365197_D003042_1_287_294_cocaine_D019964_1_303_316_mood disorder	This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders. 243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.
CID	10365197_D003042_0_0_7_Cocaine_D019964_0_16_29_mood disorder	Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.
UN	10365197_D003042_1_287_294_cocaine_D019970_1_318_322_CIMD	This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders. 243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.
UN	10406016_C007789_3_305_313_fucoidan_D001925_3_362_374_brain damage	We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.
UN	10406016_C007789_0_10_18_fucoidan_D002543_0_52_76_intracerebral hemorrhage	Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.
UN	10406016_C007789_7_757_765_Fucoidan_D006406_7_854_863_hematomas	Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.
UN	10406016_C007789_7_757_765_Fucoidan_D007249_7_889_901_inflammation	Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.
CID	10406016_C007789_7_757_765_Fucoidan_D020141_7_801_824_impaired blood clotting	Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.
CID	10411803_D015313_2_305_314_cefotetan_D000743_2_323_340_hemolytic anemias	We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.
CID	10411803_D015313_0_67_76_cefotetan_D000743_0_14_30_hemolytic anemia	Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.
UN	10414674_D000082_8_1110_1123_acetaminophen_D001791_8_1072_1092_platelet aggregation	In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).
UN	10414674_D000082_11_1517_1530_acetaminophen_D013345_11_1575_1578_SAH	Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.
UN	10414674_D000082_3_483_496_acetaminophen_D017542_3_594_604_aneurysmal	Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.
UN	10414674_D000244_6_839_860_adenosine diphosphate_D001791_6_795_815_platelet aggregation	Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.
CID	10414674_D007660_6_895_905_ketoprofen_D001791_6_795_815_platelet aggregation	Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.
UN	10414674_D007660_12_1583_1593_ketoprofen_D002532_12_1629_1645_artery aneurysms	If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.
CID	10414674_D007660_9_1254_1264_ketoprofen_D006406_9_1310_1318_hematoma	One patient in the ketoprofen group developed a postoperative intracranial hematoma.
UN	10414674_D007660_11_1498_1508_Ketoprofen_D013345_11_1575_1578_SAH	Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.
UN	10414674_D007660_3_402_412_ketoprofen_D013345_3_363_366_SAH	Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.
UN	10414674_D007660_3_402_412_ketoprofen_D017542_3_594_604_aneurysmal	Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.
UN	10520387_D004809_2_289_298_ephedrine_D007022_2_334_345_hypotensive	We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response.
CID	10520387_D004809_5_753_762_ephedrine_D013610_5_714_725_tachycardia	However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.
UN	10520387_D004809_6_1019_1028_ephedrine_D017202_6_933_952_myocardial ischemia	Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.
CID	10520387_D015742_4_656_664_propofol_D007022_4_632_643_hypotensive	The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.
CID	10520387_D015742_2_302_310_propofol_D007022_2_334_345_hypotensive	We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response.
CID	10520387_D015742_5_783_791_propofol_D013610_5_714_725_tachycardia	However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.
UN	10520387_D015742_6_1029_1037_propofol_D017202_6_933_952_myocardial ischemia	Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.
UN	10523326_C002744_1_221_234_nitrotyrosine_D006973_1_280_292_hypertension	We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.
CID	10523326_D007854_9_1569_1573_lead_D006973_9_1582_1594_hypertension	In conclusion, lead-induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.
CID	10523326_D007854_0_50_54_lead_D006973_0_63_75_hypertension	Nitric oxide synthase expression in the course of lead-induced hypertension.
CID	10523326_D007854_1_267_271_lead_D006973_1_280_292_hypertension	We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.
CID	10523326_D007854_2_369_373_lead_D006973_2_382_394_hypertension	This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.
UN	10523326_D008315_6_1189_1192_MDA_D006973_6_1160_1172_hypertension	Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.
UN	10523326_D009569_0_0_12_Nitric oxide_D006973_0_63_75_hypertension	Nitric oxide synthase expression in the course of lead-induced hypertension.
UN	10523326_D010100_1_114_120_oxygen_D006973_1_280_292_hypertension	We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.
UN	10523326_D014810_6_1122_1131_Vitamin E_D006973_6_1160_1172_hypertension	Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.
UN	10524660_D005996_8_1062_1065_GTN_D006261_8_1074_1082_headache	In the controls, the GTN-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.
UN	10524660_D005996_3_578_597_glyceryl trinitrate_D006261_3_533_541_headache	In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.
UN	10524660_D005996_0_0_19_Glyceryl trinitrate_D020325_0_77_95_migraine with aura	Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.
CID	10524660_D005996_0_0_19_Glyceryl trinitrate_D020326_0_39_60_migraine without aura	Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.
UN	10524660_D009569_11_1518_1520_NO_D003866_11_1480_1490_depression	Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.
UN	10524660_D009569_11_1518_1520_NO_D006261_11_1631_1639_headache	Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.
UN	10524660_D009569_2_366_368_NO_D010146_2_385_389_pain	In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.
UN	10524660_D009569_10_1394_1396_NO_D010146_10_1416_1420_pain	The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.
UN	10524660_D009569_10_1394_1396_NO_D020325_10_1435_1453_migraine with aura	The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.
CID	10524660_D009569_2_366_368_NO_D020326_2_404_425_migraine without aura	In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.
UN	10526274_C030852_4_674_677_VNB_D002289_4_712_717_NSCLC	In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.
UN	10526274_C030852_0_17_28_vinorelbine_D002289_0_32_60_nonsmall cell lung carcinoma	Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.
UN	10526274_C056507_0_0_11_Gemcitabine_D002289_0_32_60_nonsmall cell lung carcinoma	Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.
UN	10526274_C056507_4_666_669_GEM_D002289_4_712_717_NSCLC	In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.
UN	10526274_D002945_4_767_776_cisplatin_D002289_4_712_717_NSCLC	In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.
UN	10533019_D002122_2_224_240_calcium chloride_D013746_2_272_278_tetany	The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.
UN	10533019_D002122_0_65_81_calcium chloride_D013746_0_53_59_tetany	Rapid reversal of life-threatening diltiazem-induced tetany with calcium chloride.
UN	10533019_D002122_3_542_558_calcium chloride_D013746_3_468_474_tetany	The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.
UN	10533019_D004110_1_191_200_diltiazem_D012131_1_138_156_respiratory arrest	We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.
CID	10533019_D004110_0_35_44_diltiazem_D013746_0_53_59_tetany	Rapid reversal of life-threatening diltiazem-induced tetany with calcium chloride.
CID	10533019_D004110_1_191_200_diltiazem_D013746_1_119_125_tetany	We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.
CID	10533019_D004110_3_523_532_diltiazem_D013746_3_468_474_tetany	The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.
UN	10539815_D000809_0_77_88_angiotensin_D006333_0_56_69_heart failure	Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)
UN	10539815_D000809_3_601_612_angiotensin_D006333_3_578_581_CHF	OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.
UN	10539815_D000809_0_77_88_angiotensin_D018487_0_154_182_left ventricular dysfunction	Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)
UN	10539815_D000809_0_77_88_angiotensin_D051437_0_14_38_decreased renal function	Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)
UN	10539815_D000809_3_601_612_angiotensin_D051437_3_533_560_reduction in renal function	OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.
UN	10539815_D003404_7_1256_1266_creatinine_D003920_7_1335_1343_diabetes	We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.
UN	10539815_D003404_7_1256_1266_creatinine_D006973_7_1321_1333_hypertension	We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.
UN	10539815_D003404_6_1055_1065_creatinine_D051437_6_999_1023_Decreased renal function	Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline.
UN	10539815_D004232_7_1370_1378_diuretic_D003920_7_1335_1343_diabetes	We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.
UN	10539815_D004232_9_1615_1623_diuretic_D003920_9_1637_1645_diabetes	By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.
UN	10539815_D004232_7_1370_1378_diuretic_D006973_7_1321_1333_hypertension	We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.
CID	10539815_D004232_11_2060_2068_Diuretic_D051437_11_2124_2148_decreased renal function	Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).
UN	10539815_D004656_9_1587_1596_enalapril_D003920_9_1637_1645_diabetes	By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.
UN	10539815_D004656_4_789_798_enalapril_D006333_4_820_823_CHF	METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.
UN	10539815_D004656_4_789_798_enalapril_D018487_4_695_723_Left Ventricular Dysfunction	METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.
CID	10539815_D004656_8_1445_1454_enalapril_D051437_8_1487_1511_decreased renal function	RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).
CID	10539815_D004656_11_2156_2165_enalapril_D051437_11_2124_2148_decreased renal function	Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).
CID	10565806_C076029_1_206_216_olanzapine_D001714_1_162_171_hypomania	We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.
CID	10565806_C076029_0_35_45_olanzapine_D001714_0_0_9_Hypomania	Hypomania-like syndrome induced by olanzapine.
UN	10565806_C076029_1_206_216_olanzapine_D011618_1_120_138_psychotic disorder	We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.
CID	10579464_C121249_6_901_908_NRA0160_D002375_6_945_954_catalepsy	NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given.
UN	10579464_C121249_4_639_646_NRA0160_D006948_4_683_696_hyperactivity	NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.
CID	10579464_D003024_6_913_922_clozapine_D002375_6_945_954_catalepsy	NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given.
UN	10579464_D003024_4_651_660_clozapine_D006948_4_683_696_hyperactivity	NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.
CID	10579464_D008694_4_708_723_methamphetamine_D006948_4_683_696_hyperactivity	NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.
UN	10669626_D002118_14_2873_2880_calcium_D002114_14_3055_3068_calcification	Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.
UN	10669626_D002118_13_2797_2804_calcium_D061205_13_2748_2768_artery calcification	There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.
UN	10669626_D010710_8_1907_1916_phosphate_D061205_8_1853_1873_artery calcification	This observation suggests that increased susceptibility to Warfarin-induced artery calcification could be related to higher serum phosphate levels.
UN	10669626_D010710_7_1475_1484_phosphate_D061205_7_1507_1527_artery calcification	Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.
UN	10669626_D014807_12_2511_2520_vitamin D_D002114_12_2481_2494_calcification	In the current study, we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D-treated rats at 3 and 4 days.
UN	10669626_D014807_9_1993_2002_vitamin D_D061205_9_2019_2039_artery calcification	The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.
UN	10669626_D014807_10_2055_2064_vitamin D_D061205_10_2084_2111_calcification of the artery	High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.
UN	10669626_D014807_0_67_76_vitamin D_D061205_0_17_37_artery calcification	Warfarin-induced artery calcification is accelerated by growth and vitamin D.
UN	10669626_D014807_13_2600_2609_vitamin D_D061205_13_2618_2638_artery calcification	There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.
UN	10669626_D014807_13_2727_2736_vitamin D_D061205_13_2748_2768_artery calcification	There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.
UN	10669626_D014807_1_126_135_vitamin D_D061205_1_168_188_artery calcification	The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.
UN	10669626_D014807_15_3178_3187_vitamin D_D061205_15_3136_3156_artery calcification	High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.
UN	10669626_D014812_11_2165_2174_vitamin K_D061205_11_2219_2246_calcification of the artery	High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.
CID	10669626_D014859_0_0_8_Warfarin_D061205_0_17_37_artery calcification	Warfarin-induced artery calcification is accelerated by growth and vitamin D.
CID	10669626_D014859_1_223_231_Warfarin_D061205_1_168_188_artery calcification	The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.
CID	10669626_D014859_11_2186_2194_Warfarin_D061205_11_2219_2246_calcification of the artery	High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.
CID	10669626_D014859_5_864_872_Warfarin_D061205_5_881_901_artery calcification	To directly examine the importance of growth to Warfarin-induced artery calcification in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.
CID	10669626_D014859_2_500_508_Warfarin_D061205_2_476_496_artery calcification	The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin-treated rats.
CID	10669626_D014859_3_550_558_Warfarin_D061205_3_580_607_calcification of the artery	Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.
CID	10669626_D014859_8_1836_1844_Warfarin_D061205_8_1853_1873_artery calcification	This observation suggests that increased susceptibility to Warfarin-induced artery calcification could be related to higher serum phosphate levels.
CID	10669626_D014859_15_3193_3201_Warfarin_D061205_15_3136_3156_artery calcification	High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.
CID	10669626_D014859_9_2007_2015_Warfarin_D061205_9_2019_2039_artery calcification	The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.
CID	10669626_D014859_6_1112_1120_Warfarin_D061205_6_1144_1171_calcification of the artery	Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.
CID	10669626_D014859_7_1658_1666_Warfarin_D061205_7_1675_1695_artery calcification	Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.
UN	10669626_D015055_16_3347_3369_gamma-carboxyglutamate_D002114_16_3447_3460_calcification	These observations indicate that although the gamma-carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor, they are not required for its accumulation at calcification sites.
UN	10669626_D015055_15_3281_3299_gamma-carboxylated_D061205_15_3136_3156_artery calcification	High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.
CID	10683478_D001058_4_699_710_apomorphine_D006948_4_719_732_hyperactivity	In rats, detection of apomorphine-induced hyperactivity was facilitated by a period of acclimatization to the test conditions.
CID	10683478_D001058_5_879_890_apomorphine_D007035_5_912_923_hypothermia	Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug-induced hypothermia.
UN	10683478_D004298_2_465_473_dopamine_D007035_2_417_428_hypothermia	Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.
UN	10683478_D018491_2_324_340_dopamine agonist_D007035_2_417_428_hypothermia	Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.
UN	10692744_D000086_1_69_82_acetazolamide_D003221_1_48_57_confusion	Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.
CID	10692744_D000086_0_0_13_Acetazolamide_D005862_0_22_40_Gerstmann syndrome	Acetazolamide-induced Gerstmann syndrome.
CID	10692744_D000086_2_176_189_acetazolamide_D005862_2_198_216_Gerstmann syndrome	We report a case of acetazolamide-induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.
UN	10692744_D000086_1_69_82_acetazolamide_D007674_1_138_154_renal impairment	Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.
UN	10704919_D010100_7_1115_1121_oxygen_D006461_7_1204_1213_hemolysis	This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM-induced hemolysis.
UN	10704919_D011188_9_1428_1429_K_D006461_9_1369_1378_Hemolysis	Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.
CID	10704919_D013629_2_404_407_TAM_D000743_2_416_432_hemolytic anemia	This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.
UN	10704919_D013629_1_101_110_Tamoxifen_D001943_1_188_201_breast cancer	Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.
CID	10704919_D013629_4_657_660_TAM_D006461_4_675_684_hemolysis	The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions.
CID	10704919_D013629_3_506_509_TAM_D006461_3_518_527_hemolysis	TAM induces hemolysis of erythrocytes as a function of concentration.
CID	10704919_D013629_12_1894_1897_TAM_D006461_12_1843_1852_hemolysis	These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.
CID	10704919_D013629_0_43_52_tamoxifen_D006461_0_0_9_Hemolysis	Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure.
CID	10704919_D013629_13_2025_2028_TAM_D006461_13_2037_2046_hemolysis	Therefore, TAM-induced hemolysis results from a structural perturbation of red cell membrane, leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane.
CID	10704919_D013629_9_1389_1392_TAM_D006461_9_1369_1378_Hemolysis	Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.
CID	10704919_D013629_7_1192_1195_TAM_D006461_7_1204_1213_hemolysis	This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM-induced hemolysis.
CID	10704919_D013629_6_847_850_TAM_D006461_6_827_836_hemolytic	The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.
CID	10704919_D013629_6_1007_1010_TAM_D006461_6_1019_1028_hemolysis	The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.
UN	10704919_D017665_6_981_989_hydroxyl_D006461_6_1019_1028_hemolysis	The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.
UN	10704919_D024502_6_889_905_alpha-tocopherol_D006461_6_827_836_hemolytic	The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.
UN	10704919_D024505_12_1856_1867_tocopherols_D006461_12_1843_1852_hemolysis	These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.
UN	10706004_D000255_0_22_25_ATP_D006973_0_106_118_hypertension	Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.
UN	10706004_D000255_9_1250_1253_ATP_D006973_9_1165_1177_hypertension	After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.
UN	10706004_D009569_11_1380_1382_NO_D003866_11_1441_1450_depressed	Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.
CID	10706004_D009569_0_83_95_nitric oxide_D006973_0_106_118_hypertension	Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.
CID	10706004_D009569_2_224_226_NO_D006973_2_255_267_hypertension	Inhibition of NO synthesis induces sustained hypertension.
CID	10706004_D009569_11_1380_1382_NO_D006973_11_1413_1425_hypertension	Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.
CID	10706004_D009569_4_514_516_NO_D006973_4_527_539_hypertension	To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.
UN	10706004_D011188_11_1551_1552_K_D003866_11_1441_1450_depressed	Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.
UN	10706004_D011188_0_56_57_K_D006973_0_106_118_hypertension	Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.
UN	10706004_D011188_4_501_502_K_D006973_4_527_539_hypertension	To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.
UN	10706004_D012964_11_1451_1453_Na_D003866_11_1441_1450_depressed	Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.
UN	10706004_D012964_11_1451_1453_Na_D006973_11_1413_1425_hypertension	Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.
UN	10706004_D019331_4_600_634_N(G)-nitro-L-arginine methyl ester_D006973_4_527_539_hypertension	To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.
UN	10721819_D001971_8_1531_1544_bromocriptine_D001919_8_1568_1579_bradycardia	These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.
UN	10721819_D001971_9_1803_1816_bromocriptine_D001919_9_1856_1867_bradycardia	They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.
CID	10721819_D001971_5_805_818_Bromocriptine_D007022_5_827_838_hypotension	Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v. domperidone (0.5 mg/kg).
CID	10721819_D001971_4_726_739_bromocriptine_D007022_4_776_787_hypotension	In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.
CID	10721819_D001971_0_56_69_bromocriptine_D013610_0_78_89_tachycardia	Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats.
CID	10721819_D001971_9_1803_1816_bromocriptine_D013610_9_1788_1799_tachycardia	They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.
CID	10721819_D001971_8_1531_1544_bromocriptine_D013610_8_1553_1564_tachycardia	These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.
CID	10721819_D001971_1_132_145_bromocriptine_D013610_1_154_165_tachycardia	It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.
CID	10721819_D001971_2_520_533_bromocriptine_D013610_2_542_553_tachycardia	This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine-induced tachycardia in conscious rats.
CID	10721819_D004294_5_986_997_domperidone_D001919_5_931_942_bradycardia	Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v. domperidone (0.5 mg/kg).
UN	10721819_D004294_5_986_997_domperidone_D007022_5_827_838_hypotension	Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v. domperidone (0.5 mg/kg).
UN	10721819_D004294_5_986_997_domperidone_D013610_5_891_902_tachycardia	Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v. domperidone (0.5 mg/kg).
UN	10721819_D004298_9_1898_1906_dopamine_D001919_9_1856_1867_bradycardia	They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.
UN	10721819_D004298_9_1898_1906_dopamine_D013610_9_1788_1799_tachycardia	They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.
UN	10721819_D004298_1_231_239_dopamine_D013610_1_154_165_tachycardia	It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.
CID	10721819_D007545_5_857_870_isoproterenol_D001919_5_931_942_bradycardia	Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v. domperidone (0.5 mg/kg).
CID	10721819_D007545_8_1472_1485_isoproterenol_D001919_8_1568_1579_bradycardia	These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.
CID	10721819_D007545_3_573_586_Isoproterenol_D006332_3_619_638_cardiac hypertrophy	Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate.
UN	10721819_D007545_5_857_870_isoproterenol_D007022_5_827_838_hypotension	Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v. domperidone (0.5 mg/kg).
UN	10721819_D007545_8_1472_1485_isoproterenol_D013610_8_1553_1564_tachycardia	These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.
UN	10721819_D007545_2_492_505_isoproterenol_D013610_2_542_553_tachycardia	This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine-induced tachycardia in conscious rats.
UN	10721819_D007545_0_39_52_isoproterenol_D013610_0_78_89_tachycardia	Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats.
UN	10728962_D014667_0_0_11_Vasopressin_D006333_0_72_85_heart failure	Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
UN	10728962_D014667_2_367_378_vasopressin_D006333_2_291_304_heart failure	In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.
CID	10728962_D014667_0_0_11_Vasopressin_D007022_0_50_61_hypotension	Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
UN	10728962_D020105_2_343_352_milrinone_D006333_2_291_304_heart failure	In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.
UN	10728962_D020105_1_135_144_milrinone_D006333_1_172_185_heart failure	The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.
UN	10728962_D020105_0_32_41_milrinone_D006333_0_72_85_heart failure	Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
CID	10728962_D020105_0_32_41_milrinone_D007022_0_50_61_hypotension	Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
CID	10728962_D020105_2_343_352_milrinone_D007022_2_310_321_hypotension	In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.
CID	10737864_D003000_3_539_548_clonidine_D001919_3_584_595_bradycardia	Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that clonidine induces sympathetic withdrawal and bradycardia, we hypothesized that clonidine's developmental effects on cardiac rate and ultrasound production would mirror each other.
CID	10737864_D003000_5_1038_1047_clonidine_D001919_5_1056_1067_bradycardia	Age-related changes in ultrasound production corresponded with changes in cardiovascular variables, including baseline cardiac rate and clonidine-induced bradycardia.
CID	10739826_D003276_0_23_42_oral contraceptives_D054556_0_59_81_venous thromboembolism	Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.
CID	10739826_D003276_1_188_207_oral contraceptives_D054556_1_161_164_VTE	The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.
CID	10739826_D003276_5_759_761_OC_D054556_5_718_721_VTE	The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.
CID	10743446_D002211_1_317_326_capsaicin_D006930_1_293_305_hyperalgesia	We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.
CID	10743446_D002211_0_131_140_capsaicin_D006930_0_95_107_hyperalgesia	Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.
CID	10743446_D002211_1_317_326_capsaicin_D010146_1_259_263_pain	We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.
UN	10743446_D007649_9_1214_1222_ketamine_D006930_9_1259_1271_hyperalgesia	The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.
UN	10743446_D007649_0_50_58_ketamine_D006930_0_95_107_hyperalgesia	Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.
UN	10743446_D007649_1_210_218_ketamine_D010146_1_259_263_pain	We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.
UN	10743446_D008012_9_1227_1236_lidocaine_D006930_9_1259_1271_hyperalgesia	The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.
UN	10743446_D008012_7_1027_1036_Lidocaine_D006930_7_1073_1085_hyperalgesia	Lidocaine reduced the area of punctate-evoked hyperalgesia significantly.
UN	10743446_D008012_0_63_72_lidocaine_D006930_0_95_107_hyperalgesia	Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.
UN	10743446_D008012_1_223_232_lidocaine_D010146_1_259_263_pain	We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.
CID	10791295_D001058_0_15_26_apomorphine_D010554_0_35_54_aggressive behavior	Development of apomorphine-induced aggressive behavior: comparison of adult male and female Wistar rats.
CID	10791295_D001058_2_323_334_apomorphine_D010554_2_378_397_aggressive behavior	In male animals, repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent.
CID	10791295_D001058_4_684_695_apomorphine_D010554_4_704_723_aggressive behavior	In conclusion, the present study demonstrates gender differences in the development of the apomorphine-induced aggressive behavior and indicates that the female rats do not fill the validation criteria for use in this method.
UN	1079693_D000305_12_1385_1400_corticosteroids_D002386_12_1477_1486_cataracts	Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
UN	1079693_D000305_8_977_992_corticosteroids_D014605_8_893_900_uveitis	Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
CID	1079693_D006886_11_1246_1264_hydroxychloroquine_D012164_11_1312_1329_chorioretinopathy	We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.
CID	10807237_D003042_11_1320_1327_Cocaine_D017542_11_1344_1362_aneurysmal rupture	CONCLUSION: Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms.
UN	10835440_D009553_3_621_631_nimodipine_D002544_3_512_527_ischemic stroke	METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).
CID	10835440_D009553_6_931_941_Nimodipine_D007022_6_992_1016_reduction in systolic BP	Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.
CID	10835440_D009553_1_198_208_nimodipine_D007022_1_217_244_reduction in blood pressure	BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.
UN	10835440_D009553_1_123_133_Nimodipine_D020521_1_148_154_Stroke	BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.
UN	10835440_D009553_0_22_32_nimodipine_D020521_0_69_81_acute stroke	Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.
UN	10835440_D009553_10_1829_1839_nimodipine_D020521_10_1846_1858_acute stroke	CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.
UN	10840460_D000171_2_331_339_acrolein_D003556_2_360_368_cystitis	Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.
CID	10840460_D003520_0_0_16_Cyclophosphamide_D003556_0_25_33_cystitis	Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.
CID	10840460_D003520_14_2171_2173_CP_D003556_14_2182_2190_cystitis	CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.
CID	10840460_D003520_14_2171_2173_CP_D010146_14_2306_2323_painful syndromes	CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.
UN	10840460_D003520_0_0_16_Cyclophosphamide_D059265_0_105_118_visceral pain	Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.
UN	10840460_D003520_14_2171_2173_CP_D059265_14_2250_2263_visceral pain	CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.
UN	10840460_D009020_7_1261_1269_Morphine_D001523_7_1302_1322_behavioral disorders	Morphine dose-dependently reversed these behavioral disorders.
UN	10840460_D009020_10_1532_1540_morphine_D004487_10_1625_1630_edema	At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.
CID	1085609_D007538_0_50_59_isoniazid_D012640_0_31_42_convulsions	Neonatal pyridoxine responsive convulsions due to isoniazid therapy.
UN	1085609_D007538_1_92_101_isoniazid_D014376_1_156_168_tuberculosis	A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.
UN	1085609_D011736_0_9_19_pyridoxine_D012640_0_31_42_convulsions	Neonatal pyridoxine responsive convulsions due to isoniazid therapy.
UN	1085609_D011736_3_334_344_pyridoxine_D012640_3_276_280_fits	The fits ceased within 4 hours of administering intramuscular pyridoxine, suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication.
UN	10901305_D007649_7_1324_1332_ketamine_D004204_7_1368_1379_dislocation	RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).
UN	10901305_D007649_0_0_8_Ketamine_D050723_0_50_59_fractures	Ketamine sedation for the reduction of children's fractures in the emergency department.
UN	10901305_D007649_2_322_330_ketamine_D050723_2_375_384_fractures	The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.
UN	10901305_D007649_7_1324_1332_ketamine_D050723_7_1356_1364_fracture	RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).
UN	10910842_D000109_0_82_95_acetylcholine_D001284_0_58_65_atrophy	Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.
UN	10910842_D000109_15_2314_2327_acetylcholine_D009133_15_2267_2281_muscle atrophy	We suggest that the observed effects are dose-dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression.
UN	10910842_D000109_0_82_95_acetylcholine_D018908_0_21_39_muscle dysfunction	Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.
CID	10910842_D011239_13_1927_1939_prednisolone_D009133_13_1986_2000_muscle atrophy	Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.
UN	10910842_D011239_13_1927_1939_prednisolone_D009468_13_1895_1920_neuromuscular dysfunction	Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.
CID	10910842_D011239_0_0_12_Prednisolone_D018908_0_21_39_muscle dysfunction	Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.
UN	10910842_D014403_5_920_934_d-tubocurarine_D013746_5_852_859_tetanic	On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.
CID	11007689_D016559_7_1087_1097_tacrolimus_D057049_7_1030_1033_TMA	However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.
CID	11007689_D016559_6_913_923_tacrolimus_D057049_6_935_938_TMA	With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.
CID	11007689_D016559_0_17_27_tacrolimus_D057049_0_39_65_thrombotic microangiopathy	Cyclosporine and tacrolimus-associated thrombotic microangiopathy.
CID	11007689_D016572_1_146_158_cyclosporine_D057049_1_114_117_TMA	The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.
CID	11007689_D016572_5_810_822_cyclosporine_D057049_5_831_834_TMA	As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.
CID	11007689_D016572_7_1070_1082_cyclosporine_D057049_7_1030_1033_TMA	However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.
CID	11007689_D016572_8_1186_1198_cyclosporine_D057049_8_1207_1210_TMA	We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.
CID	11007689_D016572_0_0_12_Cyclosporine_D057049_0_39_65_thrombotic microangiopathy	Cyclosporine and tacrolimus-associated thrombotic microangiopathy.
UN	11009181_D001058_7_1316_1327_apomorphine_D001523_7_1407_1418_psychiatric	The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.
UN	11009181_D001058_6_1174_1185_apomorphine_D004409_6_1265_1276_dyskinesias	In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias.
UN	11009181_D001058_8_1505_1516_apomorphine_D010300_8_1542_1561_Parkinson's disease	Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.
UN	11009181_D001058_2_327_338_apomorphine_D010300_2_273_292_Parkinson's disease	While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study.
CID	11009181_D007980_6_1248_1256_levodopa_D004409_6_1265_1276_dyskinesias	In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias.
UN	11022397_D010862_12_1551_1562_pilocarpine_D008569_12_1584_1609_impairment in word recall	OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.
CID	11022397_D012601_12_1564_1575_scopolamine_D008569_12_1584_1609_impairment in word recall	OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.
CID	11022397_D012601_15_2007_2018_scopolamine_D008569_15_2027_2052_impairment in word recall	Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).
UN	11022397_D014331_12_1535_1546_tropicamide_D008569_12_1584_1609_impairment in word recall	OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.
UN	11027904_D004091_3_643_656_hydromorphone_D010146_3_543_547_pain	By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.
UN	11027904_D008691_2_344_353_methadone_D009293_2_315_329_opioid addicts	This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).
UN	11027904_D008691_0_18_27_methadone_D010146_0_0_4_Pain	Pain responses in methadone-maintained opioid abusers.
UN	11027904_D020910_3_699_708_ketorolac_D010146_3_543_547_pain	By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.
UN	11027905_D007649_0_32_40_ketamine_D009369_0_44_50_cancer	Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
UN	11027905_D007649_2_302_310_ketamine_D009437_2_396_412_neuropathic pain	Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.
UN	11027905_D007649_11_1622_1630_Ketamine_D009437_11_1699_1715_neuropathic pain	Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.
UN	11027905_D007649_11_1622_1630_Ketamine_D010146_11_1675_1679_pain	Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.
UN	11027905_D009020_0_63_71_morphine_D009369_0_44_50_cancer	Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
UN	11027905_D009020_3_548_556_morphine_D009369_3_503_509_cancer	A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.
UN	11027905_D009020_11_1643_1651_morphine_D009437_11_1699_1715_neuropathic pain	Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.
UN	11027905_D009020_3_548_556_morphine_D010146_3_525_529_pain	A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.
UN	11027905_D009020_1_174_182_morphine_D010146_1_151_155_Pain	Pain not responsive to morphine is often problematic.
UN	11027905_D009020_11_1643_1651_morphine_D010146_11_1675_1679_pain	Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.
UN	11027905_D016202_2_253_273_N-methyl-D-aspartate_D009437_2_396_412_neuropathic pain	Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.
UN	11027905_D016202_2_253_273_N-methyl-D-aspartate_D010146_2_372_376_pain	Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.
UN	11058428_D000305_2_299_313_corticosteroid_D009135_2_314_322_myopathy	In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.
UN	11058428_D000305_6_1023_1037_corticosteroid_D009135_6_1038_1046_myopathy	To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.
CID	11058428_D008775_2_338_356_methylprednisolone_D009135_2_314_322_myopathy	In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.
CID	11058428_D008775_6_966_984_methylprednisolone_D009135_6_1038_1046_myopathy	To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.
UN	11058428_D008775_1_147_165_methylprednisolone_D013119_1_208_226_spinal cord injury	Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.
UN	11058428_D008775_0_10_28_methylprednisolone_D013119_0_50_68_spinal cord injury	High-dose methylprednisolone may do more harm for spinal cord injury.
UN	11058428_D008775_5_829_847_methylprednisolone_D013119_5_862_880_spinal cord injury	Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.
UN	11058428_D013256_5_780_787_steroid_D013119_5_862_880_spinal cord injury	Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.
UN	11063349_D003404_6_817_827_creatinine_D007674_6_760_774_nephrotoxicity	RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].
CID	11063349_D016559_4_494_497_Tac_D007674_4_498_512_nephrotoxicity	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.
UN	11063349_D016559_4_532_535_Tac_D008232_4_581_624_posttransplant lymphoproliferative disorder	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.
UN	11063349_D016559_4_532_535_Tac_D056486_4_654_668_hepatotoxicity	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.
CID	11063349_D016572_4_487_490_CsA_D007674_4_498_512_nephrotoxicity	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.
UN	11063349_D016572_4_525_528_CsA_D008232_4_581_624_posttransplant lymphoproliferative disorder	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.
UN	11063349_D016572_4_525_528_CsA_D056486_4_654_668_hepatotoxicity	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.
UN	11063349_D020123_11_1164_1168_RAPA_D008232_11_1233_1237_PTLD	RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.
UN	11063349_D020123_11_1164_1168_RAPA_D011014_11_1215_1224_pneumonia	RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.
UN	11063349_D020123_14_1467_1471_RAPA_D011020_14_1563_1593_Pneumocystis carinii pneumonia	However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.
UN	11063349_D020123_11_1164_1168_RAPA_D013281_11_1255_1269_aphtous ulcers	RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.
CID	11077455_D020888_1_246_256_vigabatrin_D014786_1_190_215_visual field constriction	PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.
CID	11077455_D020888_2_383_393_vigabatrin_D014786_2_405_422_visual field loss	The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.
CID	11077455_D020888_0_120_130_vigabatrin_D014786_0_142_167_visual field constriction	Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.
CID	11077455_D020888_11_1553_1563_vigabatrin_D014786_11_1497_1522_visual field constriction	CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.
UN	11078231_D000109_6_770_783_acetylcholine_D023921_6_798_822_coronary artery stenosis	Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.
CID	11078231_D004280_10_1236_1246_dobutamine_D000788_10_1296_1319_coronary spastic angina	These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.
CID	11078231_D004280_3_482_492_dobutamine_D003329_3_453_467_coronary spasm	The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.
CID	11078231_D004280_10_1236_1246_dobutamine_D003329_10_1259_1273_coronary spasm	These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.
CID	11078231_D004280_0_56_66_dobutamine_D003329_0_27_48_coronary artery spasm	Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.
CID	11079278_D004280_0_76_86_dobutamine_D017202_0_95_114_myocardial ischemia	Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.
UN	11079278_D008790_12_1445_1455_metoprolol_D017202_12_1493_1512_myocardial ischemia	CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.
UN	11079278_D008790_0_48_58_metoprolol_D017202_0_95_114_myocardial ischemia	Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.
CID	11099450_D007980_1_256_264_levodopa_D004409_1_273_284_dyskinesias	The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).
UN	11099450_D007980_1_256_264_levodopa_D010300_1_227_239_parkinsonian	The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).
UN	11099450_D007980_5_1129_1137_levodopa_D010300_5_1172_1184_parkinsonian	The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.
UN	11135224_C056507_14_2146_2157_gemcitabine_D002289_14_2214_2219_NSCLC	CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.
UN	11135224_C056507_0_27_38_gemcitabine_D002289_0_126_154_nonsmall cell lung carcinoma	Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
UN	11135224_C056507_3_542_553_gemcitabine_D002289_3_586_591_NSCLC	METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.
UN	11135224_D002945_14_2131_2140_cisplatin_D002289_14_2214_2219_NSCLC	CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.
UN	11135224_D002945_0_12_21_cisplatin_D002289_0_126_154_nonsmall cell lung carcinoma	Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
UN	11135224_D002945_1_168_177_Cisplatin_D002289_1_259_287_nonsmall cell lung carcinoma	BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).
UN	11135224_D002945_4_834_843_cisplatin_D002289_4_659_664_NSCLC	Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.
UN	11135224_D002945_3_527_536_cisplatin_D002289_3_586_591_NSCLC	METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.
UN	11135224_D017239_14_2119_2129_paclitaxel_D002289_14_2214_2219_NSCLC	CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.
UN	11135224_D017239_4_768_778_paclitaxel_D002289_4_659_664_NSCLC	Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.
UN	11135224_D017239_3_515_525_paclitaxel_D002289_3_586_591_NSCLC	METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.
UN	11135224_D017239_0_0_10_Paclitaxel_D002289_0_126_154_nonsmall cell lung carcinoma	Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
CID	11147747_C047426_3_351_362_venlafaxine_D014549_3_325_337_incontinence	This concerns 2 male patients who experienced incontinence while taking venlafaxine.
UN	11147747_D012701_4_478_487_serotonin_D014549_4_438_450_incontinence	In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.
CID	11147747_D016651_5_651_668_lithium carbonate_D014549_5_732_744_incontinence	In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.
CID	11147747_D017374_4_508_518_paroxetine_D014549_4_438_450_incontinence	In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.
CID	11147747_D018490_0_0_28_Serotonergic antidepressants_D014549_0_33_53_urinary incontinence	Serotonergic antidepressants and urinary incontinence.
CID	11147747_D018490_6_800_828_serotonergic antidepressants_D014549_6_774_786_incontinence	Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder.
CID	11147747_D020280_4_523_533_sertraline_D014549_4_438_450_incontinence	In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.
CID	11166519_D003042_1_224_231_cocaine_D012640_1_182_190_seizures	Mature male and female mice from six inbred stains were tested for susceptibility to behavioral seizures induced by a single injection of cocaine.
CID	11166519_D003042_0_6_13_cocaine_D012640_0_22_30_seizures	Acute cocaine-induced seizures: differential sensitivity of six inbred mouse strains.
CID	11166519_D003042_8_1039_1046_cocaine_D012640_8_1055_1063_seizures	Additional studies of these murine strains may be useful for investigating genetic influences on cocaine-induced seizures.
UN	11185967_D000431_5_710_717_alcohol_D012640_5_726_733_seizure	Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.
UN	11185967_D000431_5_710_717_alcohol_D019969_5_818_846_cocaine or amphetamine abuse	Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.
UN	11185967_D000431_5_710_717_alcohol_D019970_5_818_846_cocaine or amphetamine abuse	Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.
UN	11185967_D000661_1_196_207_amphetamine_D012640_1_238_245_seizure	OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.
UN	11185967_D000662_8_1373_1385_amphetamines_D012640_8_1395_1402_seizure	CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield.
UN	11185967_D003042_1_185_192_cocaine_D012640_1_238_245_seizure	OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.
UN	11185967_D003042_8_1361_1368_cocaine_D012640_8_1395_1402_seizure	CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield.
UN	11195262_D014635_2_308_311_VPA_D004830_2_352_376_tonic-clonic convulsions	He had been taking VPA for treatment of idiopathic generalized tonic-clonic convulsions since he was 56 years old.
CID	11195262_D014635_1_180_183_VPA_D007177_1_220_279_syndrome of inappropriate secretion of antidiuretic hormone	We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
CID	11195262_D014635_0_16_32_sodium valproate_D007177_0_40_99_syndrome of inappropriate secretion of antidiuretic hormone	Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.
UN	11198499_C023754_4_803_813_tizanidine_D006973_4_738_750_hypertension	The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.
CID	11198499_C023754_0_40_50_tizanidine_D007022_0_0_11_Hypotension	Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.
CID	11198499_C023754_4_803_813_tizanidine_D007022_4_765_776_hypotension	The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.
UN	11198499_C023754_4_803_813_tizanidine_D009128_4_856_866_spasticity	The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.
UN	11198499_C023754_5_896_906_tizanidine_D009128_5_1021_1031_spasticity	The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.
UN	11198499_D000809_0_80_91_angiotensin_D006973_0_132_144_hypertension	Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.
UN	11198499_D000809_4_686_697_angiotensin_D007022_4_765_776_hypotension	The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.
UN	11198499_D000809_3_457_468_angiotensin_D007022_3_539_550_hypotension	Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked.
UN	11198499_D000809_0_80_91_angiotensin_D007022_0_0_11_Hypotension	Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.
UN	11198499_D000809_4_686_697_angiotensin_D009128_4_856_866_spasticity	The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.
UN	11198499_D017706_4_671_681_lisinopril_D006973_4_738_750_hypertension	The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.
CID	11198499_D017706_4_671_681_lisinopril_D007022_4_765_776_hypotension	The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.
UN	11198499_D017706_4_671_681_lisinopril_D009128_4_856_866_spasticity	The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.
CID	11206082_C036150_0_59_73_beta-carboline_D012640_0_82_90_seizures	Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.
UN	11206082_D001569_1_439_453_benzodiazepine_D012640_1_301_309_seizures	Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to seizures induced by a single i.p. injection of methyl beta-carboline-3-carboxylate (beta-CCM), an inverse agonist of the GABA(A) receptor benzodiazepine site.
UN	11206082_D003975_3_663_671_diazepam_D012640_3_770_778_seizures	We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p. injections.
UN	11206082_D005680_0_169_173_GABA_D012640_0_82_90_seizures	Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.
UN	11206082_D005680_1_422_426_GABA_D012640_1_301_309_seizures	Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to seizures induced by a single i.p. injection of methyl beta-carboline-3-carboxylate (beta-CCM), an inverse agonist of the GABA(A) receptor benzodiazepine site.
CID	11206082_D010433_3_744_761_pentylenetetrazol_D012640_3_770_778_seizures	We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p. injections.
CID	11206082_D010852_3_728_738_picrotoxin_D012640_3_770_778_seizures	We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p. injections.
UN	11208990_D000109_10_1358_1371_acetylcholine_D007674_10_1429_1440_nephropathy	In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.
UN	11208990_D004317_7_1031_1034_ADR_C537346_7_1059_1082_mesangial proliferation	RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.
UN	11208990_D004317_7_1031_1034_ADR_D009395_7_1092_1123_tubulointerstitial inflammation	RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.
CID	11208990_D004317_2_393_403_adriamycin_D009404_2_341_359_nephrotic syndrome	We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).
UN	11208990_D009569_0_15_27_nitric oxide_D007674_0_80_91_nephropathy	Association of nitric oxide production and apoptosis in a model of experimental nephropathy.
UN	11208990_D009569_15_1913_1915_NO_D009401_15_1983_1992_nephrosis	CONCLUSION: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR-induced nephrosis.
UN	11208990_D009569_2_275_277_NO_D009404_2_341_359_nephrotic syndrome	We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).
UN	11208990_D009573_9_1243_1250_nitrite_D007674_9_1298_1309_nephropathy	Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).
UN	11208990_D010656_10_1340_1353_phenylephrine_D007674_10_1429_1440_nephropathy	In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.
UN	11226639_C032232_4_507_518_barbiturate_D053608_4_519_527_narcosis	In particular, low doses reduced the latency to and prolonged the duration of barbiturate narcosis.
UN	11226639_C032232_7_932_943_barbiturate_D053608_7_894_902_narcosis	Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.
UN	11226639_C032232_0_29_40_barbiturate_D053608_0_49_57_narcosis	Dual effects of melatonin on barbiturate-induced narcosis in rats.
UN	11226639_C032232_3_360_371_barbiturate_D053608_3_372_380_narcosis	Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.
CID	11226639_D003975_6_813_821_diazepam_D053608_6_830_838_narcosis	Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.
CID	11226639_D007649_6_800_808_ketamine_D053608_6_830_838_narcosis	Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.
CID	11226639_D008550_0_16_25_melatonin_D053608_0_49_57_narcosis	Dual effects of melatonin on barbiturate-induced narcosis in rats.
CID	11226639_D008550_3_310_319_Melatonin_D053608_3_372_380_narcosis	Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.
CID	11226639_D008550_7_865_874_melatonin_D053608_7_894_902_narcosis	Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.
UN	11230490_D003520_9_1971_1987_cyclophosphamide_D001943_9_2014_2017_MBC	CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.
CID	11230490_D003520_9_1971_1987_cyclophosphamide_D009503_9_1885_1896_neutropenia	CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.
UN	11230490_D003520_1_386_402_cyclophosphamide_D066126_1_437_451_cardiotoxicity	PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).
UN	11230490_D004317_9_1820_1831_doxorubicin_D001943_9_2014_2017_MBC	CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.
UN	11230490_D004317_0_141_152_doxorubicin_D001943_0_223_236_breast cancer	Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
UN	11230490_D004317_2_719_725_Myocet_D001943_2_618_621_MBC	PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.
UN	11230490_D004317_1_425_436_doxorubicin_D001943_1_536_549_breast cancer	PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).
CID	11230490_D004317_9_1820_1831_doxorubicin_D009503_9_1885_1896_neutropenia	CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.
UN	11230490_D004317_9_1820_1831_doxorubicin_D066126_9_1858_1872_cardiotoxicity	CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.
UN	11230490_D004317_0_81_92_doxorubicin_D066126_0_8_22_cardiotoxicity	Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
UN	11230490_D004317_1_425_436_doxorubicin_D066126_1_437_451_cardiotoxicity	PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).
UN	11243580_D001120_6_853_863_L-arginine_D012640_6_936_947_convulsions	In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.
UN	11243580_D001120_1_174_184_L-arginine_D012640_1_241_252_convulsions	The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.
UN	11243580_D003975_5_734_742_diazepam_D012640_5_823_834_convulsions	L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.
CID	11243580_D008012_0_32_41_lidocaine_D012640_0_50_60_convulsion	The role of nitrergic system in lidocaine-induced convulsion in the mouse.
CID	11243580_D008012_7_1028_1037_lidocaine_D012640_7_1046_1057_convulsions	These results may suggest that NO is a proconvulsant mediator in lidocaine-induced convulsions.
CID	11243580_D008012_5_794_803_lidocaine_D012640_5_823_834_convulsions	L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.
CID	11243580_D008012_1_223_232_lidocaine_D012640_1_241_252_convulsions	The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.
UN	11243580_D009569_7_994_996_NO_D012640_7_1046_1057_convulsions	These results may suggest that NO is a proconvulsant mediator in lidocaine-induced convulsions.
UN	11243580_D019331_5_705_711_L-NAME_D012640_5_823_834_convulsions	L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.
UN	11243580_D019331_1_90_121_N-nitro-L-arginine-methyl ester_D012640_1_241_252_convulsions	The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.
UN	11245434_D003520_9_1318_1334_cyclophosphamide_D000740_9_1287_1293_anemia	These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.
UN	11245434_D003520_0_56_72_cyclophosphamide_D000740_0_28_34_anemia	Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.
UN	11245434_D003520_9_1318_1334_cyclophosphamide_D009369_9_1338_1344_tumors	These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.
UN	11245434_D003520_6_849_865_cyclophosphamide_D009369_6_807_813_tumors	When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.
UN	11245434_D003520_0_56_72_cyclophosphamide_D009369_0_93_99_tumors	Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.
UN	11245434_D003520_1_248_264_cyclophosphamide_D009369_1_287_293_tumors	The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.
UN	11245434_D010100_9_1474_1480_oxygen_D000740_9_1368_1374_anemia	These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.
UN	11245434_D010100_9_1474_1480_oxygen_D009369_9_1491_1496_tumor	These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.
CID	11245434_D016190_2_337_348_carboplatin_D000740_2_295_301_Anemia	Anemia was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.
UN	11245434_D016190_5_732_743_carboplatin_D009369_5_776_781_tumor	Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.
UN	11245434_D016190_4_623_634_carboplatin_D012509_4_657_664_sarcoma	Four days after carboplatin treatment, tumors (DS-sarcoma of the rat) were implanted s.c. onto the hind food dorsum.
CID	11250767_D011441_2_327_343_propylthiouracil_D005334_2_380_385_fever	METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.
CID	11250767_D011441_2_327_343_propylthiouracil_D005921_2_391_409_glomerulonephritis	METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.
UN	11250767_D011441_2_327_343_propylthiouracil_D006980_2_298_313_hyperthyroidism	METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.
CID	11250767_D011441_1_173_189_propylthiouracil_D010493_1_226_238_pericarditis	OBJECTIVE: To describe a case of propylthiouracil-induced vasculitis manifesting with pericarditis.
CID	11250767_D011441_2_327_343_propylthiouracil_D010493_2_366_378_pericarditis	METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.
UN	11250767_D011441_8_1168_1186_propylthio- uracil_D014657_8_1141_1151_vasculitis	CONCLUSION: Pericarditis may be the initial manifestation of drug-induced vasculitis attributable to propylthio- uracil therapy.
UN	11250767_D011441_7_1039_1057_propylthio- uracil_D014657_7_1012_1022_vasculitis	A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.
UN	11250767_D011441_1_173_189_propylthiouracil_D014657_1_198_208_vasculitis	OBJECTIVE: To describe a case of propylthiouracil-induced vasculitis manifesting with pericarditis.
UN	11256525_D000588_4_584_589_amine_D001002_4_518_524_anuria	Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.
UN	11256525_D000804_10_1284_1298_angiotensin II_D014652_10_1388_1408_renovascular disease	This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.
UN	11256525_D000809_8_1076_1087_angiotensin_D006333_8_986_999_heart failure	In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).
UN	11256525_D000809_8_1076_1087_angiotensin_D012078_8_950_971_renal artery stenosis	In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).
UN	11256525_D005665_4_569_579_furosemide_D001002_4_518_524_anuria	Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.
CID	11256525_D019808_0_36_44_losartan_D001002_0_19_25_anuria	Repeated transient anuria following losartan administration in a patient with a solitary kidney.
CID	11256525_D019808_1_258_266_losartan_D001002_1_245_251_anuria	We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.
CID	11256525_D019808_4_488_496_losartan_D001002_4_518_524_anuria	Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.
UN	11256525_D019808_3_422_430_losartan_D006331_3_401_421_systolic dysfunction	Due to severe systolic dysfunction losartan was prescribed.
UN	11256525_D019808_1_258_266_losartan_D006973_1_133_145_hypertensive	We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.
UN	11256525_D019808_10_1319_1327_losartan_D014652_10_1388_1408_renovascular disease	This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.
UN	11256525_D019808_1_258_266_losartan_D051436_1_177_204_chronic renal insufficiency	We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.
UN	11263551_D002118_7_888_895_calcium_D010146_7_930_934_pain	The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.
CID	11263551_D016559_8_1043_1053_tacrolimus_D010146_8_970_974_Pain	The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.
CID	11263551_D016559_7_837_847_tacrolimus_D010146_7_930_934_pain	The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.
CID	11263551_D016572_8_1027_1039_cyclosporine_D010146_8_970_974_Pain	The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.
CID	11263551_D016572_7_820_832_cyclosporine_D010146_7_930_934_pain	The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.
CID	11271907_D003520_0_44_60_cyclophosphamide_D006470_0_6_30_haemorrhagic myocarditis	Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.
CID	11271907_D003520_1_135_151_cyclophosphamide_D006470_1_70_94_Haemorrhagic myocarditis	Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy.
CID	11271907_D003520_0_44_60_cyclophosphamide_D009205_0_6_30_haemorrhagic myocarditis	Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.
CID	11271907_D003520_1_135_151_cyclophosphamide_D009205_1_70_94_Haemorrhagic myocarditis	Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy.
CID	11279304_D003630_10_1402_1405_DNR_D006333_10_1382_1395_heart failure	On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).
UN	11279304_D003630_4_676_679_DNR_D015470_4_641_655_acute leukemia	Thirteen patients with acute leukemia were treated with a DNR-containing regimen.
UN	11279304_D003630_3_579_591_daunorubicin_D015470_3_549_563_acute leukemia	We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.
UN	11279304_D003630_3_579_591_daunorubicin_D066126_3_517_531_cardiotoxicity	We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.
UN	11279304_D018943_2_223_236_anthracycline_D006331_2_337_356_cardiac dysfunction	The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.
UN	11279304_D018943_3_495_508_anthracycline_D015470_3_549_563_acute leukemia	We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.
UN	11279304_D018943_0_44_57_anthracycline_D066126_0_66_80_cardiotoxicity	Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
UN	11279304_D018943_12_1647_1660_anthracycline_D066126_12_1669_1683_cardiotoxicity	These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline-induced cardiotoxicity.
UN	11279304_D018943_2_223_236_anthracycline_D066126_2_192_206_cardiotoxicity	The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.
UN	11279304_D018943_3_495_508_anthracycline_D066126_3_517_531_cardiotoxicity	We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.
UN	11282081_D002118_1_234_236_Ca_D001281_1_209_211_AF	BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.
UN	11282081_D002118_3_477_479_Ca_D001281_3_461_463_AF	METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.
UN	11282081_D002118_2_385_387_Ca_D001281_2_362_364_AF	There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.
UN	11282081_D002118_1_234_236_Ca_D013617_1_107_125_Atrial tachycardia	BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.
UN	11282081_D002698_3_540_550_chloralose_D001281_3_461_463_AF	METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.
UN	11282081_D004110_9_1539_1548_Diltiazem_D001281_9_1569_1571_AF	Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).
UN	11282081_D009020_3_531_539_morphine_D001281_3_461_463_AF	METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.
CID	11282081_D014700_6_794_803_Verapamil_D001281_6_811_813_AF	RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.
CID	11282081_D014700_10_1720_1729_verapamil_D001281_10_1748_1750_AF	In the presence of autonomic blockade, verapamil failed to promote AF and increased, rather than decreasing, refractoriness.
CID	11282081_D014700_0_11_20_verapamil_D001281_0_24_43_atrial fibrillation	Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.
CID	11282081_D014700_12_1938_1947_verapamil_D001281_12_1957_1959_AF	Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.
CID	11282081_D014700_13_2084_2093_Verapamil_D001281_13_2103_2105_AF	CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.
CID	11284996_D005996_5_779_782_GTN_D006261_5_763_771_headache	Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls.
CID	11284996_D005996_3_554_557_GTN_D006261_3_588_596_headache	The subjects were randomly allocated to receive 0.5 microg/kg/min GTN or placebo over 20 min on two headache-free days.
CID	11284996_D005996_2_387_406_glyceryl trinitrate_D006261_2_354_362_headache	In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.
UN	11284996_D005996_2_408_411_GTN_D018781_2_441_462_tension-type headache	In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.
CID	11284996_D009569_1_164_166_NO_D006261_1_176_184_headache	It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).
CID	11284996_D009569_2_378_380_NO_D006261_2_354_362_headache	In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.
CID	11284996_D009569_9_1282_1284_NO_D006261_9_1303_1311_headache	The present study indicates that NO-induced immediate headache is not associated with release of CGRP.
CID	11284996_D009569_0_46_58_nitric oxide_D006261_0_67_75_headache	Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.
UN	11284996_D009569_0_46_58_nitric oxide_D018781_0_101_122_tension-type headache	Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.
UN	11284996_D009569_1_164_166_NO_D051270_1_188_205_primary headaches	It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).
UN	11302406_D011188_4_985_994_potassium_D003866_4_934_944_depression	The possible mechanism is depression of rapidly activating delayed rectifier potassium currents.
UN	11302406_D015725_2_310_321_fluconazole_D003324_2_379_402_coronary artery disease	CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.
UN	11302406_D015725_2_535_546_fluconazole_D006333_2_420_444_congestive heart failure	CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.
UN	11302406_D015725_6_1336_1347_fluconazole_D008133_6_1378_1409_prolongation of the QT interval	CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.
UN	11302406_D015725_5_1262_1273_fluconazole_D008133_5_1079_1094_QT prolongation	In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.
UN	11302406_D015725_2_310_321_fluconazole_D009202_2_404_418_cardiomyopathy	CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.
CID	11302406_D015725_0_0_11_Fluconazole_D016171_0_20_38_torsade de pointes	Fluconazole-induced torsade de pointes.
CID	11302406_D015725_1_72_83_fluconazole_D016171_1_95_113_torsade de pointes	OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.
CID	11302406_D015725_2_535_546_fluconazole_D016171_2_551_554_TDP	CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.
CID	11302406_D015725_3_578_589_fluconazole_D016171_3_560_563_TDP	The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
UN	11302406_D015725_5_1262_1273_fluconazole_D018879_5_1141_1175_premature ventricular contractions	In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.
UN	11302406_D015725_3_578_589_fluconazole_D018879_3_647_681_premature ventricular contractions	The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
CID	1130930_D002512_1_207_225_cephalothin sodium_D007683_1_82_104_acute tubular necrosis	Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.
CID	1130930_D002512_1_207_225_cephalothin sodium_D009846_1_140_162_oliguric renal failure	Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.
CID	1130930_D005839_1_230_248_gentamicin sulfate_D007683_1_82_104_acute tubular necrosis	Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.
CID	1130930_D005839_1_230_248_gentamicin sulfate_D009846_1_140_162_oliguric renal failure	Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.
UN	11334364_C511402_2_520_524_GSPE_D007674_2_565_579_nephrotoxicity	This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.
UN	11334364_C511402_0_207_248_IH636 grape seed proanthocyanidin extract_D008171_0_143_156_lung toxicity	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.
UN	11334364_C511402_10_2083_2087_GSPE_D009336_10_2011_2019_necrosis	Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.
UN	11334364_C511402_0_207_248_IH636 grape seed proanthocyanidin extract_D009336_0_58_66_necrotic	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.
UN	11334364_C511402_7_1675_1679_GSPE_D017695_7_1576_1589_tissue damage	Histopathological examination of kidney, heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence.
UN	11334364_C511402_0_207_248_IH636 grape seed proanthocyanidin extract_D066126_0_181_195_cardiotoxicity	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.
CID	11334364_D000082_0_86_99_acetaminophen_D007674_0_108_122_nephrotoxicity	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.
CID	11334364_D000082_2_552_555_AAP_D007674_2_565_579_nephrotoxicity	This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.
UN	11334364_D000082_0_86_99_acetaminophen_D008171_0_143_156_lung toxicity	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.
CID	11334364_D000082_0_86_99_acetaminophen_D009336_0_58_66_necrotic	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.
UN	11334364_D000082_0_86_99_acetaminophen_D066126_0_181_195_cardiotoxicity	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.
UN	11334364_D000082_2_537_550_acetaminophen_D066126_2_651_665_cardiotoxicity	This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.
UN	11334364_D000638_2_581_591_amiodarone_D007674_2_565_579_nephrotoxicity	This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.
UN	11334364_D000638_0_124_134_amiodarone_D007674_0_108_122_nephrotoxicity	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.
CID	11334364_D000638_0_124_134_amiodarone_D008171_0_143_156_lung toxicity	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.
CID	11334364_D000638_2_593_596_AMI_D008171_2_606_619_lung toxicity	This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.
CID	11334364_D000638_10_1960_1963_AMI_D009336_10_2011_2019_necrosis	Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.
UN	11334364_D000638_0_124_134_amiodarone_D066126_0_181_195_cardiotoxicity	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.
UN	11334364_D004317_0_161_172_doxorubicin_D007674_0_108_122_nephrotoxicity	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.
UN	11334364_D004317_0_161_172_doxorubicin_D008171_0_143_156_lung toxicity	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.
CID	11334364_D004317_10_1968_1971_DOX_D009336_10_2011_2019_necrosis	Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.
CID	11334364_D004317_0_161_172_doxorubicin_D066126_0_181_195_cardiotoxicity	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.
CID	11334364_D004317_2_638_641_DOX_D066126_2_651_665_cardiotoxicity	This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.
UN	11337188_D010068_1_104_113_oxacillin_D011693_1_229_245_purpuric lesions	A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.
UN	11337188_D010068_1_104_113_oxacillin_D013203_1_138_170_Staphylococcus aureus bacteremia	A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.
UN	11337188_D010068_1_104_113_oxacillin_D016470_1_138_170_Staphylococcus aureus bacteremia	A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.
CID	11337188_D010068_10_1055_1064_Oxacillin_D018366_10_1115_1142_leucocytoclastic vasculitis	Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.
CID	11337188_D010068_0_54_63_oxacillin_D018366_0_0_37_Cutaneous leucocytoclastic vasculitis	Cutaneous leucocytoclastic vasculitis associated with oxacillin.
CID	11337188_D010068_1_104_113_oxacillin_D051437_1_182_195_renal failure	A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.
CID	11379838_D000928_0_0_14_Antidepressant_D001714_0_23_28_mania	Antidepressant-induced mania in bipolar patients: identification of risk factors.
CID	11379838_D000928_1_162_177_antidepressants_D001714_1_140_145_mania	BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.
UN	11379838_D008094_3_923_930_lithium_D001714_3_711_716_manic	Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.
CID	11379838_D017367_4_1244_1249_SSRIs_D001714_4_1283_1288_manic	RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.
CID	11379838_D017367_3_849_878_serotonin reuptake inhibitors_D001714_3_711_716_manic	Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.
UN	11391224_D003042_7_1255_1262_cocaine_D005921_7_1231_1249_glomerulonephritis	These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.
UN	11391224_D003042_7_1255_1262_cocaine_D006974_7_1123_1145_malignant hypertension	These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.
UN	11391224_D003042_7_1255_1262_cocaine_D008181_7_1175_1190_lupus nephritis	These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.
UN	11391224_D003042_7_1255_1262_cocaine_D011695_7_1192_1218_Henoch-Schonlein nephritis	These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.
UN	11391224_D003042_7_1255_1262_cocaine_D057049_7_1147_1173_thrombotic microangiopathy	These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.
CID	11391224_D003042_7_1255_1262_cocaine_D058186_7_1271_1290_acute renal failure	These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.
CID	1141447_D008094_1_79_86_lithium_D003919_1_95_113_diabetes insipidus	A case of lithium-induced diabetes insipidus is reported.
CID	1141447_D008094_0_33_40_lithium_D003919_0_49_67_diabetes insipidus	The renal pathology in a case of lithium-induced diabetes insipidus.
UN	11419773_D002110_1_298_306_caffeine_D008945_1_134_155_mitral valve prolapse	We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a "natural energy" guarana health drink containing a high concentration of caffeine.
CID	11419773_D002110_1_298_306_caffeine_D014693_1_182_206_ventricular fibrillation	We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a "natural energy" guarana health drink containing a high concentration of caffeine.
UN	11426838_C093337_5_923_929_BD1063_D012640_5_981_992_convulsions	In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.
CID	11426838_D003042_9_1870_1877_cocaine_D012640_9_1822_1832_convulsive	To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.
CID	11426838_D003042_5_965_972_cocaine_D012640_5_981_992_convulsions	In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.
UN	11426838_D009838_9_1730_1750_oligodeoxynucleotide_D012640_9_1822_1832_convulsive	To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.
CID	11431197_D011899_0_0_10_Ranitidine_D009395_0_25_47_interstitial nephritis	Ranitidine-induced acute interstitial nephritis in a cadaveric renal allograft.
CID	11431197_D011899_4_345_355_ranitidine_D009395_4_370_392_interstitial nephritis	We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.
CID	11467664_D008687_1_157_180_metformin hydrochloride_D041781_1_93_113_cholestatic jaundice	We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.
CID	11467664_D008687_0_48_57_metformin_D041781_0_0_20_Cholestatic jaundice	Cholestatic jaundice associated with the use of metformin.
UN	11467664_D008687_6_652_661_metformin_D056486_6_673_687_hepatotoxicity	Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.
CID	1147734_D011441_1_225_241_propylthiouracil_D006521_1_155_192_chronic active (aggressive) hepatitis	This report presents the clinical, laboratory, and light and electron microscopic observations on a patient with chronic active (aggressive) hepatitis caused by the administration of propylthiouracil.
CID	11524350_C037663_8_1071_1082_ropivacaine_D001145_8_1000_1012_dysrhythmias	The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.
CID	11524350_C037663_11_1466_1477_ropivacaine_D006323_11_1486_1500_cardiac arrest	We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.
CID	11524350_C037663_8_1071_1082_ropivacaine_D006323_8_1017_1025_asystole	The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.
CID	11524350_C037663_7_855_866_ropivacaine_D012640_7_881_889_seizures	The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.
CID	11524350_C476513_8_970_985_levobupivacaine_D001145_8_1000_1012_dysrhythmias	The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.
CID	11524350_C476513_8_970_985_levobupivacaine_D006323_8_1017_1025_asystole	The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.
CID	11524350_C476513_7_835_850_levobupivacaine_D012640_7_881_889_seizures	The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.
UN	11524350_D002045_8_1119_1130_bupivacaine_D001145_8_1000_1012_dysrhythmias	The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.
UN	11524350_D002045_8_1119_1130_bupivacaine_D006323_8_1017_1025_asystole	The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.
UN	11524350_D002045_11_1410_1421_bupivacaine_D006323_11_1486_1500_cardiac arrest	We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.
UN	11524350_D002045_11_1566_1577_bupivacaine_D006323_11_1486_1500_cardiac arrest	We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.
UN	11524350_D002045_7_933_944_bupivacaine_D012640_7_881_889_seizures	The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.
UN	11532387_D004298_5_571_579_dopamine_D001480_5_680_682_RS	The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.
UN	11532387_D004298_5_571_579_dopamine_D013375_5_447_469_withdrawal-emergent RS	The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.
UN	11532387_D012701_5_641_650_serotonin_D001480_5_680_682_RS	The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.
UN	11532387_D012701_5_561_570_serotonin_D013375_5_447_469_withdrawal-emergent RS	The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.
CID	11532387_D018967_0_61_72_risperidone_D001480_0_0_35_Withdrawal-emergent rabbit syndrome	Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.
CID	11532387_D018967_3_323_334_risperidone_D001480_3_295_297_RS	The patient developed RS during dose reduction of risperidone.
CID	11532387_D018967_0_61_72_risperidone_D013375_0_0_35_Withdrawal-emergent rabbit syndrome	Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.
CID	11569530_C010637_4_628_638_terodiline_D016171_4_592_595_TDP	Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.
UN	11569530_C063968_4_654_659_E4031_D016171_4_592_595_TDP	Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.
CID	11569530_D016593_8_1343_1354_terfenadine_D016171_8_1324_1327_TDP	For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.
CID	11569530_D020117_4_640_649_cisapride_D016171_4_592_595_TDP	Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.
CID	11569530_D020117_8_1368_1377_cisapride_D016171_8_1324_1327_TDP	For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.
UN	11573852_D000431_6_820_827_alcohol_D000437_6_805_818_alcohol abuse	The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.
UN	11573852_D000431_6_820_827_alcohol_D012640_6_872_880_seizures	The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.
UN	11573852_D000666_9_1043_1057_amphotericin B_D000163_9_1096_1100_AIDS	The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.
UN	11573852_D000666_1_153_167_amphotericin B_D000163_1_131_135_AIDS	OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.
UN	11573852_D000666_0_0_14_Amphotericin B_D000163_0_50_54_AIDS	Amphotericin B-induced seizures in a patient with AIDS.
UN	11573852_D000666_2_299_313_amphotericin B_D004830_2_249_267_grand mal seizures	CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.
CID	11573852_D000666_1_153_167_amphotericin B_D012640_1_108_115_seizure	OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.
CID	11573852_D000666_0_0_14_Amphotericin B_D012640_0_23_31_seizures	Amphotericin B-induced seizures in a patient with AIDS.
CID	11573852_D000666_4_637_650_amphotercin B_D012640_4_593_601_seizures	Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
CID	11573852_D000666_11_1240_1254_amphotericin B_D012640_11_1215_1223_seizures	To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.
CID	11573852_D000666_9_1043_1057_amphotericin B_D012640_9_1079_1087_seizures	The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.
CID	11573852_D000666_10_1123_1137_Amphotericin B_D012640_10_1176_1184_seizures	CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.
UN	11573852_D008140_4_578_587_lorazepam_D012640_4_593_601_seizures	Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
UN	11573852_D010672_4_564_573_phenytoin_D012640_4_593_601_seizures	Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
UN	11573852_D016049_7_882_892_Didanosine_D012640_7_927_935_seizures	Didanosine also has a potential for inducing seizures.
CID	11581460_D005283_4_754_762_fentanyl_D001745_4_623_648_urinary bladder retention	Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.
CID	11581460_D005283_3_499_507_fentanyl_D001919_3_593_604_bradycardia	Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.
UN	11581460_D005283_4_754_762_fentanyl_D006869_4_701_715_hydronephrosis	Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.
CID	11581460_D005283_3_499_507_fentanyl_D007022_3_552_563_hypotension	Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.
UN	11581460_D005283_3_499_507_fentanyl_D009127_3_531_550_chest wall rigidity	Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.
CID	11581460_D005283_3_499_507_fentanyl_D012131_3_565_587_respiratory depression	Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.
CID	11581460_D005283_0_77_85_fentanyl_D016055_0_8_26_retention of urine	Bladder retention of urine as a result of continuous intravenous infusion of fentanyl: 2 case reports.
UN	11583940_C063008_5_716_737_mycophenolate mofetil_D007674_5_773_787_nephrotoxicity	Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.
UN	11583940_D020123_5_753_762_rapamycin_D007674_5_773_787_nephrotoxicity	Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.
UN	11587867_D014750_0_56_66_vincristin_D001927_0_6_25_myeloencephalopathy	Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.
CID	11587867_D014750_4_700_711_vincristine_D003711_4_608_640_degeneration of myelin and axons	Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.
CID	11587867_D014750_4_700_711_vincristine_D009410_4_608_640_degeneration of myelin and axons	Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.
UN	11587867_D014750_1_161_172_vincristine_D054198_1_222_250_acute lymphoblastic leucemia	We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.
UN	11642480_D015283_2_225_235_citalopram_D003865_2_262_278_major depression	We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.
UN	11642480_D015283_0_49_59_citalopram_D003866_0_25_34_depressed	Palpebral twitching in a depressed adolescent on citalopram.
CID	11642480_D015283_0_49_59_citalopram_D004409_0_0_19_Palpebral twitching	Palpebral twitching in a depressed adolescent on citalopram.
UN	11672959_D012460_1_194_208_sulphasalazine_D001172_1_227_247_rheumatoid arthritis	A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.
CID	11672959_D012460_1_194_208_sulphasalazine_D003872_1_98_108_dermatitis	A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.
CID	11672959_D012460_1_194_208_sulphasalazine_D005334_1_110_115_fever	A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.
CID	11672959_D012460_1_194_208_sulphasalazine_D008206_1_117_132_lymphadenopathy	A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.
CID	11672959_D012460_1_194_208_sulphasalazine_D056486_1_137_146_hepatitis	A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.
UN	11679859_D011346_15_2201_2217_prochlorperazine_D006261_15_2238_2246_headache	The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration, although no formal statistical comparisons were made.
UN	11679859_D011346_3_514_530_prochlorperazine_D006261_3_535_543_headache	Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion.
UN	11679859_D011346_15_2201_2217_prochlorperazine_D009325_15_2251_2257_nausea	The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration, although no formal statistical comparisons were made.
UN	11679859_D011346_3_514_530_prochlorperazine_D014839_3_556_564_vomiting	Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion.
CID	11679859_D011346_14_2055_2071_prochlorperazine_D017109_14_2040_2049_akathisia	CONCLUSION: A 50% reduction in the incidence of akathisia when prochlorperazine was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected.
CID	11679859_D011346_1_276_292_prochlorperazine_D017109_1_230_239_akathisia	STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.
CID	11694026_C012655_8_1371_1381_nimesulide_D000799_8_1436_1446_angioedema	Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.
CID	11694026_D000082_8_1386_1397_paracetamol_D000799_8_1436_1446_angioedema	Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.
CID	11694026_D000082_0_31_42_paracetamol_D000799_0_84_94_angioedema	Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.
CID	11694026_D000894_4_758_763_NSAID_D000799_4_782_792_angioedema	A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.
CID	11694026_D000894_2_462_467_NSAID_D000799_2_486_496_angioedema	In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.
CID	11694026_D000894_8_1457_1463_NSAIDs_D000799_8_1436_1446_angioedema	Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.
CID	11694026_D000894_9_1621_1626_NSAID_D000799_9_1635_1645_angioedema	However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of NSAID-induced angioedema.
CID	11694026_D000894_7_1171_1176_NSAID_D000799_7_1195_1205_angioedema	Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.
CID	11694026_D000894_0_60_65_NSAID_D000799_0_84_94_angioedema	Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.
UN	11704023_D013999_3_475_482_timolol_D005901_3_628_636_glaucoma	DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.
UN	11704023_D013999_0_44_51_timolol_D005901_0_129_137_glaucoma	Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma.
UN	11704023_D013999_4_954_961_timolol_D005902_4_736_755_open-angle glaucoma	METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).
UN	11704023_D013999_4_954_961_timolol_D009798_4_759_778_ocular hypertension	METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).
CID	11705128_D012254_2_459_468_ribavirin_D000743_2_477_493_hemolytic anemia	Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).
CID	11705128_D012254_13_1629_1638_ribavirin_D000743_13_1660_1664_RIHA	Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real-world population.
CID	11705128_D012254_0_26_35_ribavirin_D000743_0_44_60_hemolytic anemia	Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.
CID	11705128_D012254_8_1140_1149_ribavirin_D000743_8_1096_1100_RIHA	The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage.
UN	11705128_D012254_0_26_35_ribavirin_D006526_0_81_92_hepatitis C	Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.
UN	11705128_D012254_1_281_290_ribavirin_D019698_1_354_373_chronic hepatitis C	OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).
UN	11705128_D016898_1_305_321_interferon-alpha_D019698_1_354_373_chronic hepatitis C	OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).
UN	11706060_D002118_3_757_764_calcium_D009202_3_678_680_CM	At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.
UN	11706060_D015215_2_479_489_zidovudine_D000163_2_369_373_AIDS	To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.
UN	11706060_D019259_2_491_501_lamivudine_D000163_2_369_373_AIDS	To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.
UN	11706060_D019344_0_74_81_lactate_D000163_0_96_100_AIDS	Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.
UN	11706060_D019344_12_1507_1509_LA_D000163_12_1513_1517_AIDS	Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.
UN	11706060_D019344_1_221_223_LA_D000163_1_228_232_AIDS	Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.
UN	11706060_D019344_12_1507_1509_LA_D009202_12_1490_1492_CM	Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.
UN	11706060_D019344_1_212_219_lactate_D009202_1_185_187_CM	Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.
UN	11706060_D019344_0_74_81_lactate_D009202_0_39_53_cardiomyopathy	Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.
UN	11706060_D019344_1_221_223_LA_D028361_1_255_280_mitochondrial dysfunction	Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.
UN	11706060_D019469_2_507_516_indinavir_D000163_2_369_373_AIDS	To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.
UN	11745184_D002945_7_1124_1133_cisplatin_D001943_7_1204_1220_breast carcinoma	METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.
UN	11745184_D002945_0_20_29_cisplatin_D001943_0_71_87_breast carcinoma	A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
CID	11745184_D002945_3_502_511_cisplatin_D006311_3_535_546_ototoxicity	Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.
CID	11745184_D002945_6_1000_1009_cisplatin_D006311_6_1034_1045_ototoxicity	Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.
CID	11745184_D002945_6_1000_1009_cisplatin_D007674_6_1018_1032_nephrotoxicity	Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.
UN	11745184_D002945_19_2327_2336_cisplatin_D009369_19_2216_2221_tumor	Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.
CID	11745184_D002945_6_1000_1009_cisplatin_D009422_6_1051_1061_neuropathy	Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.
UN	11745184_D002945_3_502_511_cisplatin_D020258_3_552_565_neurotoxicity	Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.
UN	11745184_D004999_0_44_54_amifostine_D001943_0_71_87_breast carcinoma	A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
UN	11745184_D004999_7_1139_1149_amifostine_D001943_7_1204_1220_breast carcinoma	METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.
UN	11745184_D004999_6_939_949_amifostine_D006311_6_1034_1045_ototoxicity	Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.
UN	11745184_D004999_6_939_949_amifostine_D007674_6_1018_1032_nephrotoxicity	Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.
UN	11745184_D004999_19_2313_2323_amifostine_D009369_19_2216_2221_tumor	Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.
UN	11745184_D004999_6_939_949_amifostine_D009422_6_1051_1061_neuropathy	Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.
UN	11752354_C033273_2_331_340_gestodene_D009203_2_633_654_myocardial infarction	We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.
CID	11752354_D003276_1_105_124_oral contraceptives_D009203_1_141_162_myocardial infarction	BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.
CID	11752354_D003276_0_0_19_Oral contraceptives_D009203_0_36_57_myocardial infarction	Oral contraceptives and the risk of myocardial infarction.
CID	11752354_D003276_6_1822_1841_oral contraceptives_D009203_6_1747_1768_myocardial infarction	Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.
CID	11752354_D003276_4_1141_1159_oral contraceptive_D009203_4_1077_1098_myocardial infarction	An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).
CID	11752354_D003276_8_2111_2130_oral contraceptives_D009203_8_2056_2077_myocardial infarction	The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.
UN	11752354_D004967_2_420_428_estrogen_D009203_2_633_654_myocardial infarction	We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.
UN	11752354_D011372_2_268_279_progestagen_D009203_2_633_654_myocardial infarction	We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.
UN	11752354_D016912_2_371_385_levonorgestrel_D009203_2_633_654_myocardial infarction	We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.
UN	11752354_D017135_2_316_327_desogestrel_D009203_2_633_654_myocardial infarction	We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.
UN	11752998_D000241_1_328_337_adenosine_D004342_1_370_386_hypersensitivity	BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.
UN	11752998_D000241_7_1523_1532_adenosine_D004342_7_1536_1552_hypersensitivity	CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.
UN	11752998_D000241_5_1173_1182_Adenosine_D006930_5_1278_1301_mechanical hyperalgesia	RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h.
UN	11752998_D000241_8_1807_1816_adenosine_D009437_8_1749_1765_neuropathic pain	The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.
UN	11752998_D000241_5_1173_1182_Adenosine_D010146_5_1205_1209_pain	RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h.
UN	11752998_D000241_1_155_164_adenosine_D059350_1_213_235_acute and chronic pain	BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.
UN	11752998_D000241_1_155_164_adenosine_D059787_1_213_235_acute and chronic pain	BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.
UN	11752998_D002211_2_588_597_capsaicin_D004342_2_616_632_hypersensitivity	The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.
CID	11752998_D002211_4_1127_1136_capsaicin_D006930_4_1099_1108_allodynia	Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.
CID	11752998_D002211_5_1333_1342_capsaicin_D006930_5_1306_1315_allodynia	RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h.
UN	11752998_D002211_4_1127_1136_capsaicin_D010146_4_1011_1015_pain	Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.
UN	11752998_D002211_5_1333_1342_capsaicin_D010146_5_1205_1209_pain	RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h.
UN	11773892_D003404_16_2499_2509_creatinine_D006530_16_2538_2558_hepatorenal syndrome	Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.
UN	11773892_D003404_16_2499_2509_creatinine_D007676_16_2450_2454_ESRD	Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.
UN	11773892_D003404_10_1293_1303_creatinine_D007676_10_1249_1253_ESRD	Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.
CID	11773892_D016559_1_207_217_tacrolimus_D007674_1_239_250_nephrotoxic	BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.
CID	11773892_D016572_1_190_202_cyclosporine_D007674_1_239_250_nephrotoxic	BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.
CID	11807648_D014148_9_1085_1090_tAMCA_D012640_9_1033_1041_seizures	The degree of these seizures increased with increasing concentration of tAMCA.
CID	11807648_D014148_12_1410_1425_Tranexamic acid_D012640_12_1438_1448_convulsive	INTERPRETATION: Tranexamic acid retains its convulsive action within FS.
CID	11807648_D014148_5_517_522_tAMCA_D012640_5_535_545_convulsive	We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS.
CID	11807648_D014148_8_916_921_tAMCA_D012640_8_990_1000_convulsive	FINDINGS: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours.
CID	11807648_D014148_10_1123_1128_tAMCA_D012640_10_1136_1156_generalized seizures	Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.
CID	11827497_D006493_1_121_128_heparin_D001157_1_155_187_arterial or venous thromboemboli	BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.
CID	11827497_D006493_2_226_233_heparin_D013921_2_242_258_thrombocytopenia	Delayed recognition and treatment of heparin-induced thrombocytopenia contribute to poor patient outcomes.
CID	11827497_D006493_3_405_412_heparin_D013921_3_421_437_thrombocytopenia	OBJECTIVE: To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin-induced thrombocytopenia are delayed.
CID	11827497_D006493_0_14_21_heparin_D013921_0_30_46_thrombocytopenia	Delayed-onset heparin-induced thrombocytopenia.
CID	11827497_D006493_1_60_67_Heparin_D013921_1_76_92_thrombocytopenia	BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.
CID	11827497_D006493_16_1999_2006_heparin_D013921_16_2015_2031_thrombocytopenia	To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.
CID	11827497_D006493_15_1877_1884_heparin_D013921_15_1893_1909_thrombocytopenia	CONCLUSIONS: Delayed-onset heparin-induced thrombocytopenia is increasingly being recognized.
CID	11827497_D006493_6_626_633_heparin_D013921_6_642_658_thrombocytopenia	PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications.
CID	11827497_D006493_1_121_128_heparin_D054556_1_155_187_arterial or venous thromboemboli	BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.
UN	11838826_C047047_6_1066_1077_cabergoline_D001523_6_884_900_Mental Disorders	RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).
UN	11838826_C047047_6_1066_1077_cabergoline_D001714_6_918_934_bipolar disorder	RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).
UN	11838826_C047047_4_646_657_cabergoline_D006966_4_622_640_hyperprolactinemia	We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.
UN	11838826_C047047_5_792_803_cabergoline_D006966_5_760_778_hyperprolactinemia	METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.
UN	11838826_C047047_6_1066_1077_cabergoline_D011605_6_938_947_psychoses	RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).
UN	11838826_D004298_0_59_67_dopamine_D006966_0_33_51_hyperprolactinemia	Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.
UN	11838826_D018967_6_954_965_risperidone_D001523_6_884_900_Mental Disorders	RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).
UN	11838826_D018967_6_954_965_risperidone_D001714_6_918_934_bipolar disorder	RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).
CID	11838826_D018967_4_602_613_risperidone_D006966_4_622_640_hyperprolactinemia	We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.
CID	11838826_D018967_10_1538_1549_risperidone_D006966_10_1558_1576_hyperprolactinemia	CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.
CID	11838826_D018967_5_740_751_risperidone_D006966_5_760_778_hyperprolactinemia	METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.
CID	11838826_D018967_0_13_24_risperidone_D006966_0_33_51_hyperprolactinemia	Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.
UN	11838826_D018967_6_954_965_risperidone_D011605_6_938_947_psychoses	RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).
UN	11847945_D004177_4_471_479_dipyrone_D000699_4_484_493_analgesia	No other medications were involved except for dipyrone for analgesia.
CID	11847945_D007530_0_46_56_isoflurane_D002779_0_6_27_cholestatic hepatitis	Acute cholestatic hepatitis after exposure to isoflurane.
CID	11847945_D007530_1_167_177_isoflurane_D002779_1_95_116_cholestatic hepatitis	OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.
CID	11847945_D007530_0_46_56_isoflurane_D056486_0_6_27_cholestatic hepatitis	Acute cholestatic hepatitis after exposure to isoflurane.
CID	11847945_D007530_1_167_177_isoflurane_D056486_1_95_116_cholestatic hepatitis	OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.
CID	11858397_D004917_4_651_663_erythromycin_D016171_4_613_631_torsade de pointes	This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.
UN	11858397_D008787_0_30_44_metoclopramide_D002037_0_91_115_left bundle branch block	Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.
CID	11858397_D008787_3_569_583_metoclopramide_D016171_3_505_523_torsade de pointes	We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.
CID	11858397_D008787_0_30_44_metoclopramide_D016171_0_0_18_Torsade de pointes	Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.
CID	11858397_D008787_6_850_864_metoclopramide_D016171_6_874_892_torsade de pointes	This is the first documentation that metoclopramide provokes torsade de pointes clinically.
CID	11858397_D020117_4_637_646_cisapride_D016171_4_613_631_torsade de pointes	This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.
UN	11860278_D000109_8_1100_1113_acetylcholine_D012640_8_1061_1069_seizures	Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.
UN	11860278_D004298_3_428_430_DA_D004827_3_462_470_epilepsy	In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.
CID	11860278_D007608_7_1007_1009_KA_D012640_7_908_916_seizures	However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.
CID	11860278_D010862_7_888_899_pilocarpine_D012640_7_908_916_seizures	However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.
UN	11860278_D010862_4_614_625_pilocarpine_D020258_4_547_560_neurotoxicity	Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.
UN	11860278_D018698_8_1086_1095_glutamate_D012640_8_1061_1069_seizures	Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.
UN	11860495_C018370_0_87_108_pregnenolone sulphate_D000647_0_68_75_amnesic	Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.
UN	11860495_C018370_4_708_713_PREGS_D000647_4_737_744_amnesic	Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.
UN	11860495_D005680_4_771_775_GABA_D000647_4_737_744_amnesic	Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.
CID	11860495_D012601_10_1936_1947_scopolamine_D000647_10_1956_1963_amnesia	Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.
CID	11860495_D012601_7_1427_1438_scopolamine_D000647_7_1447_1454_amnesia	The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.
UN	11860495_D013256_0_0_7_Steroid_D000647_0_68_75_amnesic	Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.
UN	11861791_C434926_8_1139_1143_PJ34_D006331_8_1167_1186_cardiac dysfunction	Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.
UN	11861791_D004317_11_1596_1599_DOX_D005117_11_1554_1575_cardiac complications	PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.
CID	11861791_D004317_0_72_83_doxorubicin_D006333_0_92_105_heart failure	Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.
UN	11861791_D004317_3_538_541_DOX_D066126_3_550_564_cardiotoxicity	Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.
UN	11861791_D004317_2_397_408_doxorubicin_D066126_2_379_393_cardiotoxicity	Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.
UN	11861791_D004317_10_1470_1473_DOX_D066126_10_1452_1466_cardiotoxicity	Thus, PARP activation contributes to the cardiotoxicity of DOX.
UN	11861791_D011064_0_14_30_poly(ADP-ribose)_D006333_0_92_105_heart failure	Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.
UN	11861791_D018943_2_440_453_anthracycline_D066126_2_379_393_cardiotoxicity	Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.
UN	11868798_D000666_5_751_754_AmB_D006402_5_681_704_hematological disorders	METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.
CID	11868798_D000666_0_57_71_amphotericin B_D007008_0_80_91_hypokalemia	Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?
CID	11868798_D000666_4_618_621_AmB_D007008_4_579_590_hypokalemia	This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.
CID	11868798_D000666_9_1516_1519_AmB_D007008_9_1442_1453_hypokalemia	CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.
UN	11868798_D000666_1_169_183_amphotericin B_D007674_1_123_137_Nephrotoxicity	OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.
UN	11868798_D000666_5_764_767_AmB_D009181_5_849_865_fungal infection	METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.
UN	11868798_D000666_0_57_71_amphotericin B_D009369_0_95_101_cancer	Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?
UN	11868798_D000666_4_618_621_AmB_D009503_4_594_605_neutropenic	This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.
UN	11868798_D000666_9_1516_1519_AmB_D009503_9_1492_1503_neutropenic	CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.
UN	11868798_D011188_9_1407_1416_potassium_D007008_9_1442_1453_hypokalemia	CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.
UN	11868798_D011188_9_1474_1483_potassium_D007008_9_1442_1453_hypokalemia	CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.
UN	11868798_D011188_4_541_550_potassium_D007008_4_579_590_hypokalemia	This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.
UN	11868798_D011188_4_541_550_potassium_D009503_4_594_605_neutropenic	This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.
UN	11868798_D011188_9_1474_1483_potassium_D009503_9_1492_1503_neutropenic	CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.
UN	11868798_D013148_5_777_791_spironolactone_D006402_5_681_704_hematological disorders	METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.
UN	11868798_D013148_9_1381_1395_spironolactone_D007008_9_1442_1453_hypokalemia	CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.
UN	11868798_D013148_4_516_530_spironolactone_D007008_4_579_590_hypokalemia	This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.
UN	11868798_D013148_5_777_791_spironolactone_D009181_5_849_865_fungal infection	METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.
UN	11868798_D013148_0_0_14_Spironolactone_D009369_0_95_101_cancer	Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?
UN	11868798_D013148_4_516_530_spironolactone_D009503_4_594_605_neutropenic	This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.
UN	11897407_C067171_3_452_467_99mTc-glucarate_D007238_3_337_344_infarct	A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ. 99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.
UN	11897407_C067171_0_0_15_99mTc-glucarate_D009203_0_55_76_myocardial infarction	99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.
UN	11897407_D005937_3_379_392_glucaric acid_D007238_3_337_344_infarct	A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ. 99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.
UN	11897407_D005937_3_379_392_glucaric acid_D009203_3_588_609_myocardial infarction	A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ. 99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.
UN	11897407_D007545_4_691_704_isoproterenol_D007238_4_672_679_infarct	Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.
CID	11897407_D007545_3_560_573_isoproterenol_D009203_3_588_609_myocardial infarction	A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ. 99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.
CID	11897407_D007545_0_33_46_isoproterenol_D009203_0_55_76_myocardial infarction	99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.
UN	11900788_D001285_5_485_493_atropine_D002375_5_538_547_catalepsy	Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.
UN	11900788_D008464_4_338_350_mecamylamine_D002375_4_386_395_catalepsy	Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.
CID	11900788_D009020_4_424_432_morphine_D002375_4_386_395_catalepsy	Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.
CID	11900788_D009020_1_127_135_morphine_D002375_1_106_115_catalepsy	In the present study, effects of nicotine on catalepsy induced by morphine in mice have been investigated.
CID	11900788_D009020_2_168_176_Morphine_D002375_2_219_228_catalepsy	Morphine but not nicotine induced a dose-dependent catalepsy.
CID	11900788_D009020_0_25_33_morphine_D002375_0_42_51_catalepsy	Nicotine potentiation of morphine-induced catalepsy in mice.
CID	11900788_D009020_7_779_787_morphine_D002375_7_788_797_catalepsy	It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.
CID	11900788_D009020_5_559_567_morphine_D002375_5_538_547_catalepsy	Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.
UN	11900788_D009270_5_514_522_naloxone_D002375_5_538_547_catalepsy	Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.
CID	11900788_D009538_0_0_8_Nicotine_D002375_0_42_51_catalepsy	Nicotine potentiation of morphine-induced catalepsy in mice.
CID	11900788_D009538_5_573_581_nicotine_D002375_5_538_547_catalepsy	Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.
CID	11900788_D009538_1_94_102_nicotine_D002375_1_106_115_catalepsy	In the present study, effects of nicotine on catalepsy induced by morphine in mice have been investigated.
CID	11900788_D009538_2_185_193_nicotine_D002375_2_219_228_catalepsy	Morphine but not nicotine induced a dose-dependent catalepsy.
CID	11900788_D009538_4_438_446_nicotine_D002375_4_386_395_catalepsy	Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.
UN	11900788_D018738_4_356_369_hexamethonium_D002375_4_386_395_catalepsy	Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.
CID	11912119_D007980_0_19_27_levodopa_D004409_0_36_47_dyskinesias	Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
CID	11912119_D007980_2_362_370_levodopa_D004409_2_379_390_dyskinesias	We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.
CID	11912119_D007980_1_219_227_levodopa_D004409_1_236_247_dyskinesias	We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).
UN	11912119_D007980_1_185_193_levodopa_D010300_1_118_137_Parkinson's disease	We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).
UN	11912119_D007980_0_19_27_levodopa_D010300_0_51_70_Parkinson's disease	Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
UN	11912119_D007980_2_362_370_levodopa_D010300_2_392_411_Parkinson's disease	We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.
UN	11928786_D000241_8_935_944_adenosine_D012640_8_839_847_seizures	Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.
UN	11928786_D000241_8_935_944_adenosine_D013610_8_893_904_tachycardia	Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.
UN	11928786_D003975_8_866_874_diazepam_D012640_8_839_847_seizures	Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.
UN	11928786_D003975_8_866_874_diazepam_D013610_8_893_904_tachycardia	Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.
UN	11928786_D016642_9_946_951_Zyban_D020258_9_971_1011_neurological and cardiovascular toxicity	Zyban caused significant neurological and cardiovascular toxicity in overdose.
UN	11928786_D016642_9_946_951_Zyban_D062787_9_1015_1023_overdose	Zyban caused significant neurological and cardiovascular toxicity in overdose.
UN	11961407_D011692_6_849_852_PAN_D005921_6_1021_1039_glomerulosclerosis	Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).
CID	11961407_D011692_0_52_55_PAN_D009401_0_56_65_nephrosis	GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.
CID	11961407_D011692_5_646_671_Puromycin aminonucleoside_D009401_5_672_681_nephrosis	Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).
CID	11961407_D011692_6_849_852_PAN_D011507_6_904_915_proteinuria	Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).
UN	11961407_D014443_0_16_24_tyrosine_D009401_0_56_65_nephrosis	GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.
UN	11999899_D001058_7_1035_1045_apomophine_D009069_7_1107_1122_oral dyskinesia	Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.
CID	11999899_D012110_5_856_865_reserpine_D002375_5_835_844_catalepsy	MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.
CID	11999899_D012110_4_605_614_Reserpine_D002375_4_640_649_catalepsy	Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.
CID	11999899_D012110_9_1310_1319_reserpine_D002375_9_1278_1287_catalepsy	MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.
CID	11999899_D012110_8_1151_1160_reserpine_D002375_8_1193_1202_catalepsy	On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
CID	11999899_D012110_11_1628_1637_reserpine_D004409_11_1661_1679_abnormal movements	These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.
UN	11999899_D012110_4_605_614_Reserpine_D010300_4_681_700_Parkinson's disease	Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.
UN	11999899_D012110_11_1628_1637_reserpine_D010300_11_1754_1766_parkinsonian	These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.
CID	11999899_D012110_8_1151_1160_reserpine_D014202_8_1182_1188_tremor	On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
CID	11999899_D012110_9_1310_1319_reserpine_D014202_9_1292_1298_tremor	MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.
CID	11999899_D012110_4_605_614_Reserpine_D014202_4_629_635_tremor	Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.
CID	11999899_D012110_6_938_947_reserpine_D014202_6_928_934_tremor	However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.
UN	11999899_D016202_12_1841_1845_NMDA_D002375_12_1926_1935_catalepsy	The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model.
UN	11999899_D016202_12_1841_1845_NMDA_D014202_12_1940_1946_tremor	The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model.
UN	11999899_D016291_10_1517_1523_MK-801_D002375_10_1498_1507_catalepsy	Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.
UN	11999899_D016291_9_1229_1235_MK-801_D002375_9_1278_1287_catalepsy	MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.
UN	11999899_D016291_5_702_708_MK-801_D002375_5_835_844_catalepsy	MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.
UN	11999899_D016291_6_876_882_MK-801_D014202_6_928_934_tremor	However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.
UN	12013711_D008238_1_176_179_LSD_D001480_1_219_222_EPS	Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.
UN	12013711_D008238_0_110_113_LSD_D010468_0_41_60_visual disturbances	Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.
UN	12013711_D008238_3_533_536_LSD_D010468_3_457_476_visual disturbances	This imagery resembled visual disturbances previously experienced as "flashbacks" related to prior LSD consumption.
UN	12013711_D008238_0_110_113_LSD_D012559_0_64_77_schizophrenic	Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.
UN	12013711_D018967_1_283_294_risperidone_D001480_1_219_222_EPS	Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.
CID	12013711_D018967_4_550_561_Risperidone_D010468_4_599_618_visual disturbances	Risperidone administration was continued and the visual disturbances gradually wore off.
UN	12013711_D018967_0_0_11_Risperidone_D012559_0_64_77_schizophrenic	Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.
UN	12041669_D000961_1_107_129_antithymocyte globulin_D000741_1_142_157_aplastic anemia	A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.
UN	12041669_D000961_0_0_22_Antithymocyte globulin_D000741_0_67_82_aplastic anemia	Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.
CID	12041669_D010396_3_487_502_D-penicillamine_D000741_3_511_526_aplastic anemia	Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.
CID	12041669_D010396_1_165_180_D-penicillamine_D000741_1_142_157_aplastic anemia	A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.
CID	12041669_D010396_0_43_58_D-penicillamine_D000741_0_67_82_aplastic anemia	Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.
UN	12042105_C020243_3_494_511_calcium phosphate_D053040_3_512_527_nephrolithiasis	In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.
UN	12042105_C052342_1_36_46_Topiramate_D004827_1_172_191_refractory seizures	Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.
CID	12042105_C052342_0_0_10_Topiramate_D053040_0_19_34_nephrolithiasis	Topiramate-induced nephrolithiasis.
CID	12042105_C052342_4_562_572_topiramate_D053040_4_581_596_nephrolithiasis	We report the first two cases of topiramate-induced nephrolithiasis in the urologic literature.
UN	12063090_D002606_2_450_458_charcoal_D010146_2_400_404_pain	On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.
UN	12063090_D004177_0_0_9_Metamizol_D003248_0_55_67_constipation	Metamizol potentiates morphine antinociception but not constipation after chronic treatment.
UN	12063090_D004177_7_1550_1559_metamizol_D003248_7_1596_1608_constipation	The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.
UN	12063090_D004177_8_1677_1686_metamizol_D059350_8_1786_1798_chronic pain	These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.
CID	12063090_D009020_7_1579_1587_morphine_D003248_7_1596_1608_constipation	The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.
CID	12063090_D009020_0_22_30_morphine_D003248_0_55_67_constipation	Metamizol potentiates morphine antinociception but not constipation after chronic treatment.
UN	12063090_D009020_8_1664_1672_morphine_D059350_8_1786_1798_chronic pain	These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.
CID	12084448_D007069_0_0_10_Ifosfamide_D001927_0_11_25_encephalopathy	Ifosfamide encephalopathy presenting with asterixis.
CID	12084448_D007069_7_1139_1142_IFX_D009207_7_1099_1108_myoclonus	In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.
UN	12084448_D007069_2_347_357_ifosfamide_D010954_2_362_374_plasmacytoma	We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.
CID	12090760_D015215_0_65_79_azidothymidine_D000740_0_88_94_anemia	Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine-induced anemia and in bone marrow endothelial cells.
CID	12090760_D015215_1_149_152_AZT_D000740_1_162_168_anemia	Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).
UN	12091028_D003975_5_871_879_Diazepam_D006212_5_1086_1100_hallucinations	Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations.
CID	12091028_D007649_5_963_971_ketamine_D006212_5_1086_1100_hallucinations	Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations.
UN	12093990_C059262_9_1313_1322_cidofovir_D000257_9_1333_1353_adenovirus infection	The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.
CID	12093990_C059262_20_2576_2585_cidofovir_D009503_20_2647_2658_neutropenia	Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.
CID	12093990_C059262_20_2576_2585_cidofovir_D058186_20_2617_2642_progressive renal failure	Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.
UN	12093990_D012254_0_12_21_ribavirin_D000257_0_43_61_adenovirus disease	Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.
UN	12093990_D012254_10_1493_1502_ribavirin_D000257_10_1522_1540_adenovirus disease	OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.
UN	12093990_D012254_24_3416_3425_ribavirin_D000257_24_3372_3390_adenovirus disease	CONCLUSIONS: Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered.
UN	12093990_D012254_11_1713_1722_ribavirin_D000257_11_1745_1763_adenovirus disease	DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.
UN	12093990_D012254_22_2932_2941_ribavirin_D000257_22_2989_3007_adenovirus disease	Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.
UN	12093990_D012254_8_1265_1274_ribavirin_D000740_8_1294_1300_anemia	The most common adverse effect of intravenous ribavirin is reversible mild anemia.
UN	12093990_D012254_7_1136_1145_ribavirin_D006482_7_1177_1217_infection with hemorrhagic fever viruses	Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
UN	12093990_D012254_7_1136_1145_ribavirin_D006526_7_1111_1122_hepatitis C	Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
UN	12093990_D012254_22_2932_2941_ribavirin_D007239_22_3117_3126_infection	Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.
UN	12093990_D012254_7_962_971_Ribavirin_D018357_7_1021_1058_respiratory syncytial virus infection	Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
UN	12101159_D000082_1_183_194_paracetamol_D062787_1_140_148_overdose	A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.
UN	12101159_D000431_1_229_236_alcohol_D062787_1_140_148_overdose	A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.
UN	12101159_D001241_1_196_203_aspirin_D062787_1_140_148_overdose	A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.
UN	12101159_D002118_0_100_107_calcium_D006323_0_18_32_cardiac arrest	Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.
UN	12101159_D002118_7_815_822_calcium_D062787_7_851_859_overdose	This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.
CID	12101159_D004110_0_39_48_diltiazem_D006323_0_18_32_cardiac arrest	Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.
CID	12101159_D004110_8_965_974_diltiazem_D006323_8_944_958_cardiac arrest	It should be considered early in cases of cardiac arrest after diltiazem overdose.
CID	12101159_D004110_0_39_48_diltiazem_D062787_0_49_57_overdose	Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.
CID	12101159_D004110_8_965_974_diltiazem_D062787_8_975_983_overdose	It should be considered early in cases of cardiac arrest after diltiazem overdose.
CID	12101159_D004110_7_841_850_diltiazem_D062787_7_851_859_overdose	This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.
UN	12101159_D007547_1_205_215_isosorbide_D062787_1_140_148_overdose	A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.
UN	12101159_D009566_1_216_223_nitrate_D062787_1_140_148_overdose	A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.
CID	12139551_D008787_6_756_770_metoclopramide_D006323_6_731_745_cardiac arrest	We interpret this as episodes of cardiac arrest caused by metoclopramide.
CID	12139551_D008787_1_197_211_metoclopramide_D006323_1_240_248_asystole	We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly.
CID	12139551_D008787_0_33_47_metoclopramide_D006323_0_0_14_Cardiac arrest	Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.
CID	12139551_D008787_3_454_468_metoclopramide_D006323_3_508_516_asystole	After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of metoclopramide was immediately (within s) followed by asystole.
UN	12180796_D009569_1_367_379_nitric oxide_D001167_1_223_232_Arteritis	Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).
UN	12180796_D009569_0_47_59_nitric oxide_D001167_0_151_160_arteritis	Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.
UN	12180796_D009569_0_47_59_nitric oxide_D009369_0_110_115_tumor	Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.
UN	12180796_D009569_1_367_379_nitric oxide_D009369_1_439_444_tumor	Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).
CID	12180796_D013806_0_195_207_theophylline_D001167_0_151_160_arteritis	Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.
UN	12180796_D013806_1_281_293_theophylline_D009369_1_439_444_tumor	Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).
UN	12180796_D013806_0_195_207_theophylline_D009369_0_110_115_tumor	Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.
CID	12180796_D018818_0_180_190_fenoldopam_D001167_0_151_160_arteritis	Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.
UN	12180796_D018818_1_266_276_fenoldopam_D009369_1_439_444_tumor	Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).
UN	12180796_D018818_0_180_190_fenoldopam_D009369_0_110_115_tumor	Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.
UN	12198388_D000109_7_1136_1139_ACh_D012640_7_1194_1205_convulsions	Hippocampal ACh also was measured during testing for handling-induced convulsions.
UN	12198388_D000109_11_1637_1640_ACh_D012640_11_1690_1701_convulsions	When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.
UN	12198388_D000109_0_37_50_acetylcholine_D012640_0_112_119_seizure	The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines.
UN	12198388_D000431_12_1976_1983_ethanol_D012640_12_1941_1952_convulsants	CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.
UN	12198388_D000431_3_660_667_alcohol_D012640_3_686_693_Seizure	METHODS: Cholinergic convulsant sensitivity was examined in alcohol-na  ve Withdrawal Seizure-Prone (WSP) and-Resistant (WSR) mice.
CID	12198388_D002217_8_1281_1290_carbachol_D012640_8_1239_1249_convulsion	RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.
UN	12198388_D002217_4_768_777_carbachol_D014202_4_854_860_tremor	Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.
CID	12198388_D009388_8_1296_1307_neostigmine_D012640_8_1239_1249_convulsion	RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.
UN	12198388_D009388_4_782_793_neostigmine_D014202_4_854_860_tremor	Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.
CID	12198388_D009538_8_1271_1279_nicotine_D012640_8_1239_1249_convulsion	RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.
UN	12198388_D009538_4_758_766_nicotine_D014202_4_854_860_tremor	Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.
CID	12202650_D002211_3_506_515_Capsaicin_D010146_3_577_581_pain	Capsaicin (10 micro g) was injected into the masseter muscle to induce pain in 11 healthy volunteers.
UN	12202650_D002211_0_0_9_Capsaicin_D063806_0_18_29_muscle pain	Capsaicin-induced muscle pain alters the excitability of the human jaw-stretch reflex.
UN	12231232_C095756_3_821_825_AIDA_D009127_3_898_913_muscle rigidity	AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.
UN	12231232_C095756_2_512_551_(RS)-1-aminoindan-1,5-dicarboxylic acid_D010300_2_367_379_parkinsonian	Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint. (RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.
UN	12231232_C097299_2_631_675_(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate_D009127_2_385_400_muscle rigidity	Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint. (RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.
UN	12231232_C097299_2_631_675_(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate_D010300_2_367_379_parkinsonian	Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint. (RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.
CID	12231232_D006220_3_878_889_haloperidol_D009127_3_898_913_muscle rigidity	AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.
UN	12231232_D006220_2_334_345_Haloperidol_D010300_2_367_379_parkinsonian	Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint. (RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.
CID	12369736_C065046_9_1679_1687_CP 93129_D009069_9_1444_1459_hyperlocomotion	Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.
UN	12369736_C103477_5_806_814_GR 55562_D009069_5_946_969_locomotor hyperactivity	GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.
CID	12369736_D003042_1_343_350_cocaine_D009069_1_308_331_locomotor hyperactivity	The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats.
CID	12369736_D003042_0_88_95_cocaine_D009069_0_104_127_locomotor hyperactivity	Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine-induced locomotor hyperactivity in rats.
CID	12369736_D003042_9_1428_1435_cocaine_D009069_9_1444_1459_hyperlocomotion	Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.
CID	12443032_D003042_0_0_7_Cocaine_D002637_0_16_26_chest pain	Cocaine related chest pain: are we seeing the tip of an iceberg?
CID	12443032_D003042_3_250_257_cocaine_D002637_3_269_279_chest pain	In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.
CID	12443032_D003042_4_441_448_cocaine_D002637_4_419_429_chest pain	The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed.
UN	12448656_D013792_9_1178_1189_thalidomide_D002292_9_1193_1213_renal cell carcinoma	CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.
UN	12448656_D013792_11_1387_1398_thalidomide_D002292_11_1403_1423_renal cell carcinoma	The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear.
UN	12448656_D013792_1_130_141_thalidomide_D002292_1_179_196_renal cell cancer	OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.
UN	12448656_D013792_0_20_31_thalidomide_D002292_0_55_75_renal cell carcinoma	A phase II study of thalidomide in advanced metastatic renal cell carcinoma.
UN	12452237_D008012_0_4_13_lidocaine_D010149_0_45_66_postoperative myalgia	Can lidocaine reduce succinylcholine induced postoperative myalgia?
UN	12452237_D008012_1_121_130_lidocaine_D063806_1_184_191_myalgia	This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.
CID	12452237_D013390_0_21_36_succinylcholine_D010149_0_45_66_postoperative myalgia	Can lidocaine reduce succinylcholine induced postoperative myalgia?
UN	12452237_D013390_1_160_175_succinylcholine_D063806_1_184_191_myalgia	This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.
CID	12464714_C093622_13_2062_2073_rizatriptan_D004244_13_2118_2127_dizziness	The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).
UN	12464714_C093622_7_1121_1132_rizatriptan_D006261_7_1084_1092_Headache	Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.
UN	12464714_C093622_4_739_750_rizatriptan_D006261_4_646_654_headache	Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.
UN	12464714_C093622_13_2062_2073_rizatriptan_D006970_13_2170_2180_somnolence	The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).
UN	12464714_C093622_0_52_63_rizatriptan_D008881_0_100_108_migraine	Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.
CID	12464714_C093622_13_2062_2073_rizatriptan_D009325_13_2144_2150_nausea	The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).
CID	12464714_C093622_9_1467_1478_Rizatriptan_D009325_9_1559_1565_nausea	Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).
UN	12464714_C093622_6_948_959_rizatriptan_D010146_6_928_932_pain	Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.
UN	12464714_C093622_5_879_890_rizatriptan_D010146_5_841_845_pain	The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.
UN	12464714_C093622_8_1295_1306_rizatriptan_D010146_8_1312_1316_pain	Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).
UN	12464714_C093622_9_1467_1478_Rizatriptan_D012001_9_1577_1588_phonophobia	Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).
UN	12464714_C093622_9_1467_1478_Rizatriptan_D014839_9_1567_1575_vomiting	Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).
UN	12464714_C093622_9_1467_1478_Rizatriptan_D020795_9_1592_1603_photophobia	Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).
UN	12464714_D002110_13_2089_2097_caffeine_D004244_13_2118_2127_dizziness	The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).
UN	12464714_D002110_7_1158_1166_caffeine_D006261_7_1084_1092_Headache	Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.
UN	12464714_D002110_4_798_806_caffeine_D006261_4_646_654_headache	Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.
UN	12464714_D002110_13_2089_2097_caffeine_D006970_13_2170_2180_somnolence	The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).
UN	12464714_D002110_0_88_96_caffeine_D008881_0_100_108_migraine	Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.
UN	12464714_D002110_2_388_396_caffeine_D008881_2_446_454_migraine	This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.
UN	12464714_D002110_9_1511_1519_caffeine_D009325_9_1559_1565_nausea	Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).
UN	12464714_D002110_6_1005_1013_caffeine_D010146_6_928_932_pain	Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.
UN	12464714_D002110_8_1440_1448_caffeine_D010146_8_1312_1316_pain	Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).
UN	12464714_D002110_9_1511_1519_caffeine_D012001_9_1577_1588_phonophobia	Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).
UN	12464714_D002110_9_1511_1519_caffeine_D014839_9_1567_1575_vomiting	Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).
UN	12464714_D002110_9_1511_1519_caffeine_D020795_9_1592_1603_photophobia	Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).
UN	12464714_D004878_13_2078_2088_ergotamine_D004244_13_2118_2127_dizziness	The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).
UN	12464714_D004878_7_1147_1157_ergotamine_D006261_7_1084_1092_Headache	Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.
UN	12464714_D004878_4_787_797_ergotamine_D006261_4_646_654_headache	Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.
UN	12464714_D004878_13_2078_2088_ergotamine_D006970_13_2170_2180_somnolence	The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).
UN	12464714_D004878_0_77_87_ergotamine_D008881_0_100_108_migraine	Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.
UN	12464714_D004878_9_1500_1510_ergotamine_D009325_9_1559_1565_nausea	Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).
UN	12464714_D004878_6_994_1004_ergotamine_D010146_6_928_932_pain	Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.
UN	12464714_D004878_8_1429_1439_ergotamine_D010146_8_1312_1316_pain	Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).
UN	12464714_D004878_9_1500_1510_ergotamine_D012001_9_1577_1588_phonophobia	Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).
UN	12464714_D004878_9_1500_1510_ergotamine_D014839_9_1567_1575_vomiting	Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).
UN	12464714_D004878_9_1500_1510_ergotamine_D020795_9_1592_1603_photophobia	Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).
UN	12464714_D012701_1_137_141_5-HT_D008881_1_245_253_migraine	Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine.
CID	12481039_D010862_6_1301_1312_pilocarpine_D012640_6_1321_1329_seizures	In contrast, the conduction velocity, the number and size of axons in the optic nerve, and the specific localization of Na(v)1.6 channels in the nodes of Ranvier were unchanged. beta2(-/-) mice displayed increased susceptibility to seizures, as indicated by reduced latency and threshold for pilocarpine-induced seizures, but seemed normal in other neurological tests.
UN	12481039_D012964_0_133_139_sodium_D012640_0_108_116_seizures	Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits.
UN	12483326_D002945_4_558_567_cisplatin_D005128_4_575_602_ocular and orbital toxicity	Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.
UN	12483326_D002945_4_558_567_cisplatin_D009916_4_575_602_ocular and orbital toxicity	Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.
UN	12483326_D016190_0_67_78_carboplatin_D005909_0_93_106_glioblastomas	Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.
UN	12483326_D016190_6_827_838_carboplatin_D005909_6_853_866_glioblastomas	CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.
CID	12483326_D016190_5_720_731_carboplatin_D009916_5_660_687_ocular and orbital toxicity	However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported.
CID	12483326_D016190_0_67_78_carboplatin_D009916_0_7_34_ocular and orbital toxicity	Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.
CID	12523465_C022189_0_38_48_zonisamide_D006212_0_0_21_Visual hallucinations	Visual hallucinations associated with zonisamide.
CID	12523465_C022189_2_336_346_zonisamide_D006212_2_282_303_visual hallucinations	Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.
UN	12523465_C022189_1_50_60_Zonisamide_D012640_1_131_139_seizures	Zonisamide is a broad-spectrum antiepileptic drug used to treat various types of seizures.
CID	12536034_D002220_1_144_157_carbamazepine_D004832_1_103_119_absence epilepsy	The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.
CID	12536034_D020888_1_162_172_vigabatrin_D004832_1_103_119_absence epilepsy	The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.
UN	12549952_D002231_2_288_299_carbimazole_D006980_2_250_265_hyperthyroidism	CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.
CID	12549952_D002231_0_50_61_carbimazole_D017114_0_0_19_Acute liver failure	Acute liver failure with concurrent bupropion and carbimazole therapy.
CID	12549952_D002231_9_1081_1092_carbimazole_D056486_9_890_904_hepatotoxicity	DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.
UN	12549952_D011433_2_304_315_propranolol_D006980_2_250_265_hyperthyroidism	CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.
CID	12549952_D016642_0_36_45_bupropion_D017114_0_0_19_Acute liver failure	Acute liver failure with concurrent bupropion and carbimazole therapy.
CID	12549952_D016642_9_1035_1044_bupropion_D017114_9_992_1011_acute liver failure	DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.
CID	12549952_D016642_10_1186_1195_bupropion_D017114_10_1156_1174_acute liver insult	CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.
CID	12549952_D016642_8_735_744_bupropion_D056486_8_753_767_hepatotoxicity	The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.
CID	12549952_D016642_9_916_925_bupropion_D056486_9_890_904_hepatotoxicity	DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.
CID	12549952_D016642_10_1186_1195_bupropion_D056486_10_1226_1237_hepatotoxic	CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.
UN	1255900_D006493_4_485_492_heparin_D013924_4_522_538_thrombophlebitis	The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.
UN	12571256_C044834_12_2323_2332_iodixanol_D007674_12_2227_2238_Nephropathy	CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.
UN	12571256_C044834_3_436_445_iodixanol_D007674_3_362_373_nephrotoxic	METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.
UN	12571256_D003404_4_579_589_creatinine_D003920_4_559_567_diabetes	The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.
CID	12571256_D007472_3_513_520_iohexol_D007674_3_362_373_nephrotoxic	METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.
UN	12574103_D003907_7_1226_1239_dexamethasone_D005921_7_1295_1313_glomerulosclerosis	Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats.
UN	12574103_D003907_8_1364_1377_dexamethasone_D005921_8_1431_1449_glomerulosclerosis	This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.
CID	12574103_D003907_2_238_251_dexamethasone_D006973_2_277_303_increase in blood pressure	The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.
CID	12574103_D003907_0_9_22_dexamethasone_D006973_0_32_44_hypertension	Prenatal dexamethasone programs hypertension and renal injury in the rat.
CID	12574103_D003907_8_1364_1377_dexamethasone_D007674_8_1399_1429_reduction in glomerular number	This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.
CID	12574103_D003907_2_238_251_dexamethasone_D007674_2_308_320_renal injury	The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.
CID	12574103_D003907_0_9_22_dexamethasone_D007674_0_49_61_renal injury	Prenatal dexamethasone programs hypertension and renal injury in the rat.
UN	12584269_D016559_12_2111_2116_FK506_D005355_12_2180_2188_fibrosis	The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).
CID	12584269_D016559_13_2323_2328_FK506_D007674_13_2279_2290_nephrotoxic	CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.
UN	12584269_D016572_11_1904_1907_CsA_D005355_11_1989_1997_fibrosis	The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).
CID	12584269_D016572_13_2301_2304_CsA_D007674_13_2279_2290_nephrotoxic	CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.
UN	12584269_D020123_12_2122_2125_SRL_D005355_12_2180_2188_fibrosis	The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).
CID	12584269_D020123_2_254_257_SRL_D007674_2_305_316_nephrotoxic	These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.
CID	12584269_D020123_13_2310_2313_SRL_D007674_13_2279_2290_nephrotoxic	CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.
UN	12589964_D004317_11_1650_1653_DOX_D005355_11_1723_1731_fibrosis	Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis.
CID	12589964_D004317_0_81_92_doxorubicin_D009202_0_60_77_myocardial damage	Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.
CID	12589964_D004317_2_458_461_DOX_D009202_2_471_485_cardiomyopathy	We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.
UN	12589964_D004317_21_2715_2718_DOX_D017202_21_2693_2708_ischemic injury	CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.
UN	12589964_D004317_22_3064_3067_DOX_D066126_22_3221_3235_cardiotoxicity	Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.
UN	12596116_D015282_0_0_10_Octreotide_D000860_0_19_28_hypoxemia	Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.
UN	12596116_D015282_2_282_292_octreotide_D005402_2_323_330_fistula	Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.
CID	12596116_D015282_0_0_10_Octreotide_D006976_0_33_55_pulmonary hypertension	Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.
UN	12600698_C005435_2_204_213_Edaravone_D002544_2_324_343_cerebral infarction	Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.
UN	12600698_C005435_0_21_30_edaravone_D015837_0_60_77_vestibulotoxicity	Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.
UN	12600698_C005435_1_178_187_edaravone_D015837_1_157_174_vestibulotoxicity	This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.
UN	12600698_C005435_6_732_741_edaravone_D015837_6_774_791_vestibulotoxicity	These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.
CID	12600698_D013307_1_136_148_streptomycin_D015837_1_157_174_vestibulotoxicity	This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.
CID	12600698_D013307_0_39_51_streptomycin_D015837_0_60_77_vestibulotoxicity	Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.
CID	12600698_D013307_6_753_765_streptomycin_D015837_6_774_791_vestibulotoxicity	These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.
UN	12615818_D003276_2_522_541_oral contraceptives_D054556_2_434_456_venous thromboembolism	Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).
UN	12615818_D004997_7_1427_1429_EE_D000152_7_1444_1448_acne	CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.
UN	12615818_D004997_1_209_226_ethinyl estradiol_D006628_1_299_308_hirsutism	BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).
UN	12615818_D004997_7_1427_1429_EE_D006628_7_1450_1459_hirsutism	CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.
UN	12615818_D004997_4_888_890_EE_D006628_4_822_831_hirsutism	METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.
UN	12615818_D004997_7_1427_1429_EE_D011085_7_1463_1467_PCOS	CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.
UN	12615818_D004997_4_888_890_EE_D011085_4_835_839_PCOS	METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.
UN	12615818_D004997_1_209_226_ethinyl estradiol_D011085_1_344_369_polycystic ovary syndrome	BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).
CID	12615818_D004997_2_483_485_EE_D054556_2_458_461_VTE	Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).
CID	12615818_D004997_0_95_112_ethinyl estradiol_D054556_0_12_34_venous thromboembolism	The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.
CID	12615818_D004997_4_888_890_EE_D054556_4_864_867_VTE	METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.
CID	12615818_D004997_7_1427_1429_EE_D054556_7_1392_1395_VTE	CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.
UN	12615818_D017373_7_1423_1426_CPA_D000152_7_1444_1448_acne	CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.
UN	12615818_D017373_1_175_194_Cyproterone acetate_D006628_1_299_308_hirsutism	BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).
UN	12615818_D017373_7_1423_1426_CPA_D006628_7_1450_1459_hirsutism	CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.
UN	12615818_D017373_4_884_887_CPA_D006628_4_822_831_hirsutism	METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.
UN	12615818_D017373_4_884_887_CPA_D011085_4_835_839_PCOS	METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.
CID	12615818_D017373_7_1423_1426_CPA_D054556_7_1392_1395_VTE	CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.
CID	12615818_D017373_4_884_887_CPA_D054556_4_864_867_VTE	METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.
CID	12615818_D017373_2_479_482_CPA_D054556_2_458_461_VTE	Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).
CID	12615818_D017373_0_55_74_cyproterone acetate_D054556_0_12_34_venous thromboembolism	The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.
UN	12617329_D003404_3_615_625_creatinine_D007674_3_552_566_Nephrotoxicity	Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.
UN	12617329_D003404_4_854_864_creatinine_D007683_4_1106_1122_tubular necrosis	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.
UN	12617329_D005839_4_1086_1088_GM_D007683_4_1106_1122_tubular necrosis	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.
CID	12617329_D005839_1_213_223_gentamicin_D058186_1_182_201_acute renal failure	In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.
UN	12617329_D005978_3_661_672_glutathione_D007674_3_552_566_Nephrotoxicity	Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.
UN	12617329_D005978_4_1022_1025_GSH_D007683_4_1106_1122_tubular necrosis	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.
UN	12617329_D006170_4_1190_1200_gum Arabic_D007683_4_1106_1122_tubular necrosis	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.
CID	12617329_D006170_1_168_178_gum Arabic_D058186_1_182_201_acute renal failure	In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.
UN	12617329_D014508_3_630_634_urea_D007674_3_552_566_Nephrotoxicity	Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.
UN	12617329_D014508_4_869_873_urea_D007683_4_1106_1122_tubular necrosis	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.
UN	12627929_C067311_8_1163_1172_docetaxel_D011471_8_1193_1208_prostate cancer	CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.
UN	12627929_C067311_0_70_79_docetaxel_D011471_0_145_160_prostate cancer	Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
UN	12627929_C067311_1_322_331_docetaxel_D011471_1_284_299_prostate cancer	STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.
CID	12627929_C067311_0_70_79_docetaxel_D054556_0_23_45_venous thromboembolism	Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
CID	12627929_C067311_7_993_1002_docetaxel_D054556_7_1019_1022_VTE	MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).
UN	12627929_D013792_0_84_95_thalidomide_D011471_0_145_160_prostate cancer	Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
UN	12627929_D013792_8_1148_1159_thalidomide_D011471_8_1193_1208_prostate cancer	CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.
CID	12627929_D013792_7_1083_1094_thalidomide_D054556_7_1105_1108_VTE	MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).
CID	12627929_D013792_0_84_95_thalidomide_D054556_0_23_45_venous thromboembolism	Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
CID	12639165_D013988_10_1449_1460_ticlopidine_D002779_10_1399_1420_Cholestatic hepatitis	CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.
CID	12639165_D013988_8_1217_1228_ticlopidine_D002779_8_1237_1248_cholestasis	The mechanisms of this ticlopidine-induced cholestasis are unclear.
CID	12639165_D013988_5_779_790_ticlopidine_D002779_5_849_870_cholestatic hepatitis	Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.
CID	12639165_D013988_4_641_652_ticlopidine_D002779_4_570_591_Cholestatic hepatitis	DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.
CID	12639165_D013988_1_75_86_ticlopidine_D002779_1_95_116_cholestatic hepatitis	OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.
CID	12639165_D013988_0_0_11_Ticlopidine_D002779_0_20_41_cholestatic hepatitis	Ticlopidine-induced cholestatic hepatitis.
CID	12639165_D013988_2_313_324_ticlopidine_D002779_2_275_296_cholestatic hepatitis	CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.
CID	12639165_D013988_5_779_790_ticlopidine_D007565_5_745_753_jaundice	Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.
CID	12639165_D013988_2_313_324_ticlopidine_D056486_2_275_296_cholestatic hepatitis	CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.
CID	12639165_D013988_5_779_790_ticlopidine_D056486_5_849_870_cholestatic hepatitis	Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.
CID	12639165_D013988_4_641_652_ticlopidine_D056486_4_570_591_Cholestatic hepatitis	DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.
CID	12639165_D013988_10_1449_1460_ticlopidine_D056486_10_1399_1420_Cholestatic hepatitis	CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.
CID	12639165_D013988_1_75_86_ticlopidine_D056486_1_95_116_cholestatic hepatitis	OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.
CID	12639165_D013988_0_0_11_Ticlopidine_D056486_0_20_41_cholestatic hepatitis	Ticlopidine-induced cholestatic hepatitis.
UN	12653683_D000450_12_1808_1819_aldosterone_D009404_12_1735_1753_nephrotic syndrome	In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.
UN	12653683_D000450_5_622_633_aldosterone_D011507_5_652_663_proteinuria	The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.
CID	12653683_D011692_0_82_107_puromycin aminonucleoside_D009404_0_116_134_nephrotic syndrome	Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.
CID	12653683_D011692_12_1723_1726_PAN_D009404_12_1735_1753_nephrotic syndrome	In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.
CID	12653683_D011692_4_536_539_PAN_D009404_4_549_567_nephrotic syndrome	We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.
CID	12653683_D011692_5_742_745_PAN_D011507_5_652_663_proteinuria	The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.
UN	12653683_D012964_0_11_17_sodium_D009404_0_116_134_nephrotic syndrome	Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.
UN	12653683_D012964_1_180_186_sodium_D009404_1_152_170_nephrotic syndrome	In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease.
UN	12653683_D012964_7_972_978_sodium_D011507_7_1011_1022_proteinuria	The kinetics of urinary sodium excretion and the appearance of proteinuria were comparable with those reported previously.
UN	12684739_D003042_3_529_536_cocaine_D005128_3_401_421_visual field defects	OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).
UN	12684739_D003042_3_529_536_cocaine_D019966_3_359_374_substance abuse	OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).
UN	12684739_D004298_3_583_591_dopamine_D005128_3_401_421_visual field defects	OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).
UN	12684739_D004298_3_583_591_dopamine_D019966_3_359_374_substance abuse	OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).
CID	12684739_D020888_3_522_525_GVG_D005128_3_401_421_visual field defects	OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).
UN	12684739_D020888_3_522_525_GVG_D019966_3_359_374_substance abuse	OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).
UN	12691807_D007980_1_75_83_Levodopa_D004409_1_92_103_dyskinesias	Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.
CID	12691807_D007980_0_0_8_Levodopa_D004421_0_31_39_dystonia	Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.
UN	12691807_D007980_3_314_322_levodopa_D008538_3_331_353_Oromandibular dystonia	In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.
UN	12691807_D007980_1_75_83_Levodopa_D010300_1_126_145_Parkinson's disease	Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.
UN	12691807_D007980_0_0_8_Levodopa_D013494_0_43_73_progressive supranuclear palsy	Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.
UN	12691807_D007980_3_314_322_levodopa_D013494_3_365_368_PSP	In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.
UN	12691807_D007980_1_75_83_Levodopa_D019578_1_150_173_multiple system atrophy	Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.
UN	12695819_D016559_8_1266_1276_tacrolimus_D020258_8_1285_1298_neurotoxicity	Diffusion-weighted imaging may be useful in predicting the outcomes of the lesions of tacrolimus-induced neurotoxicity.
UN	12695819_D016559_0_50_60_tacrolimus_D020258_0_69_82_neurotoxicity	MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients.
UN	12707296_D001120_12_1738_1748_l-arginine_D006973_12_1665_1692_increases in blood pressure	We conclude that cortisol-induced increases in blood pressure are not associated with abnormalities in the l-arginine transport system.
UN	12707296_D001120_0_0_10_L-arginine_D006973_0_53_65_hypertension	L-arginine transport in humans with cortisol-induced hypertension.
UN	12707296_D006854_12_1648_1656_cortisol_D006973_12_1665_1692_increases in blood pressure	We conclude that cortisol-induced increases in blood pressure are not associated with abnormalities in the l-arginine transport system.
UN	12707296_D006854_0_36_44_cortisol_D006973_0_53_65_hypertension	L-arginine transport in humans with cortisol-induced hypertension.
UN	12707296_D006854_1_127_135_cortisol_D006973_1_144_156_hypertension	A deficient L-arginine-nitric oxide system is implicated in cortisol-induced hypertension.
UN	12707296_D009569_1_90_102_nitric oxide_D006973_1_144_156_hypertension	A deficient L-arginine-nitric oxide system is implicated in cortisol-induced hypertension.
UN	12716030_D006493_5_802_809_heparin_D002543_5_758_761_ICH	In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.
CID	12716030_D006493_5_802_809_heparin_D006406_5_823_831_hematoma	In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.
UN	12734532_D010665_5_609_612_PPA_D009202_5_621_638_myocardial injury	In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.
UN	12734532_D010665_4_459_462_PPA_D009202_4_472_489_myocardial injury	We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.
UN	12734532_D010665_3_350_353_PPA_D009202_3_359_376_myocardial injury	Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.
CID	12734532_D010665_0_23_42_Phenylpropanolamine_D009203_0_58_79_myocardial infarction	Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.
UN	12734532_D010665_3_350_353_PPA_D062787_3_394_402_overdose	Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.
UN	12739036_D001379_2_341_353_azathioprine_D007674_2_283_300_renal involvement	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.
UN	12739036_D001379_2_341_353_azathioprine_D008180_2_243_271_systemic lupus erythematosus	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.
UN	12739036_D002738_3_413_415_CQ_D018771_3_440_450_arthralgia	Additional therapy with chloroquine (CQ) was started because of arthralgia.
UN	12739036_D003401_0_37_45_creatine_D008180_0_63_91_systemic lupus erythematosus	Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.
UN	12739036_D003520_2_358_374_cyclophosphamide_D007674_2_283_300_renal involvement	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.
UN	12739036_D003520_2_358_374_cyclophosphamide_D008180_2_243_271_systemic lupus erythematosus	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.
UN	12739036_D013256_5_586_594_steroids_D009220_5_529_537_Myositis	Myositis was suspected, and the patient was treated with steroids.
CID	12745515_D016642_5_671_680_bupropion_D012640_5_692_700_seizures	We suggest that sleep deprivation may add to the risk of bupropion-associated seizures.
CID	12745515_D016642_0_64_73_bupropion_D012640_0_0_7_Seizure	Seizure associated with sleep deprivation and sustained-release bupropion.
CID	12745515_D016642_1_158_167_bupropion_D012640_1_116_123_seizure	This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.
UN	12745515_D016642_5_671_680_bupropion_D012892_5_630_647_sleep deprivation	We suggest that sleep deprivation may add to the risk of bupropion-associated seizures.
UN	12745515_D016642_0_64_73_bupropion_D012892_0_24_41_sleep deprivation	Seizure associated with sleep deprivation and sustained-release bupropion.
UN	12745515_D016642_1_158_167_bupropion_D012892_1_176_193_sleep deprivation	This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.
UN	12757899_D004958_0_0_9_Estradiol_D001930_0_34_52_hippocampal injury	Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats.
UN	12757899_D004958_0_0_9_Estradiol_D012640_0_18_25_seizure	Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats.
UN	12757899_D004958_7_948_957_estradiol_D012640_7_961_968_seizure	These findings suggest that the effects of estradiol on seizure threshold and damage may be altered by sex-related differences in the hormonal environment.
UN	12757899_D004958_5_639_655_17beta-Estradiol_D013226_5_635_637_SE	The extent of silver-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE. 17beta-Estradiol did not alter the onset of first clonus in ovariectomized rats but accelerated it in males. 17beta-Estradiol reduced the argyrophilic neurons in the CA1 and CA3-C sectors of ovariectomized rats.
UN	12757899_D007608_1_173_184_kainic acid_D001930_1_143_161_hippocampal injury	Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).
UN	12757899_D007608_1_173_184_kainic acid_D013226_1_193_211_status epilepticus	Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).
CID	12757899_D008094_2_320_327_lithium_D013226_2_348_350_SE	We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.
CID	12757899_D010862_2_328_339_pilocarpine_D013226_2_348_350_SE	We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.
UN	12757899_D012834_5_561_567_silver_D013226_5_635_637_SE	The extent of silver-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE. 17beta-Estradiol did not alter the onset of first clonus in ovariectomized rats but accelerated it in males. 17beta-Estradiol reduced the argyrophilic neurons in the CA1 and CA3-C sectors of ovariectomized rats.
UN	12760988_D003907_12_1710_1723_dexamethasone_D010149_12_1752_1773_postoperative myalgia	Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine.
UN	12760988_D003907_4_508_521_dexamethasone_D063806_4_444_451_myalgia	The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).
UN	12760988_D003907_5_670_683_dexamethasone_D063806_5_704_711_myalgia	Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).
CID	12760988_D013390_1_122_137_succinylcholine_D010149_1_141_162_postoperative myalgia	A common side effect associated with succinylcholine is postoperative myalgia.
CID	12760988_D013390_10_1489_1504_succinylcholine_D010149_10_1513_1534_postoperative myalgia	IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.
CID	12760988_D013390_0_28_43_succinylcholine_D010149_0_0_21_Postoperative myalgia	Postoperative myalgia after succinylcholine: no evidence for an inflammatory origin.
CID	12760988_D013390_12_1780_1795_succinylcholine_D010149_12_1752_1773_postoperative myalgia	Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine.
CID	12760988_D013390_9_1319_1334_succinylcholine_D063806_9_1346_1353_myalgia	In conclusion, there is no evidence for an inflammatory origin of succinylcholine-associated myalgia.
CID	12760988_D013390_4_417_432_succinylcholine_D063806_4_444_451_myalgia	The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).
UN	12789195_D008914_5_735_744_minoxidil_D004194_5_698_714_pseudoacromegaly	This is the first case report of pseudoacromegaly as a side effect of minoxidil use.
UN	12789195_D008914_4_628_637_minoxidil_D004194_4_571_587_pseudoacromegaly	We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.
UN	12789195_D008914_0_49_58_minoxidil_D004194_0_0_16_Pseudoacromegaly	Pseudoacromegaly induced by the long-term use of minoxidil.
CID	12820454_D005485_3_525_534_flutamide_D000740_3_572_578_anemia	All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).
CID	12820454_D016729_3_445_463_leuprolide acetate_D000740_3_572_578_anemia	All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).
UN	12842176_C018021_7_1742_1757_cobalt chloride_D012640_7_1771_1782_convulsions	Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.
UN	12842176_D000431_7_1895_1902_ethanol_D012640_7_1771_1782_convulsions	Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.
UN	12842176_D000431_6_1548_1555_ethanol_D012640_6_1467_1478_convulsions	Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.
UN	12842176_D000431_6_1548_1555_ethanol_D012640_6_1658_1669_convulsions	Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.
CID	12842176_D001556_7_1821_1828_lindane_D012640_7_1771_1782_convulsions	Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.
CID	12842176_D001556_6_1451_1458_lindane_D012640_6_1467_1478_convulsions	Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.
CID	12842176_D001556_6_1642_1649_lindane_D012640_6_1658_1669_convulsions	Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.
UN	12842176_D001556_0_92_99_lindane_D020258_0_108_121_neurotoxicity	Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity.
UN	12842176_D008748_6_1338_1358_3-methylcholanthrene_D012640_6_1467_1478_convulsions	Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.
UN	12842176_D010634_6_1498_1511_phenobarbital_D012640_6_1467_1478_convulsions	Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.
CID	12851669_D003277_5_722_726_COCs_D054556_5_709_712_VTE	RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.
CID	12851669_D003277_9_1167_1171_COCs_D054556_9_1141_1144_VTE	CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.
UN	12851669_D004997_1_238_254_ethinylestradiol_D054556_1_193_196_VTE	OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).
UN	12851669_D004997_0_102_118_ethinylestradiol_D054556_0_34_56_venous thromboembolism	Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.
UN	12851669_D016912_8_981_995_levonorgestrel_D054556_8_845_848_VTE	The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.
UN	12851669_D017373_0_78_97_cyproterone acetate_D054556_0_34_56_venous thromboembolism	Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.
UN	12851669_D017373_1_213_232_cyproterone acetate_D054556_1_193_196_VTE	OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).
CID	12852481_D001241_5_1051_1054_ASA_D000014_5_1032_1045_malformations	Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.
CID	12852481_D001241_8_1691_1694_ASA_D000014_8_1731_1744_malformations	RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.
CID	12852481_D001241_13_2231_2234_ASA_D000014_13_2199_2212_malformations	Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).
UN	12852481_D001241_5_1051_1054_ASA_D005767_5_965_990_gastrointestinal toxicity	Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.
CID	12852481_D001241_8_1691_1694_ASA_D006345_8_1582_1586_VSDs	RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.
UN	12852481_D001241_8_1691_1694_ASA_D009436_8_1573_1576_MDs	RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.
CID	12852481_D001241_8_1691_1694_ASA_D065630_8_1546_1566_diaphragmatic hernia	RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.
CID	1286498_D005442_10_1679_1689_flumazenil_D009325_10_1700_1706_nausea	The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.
UN	1286498_D005442_10_1679_1689_flumazenil_D010146_10_1726_1730_pain	The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.
CID	1286498_D005442_10_1679_1689_flumazenil_D014839_10_1663_1671_vomiting	The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.
CID	12905102_D003024_0_16_25_clozapine_D003693_0_0_8_Delirium	Delirium during clozapine treatment: incidence and associated risk factors.
CID	12905102_D003024_1_135_144_clozapine_D003693_1_119_127_delirium	BACKGROUND: Incidence and risk factors for delirium during clozapine treatment require further clarification.
CID	12905102_D003024_6_1139_1148_clozapine_D003693_6_1109_1117_Delirium	CONCLUSIONS: Delirium was found in 10 % of clozapine-treated inpatients, particularly in older patients exposed to other central anticholinergics.
UN	12907309_C121465_0_26_30_MPEP_D005334_0_185_197_hyperthermia	Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.
UN	12907309_C121465_8_1490_1494_MPEP_D005334_8_1663_1675_hyperthermia	Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.
UN	12907309_C121465_0_26_30_MPEP_D020258_0_103_116_neurotoxicity	Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.
UN	12907309_D004298_0_150_158_dopamine_D005334_0_185_197_hyperthermia	Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.
UN	12907309_D004298_0_150_158_dopamine_D020258_0_103_116_neurotoxicity	Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.
CID	12907309_D008694_5_1046_1061_methamphetamine_D005334_5_1084_1096_hyperthermia	Moreover, it transiently diminished the methamphetamine (10 mg/kg sc)-induced hyperthermia and reduced basal body temperature.
UN	12907309_D008694_0_66_81_methamphetamine_D020258_0_103_116_neurotoxicity	Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.
UN	12907924_D008774_1_173_188_methylphenidate_D000544_1_138_157_Alzheimer's disease	An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.
CID	12907924_D008774_0_0_15_Methylphenidate_D009771_0_24_53_obsessive-compulsive symptoms	Methylphenidate-induced obsessive-compulsive symptoms in an elderly man.
CID	12907924_D008774_2_278_293_methylphenidate_D009771_2_202_231_obsessive-compulsive behavior	Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.
UN	12907924_D008774_1_173_188_methylphenidate_D061218_1_97_127_treatment-resistant depression	An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.
UN	12907924_D016666_2_310_321_fluvoxamine_D009771_2_202_231_obsessive-compulsive behavior	Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.
CID	12911170_D002939_1_84_97_Ciprofloxacin_D000743_1_181_197_hemolytic anemia	Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.
UN	12911170_D002939_0_0_13_Ciprofloxacin_D000744_0_55_82_autoimmune hemolytic anemia	Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.
UN	12911170_D002939_3_293_306_ciprofloxacin_D000744_3_342_369_autoimmune hemolytic anemia	In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.
CID	12911170_D002939_3_293_306_ciprofloxacin_D009395_3_315_337_interstitial nephritis	In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.
CID	12911170_D002939_0_0_13_Ciprofloxacin_D009395_0_28_50_interstitial nephritis	Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.
CID	12911170_D002939_1_84_97_Ciprofloxacin_D009395_1_154_176_interstitial nephritis	Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.
UN	12911170_D013256_4_439_446_steroid_D000743_4_371_387_Hemolytic anemia	Hemolytic anemia improved after stopping the drug and initiation of steroid therapy.
UN	12921865_C105051_6_1273_1283_ganaxolone_D012640_6_1229_1237_seizures	All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.
UN	12921865_C105051_4_778_788_ganaxolone_D012640_4_1027_1035_seizures	Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.
CID	12921865_D003042_0_52_59_cocaine_D012640_0_68_76_seizures	Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.
CID	12921865_D003042_3_623_630_cocaine_D012640_3_647_654_seizure	The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).
CID	12921865_D003042_4_1011_1018_cocaine_D012640_4_1027_1035_seizures	Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.
UN	12921865_D005680_6_1173_1177_GABA_D012640_6_1229_1237_seizures	All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.
UN	12921865_D011280_4_723_735_pregnanolone_D012640_4_1027_1035_seizures	Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.
UN	12921865_D011280_6_1252_1268_allopregnanolone_D012640_6_1229_1237_seizures	All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.
UN	12921865_D013256_1_98_106_steroids_D001523_1_177_215_neurological and psychiatric disorders	Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders.
UN	12921865_D013256_1_98_106_steroids_D009422_1_177_215_neurological and psychiatric disorders	Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders.
UN	12921865_D013256_0_35_43_steroids_D012640_0_68_76_seizures	Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.
UN	1300436_D003404_5_940_950_creatinine_D058186_5_815_856_Renal function significantly deteriorated	Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).
UN	1300436_D005665_6_1136_1146_furosemide_D015431_6_1117_1128_weight loss	Renal failure was associated with weight loss in the furosemide-treated group.
CID	1300436_D005665_5_886_896_furosemide_D058186_5_815_856_Renal function significantly deteriorated	Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).
CID	133615_D003276_2_92_110_oral contraceptive_D001778_2_161_178_blood coagulation	Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.
UN	133615_D003276_2_92_110_oral contraceptive_D013923_2_50_64_Thromboembolic	Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.
CID	1355091_C014282_11_1926_1936_cirazoline_D001919_11_1903_1914_bradycardia	Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).
CID	1355091_C014282_10_1638_1648_cirazoline_D001919_10_1603_1614_bradycardia	The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.
CID	1355091_C056299_12_2076_2088_Abbott-53693_D001919_12_2146_2157_bradycardia	On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.
CID	1355091_C056299_10_1703_1715_Abbott-53693_D001919_10_1603_1614_bradycardia	The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.
CID	1355091_D009638_13_2288_2301_noradrenaline_D001919_13_2255_2266_bradycardia	Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)
UN	1355091_D011224_12_2190_2198_prazosin_D001919_12_2146_2157_bradycardia	On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.
UN	1355091_D011224_11_1963_1971_prazosin_D001919_11_1903_1914_bradycardia	Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).
UN	1355091_D011224_0_82_90_prazosin_D006973_0_126_138_hypertensive	Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats. 1.
CID	1355091_D011224_0_82_90_prazosin_D007024_0_0_23_Orthostatic hypotension	Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats. 1.
CID	1355091_D011224_5_887_895_prazosin_D007024_5_839_862_orthostatic hypotension	However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6). 3.
UN	1355091_D015016_5_947_958_rauwolscine_D007024_5_839_862_orthostatic hypotension	However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6). 3.
CID	137340_D009020_0_32_40_morphine_D006948_0_49_79_increase in locomotor activity	Effect of humoral modulators of morphine-induced increase in locomotor activity of mice.
CID	137340_D009020_4_561_569_morphine_D006948_4_535_548_hyperactivity	In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.
CID	137340_D009020_3_320_328_morphine_D006948_3_337_350_hyperactivity	The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.
CID	137340_D009020_2_245_253_morphine_D006948_2_276_306_increase in locomotor activity	The subcutaneous administration of 10 mg/kg of morphine-HC1 produced a marked increase in locomotor activity in mice.
CID	137340_D009020_1_129_137_morphine_D006948_1_146_176_increase in locomotor activity	The effect of humoral modulators on the morphine-induced increase in locomotor activity of mice was studied.
UN	137340_D009388_4_453_464_neostigmine_D006948_4_535_548_hyperactivity	In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.
UN	137340_D010134_6_789_810_p-chlorophenylalamine_D006948_6_898_911_hyperactivity	On the other hand, pretreatment with p-chlorophenylalamine (3 X 320 mg/kg i.p., 24 hr), a serotonin depletor, caused no significant change in the hyperactivity.
UN	137340_D010830_3_400_413_physostigmine_D006948_3_337_350_hyperactivity	The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.
CID	137340_D012601_3_370_381_scopolamine_D006948_3_337_350_hyperactivity	The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.
UN	137340_D012701_6_842_851_serotonin_D006948_6_898_911_hyperactivity	On the other hand, pretreatment with p-chlorophenylalamine (3 X 320 mg/kg i.p., 24 hr), a serotonin depletor, caused no significant change in the hyperactivity.
UN	137340_D019832_4_433_448_methscopolamine_D006948_4_535_548_hyperactivity	In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.
UN	1378968_D003404_7_1156_1166_creatinine_D051437_7_1087_1100_renal failure	HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.
UN	1378968_D008094_6_955_962_Lithium_D005921_6_1027_1045_glomerulosclerosis	Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.
CID	1378968_D008094_6_955_962_Lithium_D006973_6_1000_1012_hypertension	Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.
CID	1378968_D008094_0_54_61_lithium_D007676_0_70_91_chronic renal failure	Effects of uninephrectomy and high protein feeding on lithium-induced chronic renal failure in rats.
CID	1378968_D008094_6_955_962_Lithium_D011507_6_975_986_proteinuria	Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.
CID	1415380_D011803_1_100_107_quinine_D006463_1_64_89_Hemolytic-uremic syndrome	Hemolytic-uremic syndrome following quinine ingestion is a newly described phenomenon, with just two previous descriptions of 4 cases in the literature.
CID	1415380_D011803_0_55_62_quinine_D006463_0_0_25_Hemolytic-uremic syndrome	Hemolytic-uremic syndrome associated with ingestion of quinine.
CID	1415380_D011803_7_622_629_Quinine_D006463_7_641_666_hemolytic-uremic syndrome	Quinine-associated hemolytic-uremic syndrome probably occurs more often than is recognized.
UN	1420741_D005672_0_34_46_fusidic acid_D003424_0_13_28_Crohn's disease	Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.
UN	1420741_D005672_10_1205_1217_fusidic acid_D003424_10_1263_1278_Crohn's disease	The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.
UN	1420741_D005672_11_1402_1414_fusidic acid_D015212_11_1440_1466_inflammatory bowel disease	Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.
UN	1420741_D016572_0_107_118_cyclosporin_D003424_0_13_28_Crohn's disease	Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.
UN	1423339_D011433_1_149_160_propranolol_D000544_1_101_110_Alzheimer	An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.
CID	1423339_D011433_0_34_45_propranolol_D000647_0_0_17_Amnestic syndrome	Amnestic syndrome associated with propranolol toxicity: a case report.
UN	1423339_D011433_1_149_160_propranolol_D003704_1_125_133_dementia	An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.
CID	1428568_D013999_6_909_916_timolol_D003866_6_885_895_depression	These results suggest that betaxolol could be less of a depression-inducer than timolol in predisposed patients.
CID	1428568_D013999_5_700_707_timolol_D003866_5_735_745_depression	In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).
UN	1428568_D013999_3_401_408_timolol_D005901_3_354_366_glaucomatous	Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.
UN	1428568_D015784_6_856_865_betaxolol_D003866_6_885_895_depression	These results suggest that betaxolol could be less of a depression-inducer than timolol in predisposed patients.
UN	1436384_C070935_0_100_108_LY274614_D020258_0_39_52_neurotoxicity	Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.
UN	1436384_D000596_0_124_134_amino acid_D020258_0_39_52_neurotoxicity	Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.
CID	1436384_D000661_0_19_30_amphetamine_D020258_0_39_52_neurotoxicity	Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.
CID	1436384_D000661_9_1603_1614_amphetamine_D020258_9_1582_1592_neurotoxic	The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.
UN	1436384_D004298_9_1658_1666_dopamine_D020258_9_1582_1592_neurotoxic	The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.
UN	1436384_D004298_0_69_77_dopamine_D020258_0_39_52_neurotoxicity	Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.
UN	1436384_D016202_9_1684_1688_NMDA_D020258_9_1582_1592_neurotoxic	The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.
UN	1445986_D010406_1_153_164_penicillins_D000743_1_50_66_hemolytic anemia	Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.
CID	1445986_D015313_0_0_9_Cefotetan_D000743_0_25_41_hemolytic anemia	Cefotetan-induced immune hemolytic anemia.
CID	14513889_D007654_1_164_176_ketoconazole_D004401_1_112_122_dysarthria	A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.
CID	14513889_D007654_1_164_176_ketoconazole_D010243_1_96_110_legs paralysis	A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.
CID	14513889_D007654_1_164_176_ketoconazole_D014202_1_127_133_tremor	A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.
CID	14513889_D007654_1_164_176_ketoconazole_D018908_1_71_94_weakness of extremities	A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.
CID	14568327_D007980_5_1024_1032_levodopa_D004409_5_1075_1079_LIDs	In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).
CID	14568327_D007980_4_801_809_levodopa_D004409_4_828_838_dyskinesia	Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.
CID	14568327_D007980_1_135_143_Levodopa_D004409_1_152_163_dyskinesias	Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.
CID	14568327_D007980_0_15_23_levodopa_D004409_0_32_43_dyskinesias	Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.
CID	14568327_D007980_3_623_631_levodopa_D004409_3_678_682_LIDs	Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.
UN	14568327_D007980_0_15_23_levodopa_D010300_0_47_59_parkinsonian	Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.
UN	14568327_D007980_3_623_631_levodopa_D010302_3_482_494_parkinsonism	Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.
UN	14568327_D015632_5_932_936_MPTP_D004409_5_1075_1079_LIDs	In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).
UN	14568327_D015632_4_716_720_MPTP_D004409_4_828_838_dyskinesia	Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.
UN	14568327_D015632_3_469_473_MPTP_D004409_3_678_682_LIDs	Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.
CID	14568327_D015632_3_469_473_MPTP_D010302_3_482_494_parkinsonism	Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.
CID	14596845_D000661_7_1068_1079_amphetamine_D006948_7_1041_1052_hyperactive	The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).
CID	14596845_D000661_0_89_100_amphetamine_D006948_0_41_71_behavioral cross-sensitization	A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.
CID	14596845_D000661_2_431_442_amphetamine_D006948_2_383_413_behavioral cross-sensitization	The present study examined whether female rats on various regimens of sugar access would show behavioral cross-sensitization to a low dose of amphetamine.
UN	14596845_D000661_0_89_100_amphetamine_D019966_0_17_33_sugar dependency	A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.
CID	14596845_D013395_7_1019_1026_sucrose_D006948_7_1041_1052_hyperactive	The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).
UN	14633084_D003907_10_1343_1356_dexamethasone_D003556_10_1373_1375_HC	However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.
UN	14633084_D003907_0_7_20_dexamethasone_D003556_0_73_93_hemorrhagic cystitis	Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
UN	14633084_D003907_10_1343_1356_dexamethasone_D006470_10_1373_1375_HC	However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.
UN	14633084_D003907_0_7_20_dexamethasone_D006470_0_73_93_hemorrhagic cystitis	Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
CID	14633084_D007069_9_1232_1235_IFS_D003556_9_1244_1246_HC	CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.
CID	14633084_D007069_0_54_64_ifosfamide_D003556_0_73_93_hemorrhagic cystitis	Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
CID	14633084_D007069_2_309_312_IFS_D003556_2_321_323_HC	In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.
CID	14633084_D007069_9_1232_1235_IFS_D006470_9_1244_1246_HC	CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.
CID	14633084_D007069_2_309_312_IFS_D006470_2_321_323_HC	In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.
CID	14633084_D007069_0_54_64_ifosfamide_D006470_0_73_93_hemorrhagic cystitis	Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
UN	14633084_D015080_9_1200_1205_mesna_D003556_9_1244_1246_HC	CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.
UN	14633084_D015080_10_1326_1331_mesna_D003556_10_1373_1375_HC	However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.
UN	14633084_D015080_2_281_286_mesna_D003556_2_321_323_HC	In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.
UN	14633084_D015080_0_26_31_mesna_D003556_0_73_93_hemorrhagic cystitis	Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
UN	14633084_D015080_9_1200_1205_mesna_D006470_9_1244_1246_HC	CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.
UN	14633084_D015080_2_281_286_mesna_D006470_2_321_323_HC	In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.
UN	14633084_D015080_10_1326_1331_mesna_D006470_10_1373_1375_HC	However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.
UN	14633084_D015080_0_26_31_mesna_D006470_0_73_93_hemorrhagic cystitis	Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
UN	14648024_D013256_9_818_825_steroid_D004893_9_860_876_erythema nodosum	Short-term use of steroid is very effective in ATRA-induced erythema nodosum.
CID	14648024_D014212_0_0_24_All- trans-retinoic acid_D004893_0_33_49_erythema nodosum	All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.
CID	14648024_D014212_1_130_154_all- trans-retinoic acid_D004893_1_97_113_Erythema nodosum	Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.
CID	14648024_D014212_2_296_300_ATRA_D004893_2_272_288_erythema nodosum	We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.
CID	14648024_D014212_8_718_722_ATRA_D004893_8_766_782_erythema nodosum	ATRA seemed to be the most possible etiology of erythema nodosum in our patients.
CID	14648024_D014212_9_847_851_ATRA_D004893_9_860_876_erythema nodosum	Short-term use of steroid is very effective in ATRA-induced erythema nodosum.
CID	14648024_D014212_3_443_447_ATRA_D005334_3_310_315_Fever	Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.
UN	14648024_D014212_3_443_447_ATRA_D010146_3_340_347_painful	Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.
UN	14648024_D014212_2_296_300_ATRA_D015473_2_254_257_APL	We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.
UN	14648024_D014212_0_0_24_All- trans-retinoic acid_D015473_0_67_95_acute promyelocytic leukemia	All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.
UN	14648024_D014212_1_156_160_ATRA_D015473_1_166_194_acute promyelocytic leukemia	Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.
UN	14657095_C101425_2_324_336_posaconazole_D006333_2_295_308_heart failure	His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB.
CID	14657095_D000666_0_45_59_amphotericin B_D002311_0_11_33_dilated cardiomyopathy	Reversible dilated cardiomyopathy related to amphotericin B therapy.
UN	14657095_D000666_1_213_216_AmB_D003047_1_235_253_coccidioidomycosis	We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.
CID	14657095_D000666_1_197_211_amphotericin B_D006333_1_152_165_heart failure	We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.
CID	14657095_D000666_2_357_360_AmB_D006333_2_295_308_heart failure	His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB.
UN	14659530_D005996_1_429_442_nitroglycerin_D006261_1_368_376_headache	The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.
UN	14659530_D012701_1_333_337_5-HT_D006261_1_368_376_headache	The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.
UN	14659530_D012701_12_1800_1809_serotonin_D008881_12_1850_1858_migraine	In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.
UN	14659530_D015740_12_1916_1920_CGRP_D006261_12_1887_1895_headache	In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.
UN	14659530_D015740_8_1173_1177_CGRP_D006261_8_1227_1235_headache	However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.
UN	14659530_D015740_11_1768_1772_CGRP_D006261_11_1720_1728_headache	In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.
UN	14659530_D015740_11_1768_1772_CGRP_D008881_11_1777_1785_migraine	In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.
CID	1468485_D003520_6_726_742_cyclophosphamide_D003556_6_751_771_hemorrhagic cystitis	In future, this form of therapy can offer a safe alternative in the treatment of cyclophosphamide-induced hemorrhagic cystitis.
CID	1468485_D003520_1_160_176_cyclophosphamide_D003556_1_132_152_hemorrhagic cystitis	We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.
CID	1468485_D003520_0_53_69_cyclophosphamide_D003556_0_78_98_hemorrhagic cystitis	Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.
CID	1468485_D003520_0_53_69_cyclophosphamide_D006470_0_78_98_hemorrhagic cystitis	Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.
CID	1468485_D003520_1_160_176_cyclophosphamide_D006470_1_132_152_hemorrhagic cystitis	We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.
CID	1468485_D003520_6_726_742_cyclophosphamide_D006470_6_751_771_hemorrhagic cystitis	In future, this form of therapy can offer a safe alternative in the treatment of cyclophosphamide-induced hemorrhagic cystitis.
UN	1468485_D003520_1_160_176_cyclophosphamide_D014890_1_189_213_Wegener's granulomatosis	We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.
UN	1468485_D010100_0_11_17_oxygen_D003556_0_78_98_hemorrhagic cystitis	Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.
UN	1468485_D010100_0_11_17_oxygen_D006470_0_78_98_hemorrhagic cystitis	Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.
UN	1468485_D015237_2_314_336_prostaglandin F2 alpha_D006470_2_364_374_hemorrhage	Conservative treatment, including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha, failed to totally control hemorrhage.
UN	14698717_D010672_3_449_458_phenytoin_D004827_3_477_486_epileptic	This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.
UN	14698717_D010672_2_322_331_phenytoin_D011605_2_302_311_psychosis	The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.
UN	14698717_D010672_0_38_47_phenytoin_D011605_0_0_15_Acute psychosis	Acute psychosis due to treatment with phenytoin in a nonepileptic patient.
UN	14698717_D010672_3_449_458_phenytoin_D011605_3_409_427_psychotic symptoms	This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.
UN	14698717_D010672_3_449_458_phenytoin_D012640_3_549_557_seizures	This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.
UN	14698717_D010672_2_322_331_phenytoin_D014277_2_346_366_trigeminal neuralgia	The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.
UN	14704468_C066440_1_145_156_Loreclezole_D012640_1_247_254_seizure	Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both seizure and afterdischarge durations.
UN	14736955_C102006_8_1084_1091_citrate_D007674_8_950_980_glomerular and tubular lesions	RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.
CID	14736955_D004317_0_70_81_doxorubicin_D009401_0_82_91_nephrosis	Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.
UN	14736955_D013481_14_2002_2012_superoxide_D007674_14_2036_2049_renal lesions	CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.
UN	14742097_D004809_0_53_62_ephedrine_D020018_0_87_105_sexual dysfunction	A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction.
CID	14742097_D005473_2_400_410_fluoxetine_D020018_2_354_376_sexually dysfunctional	Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.
CID	14742097_D017374_2_427_437_paroxetine_D020018_2_354_376_sexually dysfunctional	Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.
CID	14742097_D020280_2_412_422_sertraline_D020018_2_354_376_sexually dysfunctional	Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.
UN	14745746_C090450_3_257_268_anastrozole_D001943_3_341_354_breast cancer	Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.
UN	14745746_D013629_3_270_279_tamoxifen_D001943_3_341_354_breast cancer	Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.
CID	14765563_D011803_2_331_338_quinine_D003128_2_437_441_coma	Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.
CID	14765563_D011803_2_331_338_quinine_D003221_2_389_398_confusion	Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.
CID	14765563_D011803_2_331_338_quinine_D012640_2_423_431_seizures	Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.
UN	14765563_D011803_1_190_197_quinine_D020922_1_133_153_nocturnal leg cramps	Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.
CID	14975762_D004317_8_1027_1038_doxorubicin_D006333_8_1089_1102_heart failure	These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin-induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo.
UN	14975762_D004317_1_69_80_Doxorubicin_D009369_1_92_97_tumor	Doxorubicin is an anti-tumor agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.
UN	14976857_D011405_0_57_68_propafenone_D004437_0_100_117_Ebstein's anomaly	Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.
UN	14976857_D011405_2_520_531_propafenone_D054092_2_400_420_patent foramen ovale	This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.
UN	14976857_D011405_0_57_68_propafenone_D062787_0_69_77_overdose	Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.
UN	14976857_D011405_2_520_531_propafenone_D062787_2_532_540_overdose	This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.
UN	14982270_D008713_5_561_572_Methimazole_D002779_5_581_592_cholestasis	Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.
UN	14982270_D008713_2_195_206_methimazole_D006980_2_264_279_hyperthyroidism	A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.
CID	14982270_D008713_2_195_206_methimazole_D011537_2_163_170_itching	A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.
CID	14982270_D008713_0_0_11_Methimazole_D041781_0_20_40_cholestatic jaundice	Methimazole-induced cholestatic jaundice.
UN	14982270_D011433_5_612_623_propranolol_D002779_5_581_592_cholestasis	Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.
UN	14982270_D011433_2_223_234_propranolol_D006980_2_264_279_hyperthyroidism	A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.
UN	14982270_D011433_2_223_234_propranolol_D007565_2_150_158_jaundice	A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.
UN	14982270_D011433_2_223_234_propranolol_D011537_2_163_170_itching	A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.
UN	15009014_D001285_7_1046_1054_atropine_D006940_7_963_992_increases in dural blood flow	The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.
CID	15009014_D002211_5_723_732_Capsaicin_D006940_5_785_827_increases in dural and cortical blood flow	Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation.
UN	15036754_C048599_10_1565_1568_CPA_D011041_10_1662_1671_poisoning	In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.
UN	15036754_C048599_8_1314_1317_CPA_D011041_8_1462_1471_poisoning	When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.
UN	15036754_D001285_10_1608_1616_atropine_D011041_10_1662_1671_poisoning	In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.
UN	15036754_D003975_8_1319_1327_diazepam_D011041_8_1462_1471_poisoning	When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.
UN	15036754_D003975_10_1570_1578_diazepam_D011041_10_1662_1671_poisoning	In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.
UN	15036754_D007531_10_1705_1708_DFP_D011041_10_1662_1671_poisoning	In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.
UN	15036754_D010755_0_0_15_Organophosphate_D004194_0_54_79_neuropathological damages	Organophosphate-induced convulsions and prevention of neuropathological damages.
UN	15036754_D010755_0_0_15_Organophosphate_D012640_0_24_35_convulsions	Organophosphate-induced convulsions and prevention of neuropathological damages.
UN	15036754_D011220_8_1331_1335_2PAM_D011041_8_1462_1471_poisoning	When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.
UN	15036754_D011220_10_1583_1587_2PAM_D011041_10_1662_1671_poisoning	In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.
UN	15042318_D004317_1_368_379_doxorubicin_C535648_1_223_239_gastric lymphoma	The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.
CID	15042318_D004317_1_368_379_doxorubicin_D001281_1_325_344_atrial fibrillation	The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.
UN	15042318_D004317_1_368_379_doxorubicin_D009136_1_294_312_muscular dystrophy	The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.
UN	15042318_D004317_1_368_379_doxorubicin_D009223_1_244_262_myotonic dystrophy	The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.
CID	1504402_D007741_0_52_61_dilevalol_D004342_0_0_16_Hypersensitivity	Hypersensitivity immune reaction as a mechanism for dilevalol-associated hepatitis.
CID	1504402_D007741_0_52_61_dilevalol_D056486_0_73_82_hepatitis	Hypersensitivity immune reaction as a mechanism for dilevalol-associated hepatitis.
CID	1504402_D007741_1_228_237_dilevalol_D056486_1_246_258_liver injury	OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.
CID	1504402_D007741_2_318_327_dilevalol_D056486_2_336_348_liver injury	PATIENT: A 58-year-old woman with a clinical diagnosis of dilevalol-induced liver injury.
CID	1504402_D007741_8_1282_1291_dilevalol_D056486_8_1300_1312_liver injury	CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.
CID	15075188_D011692_5_586_589_PAN_D001201_5_700_707_ascites	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.
CID	15075188_D011692_11_2050_2053_PAN_D009404_11_2062_2080_nephrotic syndrome	In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.
CID	15075188_D011692_0_68_93_puromycin aminonucleoside_D009404_0_102_120_nephrotic syndrome	Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.
CID	15075188_D011692_5_586_589_PAN_D011507_5_620_631_proteinuria	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.
CID	15075188_D011692_5_586_589_PAN_D034141_5_633_648_hypoalbuminemia	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.
UN	15075188_D012964_5_668_674_sodium_D001201_5_700_707_ascites	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.
UN	15075188_D012964_1_173_179_sodium_D004487_1_206_211_edema	Nephrotic syndrome is often accompanied by sodium retention and generalized edema.
UN	15075188_D012964_1_173_179_sodium_D009404_1_130_148_Nephrotic syndrome	Nephrotic syndrome is often accompanied by sodium retention and generalized edema.
UN	15075188_D012964_11_2017_2023_sodium_D009404_11_2062_2080_nephrotic syndrome	In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.
UN	15075188_D012964_5_668_674_sodium_D011507_5_620_631_proteinuria	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.
UN	15075188_D012964_5_668_674_sodium_D034141_5_633_648_hypoalbuminemia	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.
CID	150790_D007538_0_55_64_isoniazid_D002653_0_23_42_behavioral disorder	A pyridoxine-dependent behavioral disorder unmasked by isoniazid.
CID	150790_D007538_1_213_222_isoniazid_D006948_1_119_131_hyperkinesis	A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.
UN	150790_D007538_1_213_222_isoniazid_D012893_1_151_172_sleeping difficulties	A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.
UN	150790_D011736_0_2_12_pyridoxine_D002653_0_23_42_behavioral disorder	A pyridoxine-dependent behavioral disorder unmasked by isoniazid.
UN	150790_D011736_5_539_549_pyridoxine_D006948_5_584_596_hyperkinesis	Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis.
CID	15096016_D007980_6_901_909_levodopa_D004409_6_918_929_dyskinesias	Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.
UN	15096016_D007980_6_901_909_levodopa_D009127_6_826_834_rigidity	Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.
UN	15096016_D007980_6_901_909_levodopa_D018476_6_809_821_bradykinesia	Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.
UN	15120741_D001640_3_560_571_bicuculline_D013226_3_795_797_SE	In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.
UN	15120741_D008274_3_522_524_Mg_D013226_3_795_797_SE	In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.
CID	15120741_D010862_1_113_124_pilocarpine_D012640_1_210_218_seizures	Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.
CID	15120741_D010862_1_113_124_pilocarpine_D013226_1_142_160_status epilepticus	Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.
CID	15120741_D010862_3_746_757_pilocarpine_D013226_3_795_797_SE	In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.
UN	15120741_D018698_5_1044_1053_glutamate_D013226_5_1208_1210_SE	Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from SE survivors but not other groups.
UN	15120741_D018698_4_1006_1015_glutamate_D013226_4_802_804_SE	In SE survivors, similar stimulation resulted in a population spike followed, at a variable latency, by negative DC shifts and repetitive afterdischarges of 3-60 s duration, which were blocked by ionotropic glutamate receptor antagonists.
CID	15130900_D003520_4_623_639_cyclophosphamide_D001749_4_644_658_bladder cancer	Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.
CID	15130900_D003520_10_1628_1644_cyclophosphamide_D001749_10_1661_1675_bladder cancer	CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.
CID	15130900_D003520_7_1117_1133_cyclophosphamide_D001749_7_1066_1080_bladder cancer	The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).
UN	15130900_D003520_1_178_194_cyclophosphamide_D014890_1_213_237_Wegener's granulomatosis	OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.
UN	15130900_D003520_0_74_90_cyclophosphamide_D014890_0_26_50_Wegener's granulomatosis	Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.
CID	15145918_C032302_5_1207_1218_rilmenidine_D007022_5_1256_1267_hypotension	In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.
CID	15145918_C032302_7_1521_1532_rilmenidine_D007022_7_1533_1544_hypotension	Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.
UN	15145918_D003000_1_206_215_clonidine_D007022_1_184_195_hypotensive	We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.
UN	15145918_D004967_1_150_158_estrogen_D007022_1_184_195_hypotensive	We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.
UN	15145918_D008750_8_1559_1575_alpha-methyldopa_D001523_8_1650_1678_a reduced locomotor activity	The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.
CID	15145918_D008750_5_1222_1238_alpha-methyldopa_D007022_5_1256_1267_hypotension	In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.
CID	15145918_D008750_8_1559_1575_alpha-methyldopa_D007022_8_1576_1587_hypotension	The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.
CID	15145918_D008750_7_1475_1491_alpha-methyldopa_D007022_7_1451_1462_hypotensive	Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.
UN	15145918_D048288_0_64_75_imidazoline_D007022_0_94_105_hypotension	Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.
UN	15188772_D002395_1_121_134_Catecholamine_D009202_1_143_157_cardiomyopathy	Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon.
UN	15188772_D004837_3_436_447_epinephrine_D009202_3_666_685_myocardial necrosis	A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.
CID	15188772_D004837_3_436_447_epinephrine_D017682_3_458_477_myocardial stunning	A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.
UN	15188772_D004837_0_99_110_epinephrine_D018487_0_18_69_left ventricular systolic and diastolic dysfunction	Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.
UN	15188772_D004837_0_99_110_epinephrine_D062787_0_111_119_overdose	Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.
UN	15233872_C007145_0_27_48_tincture of Crataegus_D009203_0_74_95_myocardial infarction	Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.
UN	15233872_C007145_2_316_319_TCR_D009203_2_346_367_myocardial infarction	The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.
CID	15233872_D007545_0_52_65_isoproterenol_D009203_0_74_95_myocardial infarction	Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.
UN	15266215_C406224_0_51_61_valdecoxib_D001168_0_171_180_arthritis	Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
UN	15266215_C406224_2_426_436_valdecoxib_D001172_2_524_544_rheumatoid arthritis	We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.
UN	15266215_C406224_3_760_770_valdecoxib_D001172_3_932_952_rheumatoid arthritis	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
UN	15266215_C406224_9_1751_1761_valdecoxib_D001172_9_1901_1921_rheumatoid arthritis	Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.
UN	15266215_C406224_3_760_770_valdecoxib_D010003_3_913_927_osteoarthritis	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
UN	15266215_C406224_2_426_436_valdecoxib_D010003_2_505_519_osteoarthritis	We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.
UN	15266215_C406224_9_1751_1761_valdecoxib_D010003_9_1882_1896_osteoarthritis	Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.
UN	15266215_C406224_0_51_61_valdecoxib_D013927_0_136_146_thrombotic	Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
UN	15266215_C406224_3_760_770_valdecoxib_D013927_3_713_723_thrombotic	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
UN	15266215_C406224_5_1245_1255_valdecoxib_D013927_5_1210_1220_thrombotic	Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.
UN	15266215_C406224_6_1342_1352_valdecoxib_D013927_6_1298_1308_thrombotic	The risk of serious thrombotic events was also similar for each valdecoxib dose.
UN	15266215_C406224_9_1751_1761_valdecoxib_D013927_9_1818_1828_thrombotic	Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.
CID	15266215_D001241_7_1412_1419_aspirin_D013927_7_1359_1369_Thrombotic	Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).
UN	15266215_D004008_3_809_819_diclofenac_D001172_3_932_952_rheumatoid arthritis	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
UN	15266215_D004008_3_809_819_diclofenac_D010003_3_913_927_osteoarthritis	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
UN	15266215_D004008_3_809_819_diclofenac_D013927_3_713_723_thrombotic	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
UN	15266215_D007052_3_831_840_ibuprofen_D001172_3_932_952_rheumatoid arthritis	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
UN	15266215_D007052_3_831_840_ibuprofen_D010003_3_913_927_osteoarthritis	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
UN	15266215_D007052_3_831_840_ibuprofen_D013927_3_713_723_thrombotic	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
UN	15266215_D009288_3_856_864_naproxen_D001172_3_932_952_rheumatoid arthritis	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
UN	15266215_D009288_3_856_864_naproxen_D010003_3_913_927_osteoarthritis	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
UN	15266215_D009288_3_856_864_naproxen_D013927_3_713_723_thrombotic	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
UN	15266362_D004280_2_328_338_dobutamine_D002312_2_229_256_hypertrophic cardiomyopathy	The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.
CID	15266362_D004280_6_815_825_dobutamine_D004342_6_756_772_hypersensitivity	It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.
CID	15266362_D004280_6_815_825_dobutamine_D004802_6_774_786_eosinophilic	It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.
CID	15266362_D004280_6_815_825_dobutamine_D009205_6_788_799_myocarditis	It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.
UN	15266362_D004280_2_328_338_dobutamine_D018754_2_276_297_biventricular failure	The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.
UN	1527456_D008012_0_55_65_lignocaine_D014012_0_13_21_tinnitus	Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.
UN	1527456_D008012_2_285_295_lignocaine_D014012_2_248_251_IST	This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.
UN	15275829_D000109_1_168_181_acetylcholine_D003643_1_319_324_death	Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.
UN	15275829_D000109_0_31_44_acetylcholine_D006948_0_111_125_hypolocomotion	The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.
UN	15275829_D000109_0_31_44_acetylcholine_D012640_0_98_106_seizures	The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.
UN	15275829_D000109_1_168_181_acetylcholine_D014202_1_294_301_tremors	Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.
UN	15275829_D009538_1_146_154_nicotine_D003643_1_319_324_death	Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.
UN	15275829_D009538_0_81_89_nicotine_D006948_0_111_125_hypolocomotion	The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.
UN	15275829_D009538_4_563_571_nicotine_D006948_4_593_607_hypolocomotion	We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice. beta4 -/- mice were less sensitive to the effects of nicotine both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced seizures.
UN	15275829_D009538_7_1459_1467_nicotine_D006948_7_1489_1503_hypolocomotion	Together, these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine-induced seizures and hypolocomotion.
CID	15275829_D009538_0_81_89_nicotine_D012640_0_98_106_seizures	The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.
CID	15275829_D009538_5_1218_1226_nicotine_D012640_5_1235_1243_seizures	Using in situ hybridization probes for the alpha3 and alpha5 subunits, we showed that alpha5 mRNA levels are unchanged, whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb, and the inferior and the superior colliculus of beta4 -/- brains. alpha3 +/- mice were partially resistant to nicotine-induced seizures when compared to wild-type littermates.
CID	15275829_D009538_4_563_571_nicotine_D012640_4_580_588_seizures	We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice. beta4 -/- mice were less sensitive to the effects of nicotine both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced seizures.
CID	15275829_D009538_4_860_868_nicotine_D012640_4_877_885_seizures	We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice. beta4 -/- mice were less sensitive to the effects of nicotine both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced seizures.
CID	15275829_D009538_7_1459_1467_nicotine_D012640_7_1476_1484_seizures	Together, these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine-induced seizures and hypolocomotion.
UN	15275829_D009538_1_146_154_nicotine_D014202_1_294_301_tremors	Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.
CID	15276120_D014859_1_71_79_warfarin_D006470_1_88_96_bleeding	The annual incidence of warfarin-related bleeding at Brigham and Women's Hospital increased from 0.97/1,000 patient admissions in the first time period (January 1995 to October 1998) to 1.19/1,000 patient admissions in the second time period (November 1998 to August 2002) of this study.
CID	15276120_D014859_0_15_23_warfarin_D006470_0_35_45_hemorrhage	Time trends in warfarin-associated hemorrhage.
UN	15278670_C009250_9_1379_1390_sevoflurane_D003866_9_1484_1494_depression	It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.
UN	15278670_C009250_1_78_89_sevoflurane_D012640_1_111_122_convulsions	The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.
UN	15278670_C009250_0_15_26_sevoflurane_D012640_0_48_59_convulsions	The effects of sevoflurane on lidocaine-induced convulsions.
UN	15278670_C009250_9_1379_1390_sevoflurane_D012640_9_1403_1413_convulsive	It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.
UN	15278670_C009250_5_811_822_sevoflurane_D012640_5_767_778_convulsions	The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.
UN	15278670_C009250_4_595_606_sevoflurane_D012640_4_566_576_convulsive	There was no significant difference in the convulsive threshold between sevoflurane and enflurane.
UN	15278670_D001030_8_1206_1212_Apamin_D012640_8_1252_1262_convulsive	Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.
UN	15278670_D004737_4_611_620_enflurane_D012640_4_566_576_convulsive	There was no significant difference in the convulsive threshold between sevoflurane and enflurane.
UN	15278670_D004737_5_713_722_enflurane_D012640_5_767_778_convulsions	The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.
UN	15278670_D008012_9_1424_1433_lidocaine_D003866_9_1484_1494_depression	It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.
CID	15278670_D008012_9_1424_1433_lidocaine_D012640_9_1403_1413_convulsive	It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.
CID	15278670_D008012_0_30_39_lidocaine_D012640_0_48_59_convulsions	The effects of sevoflurane on lidocaine-induced convulsions.
CID	15278670_D008012_1_93_102_lidocaine_D012640_1_111_122_convulsions	The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.
UN	15325671_D003520_0_56_72_cyclophosphamide_D001943_0_107_120_breast cancer	Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.
UN	15325671_D003520_4_623_639_cyclophosphamide_D001943_4_583_596_breast cancer	Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.
UN	15325671_D003520_4_623_639_cyclophosphamide_D003920_4_927_944_diabetes mellitus	Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.
CID	15325671_D003520_5_1105_1121_cyclophosphamide_D006333_5_1080_1083_CHF	RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.
CID	15325671_D003520_10_1683_1699_cyclophosphamide_D006333_10_1716_1719_CHF	Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development.
UN	15325671_D003520_4_623_639_cyclophosphamide_D006973_4_881_893_hypertension	Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.
UN	15325671_D003520_0_56_72_cyclophosphamide_D066126_0_0_16_Cardiac toxicity	Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.
UN	15325671_D003520_6_1204_1220_cyclophosphamide_D066126_6_1229_1245_cardiac toxicity	Incidence of transient cyclophosphamide-related cardiac toxicity (10%) is comparable to previous recorded literature.
UN	15325671_D008558_3_355_364_melphalan_D001943_3_493_506_breast cancer	STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.
UN	15325671_D013852_3_397_405_thiotepa_D001943_3_493_506_breast cancer	STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.
UN	15325671_D016190_3_411_422_carboplatin_D001943_3_493_506_breast cancer	STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.
UN	15325671_D017239_3_343_353_paclitaxel_D001943_3_493_506_breast cancer	STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.
UN	15325671_D018943_4_959_973_anthracyclines_D001943_4_583_596_breast cancer	Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.
UN	15325671_D018943_4_959_973_anthracyclines_D003920_4_927_944_diabetes mellitus	Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.
UN	15325671_D018943_4_959_973_anthracyclines_D006333_4_746_770_congestive heart failure	Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.
UN	15325671_D018943_4_959_973_anthracyclines_D006973_4_881_893_hypertension	Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.
UN	15338796_D000420_5_592_602_salbutamol_D008173_5_523_547_obstructive lung disease	To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.
CID	15338796_D000420_12_1344_1354_Salbutamol_D014202_12_1379_1385_tremor	RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.
CID	15338796_D000420_0_23_33_salbutamol_D014202_0_0_6_Tremor	Tremor side effects of salbutamol, quantified by a laser pointer technique.
CID	15338796_D000420_1_119_129_salbutamol_D014202_1_96_102_tremor	OBJECTIVE: To study tremor side effects of salbutamol an easily applicable, quick and low-priced method is needed.
CID	1535072_D002997_2_327_339_clomipramine_D020018_2_304_323_sexual side effects	A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.
UN	1535072_D012701_4_622_631_serotonin_D001008_4_536_543_anxiety	METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n. basis in an open clinical trial.
UN	1535072_D012701_4_622_631_serotonin_D009771_4_487_516_obsessive compulsive disorder	METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n. basis in an open clinical trial.
UN	1535072_D012701_4_622_631_serotonin_D014256_4_518_534_trichotillomania	METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n. basis in an open clinical trial.
UN	1535072_D012701_4_622_631_serotonin_D019964_4_548_567_affective disorders	METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n. basis in an open clinical trial.
UN	1535072_D012701_0_54_63_serotonin_D020018_0_23_42_sexual side effects	Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.
UN	1535072_D012701_3_425_434_serotonin_D020018_3_395_414_sexual side effects	This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.
UN	1535072_D012701_4_622_631_serotonin_D020018_4_581_600_sexual side effects	METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n. basis in an open clinical trial.
UN	1535072_D012701_9_1228_1237_serotonin_D020018_9_1198_1217_sexual side effects	CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.
UN	1535072_D015016_8_999_1008_yohimbine_D001008_8_1048_1055_anxiety	Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.
UN	1535072_D015016_1_141_150_yohimbine_D007172_1_218_232_male impotence	BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.
UN	1535072_D015016_4_661_670_yohimbine_D009771_4_487_516_obsessive compulsive disorder	METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n. basis in an open clinical trial.
UN	1535072_D015016_4_661_670_yohimbine_D014256_4_518_534_trichotillomania	METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n. basis in an open clinical trial.
UN	1535072_D015016_4_661_670_yohimbine_D019964_4_548_567_affective disorders	METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n. basis in an open clinical trial.
UN	1535072_D015016_9_1150_1159_yohimbine_D020018_9_1198_1217_sexual side effects	CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.
UN	1535072_D015016_4_661_670_yohimbine_D020018_4_581_600_sexual side effects	METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n. basis in an open clinical trial.
UN	1535072_D015016_2_269_278_yohimbine_D020018_2_304_323_sexual side effects	A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.
UN	1535072_D015016_3_362_371_yohimbine_D020018_3_395_414_sexual side effects	This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.
UN	1535072_D015016_0_0_9_Yohimbine_D020018_0_23_42_sexual side effects	Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.
CID	1545575_D003520_1_135_151_cyclophosphamide_D003556_1_63_83_Hemorrhagic cystitis	Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.
CID	1545575_D003520_3_561_577_cyclophosphamide_D003556_3_590_610_hemorrhagic cystitis	In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.
CID	1545575_D003520_1_135_151_cyclophosphamide_D006470_1_63_83_Hemorrhagic cystitis	Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.
CID	1545575_D003520_3_561_577_cyclophosphamide_D006470_3_590_610_hemorrhagic cystitis	In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.
UN	1545575_D015080_5_761_766_mesna_D003556_5_839_859_hemorrhagic cystitis	In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.
UN	1545575_D015080_5_761_766_mesna_D006470_5_839_859_hemorrhagic cystitis	In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.
UN	15458908_D020849_8_1088_1098_Raloxifene_D002386_8_1125_1134_cataracts	Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).
UN	15458908_D020849_8_1088_1098_Raloxifene_D004714_8_1207_1230_endometrial hyperplasia	Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).
UN	15458908_D020849_9_1317_1327_Raloxifene_D004714_9_1462_1485_endometrial hyperplasia	CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.
UN	15458908_D020849_8_1088_1098_Raloxifene_D005705_8_1161_1180_gallbladder disease	Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).
UN	15458908_D020849_9_1317_1327_Raloxifene_D005705_9_1441_1460_gallbladder disease	CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.
UN	15458908_D020849_2_266_276_Raloxifene_D010024_2_377_389_osteoporosis	METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis.
UN	15458908_D020849_9_1317_1327_Raloxifene_D016889_9_1490_1508_endometrial cancer	CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.
UN	15458908_D020849_8_1088_1098_Raloxifene_D016889_8_1260_1278_endometrial cancer	Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).
CID	15458908_D020849_9_1317_1327_Raloxifene_D054556_9_1370_1392_venous thromboembolism	CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.
CID	15458908_D020849_5_626_636_raloxifene_D054556_5_679_701_venous thromboembolism	RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).
CID	1549199_D007980_4_738_746_levodopa_D005767_4_685_711_gastrointestinal disorders	Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.
CID	1549199_D007980_4_738_746_levodopa_D007024_4_713_736_orthostatic hypotension	Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.
UN	1549199_D007980_4_738_746_levodopa_D011618_4_755_764_psychosis	Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.
CID	1549199_D007980_4_738_746_levodopa_D020447_4_788_799_parasomnias	Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.
CID	15515654_D003676_9_1148_1151_DFO_D006319_9_1125_1129_SNHL	Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.
CID	15517007_D003520_7_845_861_cyclophosphamide_D006331_7_949_961_heart damage	However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.
UN	15517007_D003520_7_845_861_cyclophosphamide_D012595_7_976_994_systemic sclerosis	However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.
CID	15517007_D008942_7_888_900_mitoxantrone_D006331_7_949_961_heart damage	However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.
UN	15517007_D008942_7_888_900_mitoxantrone_D012595_7_976_994_systemic sclerosis	However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.
UN	15517007_D018943_7_865_879_anthracyclines_D006331_7_949_961_heart damage	However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.
UN	15517007_D018943_7_865_879_anthracyclines_D012595_7_976_994_systemic sclerosis	However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.
CID	15531665_D001205_4_521_530_vitamin C_D002318_4_563_585_cardiovascular disease	DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.
CID	15531665_D001205_3_421_430_vitamin C_D002318_3_457_479_cardiovascular disease	OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.
CID	15531665_D001205_8_1588_1597_Vitamin C_D002318_8_1637_1659_cardiovascular disease	Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.
CID	15531665_D001205_0_18_27_vitamin C_D002318_0_37_59_cardiovascular disease	Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?
UN	15531665_D001205_5_1212_1221_vitamin C_D003324_5_820_843_coronary artery disease	Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.
UN	15531665_D001205_4_521_530_vitamin C_D003324_4_597_620_coronary artery disease	DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.
UN	15531665_D001205_2_299_308_vitamin C_D003920_2_312_320_diabetic	These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis.
UN	15531665_D001205_0_18_27_vitamin C_D003920_0_79_87_diabetes	Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?
UN	15531665_D001205_4_521_530_vitamin C_D020521_4_636_642_stroke	DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.
UN	15531665_D001205_2_299_308_vitamin C_D050197_2_343_358_atherosclerosis	These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis.
UN	15531665_D005492_5_1020_1026_folate_D002318_5_1095_1117_cardiovascular disease	Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.
UN	15531665_D005492_5_1020_1026_folate_D003324_5_820_843_coronary artery disease	Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.
UN	15531665_D005492_5_1020_1026_folate_D003920_5_995_1003_diabetes	Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.
UN	15531665_D014810_5_1028_1037_vitamin E_D002318_5_1095_1117_cardiovascular disease	Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.
UN	15531665_D014810_5_1028_1037_vitamin E_D003324_5_820_843_coronary artery disease	Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.
UN	15531665_D014810_5_1028_1037_vitamin E_D003920_5_995_1003_diabetes	Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.
UN	15531665_D019207_5_1043_1056_beta-carotene_D002318_5_1095_1117_cardiovascular disease	Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.
UN	15531665_D019207_5_1043_1056_beta-carotene_D003324_5_820_843_coronary artery disease	Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.
UN	15531665_D019207_5_1043_1056_beta-carotene_D003920_5_995_1003_diabetes	Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.
UN	15565293_D004977_1_184_194_ethambutol_D009410_1_161_180_axonal degeneration	PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).
CID	15565293_D004977_5_661_664_EMB_D009901_5_674_690_optic neuropathy	METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.
CID	15565293_D004977_9_1312_1315_EMB_D009901_9_1324_1340_optic neuropathy	In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.
CID	15565293_D004977_15_2496_2499_EMB_D009901_15_2508_2524_optic neuropathy	Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.
CID	15565293_D004977_0_70_80_ethambutol_D009901_0_89_105_optic neuropathy	Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.
CID	15565293_D004977_12_2081_2084_EMB_D009901_12_2093_2109_optic neuropathy	CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.
CID	15565293_D004977_3_363_373_ethambutol_D009901_3_380_396_optic neuropathy	A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.
CID	15565293_D004977_1_184_194_ethambutol_D009901_1_203_219_optic neuropathy	PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).
UN	15565293_D004977_2_262_272_Ethambutol_D014376_2_323_335_tuberculosis	Ethambutol is an antimycobacterial agent often used to treat tuberculosis.
CID	15565293_D004977_5_649_659_ethambutol_D014786_5_731_746_visual deficits	METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.
UN	15565293_D004977_15_2561_2571_ethambutol_D051437_15_2596_2612_renal impairment	Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.
UN	15572383_D004317_8_955_965_adriamycin_D005923_8_1039_1063_focal glomerulosclerosis	RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.
UN	15572383_D004317_0_87_97_adriamycin_D007674_0_106_118_renal damage	Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage.
UN	15572383_D004317_3_534_544_adriamycin_D007674_3_488_500_renal damage	Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats.
UN	15572383_D004317_12_1675_1685_adriamycin_D007674_12_1694_1706_renal damage	CONCLUSION: Individual differences in renal ACE activity predict the severity of adriamycin-induced renal damage in this outbred rat strain.
UN	15572383_D004317_8_955_965_adriamycin_D009404_8_975_984_nephrotic	RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.
CID	15572383_D004317_9_1150_1160_adriamycin_D011507_9_1132_1143_proteinuria	Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).
CID	15572383_D004317_8_955_965_adriamycin_D011507_8_991_1002_proteinuria	RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.
CID	15572383_D004317_5_743_753_adriamycin_D011507_5_716_727_proteinuria	After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v. n = 9].
CID	15579441_D011692_4_615_640_puromycin aminonucleoside_D000860_4_600_607_hypoxia	With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.
CID	15579441_D011692_4_615_640_puromycin aminonucleoside_D009404_4_649_667_nephrotic syndrome	With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.
CID	15580403_D007372_1_240_250_interferon_D000743_1_158_174_Hemolytic anemia	BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.
UN	15580403_D007372_0_96_106_interferon_D006461_0_56_65_hemolysis	Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
UN	15580403_D007372_0_96_106_interferon_D019698_0_125_144_chronic hepatitis C	Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
CID	15580403_D012254_2_277_286_ribavirin_D000743_2_295_311_hemolytic anemia	Because of ribavirin-related hemolytic anemia, dose reduction is a common event in this therapy.
UN	15580403_D012254_0_19_28_ribavirin_D006461_0_56_65_hemolysis	Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
UN	15580403_D012254_3_447_456_ribavirin_D006461_3_484_493_hemolysis	In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy.
UN	15580403_D012254_0_111_120_ribavirin_D019698_0_125_144_chronic hepatitis C	Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
CID	15602202_D017963_0_50_62_azithromycin_D009395_0_16_38_interstitial nephritis	Recurrent acute interstitial nephritis induced by azithromycin.
UN	15632880_D002857_5_839_841_Cr_D006947_5_784_796_hyperkalemia	Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.
UN	15632880_D002857_5_839_841_Cr_D051437_5_818_837_renal insufficiency	Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.
UN	15632880_D003404_9_1531_1541_creatinine_D051437_9_1454_1473_renal insufficiency	Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.
UN	15632880_D011188_8_1288_1297_potassium_D003920_8_1252_1260_diabetes	Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).
UN	15632880_D011188_5_798_799_K_D006947_5_784_796_hyperkalemia	Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.
UN	15632880_D011188_5_798_799_K_D051437_5_818_837_renal insufficiency	Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.
UN	15632880_D013148_4_709_723_spironolactone_D006333_4_673_686_heart failure	METHODS: We performed a case control study of heart failure patients treated with spironolactone in our clinical practice.
UN	15632880_D013148_2_349_363_spironolactone_D006333_2_300_313_heart failure	Because treatments for heart failure have changed since the benefits of spironolactone were reported, the prevalence of these complications may differ in current clinical practice.
UN	15632880_D013148_3_611_625_spironolactone_D006333_3_575_588_heart failure	We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.
UN	15632880_D013148_0_0_14_Spironolactone_D006333_0_77_90_heart failure	Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
UN	15632880_D013148_1_165_179_spironolactone_D006333_1_183_196_heart failure	BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).
CID	15632880_D013148_7_1110_1124_spironolactone_D006947_7_1132_1144_hyperkalemia	RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).
CID	15632880_D013148_1_165_179_spironolactone_D006947_1_229_241_hyperkalemia	BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).
CID	15632880_D013148_0_0_14_Spironolactone_D006947_0_47_59_hyperkalemia	Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
CID	15632880_D013148_10_1671_1685_Spironolactone_D006947_10_1694_1706_hyperkalemia	CONCLUSIONS: Spironolactone-induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously.
CID	15632880_D013148_3_611_625_spironolactone_D006947_3_535_547_hyperkalemia	We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.
CID	15632880_D013148_3_611_625_spironolactone_D051437_3_552_571_renal insufficiency	We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.
CID	15632880_D013148_7_1110_1124_spironolactone_D051437_7_1157_1170_renal failure	RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).
CID	15632880_D013148_10_1671_1685_Spironolactone_D051437_10_1711_1730_renal insufficiency	CONCLUSIONS: Spironolactone-induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously.
CID	15632880_D013148_0_0_14_Spironolactone_D051437_0_23_42_renal insufficiency	Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
UN	15632880_D049971_9_1624_1632_thiazide_D051437_9_1454_1473_renal insufficiency	Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.
CID	15638391_D006220_0_113_124_haloperidol_D006966_0_83_101_hyperprolactinemia	Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.
CID	1564236_D004176_6_1176_1188_dipyridamole_D006940_6_1197_1206_hyperemia	During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.
CID	1564236_D004176_7_1430_1442_dipyridamole_D006940_7_1451_1460_hyperemia	The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in dipyridamole-induced hyperemia.
CID	1564236_D004176_9_1671_1683_dipyridamole_D006940_9_1692_1701_hyperemia	Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).
UN	1564236_D004176_6_1176_1188_dipyridamole_D023921_6_1241_1258_coronary stenosis	During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.
UN	1564236_D013793_9_1589_1597_Thallium_D006940_9_1692_1701_hyperemia	Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).
UN	1564236_D013793_0_136_144_thallium_D023921_0_100_117_coronary stenosis	Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.
CID	15649445_D006220_2_433_444_haloperidol_D004409_2_378_398_orofacial dyskinesia	In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.
CID	15649445_D006220_0_31_42_haloperidol_D004409_0_108_128_orofacial dyskinesia	Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.
CID	15649445_D006220_1_153_164_haloperidol_D004409_1_173_193_orofacial dyskinesia	Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.
CID	15649445_D012110_1_138_147_Reserpine_D004409_1_173_193_orofacial dyskinesia	Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.
CID	15649445_D012110_2_408_417_reserpine_D004409_2_378_398_orofacial dyskinesia	In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.
UN	15649445_D018698_0_80_89_glutamate_D004409_0_108_128_orofacial dyskinesia	Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.
UN	15673851_D009020_1_350_358_morphine_D001157_1_396_412_aortic occlusion	We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.
CID	15673851_D009020_5_1034_1042_morphine_D020336_5_1051_1070_spastic paraparesis	Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.
CID	15673851_D009020_8_1338_1346_morphine_D020336_8_1355_1374_spastic paraparesis	IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.
CID	15673851_D009020_9_1435_1443_morphine_D020336_9_1452_1471_spastic paraparesis	These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.
UN	15673851_D009020_0_132_140_morphine_D020760_0_174_194_spinal cord ischemia	The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.
UN	15673851_D016202_1_296_316_N-methyl-d-aspartate_D001157_1_396_412_aortic occlusion	We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.
UN	15673851_D016202_10_1650_1654_NMDA_D020258_10_1596_1606_neurotoxic	We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.
UN	15673851_D016202_9_1539_1543_NMDA_D020336_9_1452_1471_spastic paraparesis	These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.
UN	15673851_D016202_10_1650_1654_NMDA_D020760_10_1625_1645_spinal cord ischemia	We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.
UN	15673851_D016291_5_962_968_MK-801_D020336_5_1051_1070_spastic paraparesis	Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.
UN	15673851_D016291_8_1258_1264_MK-801_D020336_8_1355_1374_spastic paraparesis	IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.
UN	15673851_D018698_9_1507_1516_glutamate_D020336_9_1452_1471_spastic paraparesis	These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.
UN	15686794_D000638_1_92_102_Amiodarone_D001281_1_181_200_atrial fibrillation	Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.
UN	15686794_D000638_2_418_428_amiodarone_D001281_2_300_319_atrial fibrillation	We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.
CID	15686794_D000638_2_418_428_amiodarone_D017116_2_358_371_low back pain	We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.
CID	15686794_D000638_0_57_67_amiodarone_D017116_0_6_19_low back pain	Acute low back pain during intravenous administration of amiodarone: a report of two cases.
CID	15737522_D002443_3_467_478_ceftriaxone_D001660_3_409_424_pseudolithiasis	In this study, we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment, who often had to fast in the post-operative period.
CID	15737522_D002443_1_102_113_ceftriaxone_D001660_1_123_138_pseudolithiasis	It is well known that ceftriaxone leads to pseudolithiasis in some patients.
CID	15737522_D002443_0_0_11_Ceftriaxone_D001660_0_23_46_biliary pseudolithiasis	Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients.
CID	15764424_D000661_2_495_506_amphetamine_D006948_2_576_588_hyperkinesia	Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.
CID	15764424_D000661_1_301_312_amphetamine_D011605_1_333_342_psychosis	To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.
UN	15764424_D002395_1_188_202_catecholamines_D001523_1_251_262_psychiatric	To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.
UN	15764424_D002395_0_83_97_catecholamines_D006948_0_102_114_hyperkinesia	Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.
UN	15764424_D002395_1_188_202_catecholamines_D011605_1_208_226_psychotic symptoms	To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.
UN	15764424_D002395_0_83_97_catecholamines_D011605_0_38_47_psychosis	Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.
CID	15764424_D003042_1_317_324_cocaine_D011605_1_333_342_psychosis	To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.
CID	15764424_D008694_2_476_491_Methamphetamine_D006948_2_576_588_hyperkinesia	Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.
CID	15804801_D017239_0_42_52_paclitaxel_D003323_0_0_17_Coronary aneurysm	Coronary aneurysm after implantation of a paclitaxel-eluting stent.
CID	15811908_C012052_2_298_309_amisulpride_D006261_2_243_251_headache	CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.
CID	15811908_C012052_7_976_987_amisulpride_D006973_7_1010_1022_hypertensive	CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.
CID	15811908_C012052_6_872_883_amisulpride_D006973_6_848_860_hypertensive	In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.
UN	15811908_C012052_0_29_40_amisulpride_D010673_0_0_16_Pheochromocytoma	Pheochromocytoma unmasked by amisulpride and tiapride.
UN	15811908_C012052_1_138_149_amisulpride_D010673_1_95_111_pheochromocytoma	OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.
CID	15811908_C012052_2_298_309_amisulpride_D014839_2_256_264_vomiting	CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.
UN	15811908_C037689_5_694_703_benzamide_D010673_5_628_644_pheochromocytoma	DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.
CID	15811908_D063325_2_321_329_tiapride_D006261_2_243_251_headache	CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.
CID	15811908_D063325_6_888_896_tiapride_D006973_6_848_860_hypertensive	In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.
CID	15811908_D063325_7_993_1001_tiapride_D006973_7_1010_1022_hypertensive	CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.
UN	15811908_D063325_1_154_162_tiapride_D010673_1_95_111_pheochromocytoma	OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.
UN	15811908_D063325_0_45_53_tiapride_D010673_0_0_16_Pheochromocytoma	Pheochromocytoma unmasked by amisulpride and tiapride.
UN	15811908_D063325_7_993_1001_tiapride_D010673_7_1048_1064_pheochromocytoma	CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.
CID	15811908_D063325_2_321_329_tiapride_D014839_2_256_264_vomiting	CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.
CID	15814210_D003907_1_297_310_dexamethasone_D009422_1_218_242_neurological dysfunction	The objective of this study was to assess minor neurological dysfunction, cognitive development, and somatic development after dexamethasone therapy in very-low-birthweight infants.
CID	15814210_D003907_11_1460_1473_dexamethasone_D009422_11_1524_1549_neurological dysfunctions	After dexamethasone treatment, children showed a higher rate of minor neurological dysfunctions.
UN	15858223_C075750_10_1666_1679_15-F(2t)-IsoP_D005234_10_1719_1728_steatosis	Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.
UN	15858223_C075750_10_1666_1679_15-F(2t)-IsoP_D009336_10_1709_1717_necrosis	Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.
UN	15858223_D005978_7_1113_1124_glutathione_D056486_7_1053_1067_Liver toxicity	Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.
CID	15858223_D014635_10_1598_1601_VPA_D005234_10_1719_1728_steatosis	Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.
CID	15858223_D014635_10_1598_1601_VPA_D009336_10_1709_1717_necrosis	Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.
CID	15858223_D014635_2_398_401_VPA_D056486_2_434_448_hepatotoxicity	To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.
CID	15859940_D016572_12_1725_1737_cyclosporine_D057049_12_1660_1686_thrombotic microangiopathy	We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.
CID	15863244_D010894_9_1263_1272_piroxicam_D005317_9_1129_1160_intrauterine growth retardation	RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.
UN	15863244_D010894_8_1010_1019_piroxicam_D006345_8_919_968_ventricular septal (VSD) and midline (MD) defects	The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.
CID	15863244_D010894_9_1263_1272_piroxicam_D009139_9_1166_1210_increase of external and skeletal variations	RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.
UN	15863244_D010894_8_1010_1019_piroxicam_D009436_8_919_968_ventricular septal (VSD) and midline (MD) defects	The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.
CID	15867025_D006514_3_597_624_hepatitis B surface antigen_D006509_3_541_552_hepatitis B	Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.
CID	15867025_D006514_6_941_968_hepatitis B surface antigen_D006509_6_1000_1011_hepatitis B	All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.
UN	15867025_D006514_3_597_624_hepatitis B surface antigen_D012409_3_643_650_rubella	Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.
CID	15893386_D013390_3_465_480_succinylcholine_D014313_3_445_457_jaw of steel	Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.
CID	15893386_D013390_0_0_15_Succinylcholine_D014313_0_24_48_masseter muscle rigidity	Succinylcholine-induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.
UN	15893386_D015742_4_642_650_propofol_D008305_4_716_738_malignant hyperthermia	Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.
UN	15897593_D003630_5_1139_1151_daunorubicin_D001855_5_1101_1117_myelosuppression	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
UN	15897593_D003630_0_98_110_daunorubicin_D001855_0_29_45_myelosuppression	Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
CID	15897593_D003630_3_742_754_daunorubicin_D006402_3_530_550_hematologic toxicity	EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
CID	15897593_D003630_5_1139_1151_daunorubicin_D015431_5_1122_1133_weight loss	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
UN	15897593_D003630_1_160_172_daunorubicin_D066126_1_339_355_cardiac toxicity	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
UN	15897593_D004317_5_1346_1357_doxorubicin_D001855_5_1280_1296_myelosuppression	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
UN	15897593_D004317_0_119_130_doxorubicin_D001855_0_29_45_myelosuppression	Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
UN	15897593_D004317_1_177_188_doxorubicin_D001855_1_318_334_myelosuppression	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
CID	15897593_D004317_3_760_771_doxorubicin_D006402_3_530_550_hematologic toxicity	EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
CID	15897593_D004317_5_1346_1357_doxorubicin_D015431_5_1298_1309_weight loss	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
UN	15897593_D004317_1_177_188_doxorubicin_D066126_1_339_355_cardiac toxicity	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
UN	15897593_D005047_0_84_93_etoposide_D001855_0_29_45_myelosuppression	Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
UN	15897593_D005047_5_1156_1165_etoposide_D001855_5_1101_1117_myelosuppression	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
CID	15897593_D005047_8_1881_1890_etoposide_D006402_8_1957_1977_hematologic toxicity	Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.
CID	15897593_D005047_3_731_740_etoposide_D006402_3_530_550_hematologic toxicity	EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
UN	15897593_D005047_8_1881_1890_etoposide_D009362_8_1830_1840_metastases	Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.
CID	15897593_D005047_5_1156_1165_etoposide_D015431_5_1122_1133_weight loss	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
UN	15897593_D005047_1_216_225_etoposide_D066126_1_339_355_cardiac toxicity	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
UN	15897593_D011034_1_197_215_epipodophyllotoxin_D001855_1_318_334_myelosuppression	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
UN	15897593_D011034_1_197_215_epipodophyllotoxin_D066126_1_339_355_cardiac toxicity	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
UN	15897593_D018943_1_145_159_anthracyclines_D001855_1_318_334_myelosuppression	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
UN	15897593_D018943_2_434_447_anthracycline_D066126_2_456_470_cardiotoxicity	Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
UN	15897593_D064730_0_0_11_Dexrazoxane_D001855_0_29_45_myelosuppression	Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
UN	15897593_D064730_5_1081_1092_dexrazoxane_D001855_5_1101_1117_myelosuppression	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
UN	15897593_D064730_3_581_592_dexrazoxane_D006402_3_530_550_hematologic toxicity	EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
UN	15897593_D064730_8_1851_1862_dexrazoxane_D009362_8_1830_1840_metastases	Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.
UN	15897593_D064730_5_1081_1092_dexrazoxane_D015431_5_1122_1133_weight loss	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
UN	15897593_D064730_2_386_394_ICRF-187_D066126_2_456_470_cardiotoxicity	Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
CID	15899738_D003401_0_41_49_creatine_D001281_0_5_24_atrial fibrillation	Lone atrial fibrillation associated with creatine monohydrate supplementation.
UN	1592014_C005618_7_971_973_BE_D003643_7_947_952_death	Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.
CID	1592014_C005618_0_43_58_benzoylecgonine_D012640_0_0_8_Seizures	Seizures induced by the cocaine metabolite benzoylecgonine in rats.
CID	1592014_C005618_9_1190_1192_BE_D012640_9_1225_1233_seizures	BE-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without seizures.
CID	1592014_C005618_6_705_707_BE_D012640_6_716_724_seizures	BE-Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine.
CID	1592014_C005618_10_1354_1356_BE_D012640_10_1365_1373_seizures	The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.
UN	1592014_D003042_7_849_856_cocaine_D003643_7_947_952_death	Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.
CID	1592014_D003042_0_24_31_cocaine_D012640_0_0_8_Seizures	Seizures induced by the cocaine metabolite benzoylecgonine in rats.
CID	1592014_D003042_9_1281_1288_cocaine_D012640_9_1314_1322_seizures	BE-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without seizures.
CID	1592014_D003042_10_1438_1445_cocaine_D012640_10_1454_1462_seizures	The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.
CID	1592014_D003042_7_849_856_cocaine_D012640_7_865_873_seizures	Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.
UN	1592014_D003042_1_92_99_cocaine_D020521_1_183_190_strokes	The half-life (t1/2) of cocaine is relatively short, but some of the consequences of its use, such as seizures and strokes, can occur hours after exposure.
CID	15930398_D015742_0_83_91_propofol_D000647_0_43_50_amnesia	Assessment of the onset and persistence of amnesia during procedural sedation with propofol.
UN	15957009_C507242_0_40_49_Ro4368554_D008569_0_120_137_memory deficiency	The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.
CID	15957009_D012601_5_1151_1162_scopolamine_D008569_5_1124_1139_memory deficits	Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).
UN	15957009_D012701_6_1496_1500_5-HT_D008569_6_1361_1375_memory deficit	In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.
UN	15957009_D014236_5_1072_1083_metrifonate_D008569_5_1124_1139_memory deficits	Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).
UN	15957009_D014364_5_1167_1170_TRP_D008569_5_1124_1139_memory deficits	Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).
UN	1595783_D000638_2_192_202_amiodarone_D000542_2_321_349_hypersensitivity pneumonitis	The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.
CID	1595783_D000638_2_192_202_amiodarone_D004342_2_321_349_hypersensitivity pneumonitis	The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.
CID	1595783_D000638_1_31_41_Amiodarone_D011014_1_153_164_pneumonitis	Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.
CID	15974569_D002211_2_433_442_capsaicin_D006930_2_451_474_mechanical hyperalgesia	Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.
UN	15974569_D002211_2_433_442_capsaicin_D010146_2_339_343_pain	Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.
CID	15974569_D002351_2_387_398_carrageenan_D006930_2_407_427_thermal hyperalgesia	Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.
UN	15974569_D002351_2_387_398_carrageenan_D010146_2_339_343_pain	Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.
UN	15974569_D005557_2_357_365_formalin_D006930_2_407_427_thermal hyperalgesia	Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.
UN	15974569_D005557_2_357_365_formalin_D010146_2_339_343_pain	Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.
UN	15974569_D007608_0_43_50_kainate_D010146_0_106_110_pain	Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.
CID	15985056_D001418_4_346_354_baclofen_D006606_4_372_379_hiccups	Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.
UN	15985056_D001569_7_598_613_benzodiazepines_D006606_7_768_775_hiccups	Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.
UN	15985056_D003907_7_559_572_dexamethasone_D006606_7_768_775_hiccups	Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.
UN	15985056_D008775_7_577_595_methylprednisolone_D006606_7_768_775_hiccups	Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.
UN	15985056_D008874_7_615_624_midazolam_D006606_7_768_775_hiccups	Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.
CID	15985056_D017963_10_1204_1216_azithromycin_D006606_10_1246_1253_hiccups	Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient.
CID	15985056_D017963_1_106_118_azithromycin_D006606_1_84_91_hiccups	OBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.
CID	15985056_D017963_0_9_21_azithromycin_D006606_0_33_40_hiccups	Possible azithromycin-associated hiccups.
CID	15985056_D017963_2_210_222_azithromycin_D006606_2_186_193_hiccups	CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.
CID	15985056_D017963_4_316_328_azithromycin_D006606_4_372_379_hiccups	Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.
UN	15985056_D017963_2_210_222_azithromycin_D010612_2_244_255_pharyngitis	CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.
UN	16005948_D003042_7_981_988_cocaine_D003643_7_965_970_death	Importantly, GNC92H2 prevented death even post-cocaine injection.
CID	16005948_D003042_6_772_779_cocaine_D012640_6_897_905_seizures	Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.
UN	16005948_D003042_1_119_126_cocaine_D062787_1_179_195_cocaine overdose	The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.
UN	16006300_C019248_11_1568_1579_Pamidronate_D006934_11_1679_1692_hypercalcemia	Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.
CID	16006300_C019248_11_1568_1579_Pamidronate_D006996_11_1631_1643_hypocalcemia	Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.
UN	16006300_C097949_3_620_643_1,25-dihydroxyvitamin D_D000471_3_539_558_metabolic alkalosis	RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.
UN	16006300_C097949_3_620_643_1,25-dihydroxyvitamin D_D058186_3_503_528_acute renal insufficiency	RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.
UN	16006300_D002118_2_389_396_calcium_D006934_2_358_371_hypercalcemia	METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome.
UN	16006300_D002118_6_802_809_calcium_D006996_6_910_922_hypocalcemia	The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.
CID	16006300_D002119_1_149_166_calcium carbonate_D006934_1_175_188_hypercalcemia	OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.
CID	1601297_D003042_2_232_239_cocaine_D002037_2_371_390_bundle branch block	Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.
UN	1601297_D003042_2_232_239_cocaine_D007511_2_357_365_ischemia	Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.
UN	1601297_D003042_0_83_90_cocaine_D009202_0_33_50_myocardial injury	Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers.
CID	1601297_D003042_2_232_239_cocaine_D009203_2_334_355_myocardial infarction	Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.
UN	1601297_D003042_1_135_142_cocaine_D012559_1_194_207_schizophrenic	The electrocardiograms (ECG) of 99 cocaine-abusing patients were compared with the ECGs of 50 schizophrenic controls.
UN	16047871_D014859_0_0_8_Warfarin_C535509_0_17_44_leukocytoclastic vasculitis	Warfarin-induced leukocytoclastic vasculitis.
UN	16047871_D014859_3_329_337_warfarin_C535509_3_310_312_LV	We report 4 patients with late-onset LV probably due to warfarin.
UN	16047871_D014859_4_415_423_warfarin_D012871_4_369_383_skin eruptions	All 4 patients presented with skin eruptions that developed after receiving warfarin for several years.
CID	16047871_D014859_5_572_580_warfarin_D018366_5_520_540_LV Cutaneous lesions	The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.
CID	1610717_D003042_0_0_7_Cocaine_D012640_0_26_34_seizures	Cocaine-induced brainstem seizures and behavior.
UN	16116131_D001058_2_473_484_apomorphine_D004409_2_434_444_dyskinetic	Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.
UN	16116131_D001058_2_473_484_apomorphine_D010300_2_317_334_Parkinson disease	Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.
CID	16116131_D007980_1_141_149_levodopa_D004409_1_158_168_dyskinesia	The neural mechanisms and circuitry involved in levodopa-induced dyskinesia are unclear.
UN	16132524_D016190_0_39_50_carboplatin_D005909_0_98_110_glioblastoma	Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma -- clinical observations.
CID	16132524_D017239_6_946_956_paclitaxel_D001929_6_994_1005_brain edema	Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.
UN	16132524_D017239_0_28_38_paclitaxel_D005909_0_98_110_glioblastoma	Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma -- clinical observations.
UN	16157917_C047781_1_172_183_lamotrigine_C562694_1_154_157_IGE	Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).
UN	16157917_C047781_0_0_11_Lamotrigine_C562694_0_65_98_idiopathic generalized epilepsies	Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.
CID	16157917_C047781_4_442_445_LTG_D009207_4_458_460_MJ	In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.
CID	16157917_C047781_2_281_284_LTG_D009207_2_297_299_MJ	In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.
CID	16157917_C047781_3_388_391_LTG_D009207_3_368_370_MJ	MJ disappeared when LTG dose was decreased by 25 to 50%.
CID	16157917_C047781_0_0_11_Lamotrigine_D009207_0_52_61_myoclonus	Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.
CID	16157917_C047781_1_185_188_LTG_D009207_1_240_255_myoclonic jerks	Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).
CID	16160878_D001058_7_1329_1340_apomorphine_D010409_7_1349_1364_penile erection	Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.
UN	16160878_D003345_7_1414_1428_corticosterone_D010409_7_1349_1364_penile erection	Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.
UN	16160878_D014579_9_1630_1634_U-II_D001523_9_1670_1691_psychiatric disorders	These data suggest that U-II may be involved in some aspects of psychiatric disorders.
UN	16160878_D014579_2_197_201_U-II_D001919_2_226_237_bradycardia	Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.
UN	16160878_D014579_2_197_201_U-II_D006973_2_209_221_hypertension	Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.
UN	16160878_D014579_7_1276_1280_U-II_D010409_7_1349_1364_penile erection	Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.
CID	1616457_D010424_1_142_155_pentobarbital_D000647_1_122_129_amnesia	Dissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital (15 mg/kg, ip) was carried out.
CID	1616457_D010424_0_41_54_pentobarbital_D000647_0_23_30_amnesia	Learning of rats under amnesia caused by pentobarbital.
CID	16167916_D020849_10_1402_1412_raloxifene_D054556_10_1372_1394_venous thromboembolism	CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.
CID	16174948_D003042_0_49_56_cocaine_D013345_0_68_91_subarachnoid hemorrhage	Absence of acute cerebral vasoconstriction after cocaine-associated subarachnoid hemorrhage.
CID	16174948_D003042_4_612_619_cocaine_D013345_4_536_539_SAH	METHODS: We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites.
CID	16174948_D003042_11_1982_1989_cocaine_D013345_11_1962_1965_SAH	CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.
CID	16174948_D003042_3_399_406_cocaine_D013345_3_418_441_subarachnoid hemorrhage	Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.
UN	16174948_D003042_1_107_114_Cocaine_D013901_1_144_171_neurovascular complications	INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.
UN	16174948_D003042_1_107_114_Cocaine_D014657_1_213_223_vasculitis	INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.
UN	16174948_D003042_11_1982_1989_cocaine_D014657_11_1881_1891_vasculitis	CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.
CID	16174948_D003042_11_1982_1989_cocaine_D017542_11_1951_1961_aneurysmal	CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.
CID	16181582_D014635_0_0_9_Valproate_D001927_0_18_32_encephalopathy	Valproate-induced encephalopathy.
CID	16181582_D014635_1_34_43_Valproate_D001927_1_52_66_encephalopathy	Valproate-induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals.
CID	16181582_D014635_5_392_401_valproate_D001927_5_410_424_encephalopathy	A case of valproate-induced encephalopathy is presented.
UN	16181582_D014635_1_34_43_Valproate_D004827_1_124_133_epileptic	Valproate-induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals.
CID	16192988_D008694_3_456_460_METH_D001523_3_420_434_aggressiveness	This increase in aggressiveness was not secondary to METH-induced hyperactivity.
CID	16192988_D008694_2_340_344_METH_D001523_2_369_383_aggressiveness	Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice.
UN	16192988_D008694_3_456_460_METH_D006948_3_469_482_hyperactivity	This increase in aggressiveness was not secondary to METH-induced hyperactivity.
UN	16225977_C012052_0_0_11_Amisulpride_D012559_0_55_68_schizophrenic	Amisulpride related tic-like symptoms in an adolescent schizophrenic.
CID	16225977_C012052_0_0_11_Amisulpride_D013981_0_20_37_tic-like symptoms	Amisulpride related tic-like symptoms in an adolescent schizophrenic.
CID	16225977_C012052_4_578_589_amisulpride_D013981_4_511_528_tic-like symptoms	The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.
UN	16225977_C012052_3_466_477_amisulpride_D020820_3_413_447_involuntary eye-blinking movements	We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).
UN	16225977_C069541_9_1116_1126_quetiapine_D013981_9_998_1015_tic-like symptoms	Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.
UN	16225977_C069541_2_321_331_quetiapine_D013981_2_233_250_tic-like symptoms	However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
UN	16225977_C076029_1_159_169_olanzapine_D013981_1_70_83_Tic disorders	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.
UN	16225977_C092292_1_174_185_ziprasidone_D013981_1_70_83_Tic disorders	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.
UN	16225977_D003024_9_1128_1137_clozapine_D013981_9_998_1015_tic-like symptoms	Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.
UN	16225977_D003024_2_335_344_clozapine_D013981_2_233_250_tic-like symptoms	However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
UN	16225977_D018967_1_146_157_risperidone_D013981_1_70_83_Tic disorders	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.
CID	16274958_D017255_0_24_33_acitretin_D055154_0_10_19_dysphonia	Recurrent dysphonia and acitretin.
CID	16274958_D017255_3_271_280_acitretin_D055154_3_289_298_dysphonia	To our knowledge, this is the first case of acitretin-induced dysphonia.
CID	16274958_D017255_1_115_124_acitretin_D055154_1_80_89_dysphonia	We report the case of a woman complaining of dysphonia while she was treated by acitretin.
CID	1628552_D002738_0_0_11_Chloroquine_D001766_0_46_55_blindness	Chloroquine related complete heart block with blindness: case report.
CID	1628552_D002738_2_318_329_chloroquine_D002037_2_429_454_right bundle branch block	Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
CID	1628552_D002738_1_122_133_chloroquine_D004244_1_226_235_dizziness	A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.
CID	1628552_D002738_1_122_133_chloroquine_D004417_1_216_224_dyspnoea	A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.
CID	1628552_D002738_1_122_133_chloroquine_D005221_1_201_214_fatiguability	A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.
CID	1628552_D002738_3_570_581_chloroquine_D006333_3_523_536_heart failure	The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.
CID	1628552_D002738_2_318_329_chloroquine_D012164_2_330_341_retinopathy	Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
CID	1628552_D002738_1_122_133_chloroquine_D013575_1_251_267_syncopal attacks	A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.
UN	1628552_D002738_1_122_133_chloroquine_D015354_1_171_194_deterioration of vision	A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.
UN	16298782_D000617_2_555_569_aminoglycoside_D006311_2_440_448_ototoxic	Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.
UN	16298782_D000617_1_289_303_Aminoglycoside_D006316_1_192_219_high-frequency hearing loss	The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost.
UN	16298782_D000617_2_555_569_aminoglycoside_D006319_2_578_604_sensorineural hearing loss	Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.
UN	16298782_D005839_1_230_240_gentamicin_D006316_1_192_219_high-frequency hearing loss	The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost.
CID	16298782_D005839_6_940_950_gentamicin_D034381_6_959_971_hearing loss	L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.
UN	16298782_D009569_2_486_488_NO_D006311_2_440_448_ototoxic	Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.
UN	16298782_D009569_1_89_101_nitric oxide_D006316_1_192_219_high-frequency hearing loss	The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost.
UN	16298782_D009569_2_519_521_NO_D006319_2_578_604_sensorineural hearing loss	Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.
UN	16298782_D019331_0_0_29_Nitro-L-arginine methyl ester_D006311_0_72_83_ototoxicity	Nitro-L-arginine methyl ester: a potential protector against gentamicin ototoxicity.
UN	16298782_D019331_1_148_154_L-NAME_D006316_1_192_219_high-frequency hearing loss	The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost.
UN	16298782_D019331_6_925_931_L-NAME_D034381_6_959_971_hearing loss	L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.
UN	16330766_C040029_5_917_927_gabapentin_D006930_5_1052_1074_secondary hyperalgesia	Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary hyperalgesia.
UN	16330766_C040029_4_679_689_gabapentin_D009437_4_711_727_neuropathic pain	The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.
CID	16330766_D002211_5_1034_1043_capsaicin_D006930_5_1052_1074_secondary hyperalgesia	Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary hyperalgesia.
CID	16337777_D010862_3_741_752_pilocarpine_D004833_3_762_784_temporal lobe epilepsy	In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.
UN	16337777_D010862_3_741_752_pilocarpine_D013226_3_537_555_status epilepticus	In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.
CID	1636026_D013496_7_1075_1083_suprofen_D058186_7_1091_1123_acute declines in renal function	In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.
CID	1636026_D013496_1_66_74_suprofen_D058186_1_119_138_acute renal failure	Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.
UN	1636026_D014527_2_408_417_uric acid_D007674_2_221_232_nephrotoxic	The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.
UN	1636026_D014527_7_1189_1198_uric acid_D058186_7_1091_1123_acute declines in renal function	In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.
CID	16364460_D012601_9_1609_1620_scopolamine_D000647_9_1629_1636_amnesia	Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.
CID	16364460_D012601_0_73_84_scopolamine_D000647_0_93_100_amnesia	Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.
CID	16364460_D012601_1_168_179_scopolamine_D000647_1_224_231_amnesia	The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.
UN	16364460_D016713_0_18_28_ritanserin_D000647_0_93_100_amnesia	Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.
UN	16364460_D016713_1_135_145_ritanserin_D000647_1_224_231_amnesia	The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.
UN	16364460_D016713_9_1546_1556_ritanserin_D000647_9_1629_1636_amnesia	Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.
UN	1639466_D000809_1_204_215_angiotensin_D000419_1_273_284_albuminuria	The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.
UN	1639466_D000809_1_204_215_angiotensin_D006978_1_392_417_renovascular hypertension	The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.
UN	1639466_D002118_1_160_167_calcium_D000419_1_273_284_albuminuria	The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.
UN	1639466_D002118_0_22_29_calcium_D006978_0_91_116_renovascular hypertension	Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.
UN	1639466_D002118_0_22_29_calcium_D009400_0_62_77_nephrosclerosis	Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.
UN	1639466_D004656_1_244_253_enalapril_D000419_1_273_284_albuminuria	The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.
UN	1639466_D004656_8_1197_1206_enalapril_D005921_8_1157_1175_glomerulosclerosis	Renal plasma flow increased, but albumin excretion and glomerulosclerosis did not change after enalapril treatment.
UN	1639466_D004656_11_1690_1699_enalapril_D006973_11_1759_1771_hypertensive	In addition, glomerular size was higher in the nitrendipine-treated group (14.9 +/- 0.17 10(-3) mm2) but lower in the enalapril-treated group (11.5 +/- 0.15 10(-3) mm2) compared with the hypertensive controls (12.1 +/- 0.17 10(-3) mm2).(ABSTRACT TRUNCATED AT 250 WORDS)
UN	1639466_D004656_2_582_591_enalapril_D006973_2_551_563_hypertensive	Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).
UN	1639466_D004656_1_244_253_enalapril_D006978_1_392_417_renovascular hypertension	The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.
CID	1639466_D009568_9_1238_1250_nitrendipine_D000419_9_1265_1276_albuminuria	In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.
UN	1639466_D009568_10_1468_1480_nitrendipine_D005921_10_1408_1426_glomerulosclerosis	Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/- 0.1 versus 0.13 +/- 0.04).
UN	1639466_D009568_10_1468_1480_nitrendipine_D006973_10_1513_1525_hypertensive	Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/- 0.1 versus 0.13 +/- 0.04).
UN	1639466_D009568_0_46_58_nitrendipine_D006978_0_91_116_renovascular hypertension	Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.
CID	1639466_D009568_0_46_58_nitrendipine_D009400_0_62_77_nephrosclerosis	Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.
UN	16403073_D007654_2_337_349_ketoconazole_D003324_2_223_246_coronary artery disease	We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.
CID	16403073_D007654_6_703_715_ketoconazole_D008133_6_775_791_long QT syndrome	This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.
CID	16403073_D007654_2_337_349_ketoconazole_D008133_2_272_293_prolonged QT interval	We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.
UN	16403073_D007654_2_337_349_ketoconazole_D009181_2_367_383_fungal infection	We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.
CID	16403073_D007654_0_0_12_Ketoconazole_D016171_0_21_40_torsades de pointes	Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
CID	16403073_D007654_2_337_349_ketoconazole_D016171_2_319_322_TdP	We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.
CID	16403073_D007654_5_614_626_ketoconazole_D016171_5_668_671_TdP	We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP.
UN	16418614_D011441_0_0_3_PTU_D006111_0_61_76_Graves' disease	PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.
UN	16418614_D011441_0_0_3_PTU_D014424_0_41_56_Turner Syndrome	PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.
CID	16418614_D011441_0_0_3_PTU_D014657_0_15_25_vasculitis	PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.
CID	16418614_D011441_4_510_513_PTU_D014657_4_526_536_vasculitis	The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.
UN	16428221_D008774_3_392_407_methylphenidate_D002544_3_456_473_ischaemic strokes	We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.
UN	16428221_D008774_2_292_307_methylphenidate_D002544_2_251_267_ischaemic stroke	Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.
UN	16428221_D008774_3_392_407_methylphenidate_D006948_3_415_428_hyperactivity	We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.
UN	16428221_D008774_2_292_307_methylphenidate_D019969_2_195_212_amphetamine abuse	Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.
CID	16428221_D008774_0_35_50_methylphenidate_D020293_0_0_19_Cerebral vasculitis	Cerebral vasculitis following oral methylphenidate intake in an adult: a case report.
UN	16428827_C004742_5_764_772_daidzein_D000647_5_860_867_amnesia	Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.
UN	16428827_C004742_0_0_8_Daidzein_D000647_0_89_96_amnesia	Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.
UN	16428827_C004742_8_1271_1279_daidzein_D000647_8_1398_1405_amnesia	These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.
UN	16428827_C004742_4_611_619_daidzein_D007859_4_670_704_impairments of learning and memory	In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.
UN	16428827_C004742_4_611_619_daidzein_D008569_4_670_704_impairments of learning and memory	In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.
UN	16428827_D000109_1_237_250_acetylcholine_D000544_1_301_320_Alzheimer's disease	The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).
UN	16428827_D000109_8_1301_1314_acetylcholine_D000647_8_1398_1405_amnesia	These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.
UN	16428827_D002794_1_102_109_choline_D000544_1_301_320_Alzheimer's disease	The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).
UN	16428827_D002794_0_19_26_choline_D000647_0_89_96_amnesia	Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.
CID	16428827_D012601_8_1378_1389_scopolamine_D000647_8_1398_1405_amnesia	These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.
CID	16428827_D012601_5_840_851_scopolamine_D000647_5_860_867_amnesia	Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.
UN	16428827_D012601_4_650_661_scopolamine_D007859_4_670_704_impairments of learning and memory	In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.
UN	16471092_C099041_1_232_243_tolterodine_D053201_1_221_224_OAB	OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.
UN	16471092_C099041_0_89_100_tolterodine_D053201_0_64_82_overactive bladder	Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.
UN	16563323_C071741_11_1183_1195_remifentanil_D001049_11_1291_1296_apnea	CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.
UN	16563323_C071741_11_1183_1195_remifentanil_D009207_11_1216_1225_myoclonus	CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.
UN	16563323_C071741_8_845_857_remifentanil_D009207_8_804_813_myoclonus	MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).
UN	16563323_C071741_0_0_12_Remifentanil_D009207_0_34_43_myoclonus	Remifentanil pretreatment reduces myoclonus after etomidate.
UN	16563323_C071741_11_1183_1195_remifentanil_D009325_11_1298_1304_nausea	CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.
UN	16563323_C071741_11_1183_1195_remifentanil_D011537_11_1309_1317_pruritus	CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.
UN	16563323_D005045_11_1232_1241_etomidate_D001049_11_1291_1296_apnea	CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.
CID	16563323_D005045_1_258_267_etomidate_D009207_1_216_225_myoclonus	STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.
CID	16563323_D005045_0_50_59_etomidate_D009207_0_34_43_myoclonus	Remifentanil pretreatment reduces myoclonus after etomidate.
CID	16563323_D005045_12_1384_1393_etomidate_D009207_12_1357_1366_myoclonus	Men experience increased incidence of myoclonus than women after etomidate administration.
CID	16563323_D005045_11_1232_1241_etomidate_D009207_11_1216_1225_myoclonus	CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.
CID	16563323_D005045_10_1127_1136_etomidate_D009207_10_1111_1120_myoclonus	In the placebo group, male patients were associated with significantly increased incidence of myoclonus after etomidate administration.
UN	16563323_D005045_11_1232_1241_etomidate_D009325_11_1298_1304_nausea	CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.
UN	16563323_D005045_11_1232_1241_etomidate_D011537_11_1309_1317_pruritus	CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.
CID	16574712_D018817_0_0_4_MDMA_D003072_0_85_134_impaired social and emotional judgement processes	MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.
UN	16574712_D018817_1_207_211_MDMA_D008569_1_160_175_memory deficits	In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).
UN	16574713_D012701_1_308_312_5-HT_D020258_1_313_331_neurotoxic lesions	Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.
CID	16574713_D018817_10_1855_1859_MDMA_D008569_10_1889_1907_memory impairments	While the use of MDMA in quantities that may be considered "moderate" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.
CID	16574713_D018817_8_1650_1654_MDMA_D008569_8_1607_1624_memory impairment	In contrast, no evidence of memory impairment was observed in moderate MDMA users.
UN	16574713_D018817_1_295_299_MDMA_D020258_1_313_331_neurotoxic lesions	Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.
UN	16584858_C009591_3_740_770_triphenyl tetrazolium chloride_D017202_3_831_850_ischemic myocardium	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
UN	16584858_C013592_7_1573_1583_mangiferin_D006331_7_1720_1734_cardiac damage	From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.
UN	16584858_C013592_7_1573_1583_mangiferin_D009203_7_1632_1634_MI	From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.
UN	16584858_C013592_6_1466_1476_mangiferin_D009203_6_1520_1522_MI	Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.
UN	16584858_C013592_3_713_723_mangiferin_D017202_3_831_850_ischemic myocardium	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
UN	16584858_D001205_4_1064_1073_Vitamin C_D009203_4_1124_1126_MI	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
UN	16584858_D003401_2_579_587_creatine_D009202_2_459_476_myocardial damage	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
UN	16584858_D004121_5_1211_1230_dimethyl sulphoxide_D009203_5_1271_1273_MI	Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
UN	16584858_D005978_4_1089_1100_glutathione_D009203_4_1124_1126_MI	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
UN	16584858_D007501_2_667_671_iron_D009202_2_459_476_myocardial damage	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
UN	16584858_D007545_2_377_381_ISPH_D009202_2_459_476_myocardial damage	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
CID	16584858_D007545_7_1619_1623_ISPH_D009203_7_1632_1634_MI	From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.
CID	16584858_D007545_6_1507_1511_ISPH_D009203_6_1520_1522_MI	Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.
CID	16584858_D007545_1_265_269_ISPH_D009203_1_279_300_myocardial infarction	The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
CID	16584858_D007545_0_72_85_isoproterenol_D009203_0_94_115_myocardial infarction	Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.
UN	16584858_D013481_4_897_907_superoxide_D009203_4_1124_1126_MI	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
UN	16584858_D014527_2_632_641_uric acid_D009202_2_459_476_myocardial damage	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
UN	16584858_D014810_4_1075_1084_Vitamin E_D009203_4_1124_1126_MI	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
UN	16584858_D019344_2_547_554_lactate_D009202_2_459_476_myocardial damage	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
UN	16584858_D059808_1_191_201_polyphenol_D009203_1_279_300_myocardial infarction	The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
UN	16586083_C109794_6_974_1014_N-terminal pro brain natriuretic peptide_D002318_6_1164_1187_cardiovascular toxicity	Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.
CID	16586083_D016861_1_274_299_cyclooxygenase inhibitors_D006333_1_238_251_heart failure	Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.
CID	16586083_D016861_1_274_299_cyclooxygenase inhibitors_D006973_1_221_233_hypertension	Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.
CID	16586083_D016861_1_274_299_cyclooxygenase inhibitors_D009203_1_190_211_myocardial infarction	Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.
CID	16586083_D016861_1_274_299_cyclooxygenase inhibitors_D020521_1_213_219_stroke	Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.
CID	16596970_D010862_0_0_11_Pilocarpine_D001308_0_41_87_impairment in auditory location discrimination	Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.
UN	16596970_D010862_0_0_11_Pilocarpine_D012640_0_12_20_seizures	Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.
CID	16596970_D010862_5_612_623_Pilocarpine_D013226_5_646_664_status epilepticus	Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.
UN	16600756_D011464_9_914_918_PGI2_D053201_9_972_975_OAB	However, urinary PGI2 was not different between controls and patients with OAB.
UN	16600756_D011464_11_1140_1144_PGI2_D053201_11_1207_1210_OAB	Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.
CID	16600756_D015232_10_1006_1010_PGE2_D053201_10_994_997_OAB	In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).
CID	16600756_D015232_8_794_798_PGE2_D053201_8_859_862_OAB	RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).
CID	16600756_D015237_8_803_812_PGF2alpha_D053201_8_859_862_OAB	RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).
UN	16629641_C026956_8_1146_1156_Viramidine_D000743_8_1293_1309_hemolytic anemia	Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.
UN	16629641_C026956_8_1146_1156_Viramidine_D019698_8_1327_1346_chronic hepatitis C	Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.
UN	16629641_D007372_2_293_303_interferon_D006526_2_241_254_HCV infection	The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
CID	16629641_D012254_8_1254_1263_ribavirin_D000743_8_1293_1309_hemolytic anemia	Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.
UN	16629641_D012254_4_550_559_ribavirin_D002318_4_681_714_renal or cardiovascular disorders	Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.
UN	16629641_D012254_4_550_559_ribavirin_D006461_4_568_577_hemolysis	Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.
UN	16629641_D012254_2_308_317_ribavirin_D006526_2_241_254_HCV infection	The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
UN	16629641_D012254_4_550_559_ribavirin_D007674_4_681_714_renal or cardiovascular disorders	Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.
UN	16629641_D012254_8_1254_1263_ribavirin_D019698_8_1327_1346_chronic hepatitis C	Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.
CID	16634859_D000431_3_470_477_alcohol_D006130_3_492_509_growth impairment	This study examined the utility of biometry for detecting alcohol-related fetal growth impairment.
CID	16634859_D000431_11_1696_1703_alcohol_D006130_11_1779_1804_reduced cerebellar growth	Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.
UN	1664218_C042315_0_49_59_NSC 343499_D002289_0_64_90_non-small cell lung cancer	Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.
UN	1664218_D000677_0_22_31_amsacrine_D002289_0_64_90_non-small cell lung cancer	Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.
CID	16680561_C476217_9_1314_1324_cinacalcet_D006261_9_1237_1245_headache	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.
CID	16680561_C476217_9_1170_1180_cinacalcet_D009325_9_1226_1232_nausea	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.
CID	16680561_C476217_9_1314_1324_cinacalcet_D009325_9_1226_1232_nausea	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.
CID	16680561_D003891_9_1299_1310_desipramine_D006261_9_1237_1245_headache	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.
CID	16680561_D003891_9_1299_1310_desipramine_D009325_9_1226_1232_nausea	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.
CID	16710500_D004977_3_301_311_ethambutol_D009901_3_329_345_optic neuropathy	CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.
CID	16710500_D004977_0_0_10_Ethambutol_D009901_0_22_38_optic neuropathy	Ethambutol-associated optic neuropathy.
UN	16710500_D004977_1_54_64_Ethambutol_D014376_1_93_105_tuberculosis	INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.
CID	16710500_D004977_10_876_886_Ethambutol_D014786_10_922_933_visual loss	CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.
UN	16720068_D000525_3_374_384_alprazolam_D009127_3_477_492_muscle rigidity	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
CID	16720068_D000525_0_93_103_alprazolam_D009459_0_9_39_neuroleptic malignant syndrome	Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.
CID	16720068_D000525_7_1160_1170_alprazolam_D009459_7_1102_1105_NMS	This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
UN	16720068_D000525_3_374_384_alprazolam_D011596_3_425_448_psychomotor retardation	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
UN	16720068_D000525_3_374_384_alprazolam_D014202_3_498_505_tremors	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
UN	16720068_D001971_6_851_864_bromocriptine_D005334_6_919_924_fever	The patient received bromocriptine and diazepam to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
UN	16720068_D003975_6_869_877_diazepam_D005334_6_919_924_fever	The patient received bromocriptine and diazepam to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
UN	16720068_D017374_3_359_369_paroxetine_D009127_3_477_492_muscle rigidity	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
CID	16720068_D017374_0_78_88_paroxetine_D009459_0_9_39_neuroleptic malignant syndrome	Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.
CID	16720068_D017374_7_1145_1155_paroxetine_D009459_7_1102_1105_NMS	This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
UN	16720068_D017374_3_359_369_paroxetine_D011596_3_425_448_psychomotor retardation	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
UN	16720068_D017374_3_359_369_paroxetine_D014202_3_498_505_tremors	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
CID	16725121_D003042_1_390_397_cocaine_D012640_1_371_379_seizures	Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.
CID	16725121_D003042_6_1076_1083_cocaine_D012640_6_1039_1049_convulsive	Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.
CID	16725121_D003042_5_938_945_cocaine_D012640_5_954_965_convulsions	Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.
UN	16725121_D003891_5_833_844_desipramine_D012640_5_904_915_convulsions	Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.
UN	16725121_D003891_10_1527_1538_Desipramine_D012640_10_1574_1582_seizures	Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.
UN	16725121_D003891_7_1265_1276_desipramine_D012640_7_1312_1323_convulsions	These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.
UN	16725121_D003891_6_1003_1014_desipramine_D012640_6_1039_1049_convulsive	Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.
CID	16725121_D008012_10_1564_1573_lidocaine_D012640_10_1574_1582_seizures	Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.
CID	16725121_D008012_5_886_895_lidocaine_D012640_5_904_915_convulsions	Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.
CID	16725121_D008012_7_1302_1311_lidocaine_D012640_7_1312_1323_convulsions	These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.
CID	16725121_D008012_6_1062_1071_lidocaine_D012640_6_1039_1049_convulsive	Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.
UN	16725121_D009638_1_268_282_norepinephrine_D012640_1_371_379_seizures	Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.
UN	16725121_D009638_0_19_33_norepinephrine_D012640_0_174_185_convulsions	Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.
UN	16755009_D002784_12_1771_1782_cholesterol_D003072_12_1662_1684_cognitive dysfunctions	Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.
CID	16755009_D003975_4_582_590_Diazepam_D000647_4_625_632_amnesia	Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.
UN	16755009_D010936_8_1061_1064_DCE_D000647_8_1078_1085_amnesia	Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).
UN	16755009_D010936_12_1604_1607_DCE_D003072_12_1662_1684_cognitive dysfunctions	Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.
CID	16755009_D012601_4_593_604_scopolamine_D000647_4_625_632_amnesia	Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.
CID	16755009_D012601_8_1097_1108_scopolamine_D000647_8_1078_1085_amnesia	Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).
CID	16787750_D014635_2_356_359_VPA_D001855_2_331_354_bone marrow suppression	Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.
CID	16787750_D014635_0_0_13_Valproic acid_D001927_0_22_36_encephalopathy	Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.
CID	16787750_D014635_2_387_390_VPA_D001927_2_399_413_encephalopathy	Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.
CID	16787750_D014635_3_436_439_VPA_D001927_3_448_462_encephalopathy	The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.
CID	16787750_D014635_4_640_643_VPA_D001927_4_661_675_encephalopathy	There is still no proof of causative effect of VPA in patients with encephalopathy, but only of an association with an assumed causal relation.
CID	16787750_D014635_5_764_767_VPA_D001927_5_779_793_encephalopathy	We report 19 patients with VPA-associated encephalopathy in Germany from the years 1994 to 2003, none of whom had been published previously.
CID	16787750_D014635_3_436_439_VPA_D003244_3_467_489_impaired consciousness	The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.
CID	16787750_D014635_2_356_359_VPA_D010195_2_317_329_pancreatitis	Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.
UN	16787750_D014635_3_436_439_VPA_D012640_3_542_549_seizure	The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.
UN	16787750_D014635_3_436_439_VPA_D022124_3_577_591_hyperammonemia	The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.
CID	16787750_D014635_2_387_390_VPA_D056486_2_368_382_hepatotoxicity	Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.
UN	16820346_C065179_4_624_630_Atorva_D006973_4_652_664_hypertension	Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).
UN	16820346_C065179_1_134_140_atorva_D006973_1_173_185_hypertension	To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.
UN	16820346_C065179_7_1036_1048_atorvastatin_D006973_7_1094_1106_hypertension	Thus, atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.
UN	16820346_C065179_0_0_12_Atorvastatin_D006973_0_58_70_hypertension	Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.
CID	16820346_D003907_4_640_643_dex_D006973_4_652_664_hypertension	Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).
CID	16820346_D003907_1_160_163_dex_D006973_1_173_185_hypertension	To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.
CID	16820346_D003907_0_36_49_dexamethasone_D006973_0_58_70_hypertension	Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.
CID	16820346_D003907_7_1072_1085_dexamethasone_D006973_7_1094_1106_hypertension	Thus, atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.
UN	16820346_D013481_4_737_747_superoxide_D006973_4_652_664_hypertension	Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).
UN	16826348_D003561_4_576_596_cytosine arabinoside_D006987_4_705_713_numbness	The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.
CID	16826348_D003561_0_42_62_cytosine arabinoside_D010523_0_0_21_Peripheral neuropathy	Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.
UN	16826348_D003561_0_42_62_cytosine arabinoside_D015470_0_91_113_acute myeloid leukemia	Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.
UN	16826348_D008775_6_1065_1083_methylprednisolone_D006086_6_995_1020_graft-versus-host disease	This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.
UN	16826348_D008775_6_1065_1083_methylprednisolone_D009422_6_836_846_neuropathy	This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.
UN	16844102_D003676_5_836_839_DFO_D005334_5_866_878_hyperthermia	The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
UN	16844102_D003676_8_1149_1152_DFO_D009422_8_1179_1194_neuronal damage	This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.
UN	16844102_D003676_0_31_43_deferoxamine_D020258_0_71_84_neurotoxicity	Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.
UN	16844102_D004298_5_669_677_dopamine_D005334_5_866_878_hyperthermia	The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
UN	16844102_D007501_2_348_352_iron_D020258_2_381_394_neurotoxicity	This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.
CID	16844102_D008694_5_855_857_MA_D005334_5_866_878_hyperthermia	The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
CID	16844102_D008694_8_1168_1170_MA_D009422_8_1179_1194_neuronal damage	This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.
UN	16844102_D008694_2_370_372_MA_D020258_2_381_394_neurotoxicity	This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.
UN	16844102_D008694_1_103_105_MA_D020258_1_128_141_neurotoxicity	Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.
UN	16844102_D008694_0_47_62_methamphetamine_D020258_0_71_84_neurotoxicity	Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.
UN	16844102_D010100_2_305_311_oxygen_D020258_2_381_394_neurotoxicity	This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.
UN	16844102_D012701_5_684_693_serotonin_D005334_5_866_878_hyperthermia	The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
UN	16844102_D024502_5_823_831_alpha-TC_D005334_5_866_878_hyperthermia	The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
UN	16844102_D024502_8_1136_1144_alpha-TC_D009422_8_1179_1194_neuronal damage	This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.
UN	16844102_D024502_0_10_26_alpha-tocopherol_D020258_0_71_84_neurotoxicity	Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.
CID	16858720_D014859_9_1143_1151_Warfarin_D002543_9_1160_1181_cerebral haemorrhages	CONCLUSIONS: Warfarin-induced cerebral haemorrhages are a major clinical problem with a high fatality rate.
CID	16858720_D014859_11_1335_1343_warfarin_D002543_11_1352_1373_cerebral haemorrhages	A significant proportion of warfarin-related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin.
CID	16858720_D014859_3_498_506_warfarin_D002543_3_547_567_cerebral haemorrhage	Medical records were studied retrospectively to evaluate whether warfarin and warfarin-drug interactions could have caused the cerebral haemorrhage.
CID	16858720_D014859_1_151_159_warfarin_D002543_1_168_189_cerebral haemorrhages	PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden.
CID	16858720_D014859_1_197_205_warfarin_D002543_1_168_189_cerebral haemorrhages	PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden.
CID	16858720_D014859_0_32_40_warfarin_D002543_0_0_20_Cerebral haemorrhage	Cerebral haemorrhage induced by warfarin - the influence of drug-drug interactions.
CID	16867021_C052075_11_1536_1539_THP_D002375_11_1616_1625_catalepsy	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
CID	16867021_C052075_4_763_766_THP_D002375_4_867_876_catalepsy	Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).
CID	16867021_C052075_3_677_689_thioperamide_D002375_3_734_743_catalepsy	Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.
UN	16867021_C052075_7_1189_1192_THP_D006948_7_1174_1187_hyperactivity	On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).
UN	16867021_C069357_3_649_653_RAMH_D002375_3_734_743_catalepsy	Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.
UN	16867021_D000661_2_372_383_amphetamine_D002375_2_319_328_catalepsy	The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.
UN	16867021_D000661_11_1636_1647_amphetamine_D002375_11_1616_1625_catalepsy	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
CID	16867021_D000661_7_1154_1165_amphetamine_D006948_7_1174_1187_hyperactivity	On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).
CID	16867021_D000661_11_1636_1647_amphetamine_D006948_11_1656_1669_hyperactivity	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
UN	16867021_D001058_11_1683_1694_apomorphine_D002375_11_1616_1625_catalepsy	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
UN	16867021_D001058_2_330_341_apomorphine_D002375_2_319_328_catalepsy	The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.
UN	16867021_D001058_11_1683_1694_apomorphine_D006948_11_1656_1669_hyperactivity	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
CID	16867021_D006220_11_1596_1607_haloperidol_D002375_11_1616_1625_catalepsy	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
CID	16867021_D006220_4_810_821_haloperidol_D002375_4_867_876_catalepsy	Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).
CID	16867021_D006220_3_447_458_haloperidol_D002375_3_422_431_Catalepsy	Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.
UN	16867021_D006220_11_1596_1607_haloperidol_D006948_11_1656_1669_hyperactivity	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
UN	16867021_D006632_2_264_273_histamine_D002375_2_319_328_catalepsy	The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.
CID	1687392_C534628_4_401_410_SCH 23390_D002375_4_441_450_catalepsy	Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation. 3.
CID	1687392_C534628_2_268_277_SCH 23390_D002375_2_314_323_catalepsy	Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.
UN	1687392_D004298_6_701_709_dopamine_D002375_6_680_689_catalepsy	Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists. 5.
UN	1687392_D004298_1_106_114_dopamine_D002375_1_85_94_catalepsy	The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined. 2.
UN	1687392_D004298_0_29_37_dopamine_D002375_0_59_68_catalepsy	Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice. 1.
CID	1687392_D005476_5_551_563_fluphenazine_D002375_5_530_539_catalepsy	D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride. 4.
CID	1687392_D013469_4_416_425_sulpiride_D002375_4_441_450_catalepsy	Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation. 3.
CID	1687392_D013469_2_296_305_sulpiride_D002375_2_314_323_catalepsy	Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.
UN	1687392_D015647_6_607_616_SKF 38393_D002375_6_680_689_catalepsy	Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists. 5.
UN	1687392_D015647_5_480_489_SKF 38393_D002375_5_530_539_catalepsy	D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride. 4.
UN	1687392_D019257_5_505_515_quinpirole_D002375_5_530_539_catalepsy	D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride. 4.
UN	1687392_D019257_6_622_632_quinpirole_D002375_6_680_689_catalepsy	Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists. 5.
CID	16904497_D002045_3_428_439_bupivacaine_D011128_3_347_368_cauda equina syndrome	The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.
UN	16904497_D013256_18_1656_1663_steroid_D009422_18_1616_1640_neurologic deterioration	Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important.
UN	16904497_D013256_4_540_547_steroid_D010146_4_485_512_low back and right leg pain	CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.
UN	16904497_D013256_0_37_44_steroid_D011128_0_0_21_Cauda equina syndrome	Cauda equina syndrome after epidural steroid injection: a case report.
UN	16904497_D013256_1_173_180_steroid_D011843_1_128_141_radiculopathy	OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.
UN	16904497_D013256_4_540_547_steroid_D017116_4_485_512_low back and right leg pain	CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.
UN	16904497_D014221_3_410_423_triamcinolone_D011128_3_347_368_cauda equina syndrome	The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.
UN	16938416_C032109_2_404_438_estradiol- and testosterone esters_D050197_2_451_466_atherosclerosis	METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis.
UN	16938416_D000431_7_1176_1183_alcohol_D003920_7_1119_1127_diabetes	The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or alcohol use.
UN	16938416_D002784_7_1129_1140_cholesterol_D003920_7_1119_1127_diabetes	The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or alcohol use.
UN	16938416_D004967_2_373_381_estrogen_D050197_2_451_466_atherosclerosis	METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis.
CID	16938416_D013739_0_10_22_testosterone_D050197_0_42_57_atherosclerosis	High-dose testosterone is associated with atherosclerosis in postmenopausal women.
CID	16938416_D013739_9_1295_1307_testosterone_D050197_9_1337_1352_atherosclerosis	CONCLUSION: Our results suggest that high-dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless.
UN	16960342_D019259_0_120_130_lamivudine_D005355_0_89_98_cirrhosis	Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.
UN	16960342_D019259_10_1289_1299_lamivudine_D005355_10_1329_1338_cirrhosis	The administration of lamivudine to patients with HBV-related cirrhosis, like our present case, should be considered as an initial medical therapeutic option, especially in countries where liver transplantation is not reliably available.
UN	16960342_D019259_0_120_130_lamivudine_D006509_0_63_74_hepatitis B	Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.
UN	1700207_C032151_4_545_556_cibenzoline_D001145_4_602_613_arrhythmias	Ten and 5 mg/kg i.v. (+)-cibenzoline suppressed digitalis- and adrenaline-induced arrhythmias, respectively.
UN	1700207_C032151_5_680_691_cibenzoline_D001145_5_730_741_arrhythmias	The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).
UN	1700207_C032151_0_45_56_cibenzoline_D001145_0_67_90_ventricular arrhythmias	Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.
UN	1700207_C032151_1_142_153_cibenzoline_D001145_1_185_207_ventricular arrhythmia	Antiarrhythmic effects of (+)-cibenzoline and (-)-cibenzoline were examined using two canine ventricular arrhythmia models.
UN	1700207_C032151_6_861_872_cibenzoline_D001145_6_906_916_arrhythmia	A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.
UN	1700207_C032151_7_1045_1056_cibenzoline_D001145_7_1095_1105_arrhythmia	The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).
UN	1700207_D002118_3_432_434_Ca_D001145_3_386_407_Adrenaline arrhythmia	Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
UN	1700207_D004070_7_1061_1070_digitalis_D001145_7_1095_1105_arrhythmia	The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).
UN	1700207_D004070_6_888_897_digitalis_D001145_6_906_916_arrhythmia	A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.
UN	1700207_D004070_2_216_225_Digitalis_D001145_2_226_236_arrhythmia	Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.
UN	1700207_D004070_5_696_705_digitalis_D001145_5_730_741_arrhythmias	The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).
UN	1700207_D004070_4_568_577_digitalis_D001145_4_602_613_arrhythmias	Ten and 5 mg/kg i.v. (+)-cibenzoline suppressed digitalis- and adrenaline-induced arrhythmias, respectively.
CID	1700207_D004837_7_1076_1086_adrenaline_D001145_7_1095_1105_arrhythmia	The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).
CID	1700207_D004837_6_962_972_adrenaline_D001145_6_981_992_arrhythmias	A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.
CID	1700207_D004837_5_711_721_adrenaline_D001145_5_730_741_arrhythmias	The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).
CID	1700207_D004837_4_583_593_adrenaline_D001145_4_602_613_arrhythmias	Ten and 5 mg/kg i.v. (+)-cibenzoline suppressed digitalis- and adrenaline-induced arrhythmias, respectively.
UN	1700207_D006221_3_491_500_halothane_D001145_3_386_407_Adrenaline arrhythmia	Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
CID	1700207_D010042_2_342_349_ouabain_D001145_2_226_236_arrhythmia	Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.
UN	1700207_D010424_2_353_366_pentobarbital_D001145_2_226_236_arrhythmia	Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.
UN	1700207_D012964_2_261_263_Na_D001145_2_226_236_arrhythmia	Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.
UN	17019386_D008353_2_139_147_mannitol_D001929_2_158_169_brain edema	AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.
UN	17019386_D008353_2_139_147_mannitol_D001932_2_196_207_brain tumor	AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.
UN	17019386_D008353_5_573_581_mannitol_D001932_5_624_635_brain tumor	As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients.
UN	17019386_D008353_11_1474_1482_mannitol_D004487_11_1610_1615_edema	CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.
UN	17019386_D008353_0_11_19_mannitol_D005910_0_42_49_gliomas	Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon.
UN	17019386_D008353_11_1474_1482_mannitol_D005910_11_1521_1528_gliomas	CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.
UN	17019386_D008353_10_1284_1292_mannitol_D008579_10_1224_1234_meningioma	In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.
UN	17019386_D008353_10_1284_1292_mannitol_D009362_10_1239_1249_metastases	In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.
CID	17019386_D008353_2_139_147_mannitol_D019586_2_180_192_elevated ICP	AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.
UN	17020434_C055162_5_701_712_Clopidogrel_D001281_5_681_700_Atrial Fibrillation	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.
UN	17020434_C055162_5_840_851_clopidogrel_D004617_5_887_901_embolic events	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.
UN	17020434_C081309_5_724_734_Irbesartan_D001281_5_681_700_Atrial Fibrillation	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.
UN	17020434_C081309_5_724_734_Irbesartan_D004617_5_887_901_embolic events	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.
UN	17020434_C426686_4_448_460_Ximelagatran_D004617_4_577_591_embolic events	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.
CID	17020434_C426686_4_448_460_Ximelagatran_D056486_4_636_659_abnormal liver function	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.
UN	17020434_C479958_6_903_914_Idraparinux_D001281_6_975_994_atrial fibrillation	Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.
UN	17020434_D000804_7_1041_1055_angiotensin II_D001281_7_1096_1115_atrial fibrillation	Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.
UN	17020434_D000804_7_1041_1055_angiotensin II_D020257_7_1124_1143_cardiac remodelling	Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.
UN	17020434_D000809_7_996_1007_Angiotensin_D001281_7_1096_1115_atrial fibrillation	Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.
UN	17020434_D000809_7_996_1007_Angiotensin_D020257_7_1124_1143_cardiac remodelling	Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.
UN	17020434_D001241_5_857_864_aspirin_D001281_5_681_700_Atrial Fibrillation	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.
UN	17020434_D001241_5_857_864_aspirin_D004617_5_887_901_embolic events	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.
UN	17020434_D001241_3_378_385_aspirin_D020521_3_400_407_strokes	Overall, in high-risk patients, warfarin is superior to aspirin in preventing strokes, with a relative risk reduction of 36%.
UN	17020434_D014812_4_529_538_vitamin K_D004617_4_577_591_embolic events	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.
UN	17020434_D014812_4_529_538_vitamin K_D056486_4_636_659_abnormal liver function	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.
UN	17020434_D014859_5_798_806_warfarin_D001281_5_681_700_Atrial Fibrillation	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.
UN	17020434_D014859_5_798_806_warfarin_D004617_5_887_901_embolic events	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.
UN	17020434_D014859_2_230_238_warfarin_D020521_2_259_265_stroke	Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%.
UN	17020434_D014859_3_354_362_warfarin_D020521_3_400_407_strokes	Overall, in high-risk patients, warfarin is superior to aspirin in preventing strokes, with a relative risk reduction of 36%.
UN	17042884_C069541_0_62_72_quetiapine_D001480_0_52_55_EPS	Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
UN	17042884_C069541_7_1103_1106_QTP_D001480_7_1071_1074_EPS	Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).
UN	17042884_C069541_1_208_218_quetiapine_D001714_1_236_249_bipolar mania	OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.
UN	17042884_C069541_0_62_72_quetiapine_D001714_0_112_125_bipolar mania	Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
UN	17042884_C069541_10_1643_1653_quetiapine_D014202_10_1623_1629_tremor	Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
UN	17042884_C069541_9_1444_1454_quetiapine_D017109_9_1409_1418_akathisia	The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).
CID	17042884_D006220_11_1816_1827_Haloperidol_D001480_11_1947_1970_extrapyramidal syndrome	Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.
CID	17042884_D006220_8_1247_1258_haloperidol_D001480_8_1200_1203_EPS	Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.
CID	17042884_D006220_11_1816_1827_Haloperidol_D014202_11_1915_1921_tremor	Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.
CID	17042884_D006220_11_1816_1827_Haloperidol_D017109_11_1884_1893_akathisia	Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.
CID	17042884_D008094_7_1109_1111_Li_D001480_7_1071_1074_EPS	Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).
CID	17042884_D008094_10_1799_1806_lithium_D014202_10_1770_1776_tremor	Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
UN	17042884_D008094_9_1509_1511_Li_D017109_9_1409_1418_akathisia	The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).
UN	17042884_D014635_7_1112_1115_DVP_D001480_7_1071_1074_EPS	Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).
UN	17042884_D014635_9_1512_1515_DVP_D017109_9_1409_1418_akathisia	The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).
UN	17042910_C065179_0_24_36_atorvastatin_D006973_0_62_74_hypertension	Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat. 1.
CID	17042910_D003907_1_105_108_Dex_D006973_1_118_130_hypertension	Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.
CID	17042910_D003907_0_40_53_dexamethasone_D006973_0_62_74_hypertension	Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat. 1.
UN	17042910_D009569_2_405_407_NO_D006973_2_455_467_hypertension	Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.
UN	17042910_D009569_1_191_203_nitric oxide_D006973_1_118_130_hypertension	Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.
UN	17042910_D013481_2_420_423_O2-_D006973_2_455_467_hypertension	Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.
UN	17049862_D001285_4_498_506_atropine_D001919_4_471_482_bradycardia	Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.
UN	17049862_D004837_4_511_521_adrenaline_D001919_4_471_482_bradycardia	Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.
CID	17049862_D010672_4_410_419_phenytoin_D001919_4_471_482_bradycardia	Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.
UN	17049862_D010672_5_557_566_phenytoin_D007035_5_571_582_hypothermia	The cardiac depressant actions of phenytoin and hypothermia can be additive.
UN	17049862_D010672_6_618_627_phenytoin_D007035_6_647_658_hypothermia	Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.
UN	17049862_D010672_0_3_12_phenytoin_D007035_0_38_49_hypothermic	Is phenytoin administration safe in a hypothermic child?
UN	17049862_D010672_3_311_320_phenytoin_D012640_3_379_386_seizure	Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis.
UN	17074608_D005998_1_175_182_glycine_D000592_1_116_149_disorder of amino acid metabolism	Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.
UN	17074608_D005998_1_175_182_glycine_D020158_1_84_110_Nonketotic hyperglycinemia	Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.
CID	17074608_D014635_0_0_9_Valproate_D001927_0_29_43_encephalopathy	Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.
CID	17074608_D014635_4_763_772_valproate_D001927_4_709_723_encephalopathy	This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.
CID	17074608_D014635_0_0_9_Valproate_D002819_0_18_24_chorea	Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.
CID	17074608_D014635_4_763_772_valproate_D002819_4_728_734_chorea	This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.
UN	17074608_D014635_4_763_772_valproate_D007805_4_583_597_language delay	This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.
UN	17074608_D014635_4_763_772_valproate_D008607_4_602_620_mental retardation	This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.
UN	17074608_D014635_0_0_9_Valproate_D020158_0_56_82_nonketotic hyperglycinemia	Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.
CID	17111419_C102006_8_815_829_sodium citrate_D006996_8_878_890_hypocalcemia	The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.
CID	17111419_C102006_10_1182_1189_citrate_D006996_10_1114_1126_hypocalcemia	We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity.
UN	17111419_D002034_9_950_960_bumetanide_D006996_9_1007_1019_hypocalcemia	Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.
UN	17111419_D002118_8_794_801_calcium_D006996_8_878_890_hypocalcemia	The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.
UN	17111419_D002125_7_632_649_calcium gluconate_C536214_7_669_688_muscle contractions	Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes.
UN	17111419_D049994_9_966_979_loop diuretic_D006996_9_1007_1019_hypocalcemia	Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.
UN	1711760_C009591_8_892_918_2,3,5-triphenyltetrazolium_D009410_8_858_873_neuronal injury	The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.
UN	1711760_D007530_2_274_284_isoflurane_D006973_2_325_337_hypertensive	Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.
UN	1711760_D010656_12_1405_1418_phenylephrine_D004487_12_1485_1490_edema	The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.
CID	1711760_D010656_12_1405_1418_phenylephrine_D006973_12_1427_1439_hypertension	The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.
UN	1711760_D010656_12_1405_1418_phenylephrine_D007511_12_1498_1506_ischemic	The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.
UN	1711760_D010656_12_1405_1418_phenylephrine_D009410_12_1626_1646_neuronal dysfunction	The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.
UN	1711760_D010656_12_1405_1418_phenylephrine_D020244_12_1461_1465_MCAO	The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.
UN	17147461_D000804_10_1707_1721_angiotensin II_D011507_10_1743_1754_proteinuria	Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.
UN	17147461_D000809_10_1663_1674_angiotensin_D011507_10_1624_1635_proteinuria	Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.
CID	17147461_D020123_0_0_9_Sirolimus_D007674_0_37_54_renal dysfunction	Sirolimus-associated proteinuria and renal dysfunction.
CID	17147461_D020123_7_884_893_sirolimus_D011507_7_905_916_proteinuria	The mechanisms of sirolimus-associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal.
CID	17147461_D020123_0_0_9_Sirolimus_D011507_0_21_32_proteinuria	Sirolimus-associated proteinuria and renal dysfunction.
CID	17147461_D020123_5_714_723_sirolimus_D011507_5_743_754_proteinuria	However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.
UN	17147461_D020123_9_1246_1255_sirolimus_D058186_9_1206_1229_acute renal dysfunction	The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.
UN	17147461_D020123_5_714_723_sirolimus_D058186_5_759_782_acute renal dysfunction	However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.
UN	17175308_D020123_4_460_463_SRL_D002292_4_622_641_renal cell carsinom	The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).
UN	17175308_D020123_4_460_463_SRL_D007414_4_599_616_intestinal tumors	The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).
UN	17175308_D020123_4_460_463_SRL_D007674_4_655_666_nephropathy	The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).
UN	17175308_D020123_4_460_463_SRL_D009369_4_539_548_neoplasia	The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).
CID	17175308_D020123_3_389_392_SRL_D011507_3_371_382_proteinuria	We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL conversion.
CID	17175308_D020123_2_197_206_sirolimus_D011507_2_147_158_proteinuria	More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.
CID	17175308_D020123_0_32_41_sirolimus_D011507_0_0_11_Proteinuria	Proteinuria after conversion to sirolimus in renal transplant recipients.
CID	17175308_D020123_19_1997_2000_SRL_D011507_19_1957_1968_proteinuria	Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation.
UN	17175308_D020123_4_460_463_SRL_D012514_4_558_574_Kaposi's sarcoma	The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).
UN	17175308_D020123_4_460_463_SRL_D012878_4_581_593_skin cancers	The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).
UN	17175308_D020123_4_460_463_SRL_D051436_4_494_523_chronic allograft nephropathy	The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).
UN	17194457_D012701_12_1706_1710_5-HT_D001523_12_1746_1765_aggressive behavior	Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit aggressive behavior.
CID	17194457_D013739_10_1307_1308_T_D001523_10_1344_1356_irritability	T alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and aggression.
UN	1720453_D003404_6_919_929_creatinine_D000608_6_880_893_aminoaciduria	Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.
UN	1720453_D003404_6_919_929_creatinine_D006030_6_855_865_glucosuria	Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.
UN	1720453_D003404_6_919_929_creatinine_D011507_6_867_878_proteinuria	Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.
UN	1720453_D007069_0_23_33_ifosfamide_C535700_0_73_101_malignant mesenchymal tumors	Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.
UN	1720453_D007069_11_1768_1778_ifosfamide_C535700_11_1799_1817_mesenchymal tumors	This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.
UN	1720453_D007069_1_279_289_ifosfamide_C535700_1_357_384_Malignant Mesenchymal Tumor	The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.
CID	1720453_D007069_0_23_33_ifosfamide_D007674_0_34_48_renal toxicity	Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.
UN	1720453_D007069_10_1573_1583_ifosfamide_D009369_10_1666_1671_tumor	Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.
UN	1720453_D010710_6_941_950_phosphate_D000608_6_880_893_aminoaciduria	Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.
UN	1720453_D010710_8_1404_1413_phosphate_D005198_8_1286_1304_Fanconi's syndrome	Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.
UN	1720453_D010710_6_941_950_phosphate_D006030_6_855_865_glucosuria	Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.
UN	1720453_D010710_6_941_950_phosphate_D011507_6_867_878_proteinuria	Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.
UN	17241657_C107044_5_851_856_SM 21_D012640_5_898_909_convulsions	In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.
UN	17241657_C519696_5_836_841_UMB24_D012640_5_898_909_convulsions	In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.
CID	17241657_D003042_5_882_889_cocaine_D012640_5_898_909_convulsions	In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.
CID	17241784_D019821_7_711_718_statins_D009135_7_751_759_myopathy	These observations suggest that statins may initiate an immune-mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy.
CID	17241784_D019821_8_923_930_statins_D009135_8_868_876_myopathy	The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up-regulation of MHC-I expression and antigen presentation by muscle fibres.
CID	17241784_D019821_2_233_240_statins_D009135_2_254_262_myopathy	What is less well known is a phenomenon whereby statins may induce a myopathy, which persists or may progress after stopping the drug.
CID	17241784_D019821_1_81_88_Statins_D009135_1_113_121_myopathy	Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.
CID	17242861_D010862_3_445_456_pilocarpine_D004833_3_486_508_temporal lobe epilepsy	QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.
UN	17242861_D010862_3_445_456_pilocarpine_D012640_3_465_473_seizures	QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.
UN	17242861_D010862_4_730_741_pilocarpine_D012640_4_750_758_seizures	We report QTLs identified using a B6 (host) x A/J (donor) CSS panel to localize genes involved in susceptibility to pilocarpine-induced seizures.
UN	17242861_D010862_5_858_869_pilocarpine_D012640_5_878_886_seizures	Three hundred fifty-five adult male CSS mice, 58 B6, and 39 A/J were tested for susceptibility to pilocarpine-induced seizures.
CID	17244258_D003520_0_74_90_cyclophosphamide_D003556_0_99_107_cystitis	In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide-induced cystitis in the rat.
CID	17244258_D003520_1_123_139_cyclophosphamide_D003556_1_148_156_cystitis	In cyclophosphamide-induced cystitis in the rat, detrusor function is impaired and the expression and effects of muscarinic receptors altered.
CID	17261653_D003000_5_957_966_Clonidine_D001919_5_975_986_bradycardia	Clonidine-induced bradycardia in conscious alpha2ABC-/- mice was 32.3% (10 microg/kg) and 26.6% (100 microg/kg) of the effect in wild-type mice.
UN	17263743_C009250_0_57_68_sevoflurane_D002547_0_31_45_cerebral palsy	Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.
UN	17263743_C009250_0_57_68_sevoflurane_D006323_0_0_14_Cardiac arrest	Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.
UN	17263743_D001418_2_391_399_baclofen_D002547_2_283_297_cerebral palsy	We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.
UN	17263743_D001418_2_391_399_baclofen_D004827_2_302_318_seizure disorder	We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.
UN	17263743_D001418_2_391_399_baclofen_D011595_2_344_356_restlessness	We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.
UN	17263743_D003000_3_503_512_clonidine_D001008_3_572_579_anxiety	Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
UN	17263743_D003000_0_112_121_clonidine_D002547_0_31_45_cerebral palsy	Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.
UN	17263743_D003000_2_330_339_clonidine_D004827_2_302_318_seizure disorder	We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.
CID	17263743_D003000_5_729_738_clonidine_D006323_5_750_764_cardiac arrest	There are no previous reports of clonidine-associated cardiac arrest in a child undergoing induction of anesthesia.
UN	17263743_D003000_2_330_339_clonidine_D011595_2_344_356_restlessness	We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.
UN	17285209_C044946_1_269_279_benazapril_D006973_1_203_215_hypertension	This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/benazapril 10/5 mg.
UN	17285209_D000809_10_1240_1251_angiotensin_D000799_10_1275_1296_intestinal angioedema	The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.
UN	17285209_D000809_10_1240_1251_angiotensin_D007410_10_1275_1296_intestinal angioedema	The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.
UN	17285209_D017311_1_258_268_amlodipine_D006973_1_203_215_hypertension	This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/benazapril 10/5 mg.
CID	1728522_D019980_1_116_143_amoxicillin-clavulanic acid_D006099_1_187_197_granulomas	We report the case of a patient with amoxicillin-clavulanic acid-induced hepatitis with histologic multiple granulomas.
CID	1728522_D019980_0_31_77_combination of amoxicillin and clavulanic acid_D006099_0_0_23_Granulomatous hepatitis	Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.
CID	1728522_D019980_1_116_143_amoxicillin-clavulanic acid_D056486_1_152_161_hepatitis	We report the case of a patient with amoxicillin-clavulanic acid-induced hepatitis with histologic multiple granulomas.
CID	1728522_D019980_0_31_77_combination of amoxicillin and clavulanic acid_D056486_0_0_23_Granulomatous hepatitis	Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.
UN	1728915_D002220_6_719_732_carbamazepine_D001523_6_788_799_psychiatric	Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions, the recognition of the latter syndrome has important implications for the use of this drug in elderly patients.
CID	1728915_D002220_2_168_181_carbamazepine_D001919_2_117_128_bradycardia	A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.
CID	1728915_D002220_4_442_455_carbamazepine_D013616_4_395_413_sinus tachycardias	One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.
CID	1728915_D002220_2_168_181_carbamazepine_D054537_2_133_155_atrioventricular block	A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.
CID	1728915_D002220_5_683_696_carbamazepine_D054537_5_592_625_atrioventricular conduction delay	The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.
UN	1728915_D002220_4_442_455_carbamazepine_D062787_4_456_464_overdose	One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.
UN	1732369_D004280_2_415_425_dobutamine_D006331_2_345_359_cardiac damage	To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.
UN	1732369_D004280_0_0_10_Dobutamine_D009369_0_161_167_cancer	Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer.
UN	1732369_D004280_2_415_425_dobutamine_D009369_2_498_504_cancer	To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.
CID	1732369_D004317_1_169_180_Doxorubicin_D009202_1_264_278_cardiomyopathy	Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy.
UN	1732369_D004317_2_518_529_doxorubicin_D009369_2_498_504_cancer	To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.
UN	1732369_D004317_0_108_119_doxorubicin_D009369_0_161_167_cancer	Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer.
UN	1732442_D004317_3_585_595_adriamycin_C536522_3_499_540_vacuolar degeneration of myocardial cells	The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week).
CID	1732442_D004317_0_60_70_adriamycin_D009202_0_79_93_cardiomyopathy	Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.
CID	1732442_D004317_10_1911_1921_adriamycin_D009202_10_1930_1944_cardiomyopathy	The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.
CID	1732442_D004317_2_458_468_adriamycin_D009202_2_469_483_cardiomyopathy	Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.
UN	1732442_D019797_10_1853_1857_MIBG_C536522_10_1815_1836_vacuolar degeneration	The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.
UN	1732442_D019797_0_99_133_iodine-125-metaiodobenzylguanidine_D009202_0_79_93_cardiomyopathy	Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.
UN	1732442_D019797_10_1853_1857_MIBG_D009202_10_1773_1794_myocardial impairment	The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.
CID	17343925_D012906_3_326_333_smoking_D034381_3_370_382_hearing loss	The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.
UN	17344330_D003932_0_70_76_heroin_D008133_0_12_27_QT prolongation	Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.
UN	17344330_D003932_14_1775_1781_heroin_D008133_14_1708_1723_QT prolongation	CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.
UN	17344330_D003932_14_1775_1781_heroin_D013575_14_1748_1755_syncope	CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.
UN	17344330_D003932_0_70_76_heroin_D013575_0_0_7_Syncope	Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.
UN	17344330_D003932_3_327_333_heroin_D016171_3_501_504_TdP	As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.
CID	17344330_D008691_0_56_65_methadone_D008133_0_12_27_QT prolongation	Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.
CID	17344330_D008691_14_1679_1688_Methadone_D008133_14_1708_1723_QT prolongation	CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.
CID	17344330_D008691_14_1679_1688_Methadone_D013575_14_1748_1755_syncope	CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.
CID	17344330_D008691_8_1108_1117_methadone_D013575_8_1140_1147_syncope	The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.
CID	17344330_D008691_0_56_65_methadone_D013575_0_0_7_Syncope	Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.
UN	17344330_D008691_2_307_316_methadone_D016171_2_281_284_TdP	Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.
UN	17344566_D013974_1_141_150_thyroxine_D003161_1_196_216_compartment syndrome	A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.
UN	17344566_D013974_1_141_150_thyroxine_D007037_1_117_128_hypothyroid	A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.
UN	17344566_D013974_1_141_150_thyroxine_D009135_1_221_232_myonecrosis	A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.
CID	17344566_D019821_0_0_11_Simvastatin_D003161_0_34_54_compartment syndrome	Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.
CID	17344566_D019821_1_155_166_simvastatin_D003161_1_196_216_compartment syndrome	A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.
UN	17344566_D019821_1_155_166_simvastatin_D007037_1_117_128_hypothyroid	A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.
CID	17366349_C092292_5_698_709_ziprasidone_D009459_5_687_690_NMS	This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.
CID	17366349_C092292_0_42_53_ziprasidone_D009459_0_0_30_Neuroleptic malignant syndrome	Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.
CID	17366349_C092292_2_287_298_ziprasidone_D009459_2_255_258_NMS	We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.
UN	17366349_C092292_4_622_633_ziprasidone_D012559_4_495_508_schizophrenia	The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.
CID	17400887_D013726_0_62_73_terbutaline_D001321_0_110_116_autism	Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.
UN	17400887_D013726_3_394_405_Terbutaline_D007752_3_451_464_preterm labor	Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.
UN	17400887_D013726_0_62_73_terbutaline_D020078_0_0_17_Neuroinflammation	Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.
CID	17437408_D010862_10_1987_1998_pilocarpine_D012640_10_2007_2015_seizures	A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced seizures in wild-type Wistar rats.
UN	17439425_D000493_8_988_999_Allopurinol_D006973_8_1020_1022_HT	Allopurinol did not prevent dex-HT.
UN	17439425_D000493_9_1071_1082_allopurinol_D006973_9_1138_1150_hypertension	This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.
CID	17439425_D003907_0_28_41_dexamethasone_D006973_0_50_62_hypertension	Role of xanthine oxidase in dexamethasone-induced hypertension in rats. 1.
CID	17439425_D003907_2_333_336_dex_D006973_2_319_331_hypertension	We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT). 3.
CID	17439425_D003907_2_333_336_dex_D006973_2_337_339_HT	We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT). 3.
CID	17439425_D003907_6_698_701_Dex_D006973_6_702_715_increased SBP	Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P" < 0.01).
CID	17439425_D003907_8_1016_1019_dex_D006973_8_1020_1022_HT	Allopurinol did not prevent dex-HT.
CID	17439425_D003907_6_698_701_Dex_D015431_6_758_802_decreased thymus (P < 0.001) and bodyweights	Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P" < 0.01).
UN	17439425_D009569_1_149_161_nitric oxide_D006973_1_115_117_HT	Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance. 2.
UN	17439425_D019820_0_8_16_xanthine_D006973_0_50_62_hypertension	Role of xanthine oxidase in dexamethasone-induced hypertension in rats. 1.
UN	17466854_D005839_1_241_251_gentamicin_D002386_1_311_319_cataract	PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.
CID	17466854_D005839_8_1190_1200_gentamicin_D006261_8_1316_1324_headache	CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.
CID	17466854_D005839_8_1190_1200_gentamicin_D020250_8_1294_1310_nausea, vomiting	CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.
UN	17466854_D008775_1_218_236_methylprednisolone_D002386_1_311_319_cataract	PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.
CID	17466854_D008775_8_1167_1185_methylprednisolone_D006261_8_1316_1324_headache	CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.
CID	17466854_D008775_8_1167_1185_methylprednisolone_D020250_8_1294_1310_nausea, vomiting	CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.
UN	17490790_D007501_6_1074_1078_iron_D009410_6_1090_1126_degeneration of dopaminergic neurons	These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.
UN	17490790_D007501_2_566_570_iron_D009410_2_515_551_degeneration of dopaminergic neurons	To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.
UN	17490790_D007501_1_94_98_Iron_D010300_1_164_183_Parkinson's disease	Iron accumulation is considered to be involved in the pathogenesis of Parkinson's disease.
CID	17490790_D007505_0_11_23_iron dextran_D009410_0_32_68_degeneration of dopaminergic neurons	Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.
CID	17490790_D007505_2_592_604_iron dextran_D009410_2_515_551_degeneration of dopaminergic neurons	To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.
UN	17490790_D014443_2_363_371_tyrosine_D009410_2_515_551_degeneration of dopaminergic neurons	To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.
CID	17490864_D000661_6_1042_1053_Amphetamine_D006948_6_1062_1085_locomotor hyperactivity	Amphetamine-induced locomotor hyperactivity was similar in all groups.
UN	17491223_D004280_2_429_439_dobutamine_D007511_2_606_614_ischemia	OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.
CID	17491223_D004280_0_79_89_dobutamine_D017202_0_98_117_myocardial ischemia	Assessment of a new non-invasive index of cardiac performance for detection of dobutamine-induced myocardial ischemia.
CID	17491223_D004280_1_191_201_dobutamine_D017202_1_210_229_myocardial ischemia	BACKGROUND: Electrocardiography has a very low sensitivity in detecting dobutamine-induced myocardial ischemia.
CID	17491223_D004280_2_429_439_dobutamine_D017202_2_448_467_myocardial ischemia	OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.
UN	17491223_D017256_2_475_490_Tc99m-Sestamibi_D007511_2_606_614_ischemia	OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.
UN	17491223_D017256_2_475_490_Tc99m-Sestamibi_D017202_2_448_467_myocardial ischemia	OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.
CID	1749407_D003042_0_0_7_Cocaine_D009203_0_16_37_myocardial infarction	Cocaine-induced myocardial infarction: clinical observations and pathogenetic considerations.
CID	1749407_D003042_1_188_195_cocaine_D009203_1_210_237_acute myocardial infarction	Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction.
UN	1749407_D003042_4_680_687_cocaine_D013035_4_606_611_spasm	With regard to spasm, the clinical findings are largely circumstantial, and the locus of cocaine-induced vasoconstriction remains speculative.
UN	1749407_D003042_9_1459_1466_cocaine_D013927_9_1438_1448_thrombotic	Finally, the contribution of a primary, thrombotic effect of cocaine has not been excluded.
UN	1749407_D010100_2_382_388_oxygen_D009203_2_312_339_acute myocardial infarction	In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.
UN	17511042_C417083_0_89_118_pegylated interferon alpha-2b_D019698_0_54_73_chronic hepatitis C	An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.
CID	17511042_C417083_0_89_118_pegylated interferon alpha-2b_D063726_0_26_48_delusional parasitosis	An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.
CID	17511042_C417083_5_598_627_pegylated interferon alpha-2b_D063726_5_553_575_delusional parasitosis	We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.
UN	17511042_D012254_0_123_132_ribavirin_D019698_0_54_73_chronic hepatitis C	An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.
UN	17511042_D012254_1_213_222_ribavirin_D019698_1_164_183_chronic hepatitis C	During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.
CID	17511042_D012254_0_123_132_ribavirin_D063726_0_26_48_delusional parasitosis	An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.
CID	17511042_D012254_5_639_648_ribavirin_D063726_5_553_575_delusional parasitosis	We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.
UN	17532790_D001971_4_613_626_bromocriptine_D010300_4_579_581_PD	In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).
CID	17532790_D007980_0_60_66_L-DOPA_D004409_0_75_85_dyskinesia	Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.
CID	17532790_D007980_1_87_93_L-DOPA_D004409_1_102_112_dyskinesia	L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.
UN	17532790_D007980_1_233_239_L-DOPA_D010300_1_187_189_PD	L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.
UN	17532790_D016627_4_541_558_6-hydroxydopamine_D010300_4_579_581_PD	In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).
UN	17562951_C044834_10_2098_2107_iodixanol_D003920_10_2147_2164_diabetes mellitus	CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.
CID	17562951_C044834_10_2098_2107_iodixanol_D007674_10_1967_1978_nephropathy	CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.
UN	17562951_C044834_2_473_482_iodixanol_D051436_2_500_522_chronic kidney disease	METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.
UN	17562951_D000111_6_1130_1146_N-acetylcysteine_D003920_6_1104_1121_diabetes mellitus	In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.
UN	17562951_D007479_8_1559_1568_iopamidol_D003920_8_1484_1492_diabetes	In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).
UN	17562951_D007479_10_2085_2094_iopamidol_D003920_10_2147_2164_diabetes mellitus	CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.
CID	17562951_D007479_10_2085_2094_iopamidol_D007674_10_1967_1978_nephropathy	CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.
UN	17562951_D007479_2_459_468_iopamidol_D051436_2_500_522_chronic kidney disease	METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.
UN	17574447_D010634_2_408_410_PB_D001996_2_487_503_bronchopneumonia	Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.
CID	17574447_D010634_0_52_65_phenobarbital_D002761_0_19_30_cholangitis	Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.
UN	17574447_D010634_2_408_410_PB_D004827_2_386_394_epilepsy	Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.
UN	17574447_D010634_2_408_410_PB_D006323_2_452_466_cardiac arrest	Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.
CID	17574447_D010634_5_868_870_PB_D008107_5_902_914_liver damage	Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.
UN	17574447_D010634_6_1071_1073_PB_D056487_6_1095_1129_chronic hepatic enzyme dysfunction	For this reason, each clinician should recognize this entity in the differential diagnosis of PB-related asymptomatic chronic hepatic enzyme dysfunction.
UN	17600377_C524754_7_1186_1206_maltolyl p-coumarate_D000544_7_1252_1271_Alzheimer's disease	Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.
UN	17600377_C524754_3_510_530_Maltolyl p-coumarate_D003072_3_554_572_cognitive deficits	Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.
UN	17600377_C524754_2_380_400_maltolyl p-coumarate_D003072_2_415_432_cognitive decline	In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.
UN	17600377_C524754_0_18_38_maltolyl p-coumarate_D003704_0_125_133_dementia	A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.
UN	17600377_C524754_7_1186_1206_maltolyl p-coumarate_D009410_7_1309_1323_neuronal death	Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.
UN	17600377_C544092_2_469_495_amyloid beta peptide(1-42)_D003072_2_415_432_cognitive decline	In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.
CID	17600377_D012601_2_436_447_scopolamine_D003072_2_415_432_cognitive decline	In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.
UN	17608141_D004298_7_1483_1491_dopamine_D020258_7_1492_1505_neurotoxicity	We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.
UN	17608141_D004298_2_409_417_dopamine_D020258_2_418_431_neurotoxicity	In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.
UN	17608141_D008070_3_433_451_Lipopolysaccharide_D005334_3_535_547_hyperthermia	Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.
UN	17608141_D008070_0_91_109_lipopolysaccharide_D020258_0_66_79_neurotoxicity	Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.
CID	17608141_D008694_3_510_525_methamphetamine_D005334_3_535_547_hyperthermia	Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.
UN	17608141_D008694_1_185_200_methamphetamine_D009422_1_209_237_dopaminergic terminal damage	Immunological activation has been proposed to play a role in methamphetamine-induced dopaminergic terminal damage.
UN	17608141_D008694_0_15_30_methamphetamine_D020258_0_66_79_neurotoxicity	Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.
UN	17608141_D008694_2_371_386_methamphetamine_D020258_2_418_431_neurotoxicity	In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.
UN	17608141_D008694_7_1445_1460_methamphetamine_D020258_7_1492_1505_neurotoxicity	We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.
CID	17612891_D003024_3_422_431_clozapine_D009205_3_388_399_myocarditis	RESULTS: A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine.
CID	17612891_D003024_1_120_129_clozapine_D009205_1_72_83_myocarditis	OBJECTIVE: A case of acute myocarditis associated with the commencement of clozapine is described, highlighting the onset, course and possible contributing factors.
CID	17612891_D003024_0_34_43_clozapine_D009205_0_6_17_myocarditis	Acute myocarditis associated with clozapine.
UN	17612891_D003024_9_861_870_clozapine_D011618_9_923_932_psychosis	Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.
UN	17612891_D003024_3_422_431_clozapine_D012559_3_346_359_schizophrenia	RESULTS: A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine.
CID	17615423_C413408_1_208_218_atazanavir_D012206_1_232_246_rhabdomyolysis	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.
CID	17615423_C413408_1_208_218_atazanavir_D058186_1_251_270_acute renal failure	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.
CID	17615423_D000638_1_192_202_amiodarone_D012206_1_232_246_rhabdomyolysis	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.
UN	17615423_D000638_5_940_950_amiodarone_D015658_5_970_998_human immunodeficiency virus	Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.
CID	17615423_D000638_0_91_101_amiodarone_D058186_0_26_45_acute renal failure	Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.
CID	17615423_D000638_1_192_202_amiodarone_D058186_1_251_270_acute renal failure	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.
CID	17615423_D019821_0_78_89_simvastatin_D012206_0_7_21_rhabdomyolysis	Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.
UN	17615423_D019821_5_927_938_Simvastatin_D015658_5_970_998_human immunodeficiency virus	Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.
CID	17615423_D019821_0_78_89_simvastatin_D058186_0_26_45_acute renal failure	Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.
CID	17639754_D014859_4_696_704_warfarin_D006470_4_617_625_bleeding	We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.
CID	17639754_D064704_4_709_721_levofloxacin_D006470_4_617_625_bleeding	We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.
CID	17682013_C017367_6_908_916_carmofur_D056784_6_791_810_leukoencephalopathy	RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.
CID	17682013_C110904_6_922_934_capecitabine_D056784_6_791_810_leukoencephalopathy	RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.
CID	17682013_D005472_6_874_888_5-fluorouracil_D056784_6_791_810_leukoencephalopathy	RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.
UN	17682013_D008727_1_262_274_methotrexate_D002544_1_140_164_cerebrovascular accident	BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.
UN	17682013_D008727_1_262_274_methotrexate_D007938_1_289_298_leukaemia	BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.
CID	17682013_D008727_6_836_848_methotrexate_D056784_6_791_810_leukoencephalopathy	RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.
CID	17702969_D005473_7_872_882_fluoxetine_D005315_7_904_932_fetal pulmonary hypertension	As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).
CID	17702969_D005473_0_21_31_fluoxetine_D005315_0_40_68_fetal pulmonary hypertension	Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.
CID	17702969_D005473_7_872_882_fluoxetine_D006976_7_904_932_fetal pulmonary hypertension	As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).
CID	17702969_D005473_2_227_237_fluoxetine_D006976_2_297_328_pulmonary hypertension syndrome	Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn.
CID	17702969_D005473_3_487_497_fluoxetine_D006976_3_453_475_pulmonary hypertension	The mechanism responsible for this effect is unclear and paradoxical, considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents.
CID	17702969_D005473_0_21_31_fluoxetine_D006976_0_40_68_fetal pulmonary hypertension	Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.
CID	17702969_D005473_11_1737_1747_fluoxetine_D006976_11_1774_1796_pulmonary hypertension	CONCLUSIONS: In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.
UN	17786501_D004221_8_639_649_disulfiram_D000437_8_654_672_alcohol dependence	He had been taking disulfiram for alcohol dependence for the preceding 3 years.
UN	17786501_D004221_1_155_165_disulfiram_D000437_1_170_188_alcohol dependence	AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.
CID	17786501_D004221_1_155_165_disulfiram_D009901_1_102_133_optic and peripheral neuropathy	AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.
CID	17786501_D004221_0_0_10_Disulfiram_D009901_0_29_60_optic and peripheral neuropathy	Disulfiram-induced transient optic and peripheral neuropathy: a case report.
UN	17786501_D004221_0_0_10_Disulfiram_D010523_0_29_60_optic and peripheral neuropathy	Disulfiram-induced transient optic and peripheral neuropathy: a case report.
UN	17786501_D004221_1_155_165_disulfiram_D010523_1_102_133_optic and peripheral neuropathy	AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.
UN	17854040_D012964_0_59_61_na_D006509_0_66_98_hepatitis B virus (HBV) infected	Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
UN	17854040_D012964_1_355_357_na_D006509_1_300_311_hepatitis B	This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.
UN	17854040_D012964_2_490_492_na_D006509_2_497_509_HBV infected	Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.
UN	17854040_D012964_8_1512_1514_na_D006509_8_1519_1538_HBV-HIV co-infected	To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients.
UN	17854040_D012964_2_490_492_na_D015658_2_535_551_HIV co-infection	Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.
UN	17854040_D012964_1_355_357_na_D015658_1_392_439_human immunodeficiency virus (HIV) co-infection	This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.
UN	17854040_D012964_8_1512_1514_na_D015658_8_1519_1538_HBV-HIV co-infected	To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients.
UN	17854040_D019259_8_1472_1482_lamivudine_D006509_8_1519_1538_HBV-HIV co-infected	To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients.
UN	17854040_D019259_1_279_289_lamivudine_D006509_1_300_311_hepatitis B	This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.
UN	17854040_D019259_0_26_36_lamivudine_D006509_0_66_98_hepatitis B virus (HBV) infected	Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
UN	17854040_D019259_2_479_489_lamivudine_D006509_2_497_509_HBV infected	Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.
UN	17854040_D019259_1_344_354_lamivudine_D015658_1_392_439_human immunodeficiency virus (HIV) co-infection	This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.
UN	17854040_D019259_2_479_489_lamivudine_D015658_2_535_551_HIV co-infection	Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.
UN	17854040_D019259_8_1472_1482_lamivudine_D015658_8_1519_1538_HBV-HIV co-infected	To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients.
UN	1786266_D000928_0_17_31_antidepressant_D001480_0_0_15_Rabbit syndrome	Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.
CID	17879945_D019438_3_371_380_ritonavir_D050197_3_401_423_atherosclerotic lesion	We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice.
UN	17919553_C106791_4_539_552_telithromycin_D012141_4_577_610_upper respiratory tract infection	He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.
CID	17919553_C106791_13_1961_1974_telithromycin_D056486_13_1904_1913_hepatitis	CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.
CID	17919553_C106791_0_41_54_telithromycin_D056486_0_6_15_hepatitis	Acute hepatitis attack after exposure to telithromycin.
CID	17919553_C106791_11_1548_1561_telithromycin_D056486_11_1594_1603_hepatitis	Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.
CID	17923537_D005446_1_223_245_fluocinolone acetonide_D009798_1_145_174_elevated intraocular pressure	OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.
UN	17923537_D005446_1_223_245_fluocinolone acetonide_D014605_1_198_205_uveitis	OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.
UN	17923537_D005446_0_59_81_fluocinolone acetonide_D014605_0_38_45_uveitis	Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.
CID	17931375_D006493_0_54_61_heparin_D003288_0_75_83_bruising	A study on the effect of the duration of subcutaneous heparin injection on bruising and pain.
CID	17931375_D006493_2_372_379_heparin_D003288_2_314_322_bruising	BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.
CID	17931375_D006493_7_942_949_heparin_D003288_7_926_934_bruising	Dimensions of the bruising on the heparin applied areas were measured using transparent millimetric measuring paper.
CID	17931375_D006493_13_1732_1739_heparin_D003288_13_1669_1677_bruising	CONCLUSIONS: It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin.
CID	17931375_D006493_13_1732_1739_heparin_D010146_13_1682_1686_pain	CONCLUSIONS: It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin.
CID	17931375_D006493_0_54_61_heparin_D010146_0_88_92_pain	A study on the effect of the duration of subcutaneous heparin injection on bruising and pain.
CID	17931375_D006493_1_255_262_heparin_D010146_1_188_192_pain	AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin.
CID	17931375_D006493_2_372_379_heparin_D010146_2_327_331_pain	BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.
CID	17943461_D015215_6_1139_1142_AZT_D002311_6_1174_1190_cardiac dilation	In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.
CID	17943461_D015215_0_61_64_AZT_D009202_0_73_87_cardiomyopathy	Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy.
UN	17965424_C422649_1_308_318_etoricoxib_D001172_1_351_371_rheumatoid arthritis	OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).
UN	17965424_C422649_0_33_43_etoricoxib_D001172_0_47_67_rheumatoid arthritis	Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
UN	17965424_C422649_2_492_502_etoricoxib_D001172_2_462_464_RA	PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).
CID	17965424_C422649_9_1473_1483_etoricoxib_D004487_9_1423_1429_oedema	The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
UN	17965424_C422649_8_1224_1234_etoricoxib_D005767_8_1188_1194_GI AEs	The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).
CID	17965424_C422649_9_1473_1483_etoricoxib_D006973_9_1398_1410_hypertension	The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
UN	17965424_D004008_1_323_333_diclofenac_D001172_1_351_371_rheumatoid arthritis	OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).
UN	17965424_D004008_9_1527_1537_diclofenac_D004487_9_1423_1429_oedema	The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
CID	17965424_D004008_8_1240_1250_diclofenac_D005767_8_1188_1194_GI AEs	The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).
CID	17965424_D004008_11_1872_1882_diclofenac_D005767_11_1851_1857_GI AEs	CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.
UN	17965424_D004008_9_1527_1537_diclofenac_D006973_9_1398_1410_hypertension	The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
CID	17975693_D002939_3_595_608_ciprofloxacin_D001008_3_646_663_anxious behaviour	RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.
CID	17975693_D009643_3_614_625_norfloxacin_D001008_3_646_663_anxious behaviour	RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.
CID	18004067_D000082_2_485_496_paracetamol_D017093_2_371_384_liver failure	CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.
UN	18004067_D000082_0_79_90_paracetamol_D017114_0_0_19_Acute liver failure	Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.
CID	18004067_D000082_4_696_707_paracetamol_D056486_4_635_649_hepatotoxicity	Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.
CID	18004067_D000082_1_229_240_paracetamol_D056486_1_177_191_hepatotoxicity	BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.
UN	18004067_D000431_2_345_352_alcohol_D017093_2_371_384_liver failure	CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.
UN	18004067_D000431_0_49_56_alcohol_D017114_0_0_19_Acute liver failure	Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.
UN	18004067_D000431_1_147_154_alcohol_D056486_1_177_191_hepatotoxicity	BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.
UN	18006530_C071741_2_217_229_remifentanil_D010146_2_181_185_pain	We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.
UN	18006530_C071741_0_71_83_remifentanil_D010146_0_13_17_pain	Reduction of pain during induction with target-controlled propofol and remifentanil.
UN	18006530_C071741_3_486_498_remifentanil_D010146_3_514_518_pain	A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.
UN	18006530_C071741_11_1649_1661_remifentanil_D010146_11_1570_1574_pain	CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).
CID	18006530_D015742_2_163_171_propofol_D010146_2_181_185_pain	We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.
CID	18006530_D015742_1_118_126_propofol_D010146_1_97_101_Pain	BACKGROUND: Pain on injection of propofol is unpleasant.
CID	18006530_D015742_0_58_66_propofol_D010146_0_13_17_pain	Reduction of pain during induction with target-controlled propofol and remifentanil.
CID	18006530_D015742_11_1552_1560_propofol_D010146_11_1570_1574_pain	CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).
CID	18006530_D015742_6_957_965_propofol_D010146_6_942_946_pain	Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.
CID	18020536_D001569_13_1731_1735_BZDs_D003866_13_1896_1915_depressive symptoms	However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.
CID	18020536_D001569_13_1731_1735_BZDs_D004244_13_1760_1769_dizziness	However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.
CID	18020536_D001569_13_1731_1735_BZDs_D005221_13_1817_1826_tiredness	However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.
CID	18020536_D001569_13_1731_1735_BZDs_D007319_13_1771_1789_inability to sleep	However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.
CID	18023325_D004221_1_100_110_disulfiram_D010523_1_66_87_peripheral neuropathy	Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.
UN	18023325_D004221_12_1250_1260_disulfiram_D011115_12_1215_1229_polyneuropathy	This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.
CID	18023325_D004221_0_35_45_disulfiram_D014826_0_6_22_vocal fold palsy	Acute vocal fold palsy after acute disulfiram intoxication.
UN	18023325_D004221_1_100_110_disulfiram_D062787_1_111_119_overdose	Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.
UN	18081909_C026098_2_258_261_LEV_C562694_2_195_214_idiopathic epilepsy	FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).
CID	18081909_C026098_0_26_39_levetiracetam_D001927_0_0_14_Encephalopathy	Encephalopathy induced by levetiracetam added to valproate.
CID	18081909_C026098_1_123_126_LEV_D001927_1_136_150_encephalopathy	BACKGROUND: We report on the manifestation of a levetiracetam (LEV)-induced encephalopathy.
UN	18081909_C026098_2_258_261_LEV_D012640_2_232_240_seizures	FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).
UN	18081909_D014635_2_281_290_valproate_C562694_2_195_214_idiopathic epilepsy	FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).
CID	18081909_D014635_0_49_58_valproate_D001927_0_0_14_Encephalopathy	Encephalopathy induced by levetiracetam added to valproate.
UN	18081909_D014635_2_281_290_valproate_D012640_2_232_240_seizures	FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).
CID	18083142_D003042_6_951_958_Cocaine_D001008_6_967_974_anxiety	Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.
CID	18083142_D003042_7_1242_1249_cocaine_D001008_7_1258_1265_anxiety	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
CID	18083142_D003042_8_1523_1530_cocaine_D001008_8_1539_1546_anxiety	CONCLUSIONS: These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.
CID	18083142_D003042_3_640_647_cocaine_D001008_3_656_663_anxiety	METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.
CID	18083142_D003042_4_688_695_cocaine_D001008_4_723_730_anxiety	RESULTS: We found that cocaine dose-dependently increased anxiety-like behavior in control (Dbh +/-) mice, as measured by a decrease in open arm exploration.
CID	18083142_D003042_0_89_96_cocaine_D001008_0_105_112_anxiety	Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.
UN	18083142_D004221_6_1039_1049_disulfiram_D001008_6_967_974_anxiety	Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.
UN	18083142_D004298_6_1053_1061_dopamine_D001008_6_967_974_anxiety	Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.
UN	18083142_D004298_3_467_475_dopamine_D001008_3_656_663_anxiety	METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.
UN	18083142_D009638_0_0_14_Norepinephrine_D001008_0_105_112_anxiety	Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.
UN	18083142_D009638_3_529_543_norepinephrine_D001008_3_656_663_anxiety	METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.
UN	18083142_D011224_7_1350_1358_prazosin_D001008_7_1258_1265_anxiety	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
UN	18083142_D011433_7_1222_1233_propranolol_D001008_7_1258_1265_anxiety	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
UN	18083142_D015016_7_1387_1396_yohimbine_D001008_7_1258_1265_anxiety	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
UN	18086064_D020927_6_598_613_Dexmedetomidine_D009203_6_746_767_myocardial infarction	Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).
UN	18086064_D020927_6_598_613_Dexmedetomidine_D017202_6_811_831_myocardial ischaemia	Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).
UN	18161408_D002996_5_659_661_CC_D002637_5_705_715_chest pain	CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.
CID	18161408_D002996_11_1192_1194_CC_D009203_11_1199_1220_myocardial infarction	CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.
CID	18161408_D002996_0_51_69_clomiphene citrate_D009203_0_0_21_Myocardial infarction	Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.
CID	18161408_D002996_3_358_360_CC_D013923_3_244_259_Thromboembolism	Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with CC.
UN	18162529_D004298_4_576_584_dopamine_D006966_4_542_560_hyperprolactinemia	Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.
UN	18162529_D004958_0_182_191_estradiol_D006966_0_92_110_hyperprolactinemic	Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.
UN	18162529_D004967_3_507_515_estrogen_D006966_3_385_403_hyperprolactinemia	We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.
UN	18162529_D012313_0_42_58_ribonucleic acid_D006966_0_92_110_hyperprolactinemic	Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.
UN	18162529_D013256_12_1792_1799_steroid_D006966_12_1768_1786_hyperprolactinemia	These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.
CID	18162529_D013469_4_596_605_sulpiride_D006966_4_542_560_hyperprolactinemia	Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.
CID	18177388_D000661_0_134_145_amphetamine_D054549_0_73_97_Takotsubo cardiomyopathy	Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.
CID	18177388_D000661_5_717_728_amphetamine_D054549_5_674_700_apical ballooning syndrome	In this article, we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use.
UN	18182964_D003000_0_0_9_Clonidine_D001289_0_14_54_attention-deficit/hyperactivity disorder	Clonidine for attention-deficit/hyperactivity disorder: II.
UN	18182964_D003000_2_154_163_clonidine_D001289_2_216_256_attention-deficit/hyperactivity disorder	OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).
UN	18182964_D003000_3_368_377_clonidine_D001289_3_337_341_ADHD	METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).
CID	18182964_D003000_6_794_803_clonidine_D001919_6_757_768_bradycardia	RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.
CID	18182964_D003000_11_1482_1491_clonidine_D001919_11_1511_1522_bradycardia	Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.
UN	18182964_D003000_9_1297_1306_clonidine_D006970_9_1272_1282_Drowsiness	Drowsiness was common on clonidine, but generally resolved by 6 to 8 weeks.
UN	18182964_D008774_2_183_198_methylphenidate_D001289_2_216_256_attention-deficit/hyperactivity disorder	OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).
UN	18186898_D016559_7_767_777_tacrolimus_D000138_7_838_846_acidosis	Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.
CID	18186898_D016559_10_1253_1263_tacrolimus_D005198_10_1149_1168_tubular dysfunction	We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.
CID	18186898_D016559_10_1253_1263_tacrolimus_D009135_10_1173_1181_myopathy	We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.
UN	18186898_D016559_10_1253_1263_tacrolimus_D028361_10_1205_1230_mitochondrial dysfunction	We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.
CID	18186898_D019259_10_1281_1291_lamivudine_D005198_10_1149_1168_tubular dysfunction	We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.
UN	18186898_D019259_5_525_535_Lamivudine_D006509_5_565_586_hepatitis B infection	Lamivudine was added because of de nova hepatitis B infection during her follow-up.
CID	18186898_D019259_10_1281_1291_lamivudine_D009135_10_1173_1181_myopathy	We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.
UN	18186898_D019259_10_1281_1291_lamivudine_D028361_10_1205_1230_mitochondrial dysfunction	We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.
UN	18186898_D020123_7_867_876_sirolimus_D000138_7_838_846_acidosis	Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.
UN	18201582_C084178_0_172_183_telmisartan_D006973_0_260_272_hypertension	Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.
UN	18201582_C084178_1_394_405_telmisartan_D006973_1_521_533_hypertension	OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.
UN	18201582_D017311_0_206_216_amlodipine_D006973_0_260_272_hypertension	Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.
CID	18208574_D006493_1_192_199_heparin_D013921_1_208_224_thrombocytopenia	OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.
CID	18208574_D006493_0_80_87_heparin_D013921_0_96_112_thrombocytopenia	Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.
CID	18208574_D006493_1_192_199_heparin_D013927_1_250_260_thrombosis	OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.
CID	18208574_D006493_0_80_87_heparin_D013927_0_52_62_thrombosis	Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.
UN	18217897_C467567_9_1325_1337_lenalidomide_D008223_9_1211_1220_lymphomas	Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.
UN	18217897_D013792_0_0_11_Thalidomide_D007938_0_139_147_Leukemia	Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
UN	18217897_D013792_3_535_546_thalidomide_D008223_3_516_525_lymphomas	Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.
UN	18217897_D013792_9_1187_1198_thalidomide_D008223_9_1211_1220_lymphomas	Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.
UN	18217897_D013792_0_0_11_Thalidomide_D008228_0_81_102_non-Hodgkin lymphomas	Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
UN	18217897_D013792_1_157_168_Thalidomide_D009101_1_228_244_multiple myeloma	Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.
UN	18217897_D013792_0_0_11_Thalidomide_D009369_0_128_134_Cancer	Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
UN	18217897_D013792_1_157_168_Thalidomide_D020522_1_246_266_mantle cell lymphoma	Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.
CID	18221780_D002211_3_641_650_capsaicin_D006930_3_595_607_hyperalgesia	To this end, persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.
UN	18221780_D002211_0_81_90_capsaicin_D010146_0_111_115_pain	Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.
UN	18221780_D002211_0_81_90_capsaicin_D059787_0_146_156_acute pain	Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.
UN	18221780_D003915_7_1237_1253_dextromethorphan_D059787_7_1296_1306_acute pain	Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.
UN	18221780_D009020_8_1462_1470_morphine_D010146_8_1487_1491_pain	These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.
UN	18221780_D009020_0_50_58_morphine_D010146_0_111_115_pain	Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.
UN	18221780_D009020_0_50_58_morphine_D059787_0_146_156_acute pain	Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.
UN	18221780_D009020_1_259_267_morphine_D059787_1_161_171_acute pain	In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.
UN	18221780_D009020_8_1462_1470_morphine_D059787_8_1547_1557_acute pain	These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.
UN	18221780_D009020_7_1209_1217_morphine_D059787_7_1296_1306_acute pain	Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.
UN	18221780_D016202_8_1441_1445_NMDA_D010146_8_1487_1491_pain	These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.
UN	18221780_D016202_1_180_200_N-methyl-D-aspartate_D059787_1_161_171_acute pain	In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.
UN	18221780_D016202_8_1441_1445_NMDA_D059787_8_1547_1557_acute pain	These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.
UN	18221780_D016202_0_19_23_NMDA_D059787_0_146_156_acute pain	Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.
CID	18239197_D014282_0_72_87_trihexyphenidyl_D003072_0_10_24_mental slowing	Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.
CID	18239197_D014282_7_1278_1293_trihexyphenidyl_D003072_7_1320_1335_mental slowness	Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.
CID	18239197_D014282_6_1093_1108_trihexyphenidyl_D003072_6_1153_1168_mental slowness	RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.
CID	18239197_D014282_9_1718_1733_trihexyphenidyl_D003072_9_1697_1711_mental slowing	CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.
UN	18239197_D014282_1_261_276_trihexyphenidyl_D003221_1_313_322_confusion	OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.
UN	18261172_D000806_11_1424_1428_ACEi_D007674_11_1494_1511_renal dysfunction	Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.
UN	18261172_D000806_11_1424_1428_ACEi_D011507_11_1468_1479_proteinuria	Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.
UN	18261172_D020123_2_262_265_Srl_D007674_2_273_284_nephrotoxic	The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.
CID	18261172_D020123_2_331_334_Srl_D011507_2_303_314_proteinuria	The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.
CID	18261172_D020123_3_459_462_Srl_D011507_3_431_442_proteinuria	In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.
CID	18261172_D020123_10_1325_1328_Srl_D011507_10_1254_1265_proteinuria	Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.
CID	18261172_D020123_0_43_52_sirolimus_D011507_0_15_26_proteinuria	Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.
UN	18261172_D057911_11_1429_1432_ARB_D007674_11_1494_1511_renal dysfunction	Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.
UN	18261172_D057911_11_1429_1432_ARB_D011507_11_1468_1479_proteinuria	Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.
UN	18261172_D057911_8_965_968_ARB_D011507_8_986_997_proteinuria	ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.
UN	18308784_C035054_0_0_15_Ginsenoside Rg1_D007859_0_29_51_impairment of learning	Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.
UN	18308784_C035054_3_394_397_Rg1_D007859_3_401_420_learning impairment	The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.
CID	18308784_D009020_0_71_79_morphine_D007859_0_29_51_impairment of learning	Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.
CID	18308784_D009020_3_432_440_morphine_D007859_3_401_420_learning impairment	The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.
UN	18308784_D036145_1_114_125_ginsenoside_D007859_1_181_200_learning impairment	Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.
CID	18329269_D006220_2_320_331_haloperidol_D002375_2_340_349_catalepsy	SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.
UN	18329269_D006220_2_320_331_haloperidol_D010300_2_360_379_Parkinson's disease	SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.
UN	1833784_C534628_7_1274_1283_SCH 23390_D006948_7_1217_1230_hyperactivity	Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.
UN	1833784_D004298_0_41_49_dopamine_D006948_0_90_103_hyperactivity	Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.
UN	1833784_D005476_7_1349_1361_fluphenazine_D006948_7_1217_1230_hyperactivity	Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.
CID	1833784_D009538_0_73_81_nicotine_D006948_0_90_103_hyperactivity	Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.
CID	1833784_D009538_8_1410_1418_nicotine_D006948_8_1427_1440_hyperactivity	Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.
CID	1833784_D009538_7_1200_1208_Nicotine_D006948_7_1217_1230_hyperactivity	Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.
CID	1833784_D009538_9_1522_1530_nicotine_D006948_9_1562_1575_hyperactivity	The results indicate that acute nicotine injection induces a pronounced hyperactivity in rats habituated to the test environment.
UN	1833784_D015647_8_1465_1474_SKF 38393_D006948_8_1427_1440_hyperactivity	Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.
UN	1833784_D020891_7_1313_1323_raclopride_D006948_7_1217_1230_hyperactivity	Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.
UN	18343374_D002996_10_960_962_CC_D007247_10_934_945_infertility	Extra caution is warranted in treating infertility patients with CC, and patients should be well informed of this side effect before commencement of therapy.
CID	18343374_D002996_0_47_57_clomiphene_D012170_0_8_30_retinal vein occlusion	Central retinal vein occlusion associated with clomiphene-induced ovulation.
CID	18343374_D002996_1_155_173_clomiphene citrate_D012170_1_116_138_retinal vein occlusion	OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).
CID	18343374_D002996_7_596_598_CC_D012170_7_550_572_retinal vein occlusion	RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.
CID	18343374_D002996_6_489_491_CC_D012170_6_435_457_retinal vein occlusion	MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.
CID	18343374_D002996_9_891_893_CC_D012170_9_847_869_retinal vein occlusion	CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.
UN	18343374_D002996_8_666_668_CC_D013923_8_634_648_thromboembolic	A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.
CID	18343374_D002996_8_762_764_CC_D014786_8_737_755_visual disturbance	A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.
UN	1835291_D009241_0_33_52_ipratropium bromide_D029424_0_73_110_chronic obstructive pulmonary disease	Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.
CID	1835291_D013806_5_964_976_theophylline_D002318_5_997_1040_cardiovascular and gastrointestinal systems	While side effects were rare, those experienced after theophylline use did involve the cardiovascular and gastrointestinal systems.
CID	1835291_D013806_5_964_976_theophylline_D005767_5_997_1040_cardiovascular and gastrointestinal systems	While side effects were rare, those experienced after theophylline use did involve the cardiovascular and gastrointestinal systems.
UN	1835291_D013806_0_57_69_theophylline_D029424_0_73_110_chronic obstructive pulmonary disease	Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.
UN	1835291_D013806_6_1120_1132_theophylline_D029424_6_1150_1177_chronic airflow obstruction	These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.
UN	18356633_D000583_4_828_836_amikacin_D006402_4_690_720_hematologic/oncologic disorder	Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.
UN	18356633_D000583_1_80_88_Amikacin_D007239_1_220_230_infections	Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.
CID	18356633_D000583_0_17_25_amikacin_D007674_0_26_40_nephrotoxicity	An evaluation of amikacin nephrotoxicity in the hematology/oncology population.
CID	18356633_D000583_3_460_468_amikacin_D007674_3_480_494_nephrotoxicity	To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.
UN	18356633_D000583_4_828_836_amikacin_D009369_4_690_720_hematologic/oncologic disorder	Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.
UN	18356633_D000583_1_80_88_Amikacin_D009503_1_180_199_febrile neutropenia	Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.
UN	18356633_D000617_4_753_767_aminoglycoside_D006402_4_690_720_hematologic/oncologic disorder	Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.
UN	18356633_D000617_1_95_109_aminoglycoside_D007239_1_220_230_infections	Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.
UN	18356633_D000617_4_753_767_aminoglycoside_D009369_4_690_720_hematologic/oncologic disorder	Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.
UN	18356633_D000617_1_95_109_aminoglycoside_D009503_1_180_199_febrile neutropenia	Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.
UN	18356633_D003404_5_904_914_creatinine_D007674_5_856_870_nephrotoxicity	The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.
UN	18363626_D010100_9_1608_1614_oxygen_D001919_9_1500_1511_bradycardia	Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.
CID	18363626_D020927_9_1436_1451_dexmedetomidine_D001919_9_1500_1511_bradycardia	Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.
UN	18405372_D012460_0_31_44_sulfasalazine_D001168_0_61_70_arthritis	Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.
CID	18405372_D012460_6_913_926_sulfasalazine_D056486_6_893_907_hepatotoxicity	The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions.
CID	18405372_D012460_4_667_680_sulfasalazine_D056486_4_649_663_hepatotoxicity	Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.
CID	18405372_D012460_14_1585_1598_sulfasalazine_D056486_14_1565_1579_hepatotoxicity	The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.
CID	18405372_D012460_15_1693_1706_sulfasalazine_D056486_15_1662_1676_hepatotoxicity	CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.
CID	18405372_D012460_0_31_44_sulfasalazine_D056486_0_0_14_Hepatotoxicity	Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.
UN	18410508_D004298_3_500_502_DA_D009422_3_479_496_neurodegeneration	Neurosci. 9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.
UN	18410508_D004298_4_587_589_DA_D020258_4_625_638_neurotoxicity	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.
CID	18410508_D008694_4_545_549_METH_D009422_4_524_534_CNS damage	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.
UN	18410508_D008694_5_883_887_METH_D020258_5_914_927_neurotoxicity	Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.
UN	18410508_D008694_4_688_692_METH_D020258_4_701_714_neurotoxicity	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.
UN	18410508_D008694_0_0_15_Methamphetamine_D020258_0_24_37_neurotoxicity	Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.
UN	18410508_D008694_10_1575_1579_METH_D020258_10_1580_1593_neurotoxicity	We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.
CID	18410508_D015632_3_466_470_MPTP_D009422_3_479_496_neurodegeneration	Neurosci. 9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.
CID	18410508_D015632_4_554_558_MPTP_D009422_4_524_534_CNS damage	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.
UN	18410508_D015632_4_554_558_MPTP_D020258_4_625_638_neurotoxicity	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.
CID	18417364_D009538_0_0_8_Nicotine_D009759_0_17_26_nystagmus	Nicotine-induced nystagmus correlates with midpontine activation.
CID	18417364_D009538_1_88_96_nicotine_D009759_1_105_114_nystagmus	The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.
UN	18417364_D010100_4_427_433_oxygen_D009759_4_401_404_NIN	NIN correlated with blood oxygen level-dependent (BOLD) activity levels in a midpontine site in the posterior basis pontis.
UN	18439803_C108761_0_17_42_N-(2-propylpentanoyl)urea_D012640_0_110_117_seizure	Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.
UN	18439803_D000596_0_58_68_amino acid_D012640_0_110_117_seizure	Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.
UN	18439803_D000596_6_1329_1339_amino acid_D012640_6_1272_1279_seizure	Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.
UN	18439803_D001224_6_1436_1445_aspartate_D012640_6_1272_1279_seizure	Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.
UN	18439803_D001224_7_1561_1570_aspartate_D012640_7_1668_1675_seizure	Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.
CID	18439803_D010862_6_1252_1263_pilocarpine_D012640_6_1272_1279_seizure	Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.
CID	18439803_D010862_7_1648_1659_pilocarpine_D012640_7_1668_1675_seizure	Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.
CID	18439803_D010862_2_524_535_pilocarpine_D012640_2_544_551_seizure	VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.
CID	18439803_D010862_0_90_101_pilocarpine_D012640_0_110_117_seizure	Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.
UN	18439803_D014635_6_1214_1217_VPA_D012640_6_1272_1279_seizure	Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.
UN	18439803_D014635_2_588_591_VPA_D012640_2_544_551_seizure	VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.
UN	18439803_D018698_7_1547_1556_glutamate_D012640_7_1668_1675_seizure	Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.
UN	18439803_D018698_6_1422_1431_glutamate_D012640_6_1272_1279_seizure	Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.
CID	18441470_D008094_1_163_170_lithium_D012804_1_62_84_Sinus node dysfunction	Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium.
UN	18441470_D008094_2_275_282_lithium_D013575_2_235_251_syncopal attacks	In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.
CID	18441470_D008094_0_45_52_lithium_D054537_0_9_31_atrioventricular block	Complete atrioventricular block secondary to lithium therapy.
CID	18441470_D008094_2_275_282_lithium_D054537_2_202_229_atrioventricular (AV) block	In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.
UN	18442015_D002118_8_1144_1151_calcium_D050197_8_1102_1117_atherosclerotic	Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.
CID	18442015_D002784_2_516_527_cholesterol_D006471_2_412_430_gastric hemorrhage	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
CID	18442015_D002784_2_516_527_cholesterol_D014456_2_435_440_ulcer	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
CID	18442015_D002784_4_738_749_cholesterol_D050197_4_760_775_atherosclerosis	Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.
CID	18442015_D002784_2_516_527_cholesterol_D050197_2_454_469_atherosclerosis	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
CID	18442015_D002784_8_1159_1170_cholesterol_D050197_8_1230_1245_atherosclerotic	Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.
CID	18442015_D004872_2_501_511_vitamin D2_D006471_2_412_430_gastric hemorrhage	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
CID	18442015_D004872_2_501_511_vitamin D2_D014456_2_435_440_ulcer	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
CID	18442015_D004872_4_723_733_vitamin D2_D050197_4_760_775_atherosclerosis	Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.
CID	18442015_D004872_2_501_511_vitamin D2_D050197_2_454_469_atherosclerosis	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
UN	18442015_D006632_10_1496_1505_histamine_D006471_10_1509_1527_gastric hemorrhage	Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.
UN	18442015_D006632_10_1496_1505_histamine_D014456_10_1535_1540_ulcer	Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.
UN	18442015_D006632_12_1827_1836_histamine_D050197_12_1707_1722_Atherosclerosis	Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.
UN	18442015_D006632_2_308_317_histamine_D050197_2_454_469_atherosclerosis	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
UN	18442015_D006632_10_1496_1505_histamine_D050197_10_1560_1575_atherosclerotic	Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.
UN	18442015_D010634_7_1033_1040_luminal_D014456_7_1064_1069_ulcer	Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.
UN	18442015_D014700_0_21_30_verapamil_D006471_0_34_53_gastric hemorrhagic	Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.
UN	18442015_D014700_0_21_30_verapamil_D014456_0_54_60_ulcers	Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.
UN	18442015_D014700_3_568_577_verapamil_D014456_3_586_591_ulcer	Additionally, the protective effect of verapamil on this ulcer model was evaluated.
UN	18442015_D014700_0_21_30_verapamil_D050197_0_71_86_atherosclerotic	Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.
CID	18464113_D006514_0_67_94_hepatitis-B surface antigen_D006509_0_33_44_hepatitis B	Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.
UN	18464113_D006514_0_96_101_HBSAG_D009369_0_116_122_cancer	Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.
UN	18464113_D019259_3_576_586_lamivudine_D006509_3_533_546_HBV infection	In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.
UN	18464113_D019259_0_0_10_Lamivudine_D006509_0_33_44_hepatitis B	Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.
UN	18464113_D019259_0_0_10_Lamivudine_D009369_0_116_122_cancer	Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.
UN	18464113_D019259_14_1667_1677_lamivudine_D009369_14_1761_1767_cancer	Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy.
UN	18464113_D019259_3_576_586_lamivudine_D009369_3_458_464_cancer	In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.
UN	18464113_D019259_3_576_586_lamivudine_D019337_3_493_519_hematological malignancies	In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.
UN	18464113_D019259_12_1342_1352_lamivudine_D056486_12_1366_1375_hepatitis	In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient (2.7%) of 37 patients (p < 0.006).
CID	18483878_D003520_2_392_395_CYP_D003556_2_405_413_cystitis	VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.
CID	18483878_D003520_0_132_135_CYP_D003556_0_145_153_cystitis	Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.
CID	18483878_D003520_4_754_757_CYP_D003556_4_766_774_cystitis	A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).
UN	1848636_D008790_4_603_613_metoprolol_D007008_4_637_648_hypokalemia	The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia.
CID	1848636_D013726_4_617_628_terbutaline_D007008_4_637_648_hypokalemia	The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia.
UN	18503483_C107135_0_72_82_everolimus_D020968_0_34_51_brachial neuritis	Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.
CID	18503483_D016559_0_12_22_tacrolimus_D020968_0_34_51_brachial neuritis	Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.
UN	18513945_D010121_4_583_591_Oxytocin_D006473_4_666_676_blood loss	Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.
CID	18513945_D010121_4_583_591_Oxytocin_D007022_4_600_611_hypotension	Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.
CID	18513945_D010121_7_1076_1084_oxytocin_D007022_7_1049_1060_Hypotension	Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.
UN	18513945_D010121_7_1076_1084_oxytocin_D020521_7_1179_1185_stroke	Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.
UN	18541230_D011692_3_494_519_puromycin aminonucleoside_D006402_3_528_555_hematological abnormalities	Treatment with antithrombin attenuated the puromycin aminonucleoside-induced hematological abnormalities.
UN	18541230_D011692_4_557_582_Puromycin aminonucleoside_D006949_4_613_627_hyperlipidemia	Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.
CID	18541230_D011692_1_184_209_puromycin aminonucleoside_D009401_1_218_227_nephrosis	We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.
CID	18541230_D011692_0_38_63_puromycin aminonucleoside_D009401_0_64_73_nephrosis	Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.
UN	18541230_D011692_8_1197_1222_puromycin aminonucleoside_D009404_8_1231_1249_nephrotic syndrome	These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside-induced nephrotic syndrome.
UN	18544179_C009250_10_1662_1673_sevoflurane_D001919_10_1743_1754_bradycardia	Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.
UN	18544179_C009250_10_1662_1673_sevoflurane_D007022_10_1727_1738_hypotension	Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.
UN	18544179_C009250_0_78_89_sevoflurane_D009325_0_26_32_nausea	Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.
UN	18544179_C009250_3_514_525_sevoflurane_D010146_3_485_489_pain	METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.
UN	18544179_C009250_11_1990_2001_sevoflurane_D010149_11_1852_1870_postoperative pain	CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.
UN	18544179_C009250_10_1662_1673_sevoflurane_D012131_10_1703_1725_respiratory depression	Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.
UN	18544179_C009250_0_78_89_sevoflurane_D014839_0_37_45_vomiting	Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.
UN	18544179_C009250_3_514_525_sevoflurane_D020250_3_447_480_postoperative nausea and vomiting	METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.
UN	18544179_D003907_5_963_976_dexamethasone_D009325_5_893_899_nausea	RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).
UN	18544179_D003907_5_963_976_dexamethasone_D014839_5_858_866_vomiting	RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).
UN	18544179_D003907_7_1085_1098_Dexamethasone_D020250_7_1157_1190_postoperative nausea and vomiting	Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting.
UN	18544179_D003907_5_963_976_dexamethasone_D020250_5_791_824_postoperative nausea and vomiting	RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).
CID	18544179_D005283_10_1601_1609_Fentanyl_D001919_10_1743_1754_bradycardia	Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.
CID	18544179_D005283_10_1601_1609_Fentanyl_D007022_10_1727_1738_hypotension	Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.
UN	18544179_D005283_0_9_17_fentanyl_D010146_0_66_70_pain	Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.
UN	18544179_D005283_9_1591_1599_fentanyl_D010146_9_1515_1519_Pain	Pain severity and analgesic requirements were unaffected by the omission of fentanyl.
UN	18544179_D005283_11_1771_1779_fentanyl_D010149_11_1852_1870_postoperative pain	CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.
CID	18544179_D005283_10_1601_1609_Fentanyl_D012131_10_1703_1725_respiratory depression	Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.
CID	18544179_D005283_11_1771_1779_fentanyl_D020250_11_1792_1825_postoperative nausea and vomiting	CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.
CID	18544179_D005283_5_742_750_fentanyl_D020250_5_791_824_postoperative nausea and vomiting	RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).
UN	18560792_D004298_14_2012_2020_dopamine_D006349_14_1857_1876_valve regurgitation	This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.
UN	18560792_D004298_14_2012_2020_dopamine_D010300_14_1880_1882_PD	This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.
UN	18560792_D010479_13_1549_1558_Pergolide_D006333_13_1741_1754_heart failure	Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.
UN	18560792_D010479_12_1467_1476_pergolide_D006333_12_1534_1547_heart failure	A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.
UN	18560792_D010479_2_229_238_pergolide_D010300_2_212_214_PD	Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.
UN	18560792_D010479_0_73_82_pergolide_D010300_0_40_59_Parkinson's disease	Valvular heart disease in patients with Parkinson's disease treated with pergolide.
UN	18560792_D010479_14_1905_1914_pergolide_D010300_14_1880_1882_PD	This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.
UN	18560792_D010479_5_617_626_pergolide_D010300_5_573_575_PD	METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.
CID	18589141_D006493_2_259_266_Heparin_D013921_2_275_291_thrombocytopenia	Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.
CID	18589141_D006493_3_478_485_heparin_D013921_3_505_508_HIT	The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.
CID	18589141_D006493_0_0_7_Heparin_D013921_0_16_32_thrombocytopenia	Heparin-induced thrombocytopenia after liver transplantation.
CID	18589141_D006493_14_1682_1685_UFH_D013921_14_1694_1697_HIT	None of the subjects/patients developed UFH-related HIT.
UN	18589141_D006493_1_74_103_Unfractionated heparin sodium_D013927_1_219_229_thrombosis	BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.
UN	18589141_D006495_1_113_141_low-molecular weight heparin_D013927_1_219_229_thrombosis	BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.
UN	18619688_C025946_3_430_445_3-methyladenine_D006333_3_501_514_heart failure	METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.
UN	18619688_D004317_0_0_10_Adriamycin_D003643_0_44_49_death	Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.
CID	18619688_D004317_2_340_350_adriamycin_D006333_2_315_328_heart failure	The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.
CID	18619688_D004317_11_1658_1668_adriamycin_D006333_11_1634_1647_heart failure	Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.
CID	18619688_D004317_3_540_550_adriamycin_D006333_3_501_514_heart failure	METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.
CID	18619688_D004317_10_1563_1573_adriamycin_D006333_10_1530_1543_heart failure	CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.
CID	18619688_D004317_1_170_180_adriamycin_D006333_1_145_158_heart failure	BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.
UN	18627295_D004317_0_0_11_Doxorubicin_D007249_0_35_47_inflammation	Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.
UN	18627295_D004317_2_482_485_DOX_D007249_2_436_448_inflammation	To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.
CID	18627295_D004317_0_0_11_Doxorubicin_D009202_0_12_26_cardiomyopathy	Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.
CID	18627295_D004317_2_351_354_DOX_D009202_2_355_369_cardiomyopathy	To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.
CID	18627295_D004317_7_1103_1106_DOX_D009202_7_1107_1121_cardiomyopathy	These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.
CID	18627295_D004317_8_1297_1300_DOX_D009202_8_1301_1315_cardiomyopathy	These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy.
UN	18627295_D004317_1_167_170_DOX_D066126_1_190_201_cardiotoxic	Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.
UN	18627295_D018943_1_140_153_anthracycline_D066126_1_190_201_cardiotoxic	Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.
CID	18631865_D020123_3_496_505_sirolimus_D011507_3_473_484_proteinuria	Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.
UN	18631865_D020123_1_239_248_sirolimus_D051436_1_286_315_chronic allograft nephropathy	Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.
CID	18657397_D010400_4_566_588_penicillin-G potassium_D004827_4_510_519_epileptic	After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.
UN	1867351_D015767_6_854_864_mefloquine_D008288_6_815_822_malaria	Therefore, certain limitations for malaria prophylaxis and treatment with mefloquine are recommended.
UN	18674790_C010013_6_1105_1118_doxorubicinol_D009765_6_1170_1172_OB	Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
UN	18674790_D000244_7_1701_1704_ADP_D009765_7_1215_1217_OB	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
UN	18674790_D000249_7_1606_1609_AMP_D009765_7_1573_1575_OB	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
UN	18674790_D000255_7_1661_1664_ATP_D009765_7_1215_1217_OB	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
UN	18674790_D000255_9_2012_2015_ATP_D009765_9_1887_1892_obese	In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.
UN	18674790_D000255_9_2012_2015_ATP_D066126_9_1943_1957_cardiotoxicity	In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.
CID	18674790_D004041_0_5_8_fat_D009765_0_18_23_obese	High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.
UN	18674790_D004041_0_5_8_fat_D066126_0_73_87_cardiotoxicity	High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.
UN	18674790_D004041_4_624_627_fat_D066126_4_737_751_cardiotoxicity	In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
CID	18674790_D004317_5_773_784_doxorubicin_D006331_5_873_892_cardiac dysfunction	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
UN	18674790_D004317_5_773_784_doxorubicin_D007674_5_989_1014_renal or hepatic toxicity	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
UN	18674790_D004317_0_53_64_doxorubicin_D009765_0_18_23_obese	High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.
UN	18674790_D004317_9_1923_1934_doxorubicin_D009765_9_1887_1892_obese	In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.
UN	18674790_D004317_5_773_784_doxorubicin_D056486_5_989_1014_renal or hepatic toxicity	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
UN	18674790_D004317_4_717_728_doxorubicin_D066126_4_737_751_cardiotoxicity	In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
UN	18674790_D004317_9_1923_1934_doxorubicin_D066126_9_1943_1957_cardiotoxicity	In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.
UN	18674790_D004317_1_125_135_Adriamycin_D066126_1_172_186_cardiotoxicity	Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.
UN	18674790_D004317_2_306_317_doxorubicin_D066126_2_326_340_cardiotoxicity	Recently, we have shown that moderate diet restriction remarkably protects against doxorubicin-induced cardiotoxicity.
UN	18674790_D004317_0_53_64_doxorubicin_D066126_0_73_87_cardiotoxicity	High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.
CID	18703024_D006220_5_652_663_haloperidol_D002375_5_672_681_catalepsy	No changes in haloperidol-induced catalepsy or MK-801-induced locomotion were seen following PD.
UN	18703024_D016291_5_685_691_MK-801_D002375_5_672_681_catalepsy	No changes in haloperidol-induced catalepsy or MK-801-induced locomotion were seen following PD.
UN	18726058_D010208_14_1565_1575_papaverine_D020301_14_1597_1606_vasospasm	CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.
UN	18726058_D010208_4_567_577_papaverine_D020301_4_582_591_vasospasm	METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm.
UN	18726058_D010208_5_601_611_papaverine_D020301_5_662_671_vasospasm	Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients.
UN	18726058_D010208_1_78_102_Papaverine hydrochloride_D020301_1_149_158_vasospasm	BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.
UN	18752389_C108606_12_1847_1856_ezetimibe_D056486_12_1791_1805_hepatotoxicity	We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.
UN	18752389_C108606_2_305_314_ezetimibe_D056486_2_250_261_hepatotoxic	However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.
UN	18752389_C492458_6_814_834_Simvastatinezetimibe_D003866_6_878_888_depression	Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.
CID	18752389_C492458_3_536_569_simvastatin 10 mg-ezetimibe 40 mg_D017114_3_418_443_fulminant hepatic failure	We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.
CID	18752389_C492458_12_1762_1782_simvastatinezetimibe_D056486_12_1791_1805_hepatotoxicity	We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.
CID	18752389_C492458_13_1944_1965_simvastatin-ezetimibe_D056486_13_1924_1938_hepatotoxicity	Clinicians should be aware of potential hepatotoxicity with simvastatin-ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage.
UN	18752389_C532833_10_1487_1511_simvastatin hydroxy acid_D056486_10_1572_1586_hepatotoxicity	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.
UN	18752389_D014530_10_1363_1382_uridine diphosphate_D056486_10_1572_1586_hepatotoxicity	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.
UN	18752389_D015283_6_839_851_escitalopram_D003866_6_878_888_depression	Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.
UN	18752389_D015283_6_839_851_escitalopram_D056486_6_939_953_hepatotoxicity	Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.
UN	18752389_D019821_3_511_522_simvastatin_D017114_3_418_443_fulminant hepatic failure	We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.
UN	18752389_D019821_10_1536_1547_simvastatin_D056486_10_1572_1586_hepatotoxicity	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.
UN	18752389_D019821_4_626_637_simvastatin_D056486_4_694_708_hepatotoxicity	The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity.
UN	18752389_D019821_12_1823_1834_simvastatin_D056486_12_1791_1805_hepatotoxicity	We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.
UN	18754075_D004164_0_55_69_bisphosphonate_D005923_0_117_151_focal segmental glomerulosclerosis	Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.
UN	18754075_D013256_1_279_286_steroid_D005923_1_211_245_focal segmental glomerulosclerosis	A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.
UN	18754075_D013256_1_279_286_steroid_D009404_1_185_203_nephrotic syndrome	A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.
UN	18754075_D019386_0_71_82_alendronate_D005923_0_117_151_focal segmental glomerulosclerosis	Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.
CID	18754075_D019386_0_71_82_alendronate_D011507_0_8_19_proteinuria	Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.
CID	18754075_D019386_0_71_82_alendronate_D058186_0_24_43_acute renal failure	Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.
UN	18768591_D000450_2_213_224_aldosterone_D005355_2_361_369_fibrosis	The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.
UN	18768591_D000450_6_942_953_aldosterone_D009404_6_974_983_nephrotic	Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.
CID	18768591_D004317_5_706_717_Doxorubicin_D001201_5_876_883_ascites	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
UN	18768591_D004317_1_88_99_Doxorubicin_D005355_1_199_207_fibrosis	Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.
CID	18768591_D004317_5_706_717_Doxorubicin_D006949_5_885_894_lipidemia	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
CID	18768591_D004317_0_48_59_doxorubicin_D009404_0_68_86_nephrotic syndrome	Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.
CID	18768591_D004317_5_706_717_Doxorubicin_D011507_5_746_757_proteinuria	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
UN	18768591_D004317_1_88_99_Doxorubicin_D016055_1_172_188_volume retention	Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.
CID	18768591_D004317_5_706_717_Doxorubicin_D034141_5_900_915_hypoalbuminemia	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
UN	18768591_D012964_1_140_146_sodium_D005355_1_199_207_fibrosis	Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.
UN	18768591_D012964_1_140_146_sodium_D007674_1_108_119_nephropathy	Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.
UN	18768591_D012964_7_1088_1094_sodium_D015430_7_1282_1293_weight gain	Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).
UN	18768591_D012964_1_140_146_sodium_D016055_1_172_188_volume retention	Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.
UN	18768591_D014508_8_1418_1422_urea_D009404_8_1392_1410_nephrotic syndrome	During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).
UN	18768591_D014508_8_1418_1422_urea_D014511_8_1521_1527_uremia	During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).
CID	18791946_D002939_10_983_996_ciprofloxacin_D000743_10_1051_1069_haemolytic anaemia	This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.
CID	18791946_D002939_0_63_76_ciprofloxacin_D000743_0_28_46_haemolytic anaemia	Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.
CID	18791946_D002939_2_326_339_ciprofloxacin_D007565_2_282_290_jaundice	A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.
CID	18791946_D002939_10_983_996_ciprofloxacin_D013921_10_1030_1046_thrombocytopenia	This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.
CID	18791946_D002939_0_63_76_ciprofloxacin_D013921_0_7_23_thrombocytopenia	Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.
UN	18791946_D002939_2_326_339_ciprofloxacin_D014552_2_357_380_urinary tract infection	A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.
CID	18791946_D002939_2_326_339_ciprofloxacin_D015746_2_263_277_abdominal pain	A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.
UN	18808529_D007545_1_117_130_isoproterenol_D007022_1_231_242_hypotension	The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.
CID	18808529_D007545_9_1830_1843_isoproterenol_D007511_9_1665_1681_ischaemic injury	These changes, related to ischaemic injury, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol.
CID	18808529_D007545_1_117_130_isoproterenol_D009202_1_139_156_myocardial damage	The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.
UN	18808529_D010100_1_187_193_oxygen_D007022_1_231_242_hypotension	The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.
UN	18808529_D010100_1_187_193_oxygen_D009202_1_247_271_myocardial hyperactivity	The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.
CID	18809400_D002945_2_589_598_cisplatin_D010523_2_433_454_peripheral neuropathy	We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.
UN	18809400_D002945_6_1422_1431_cisplatin_D020258_6_1440_1453_neurotoxicity	In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.
UN	18809400_D002945_4_925_934_cisplatin_D028361_4_962_986_mitochondrial impairment	Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.
UN	18809400_D002945_6_1422_1431_cisplatin_D028361_6_1351_1373_mitochondrial toxicity	In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.
UN	18809400_D008063_3_713_730_alpha-lipoic acid_D001480_3_745_758_axonal damage	This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.
UN	18809400_D008063_1_330_347_alpha-lipoic acid_D009410_1_263_294_toxic neurodegenerative cascade	The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.
UN	18809400_D008063_0_0_17_Alpha-lipoic acid_D009422_0_95_105_neuropathy	Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.
UN	18809400_D008063_8_1637_1654_alpha-lipoic acid_D010523_8_1691_1716_peripheral nerve toxicity	These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.
UN	18809400_D008063_1_133_150_alpha-lipoic acid_D020258_1_199_212_neurotoxicity	The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.
UN	18809400_D008063_5_1068_1085_Alpha-lipoic acid_D020258_5_1146_1159_neurotoxicity	Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.
UN	18809400_D008063_0_0_17_Alpha-lipoic acid_D020258_0_52_65_neurotoxicity	Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.
UN	18809400_D008063_0_0_17_Alpha-lipoic acid_D028361_0_27_47_mitochondrial damage	Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.
CID	18809400_D017239_2_574_584_paclitaxel_D010523_2_433_454_peripheral neuropathy	We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.
UN	18809400_D017239_6_1407_1417_paclitaxel_D020258_6_1440_1453_neurotoxicity	In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.
UN	18809400_D017239_4_939_949_paclitaxel_D028361_4_962_986_mitochondrial impairment	Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.
UN	18809400_D017239_6_1407_1417_paclitaxel_D028361_6_1351_1373_mitochondrial toxicity	In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.
CID	18821488_C068820_7_1200_1208_WR242511_D006456_7_1133_1147_hemoglobinuria	Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.
UN	18821488_C068820_6_939_947_WR242511_D008708_6_976_993_methemoglobinemia	RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.
CID	188339_D003276_2_262_281_Oral Contraceptives_D008113_2_233_245_Liver Tumors	The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.
CID	188339_D003276_1_187_205_oral contraceptive_D008113_1_138_150_liver tumors	Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.
CID	188339_D003276_0_70_89_oral contraceptives_D008113_0_41_53_liver tumors	Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.
UN	188339_D013256_1_206_214_steroids_D008113_1_138_150_liver tumors	Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.
CID	18951540_D007980_0_49_57_levodopa_D004409_0_66_77_dyskinesias	Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
UN	18951540_D007980_0_49_57_levodopa_D010300_0_81_100_Parkinson's disease	Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
UN	1899352_D015080_10_1142_1147_Mesna_D006417_10_1192_1201_hematuria	The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.
CID	18996674_D003042_2_339_346_cocaine_D011317_2_324_332_priapism	A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.
UN	18996674_D004837_0_15_26_epinephrine_D011317_0_63_71_priapism	Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.
CID	18997632_D002110_2_232_240_caffeine_D012640_2_269_276_seizure	Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.
CID	18997632_D002110_0_45_53_caffeine_D017180_0_10_33_ventricular tachycardia	A case of ventricular tachycardia related to caffeine pretreatment.
CID	18997632_D002110_3_581_589_caffeine_D017180_3_551_574_ventricular tachycardia	We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.
CID	18997632_D002110_2_232_240_caffeine_D018879_2_398_416_ventricular ectopy	Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.
UN	19037603_D006514_2_361_367_HBs Ag_D012216_2_391_413_rheumatologic diseases	From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.
UN	19037603_D006514_1_272_278_HBs Ag_D012216_1_303_324_rheumatologic disease	The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.
UN	19037603_D019259_0_20_30_lamivudine_D012216_0_74_97_rheumatologic disorders	Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.
CID	19058010_D007545_0_49_62_isoproterenol_D009203_0_71_92_myocardial infarction	Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.
CID	19058010_D007545_1_334_337_ISO_D009203_1_347_368_myocardial infarction	The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.
CID	19058010_D007545_4_1280_1283_ISO_D009203_4_1292_1313_myocardial infarction	These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.
UN	19058010_D010936_0_10_19_green tea_D009203_0_71_92_myocardial infarction	Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.
UN	19058010_D010936_4_1249_1258_green tea_D009203_4_1292_1313_myocardial infarction	These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.
UN	19058010_D014810_4_1263_1272_vitamin E_D009203_4_1292_1313_myocardial infarction	These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.
UN	19058010_D014810_0_24_33_vitamin E_D009203_0_71_92_myocardial infarction	Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.
CID	19058474_D014859_0_108_116_warfarin_D006471_0_27_55_gastrointestinal haemorrhage	Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.
UN	19058474_D014859_0_108_116_warfarin_D010490_0_6_22_haemopericardium	Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.
CID	19105845_D016642_3_526_535_bupropion_D012640_3_544_555_convulsions	METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.
CID	19105845_D016642_10_1793_1802_bupropion_D012640_10_1774_1784_convulsive	CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.
CID	19105845_D016642_1_196_205_bupropion_D012640_1_214_222_seizures	BACKGROUND: It is not known if there is a relationship between input rate and incidence of bupropion-induced seizures.
CID	19105845_D016642_0_55_78_bupropion hydrochloride_D012640_0_87_95_seizures	Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice.
CID	19105845_D016642_7_1137_1150_bupropion HCl_D012640_7_1188_1199_convulsions	RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.
UN	19135948_C107135_0_43_53_everolimus_D006086_0_0_25_Graft-versus-host disease	Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
CID	19135948_C107135_0_43_53_everolimus_D006504_0_108_139_sinusoidal obstruction syndrome	Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
UN	19135948_C107135_3_478_488_everolimus_D009190_3_554_578_myelodysplastic syndrome	We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.
CID	19135948_C107135_0_43_53_everolimus_D014652_0_144_159_microangiopathy	Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
UN	19135948_C107135_3_478_488_everolimus_D015470_3_596_618_acute myeloid leukemia	We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.
UN	19135948_D008727_1_227_239_methotrexate_D006086_1_272_297_graft-versus-host disease	A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
UN	19135948_D016559_0_58_68_tacrolimus_D006086_0_0_25_Graft-versus-host disease	Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
CID	19135948_D016559_0_58_68_tacrolimus_D006504_0_108_139_sinusoidal obstruction syndrome	Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
UN	19135948_D016559_3_493_503_tacrolimus_D009190_3_554_578_myelodysplastic syndrome	We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.
CID	19135948_D016559_0_58_68_tacrolimus_D014652_0_144_159_microangiopathy	Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
UN	19135948_D016559_3_493_503_tacrolimus_D015470_3_596_618_acute myeloid leukemia	We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.
UN	19139001_D000518_0_86_109_difluoromethylornithine_D015179_0_150_169_colorectal adenomas	Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
UN	19139001_D000518_1_279_302_difluoromethylornithine_D018256_1_225_243_adenomatous polyps	A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.
UN	19139001_D000518_9_1698_1702_DFMO_D034381_9_1762_1774_hearing loss	There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.
UN	19139001_D000518_2_406_410_DFMO_D034381_2_355_367_hearing loss	Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.
UN	19139001_D013467_0_114_122_sulindac_D015179_0_150_169_colorectal adenomas	Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
UN	19139001_D013467_1_315_323_sulindac_D018256_1_225_243_adenomatous polyps	A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.
CID	19139001_D013467_9_1708_1716_sulindac_D034381_9_1762_1774_hearing loss	There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.
CID	1919871_D000082_1_244_255_paracetamol_D007681_1_102_126_Renal papillary necrosis	Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.
CID	1919871_D001241_1_232_239_aspirin_D007681_1_102_126_Renal papillary necrosis	Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.
UN	19203554_D012460_1_284_298_sulphasalazine_D001745_1_242_263_urinary abnormalities	A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.
UN	19203554_D012460_5_743_757_sulphasalazine_D002637_5_813_823_chest pain	Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.
UN	19203554_D012460_1_284_298_sulphasalazine_D003093_1_168_186_ulcerative colitis	A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.
UN	19203554_D012460_1_284_298_sulphasalazine_D004802_1_225_237_eosinophilia	A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.
UN	19203554_D012460_5_743_757_sulphasalazine_D005128_5_803_811_red eyes	Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.
CID	19203554_D012460_5_743_757_sulphasalazine_D005334_5_796_801_fever	Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.
CID	19203554_D012460_1_284_298_sulphasalazine_D010996_1_207_223_pleural effusion	A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.
UN	19203554_D013256_5_903_910_steroid_D002637_5_813_823_chest pain	Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.
UN	19203554_D013256_5_903_910_steroid_D005128_5_803_811_red eyes	Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.
UN	19203554_D013256_5_903_910_steroid_D005334_5_796_801_fever	Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.
UN	19203554_D013256_6_1060_1067_steroid_D010996_6_1081_1097_pleural effusion	One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.
UN	19203554_D013256_5_903_910_steroid_D010996_5_871_888_pleural effusions	Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.
UN	19211690_D000809_11_1564_1575_angiotensin_D006973_11_1453_1465_hypertension	Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.
UN	19211690_D000809_11_1564_1575_angiotensin_D007674_11_1470_1482_renal injury	Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.
UN	19211690_D013739_0_0_12_Testosterone_D006973_0_23_35_hypertension	Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats.
UN	19211690_D013739_11_1406_1418_Testosterone_D006973_11_1453_1465_hypertension	Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.
UN	19211690_D013739_4_638_650_testosterone_D007674_4_688_700_renal injury	In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.
UN	19211690_D013739_11_1406_1418_Testosterone_D007674_11_1470_1482_renal injury	Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.
UN	19211690_D017673_0_91_95_salt_D006973_0_23_35_hypertension	Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats.
CID	19234905_D007980_2_581_589_levodopa_D004409_2_598_609_dyskinesias	Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.
UN	19234905_D014635_10_1653_1662_Valproate_D006423_10_1487_1509_homonymous hemianopsia	Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.
CID	19269743_D002211_8_1090_1099_capsaicin_D010146_8_1055_1059_pain	Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses (both p<0.001), regardless of whether first-time ratings were requested immediately, after one hour or after one day.
CID	19269743_D002211_0_66_75_capsaicin_D010146_0_84_88_pain	Explicit episodic memory for sensory-discriminative components of capsaicin-induced pain: immediate and delayed ratings.
UN	19274460_C400082_1_279_289_bortezomib_D009101_1_406_422_multiple myeloma	A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).
UN	19274460_C400082_0_84_94_bortezomib_D009101_0_166_173_myeloma	DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
UN	19274460_C400082_8_1130_1140_bortezomib_D009101_8_1281_1283_MM	The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.
UN	19274460_D003520_8_1161_1177_cyclophosphamide_D009101_8_1281_1283_MM	The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.
UN	19274460_D003520_0_47_63_cyclophosphamide_D009101_0_166_173_myeloma	DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
UN	19274460_D003520_1_242_258_cyclophosphamide_D009101_1_406_422_multiple myeloma	A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).
UN	19274460_D003907_0_95_108_dexamethasone_D009101_0_166_173_myeloma	DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
UN	1928887_D002216_0_40_49_captopril_D007022_0_21_32_hypotension	Naloxone reversal of hypotension due to captopril overdose.
UN	1928887_D002216_2_290_299_captopril_D007022_2_267_278_hypotensive	The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.
UN	1928887_D002216_4_503_512_captopril_D007022_4_521_532_hypotension	To our knowledge, this is the first reported case of captopril-induced hypotension treated with naloxone.
UN	1928887_D002216_5_658_667_captopril_D007022_5_631_642_hypotension	Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril.
UN	1928887_D002216_0_40_49_captopril_D062787_0_50_58_overdose	Naloxone reversal of hypotension due to captopril overdose.
UN	1928887_D002216_3_336_345_captopril_D062787_3_346_354_overdose	We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of naloxone.
UN	1928887_D009270_2_219_227_naloxone_D007022_2_267_278_hypotensive	The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.
UN	1928887_D009270_0_0_8_Naloxone_D007022_0_21_32_hypotension	Naloxone reversal of hypotension due to captopril overdose.
UN	1928887_D009270_5_603_611_naloxone_D007022_5_631_642_hypotension	Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril.
UN	1928887_D009270_4_546_554_naloxone_D007022_4_521_532_hypotension	To our knowledge, this is the first reported case of captopril-induced hypotension treated with naloxone.
UN	1928887_D009270_0_0_8_Naloxone_D062787_0_50_58_overdose	Naloxone reversal of hypotension due to captopril overdose.
CID	19289093_D002809_2_330_349_chondroitin sulfate_D007022_2_388_399_hypotensive	Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.
UN	19289093_D006493_3_480_487_heparin_D007022_3_588_599_hypotension	Using both contaminated heparin products and the synthetically produced derivative, we showed that the OSCS produces dose-dependent hypotension in pigs.
UN	19289093_D006493_2_262_269_heparin_D007022_2_388_399_hypotensive	Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.
CID	19299179_D015662_3_571_585_co-trimoxazole_D002780_3_456_480_intrahepatic cholestasis	Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.
UN	19299179_D015662_3_571_585_co-trimoxazole_D008100_3_519_532_liver abscess	Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.
UN	19299179_D015662_1_285_299_co-trimoxazole_D009894_1_192_215_opportunistic infection	Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.
UN	19299179_D015662_3_571_585_co-trimoxazole_D011020_3_600_603_PCP	Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.
UN	19299179_D015662_0_52_66_co-trimoxazole_D011020_0_81_103_Pneumocystis pneumonia	Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.
UN	19299179_D015662_0_52_66_co-trimoxazole_D015658_0_107_119_HIV-infected	Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.
UN	19300240_D002395_13_1472_1486_catecholamines_D009369_13_1530_1536_cancer	In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.
UN	19300240_D002395_13_1472_1486_catecholamines_D054549_13_1611_1614_ABS	In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.
UN	19300240_D005472_6_815_827_fluorouracil_D015179_6_843_860_colorectal cancer	She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
CID	19300240_D005472_0_0_14_5 flourouracil_D054549_0_23_49_apical ballooning syndrome	5 flourouracil-induced apical ballooning syndrome: a case report.
UN	19300402_C065679_1_561_568_HOE 140_D003929_1_648_724_diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
UN	19300402_C065679_6_1475_1482_HOE 140_D010523_6_1506_1522_toxic neuropathy	Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.
UN	19300402_C078665_1_588_605_des Arg10 HOE 140_D003929_1_648_724_diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
UN	19300402_C078665_6_1486_1502_des-Arg10HOE 140_D010523_6_1506_1522_toxic neuropathy	Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.
UN	19300402_D001920_0_0_10_Bradykinin_D003929_0_145_164_diabetic neuropathy	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
UN	19300402_D001920_1_549_559_bradykinin_D003929_1_648_724_diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
UN	19300402_D001920_8_1846_1856_bradykinin_D006930_8_1833_1845_hyperalgesia	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.
UN	19300402_D001920_5_1330_1340_bradykinin_D006930_5_1357_1369_hyperalgesia	It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.
UN	19300402_D001920_9_1962_1972_bradykinin_D009437_9_2056_2072_neuropathic pain	Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.
UN	19300402_D001920_1_549_559_bradykinin_D010523_1_648_724_diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
UN	19300402_D009569_0_37_49_nitric oxide_D003929_0_145_164_diabetic neuropathy	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
UN	19300402_D009569_1_409_411_NO_D003929_1_648_724_diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
UN	19300402_D009569_3_1033_1035_NO_D006930_3_1062_1083_diabetic hyperalgesia	RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.
UN	19300402_D009569_0_37_49_nitric oxide_D006930_0_112_124_hyperalgesia	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
UN	19300402_D009569_5_1296_1298_NO_D006930_5_1357_1369_hyperalgesia	It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.
UN	19300402_D009569_8_1885_1887_NO_D006930_8_1833_1845_hyperalgesia	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.
UN	19300402_D009569_9_1998_2000_NO_D009437_9_2056_2072_neuropathic pain	Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.
UN	19300402_D009569_1_409_411_NO_D010523_1_648_724_diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
CID	19300402_D013311_0_89_103_streptozotocin_D003929_0_145_164_diabetic neuropathy	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
CID	19300402_D013311_8_1688_1702_streptozotocin_D006930_8_1711_1723_hyperalgesia	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.
CID	19300402_D013311_0_89_103_streptozotocin_D006930_0_112_124_hyperalgesia	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
UN	19300402_D014750_0_73_84_vincristine_D003929_0_145_164_diabetic neuropathy	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
CID	19300402_D014750_0_73_84_vincristine_D006930_0_112_124_hyperalgesia	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
CID	19300402_D014750_5_1382_1393_vincristine_D006930_5_1357_1369_hyperalgesia	It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.
CID	19300402_D014750_8_1813_1824_vincristine_D006930_8_1833_1845_hyperalgesia	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.
CID	19308880_D014635_9_993_1006_valproic acid_D003221_9_978_987_confusion	CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.
CID	19308880_D014635_1_198_211_valproic acid_D003221_1_135_144_Confusion	INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.
CID	19308880_D014635_4_548_561_valproic acid_D003221_4_513_522_confusion	METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.
CID	19308880_D014635_6_715_728_valproic acid_D003221_6_652_661_Confusion	Confusion mostly occurred during the two first weeks following valproic acid exposure (39.7%).
CID	19308880_D014635_5_614_627_valproic acid_D003221_5_585_594_confusion	RESULTS: 272 cases of confusion were reported with valproic acid: 153 women and 119 men.
UN	19319147_C025667_12_1363_1366_PCC_D002543_12_1408_1411_ICH	We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.
CID	19319147_D014859_0_80_88_warfarin_D002543_0_100_124_intracerebral hemorrhage	Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.
CID	19319147_D014859_1_126_134_Warfarin_D002543_1_146_170_intracerebral hemorrhage	Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.
UN	19319147_D014859_1_126_134_Warfarin_D020521_1_199_205_stroke	Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.
CID	19346865_D008795_2_511_524_metronidazole_D001927_2_533_547_encephalopathy	MATERIALS AND METHODS: From November 2005 to September 2007, 8 patients (5 men and 3 women) were diagnosed as having metronidazole-induced encephalopathy (age range; 43-78 years).
CID	19346865_D008795_1_250_263_metronidazole_D001927_1_219_246_inferior colliculus lesions	OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.
CID	19346865_D008795_0_41_54_metronidazole_D001927_0_11_37_inferior colliculus lesion	Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.
CID	19346865_D008795_10_1994_2007_metronidazole_D001927_10_2016_2030_encephalopathy	CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.
UN	19346865_D008795_3_595_608_metronidazole_D007239_3_678_687_infection	They had been taking metronidazole (total dosage, 45-120 g; duration, 30 days to 2 months) to treat the infection in various organs.
UN	19356053_D003404_6_1046_1056_creatinine_D011507_6_1089_1100_proteinuria	In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.
UN	19356053_D020123_1_121_130_Sirolimus_D007674_1_214_228_nephrotoxicity	BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.
UN	19356053_D020123_10_1530_1539_sirolimus_D009404_10_1563_1572_nephrotic	In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic-range proteinuria.
CID	19356053_D020123_4_621_630_sirolimus_D011507_4_598_609_proteinuria	In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.
CID	19356053_D020123_10_1530_1539_sirolimus_D011507_10_1579_1590_proteinuria	In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic-range proteinuria.
CID	19356053_D020123_3_485_494_sirolimus_D011507_3_457_468_proteinuria	We have encountered several patients who developed substantial proteinuria associated with sirolimus use.
CID	19356053_D020123_11_1634_1643_sirolimus_D011507_11_1592_1603_Proteinuria	Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables.
CID	19356053_D020123_2_383_392_sirolimus_D011507_2_348_359_proteinuria	To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus.
CID	19356053_D020123_13_1831_1840_Sirolimus_D011507_13_1876_1887_proteinuria	CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.
CID	19356053_D020123_0_67_76_sirolimus_D011507_0_23_34_proteinuria	Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients.
UN	19356307_C008281_1_106_116_s-limonene_D003704_1_86_94_dementia	The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).
UN	19356307_C032208_1_121_139_s-perillyl alcohol_D003704_1_86_94_dementia	The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).
UN	19356307_C032208_2_336_354_s-perillyl alcohol_D008569_2_368_397_deficit of associative memory	These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.
UN	19356307_D012601_0_64_75_scopolamine_D003704_0_44_52_dementia	Components of lemon essential oil attenuate dementia induced by scopolamine.
CID	19356307_D012601_2_314_325_scopolamine_D008569_2_295_310_memory impaired	These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.
UN	19370593_D004967_11_1473_1482_oestrogen_D001943_11_1703_1716_breast cancer	Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.
CID	19370593_D004967_11_1473_1482_oestrogen_D005705_11_1563_1582_gallbladder disease	Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.
CID	19370593_D004967_11_1473_1482_oestrogen_D020521_11_1552_1558_stroke	Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.
CID	19370593_D004967_11_1473_1482_oestrogen_D054556_11_1527_1550_venous thrombo-embolism	Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.
CID	19387625_D002211_5_716_725_capsaicin_D006930_5_744_756_hyperalgesia	Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.
CID	19387625_D002211_4_571_580_capsaicin_D006930_4_531_543_hyperalgesia	Furthermore, it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin-untreated, control condition.
CID	19387625_D002211_2_234_243_capsaicin_D006930_2_262_274_hyperalgesia	However, it is not known that how pain intensity ratings are affected by attention in capsaicin-induced secondary hyperalgesia.
CID	19387625_D002211_0_54_63_capsaicin_D006930_0_82_94_hyperalgesia	Attentional modulation of perceived pain intensity in capsaicin-induced secondary hyperalgesia.
UN	19387625_D002211_5_716_725_capsaicin_D010146_5_795_799_pain	Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.
UN	19387625_D002211_0_54_63_capsaicin_D010146_0_36_40_pain	Attentional modulation of perceived pain intensity in capsaicin-induced secondary hyperalgesia.
UN	19387625_D002211_2_234_243_capsaicin_D010146_2_182_186_pain	However, it is not known that how pain intensity ratings are affected by attention in capsaicin-induced secondary hyperalgesia.
UN	19445921_C066201_8_1222_1240_salvianolic acid A_D006331_8_1311_1330_cardiac dysfunction	Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.
UN	19445921_C066201_9_1425_1443_salvianolic acid A_D009202_9_1474_1491_myocardial damage	The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.
UN	19445921_C066201_1_179_197_salvianolic acid A_D009203_1_223_244_myocardial infarction	The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.
UN	19445921_C066201_0_27_45_salvianolic acid A_D009203_0_71_92_myocardial infarction	Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.
UN	19445921_D000244_7_1154_1157_ADP_D012131_7_1073_1096_respiratory dysfunction	In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.
UN	19445921_D007545_8_1289_1302_isoproterenol_D009202_8_1335_1352_myocardial injury	Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.
UN	19445921_D007545_9_1452_1465_isoproterenol_D009202_9_1474_1491_myocardial damage	The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.
CID	19445921_D007545_10_1681_1694_isoproterenol_D009203_10_1703_1724_myocardial infarction	The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.
CID	19445921_D007545_0_49_62_isoproterenol_D009203_0_71_92_myocardial infarction	Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.
CID	19445921_D007545_1_201_214_isoproterenol_D009203_1_223_244_myocardial infarction	The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.
UN	19445921_D007545_7_1176_1189_isoproterenol_D012131_7_1073_1096_respiratory dysfunction	In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.
UN	19473225_D000596_1_252_262_amino acid_D010523_1_108_129_peripheral neuropathy	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.
UN	19473225_D000596_1_252_262_amino acid_D020258_1_304_317_neurotoxicity	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.
UN	19473225_D017239_3_629_632_PAC_D010051_3_544_558_ovarian cancer	Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).
CID	19473225_D017239_7_1510_1513_PAC_D010523_7_1482_1506_peripheral neurotoxicity	This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.
CID	19473225_D017239_1_191_201_paclitaxel_D010523_1_108_129_peripheral neuropathy	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.
CID	19473225_D017239_2_407_410_PAC_D010523_2_419_440_peripheral neuropathy	This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.
CID	19473225_D017239_0_90_100_paclitaxel_D010523_0_62_86_peripheral neurotoxicity	Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.
UN	19473225_D017239_1_300_303_PAC_D020258_1_304_317_neurotoxicity	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.
UN	19473225_D018698_3_681_690_glutamate_D010051_3_544_558_ovarian cancer	Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).
UN	19473225_D018698_7_1409_1418_glutamate_D010523_7_1482_1506_peripheral neurotoxicity	This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.
UN	19473225_D018698_2_366_375_glutamate_D010523_2_419_440_peripheral neuropathy	This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.
UN	19473225_D018698_0_10_19_glutamate_D010523_0_62_86_peripheral neurotoxicity	Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.
UN	19473225_D018698_1_263_272_glutamine_D020258_1_304_317_neurotoxicity	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.
UN	19581773_C417083_1_192_227_pegylated interferon (IFN) alpha-2b_D004172_1_148_156_diplopia	A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).
CID	19581773_C417083_0_40_60_pegylated interferon_D009157_0_15_32_ocular myasthenia	Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
CID	19581773_C417083_6_845_867_pegylated IFN alpha-2b_D009157_6_788_805_ocular myasthenia	The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.
UN	19581773_C417083_6_845_867_pegylated IFN alpha-2b_D019698_6_886_889_CHC	The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.
UN	19581773_C417083_1_192_227_pegylated interferon (IFN) alpha-2b_D019698_1_246_265_chronic hepatitis C	A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).
UN	19581773_C417083_0_40_60_pegylated interferon_D019698_0_89_108_chronic hepatitis C	Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
UN	19581773_D012254_1_232_241_ribavirin_D004172_1_148_156_diplopia	A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).
CID	19581773_D012254_0_65_74_ribavirin_D009157_0_15_32_ocular myasthenia	Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
UN	19581773_D012254_0_65_74_ribavirin_D019698_0_89_108_chronic hepatitis C	Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
UN	19581773_D012254_1_232_241_ribavirin_D019698_1_246_265_chronic hepatitis C	A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).
UN	19581773_D012254_6_872_881_ribavirin_D019698_6_886_889_CHC	The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.
UN	19631624_D002188_5_952_960_cannabis_D006948_5_903_916_hyperactivity	Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.
UN	19631624_D002188_5_952_960_cannabis_D007859_5_854_885_Deficits in learning and memory	Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.
UN	19631624_D002188_5_952_960_cannabis_D008569_5_854_885_Deficits in learning and memory	Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.
UN	19631624_D018817_8_1179_1186_ecstasy_D006948_8_1196_1209_hyperactivity	A conjunction analysis of the encode and recall phases of the task revealed ecstasy-specific hyperactivity in bilateral frontal regions, left temporal, right parietal, bilateral temporal, and bilateral occipital brain regions.
CID	19631624_D018817_1_139_146_ecstasy_D007859_1_161_195_impairments in learning and memory	It has been consistently shown that ecstasy users display impairments in learning and memory performance.
CID	19631624_D018817_0_32_39_ecstasy_D007859_0_0_28_Learning and memory deficits	Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.
CID	19631624_D018817_0_32_39_ecstasy_D008569_0_0_28_Learning and memory deficits	Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.
CID	19631624_D018817_1_139_146_ecstasy_D008569_1_161_195_impairments in learning and memory	It has been consistently shown that ecstasy users display impairments in learning and memory performance.
UN	19631624_D018817_12_1883_1890_ecstasy_D020258_12_1861_1871_neurotoxic	These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy.
UN	19642243_C096918_0_45_54_tenofovir_D000163_0_37_41_AIDS	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
UN	19642243_C096918_2_290_299_Tenofovir_D005198_2_342_358_Fanconi syndrome	Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.
UN	19642243_C096918_0_45_54_tenofovir_D010019_0_103_116_osteomyelitis	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
UN	19642243_C096918_4_571_580_tenofovir_D051437_4_603_616_renal failure	Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.
UN	19642243_C096918_0_45_54_tenofovir_D058186_0_0_19_Acute renal failure	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
UN	19642243_D014640_0_81_91_vancomycin_D000163_0_37_41_AIDS	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
UN	19642243_D014640_0_81_91_vancomycin_D010019_0_103_116_osteomyelitis	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
CID	19642243_D014640_0_81_91_vancomycin_D058186_0_0_19_Acute renal failure	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
CID	19657887_D000431_5_734_741_alcohol_D004417_5_808_815_dyspnea	In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.
CID	19657887_D000431_5_734_741_alcohol_D005483_5_769_789_flushing of the face	In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.
CID	19657887_D000431_5_734_741_alcohol_D013610_5_791_802_tachycardia	In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.
UN	19657887_D004221_8_1022_1032_disulfiram_D005483_8_1052_1060_flushing	Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.
UN	19657887_D004221_8_1022_1032_disulfiram_D007022_8_1079_1099_arterial hypotension	Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.
UN	19657887_D004221_8_1022_1032_disulfiram_D013610_8_1062_1073_tachycardia	Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.
CID	19674115_D011718_3_330_342_pyrazinamide_D000857_3_300_318_olfactory disorder	We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.
CID	19674115_D011718_0_30_42_pyrazinamide_D000857_0_10_18_dysosmia	Recurrent dysosmia induced by pyrazinamide.
CID	19674115_D011718_5_522_534_pyrazinamide_D000857_5_484_492_Dysosmia	Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.
UN	19674115_D011718_1_44_56_Pyrazinamide_D033461_1_108_121_hyperuricemia	Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.
UN	19674115_D011718_1_44_56_Pyrazinamide_D056486_1_90_106_hepatic toxicity	Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.
UN	1967484_D013469_2_204_213_sulpiride_D004409_2_222_240_tardive dyskinesia	Although initially thought to be free of extrapyramidal side effects, sulpiride-induced tardive dyskinesia and parkinsonism have been reported occasionally.
CID	1967484_D013469_4_456_465_sulpiride_D004421_4_474_490_tardive dystonia	We could not find any previous reports of sulpiride-induced tardive dystonia.
CID	1967484_D013469_0_0_9_Sulpiride_D004421_0_18_34_tardive dystonia	Sulpiride-induced tardive dystonia.
CID	1967484_D013469_3_395_404_sulpiride_D004421_3_355_363_dystonia	We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy.
UN	1967484_D013469_2_204_213_sulpiride_D010302_2_245_257_parkinsonism	Although initially thought to be free of extrapyramidal side effects, sulpiride-induced tardive dyskinesia and parkinsonism have been reported occasionally.
UN	19692487_D008094_0_38_45_lithium_D011141_0_54_62_polyuria	Mice lacking mPGES-1 are resistant to lithium-induced polyuria.
UN	19692487_D008094_1_125_132_lithium_D011141_1_141_149_polyuria	Cyclooxygenase-2 activity is required for the development of lithium-induced polyuria.
UN	19692487_D008094_6_677_684_lithium_D011141_6_693_701_polyuria	In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.
UN	19692487_D008094_12_1528_1535_lithium_D011141_12_1544_1552_polyuria	We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.
UN	19692487_D008094_3_296_303_lithium_D011141_3_312_320_polyuria	The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
UN	19692487_D011458_3_353_368_prostaglandin E_D011141_3_312_320_polyuria	The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
UN	19692487_D015232_12_1512_1518_PGE(2)_D011141_12_1544_1552_polyuria	We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.
CID	19692487_D018021_4_416_420_LiCl_D011141_4_484_492_polyuria	A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.
UN	1969772_D004298_9_1548_1556_dopamine_D007022_9_1713_1724_hypotension	Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.
CID	1969772_D009599_7_1299_1312_nitroprusside_D007022_7_1321_1332_hypotension	Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).
UN	1969772_D012964_7_1292_1298_sodium_D007022_7_1321_1332_hypotension	Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).
CID	1969772_D018818_4_527_537_fenoldopam_D007022_4_562_573_hypotension	The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.
CID	1969772_D018818_0_65_75_fenoldopam_D007022_0_40_51_hypotension	Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.
CID	1969772_D018818_7_1204_1214_fenoldopam_D007022_7_1223_1234_hypotension	Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).
CID	19707748_D064704_5_612_624_levofloxacin_D012640_5_633_641_seizures	RESULTS: Six cases of levofloxacin-induced seizures have been reported in the literature.
CID	19707748_D064704_1_347_359_levofloxacin_D012640_1_368_376_seizures	PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.
CID	19707748_D064704_0_25_37_levofloxacin_D012640_0_0_8_Seizures	Seizures associated with levofloxacin: case presentation and literature review.
CID	19719056_D002351_10_1211_1222_carrageenan_D004487_10_1239_1244_edema	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.
CID	19719056_D002351_10_1211_1222_carrageenan_D010146_10_1185_1193_writhing	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.
UN	19719056_D019342_10_1165_1176_acetic acid_D004487_10_1239_1244_edema	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.
UN	19719056_D019342_10_1165_1176_acetic acid_D010146_10_1185_1193_writhing	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.
CID	19721134_D000157_1_207_216_aconitine_D001145_1_260_270_arrhythmia	This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.
CID	19721134_D000157_5_1065_1074_aconitine_D001145_5_1017_1027_arrhythmic	These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.
UN	19721134_D000157_3_679_688_aconitine_D014693_3_511_551_ventricular tachycardia and fibrillation	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
UN	19721134_D000157_3_679_688_aconitine_D017180_3_511_551_ventricular tachycardia and fibrillation	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
UN	19721134_D002118_3_648_650_Ca_D001145_3_614_624_arrhythmic	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
UN	19721134_D002118_3_648_650_Ca_D014693_3_511_551_ventricular tachycardia and fibrillation	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
UN	19721134_D002118_3_648_650_Ca_D017180_3_511_551_ventricular tachycardia and fibrillation	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
CID	19721134_D010042_5_1078_1085_ouabain_D001145_5_1017_1027_arrhythmic	These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.
CID	19721134_D010042_1_233_240_ouabain_D001145_1_260_270_arrhythmia	This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.
UN	19721134_D010042_3_692_699_ouabain_D014693_3_511_551_ventricular tachycardia and fibrillation	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
UN	19721134_D010042_3_692_699_ouabain_D017180_3_511_551_ventricular tachycardia and fibrillation	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
UN	19721134_D010862_3_426_437_pilocarpine_D001145_3_469_480_arrhythmias	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
UN	19721134_D010862_5_970_981_pilocarpine_D001145_5_1017_1027_arrhythmic	These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.
UN	19721134_D010862_3_426_437_pilocarpine_D014693_3_511_551_ventricular tachycardia and fibrillation	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
UN	19721134_D010862_3_426_437_pilocarpine_D017180_3_511_551_ventricular tachycardia and fibrillation	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
UN	19729346_D010098_1_238_247_oxycodone_D010146_1_377_381_pain	This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release oxycodone in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily pain.
UN	19729346_D010098_6_1316_1325_oxycodone_D059350_6_1210_1222_chronic pain	This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.
UN	19759529_C076029_8_1586_1596_olanzapine_D006948_8_1679_1692_hyperactivity	Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.
UN	19759529_C094645_8_1612_1624_aripiprazole_D006948_8_1679_1692_hyperactivity	Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.
CID	19759529_D000661_7_1427_1438_amphetamine_D006948_7_1402_1415_hyperactivity	In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).
UN	19759529_D003024_8_1598_1607_clozapine_D006948_8_1679_1692_hyperactivity	Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.
UN	19759529_D004298_7_1464_1472_dopamine_D006948_7_1402_1415_hyperactivity	In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).
UN	19759529_D004298_1_202_210_dopamine_D012559_1_138_151_Schizophrenia	Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission.
UN	19759529_D006220_8_1559_1570_haloperidol_D006948_8_1679_1692_hyperactivity	Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.
UN	19759529_D016202_6_1339_1343_NMDA_D006948_6_1322_1335_hyperactivity	Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.
UN	19759529_D016202_2_311_315_NMDA_D012559_2_334_347_schizophrenic	However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.
CID	19759529_D016291_6_1280_1286_MK-801_D006948_6_1322_1335_hyperactivity	Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.
UN	19759529_D018698_2_279_288_glutamate_D012559_2_334_347_schizophrenic	However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.
UN	19761039_D010936_7_1094_1116_Hibiscus rosa sinensis_D004409_7_1175_1185_dyskinesia	The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.
CID	19761039_D012110_7_1147_1156_reserpine_D004409_7_1175_1185_dyskinesia	The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.
CID	19761039_D012110_1_193_202_reserpine_D004409_1_221_231_dyskinesia	Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.
UN	19767176_C020972_9_1322_1326_PDTC_D009410_9_1390_1403_neuronal loss	In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.
UN	19767176_C020972_8_1219_1223_PDTC_D013226_8_1247_1265_status epilepticus	A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.
UN	19767176_C020972_0_0_27_Pyrrolidine dithiocarbamate_D013226_0_76_94_status epilepticus	Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.
UN	19767176_C020972_4_636_640_PDTC_D013226_4_662_680_status epilepticus	Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.
UN	19767176_C020972_3_467_471_PDTC_D013226_3_475_493_status epilepticus	The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.
UN	19767176_D010100_10_1463_1469_oxygen_D009410_10_1554_1569_neuronal damage	These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.
UN	19767176_D010100_2_272_278_oxygen_D009410_2_353_368_neuronal damage	Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.
UN	19767176_D010100_10_1463_1469_oxygen_D012640_10_1535_1542_seizure	These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.
CID	19767176_D010862_0_64_75_pilocarpine_D013226_0_76_94_status epilepticus	Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.
UN	19803309_D013390_1_292_305_suxamethonium_D009224_1_136_154_myotonia congenita	We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.
CID	19803309_D013390_1_292_305_suxamethonium_D014313_1_236_250_masseter spasm	We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.
CID	19820426_C558899_2_302_321_lopinavir/ritonavir_D001919_2_403_414_bradycardia	One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.
CID	19820426_C558899_2_302_321_lopinavir/ritonavir_D002311_2_268_290_dilated cardiomyopathy	One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.
CID	19820426_C558899_2_302_321_lopinavir/ritonavir_D006327_2_252_263_heart block	One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.
UN	19820426_C558899_0_55_74_lopinavir/ritonavir_D066126_0_27_43_cardiac toxicity	Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy.
CID	19843802_D004837_3_430_441_epinephrine_D006973_3_494_506_hypertensive	However, a bolus of epinephrine injected through an alternative catheter provoked a hypertensive crisis.
CID	1987816_D008094_7_846_853_Lithium_D011141_7_862_870_polyuria	Lithium-induced polyuria seems to be related to extrarenal as well as to renal effects.
UN	19884587_D002511_9_1814_1828_cephalosporins_D000014_9_1902_1915_birth defects	CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.
UN	19884587_D004917_9_1795_1808_erythromycins_D000014_9_1902_1915_birth defects	CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.
CID	19884587_D009582_10_1934_1949_nitrofurantoins_D000014_10_1979_1992_birth defects	Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.
CID	19884587_D009582_7_1314_1329_Nitrofurantoins_D000853_7_1351_1363_anophthalmia	Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).
CID	19884587_D009582_7_1314_1329_Nitrofurantoins_D002971_7_1531_1540_cleft lip	Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).
CID	19884587_D009582_7_1314_1329_Nitrofurantoins_D002972_7_1546_1558_cleft palate	Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).
CID	19884587_D009582_7_1314_1329_Nitrofurantoins_D006344_7_1475_1496_atrial septal defects	Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).
CID	19884587_D009582_7_1314_1329_Nitrofurantoins_D008850_7_1367_1381_microphthalmos	Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).
CID	19884587_D009582_7_1314_1329_Nitrofurantoins_D018636_7_1413_1444_hypoplastic left heart syndrome	Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).
UN	19884587_D010406_9_1782_1793_penicillins_D000014_9_1902_1915_birth defects	CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.
CID	19884587_D013449_10_1917_1929_Sulfonamides_D000014_10_1979_1992_birth defects	Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.
CID	19884587_D013449_6_926_938_Sulfonamides_D000757_6_960_971_anencephaly	Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).
CID	19884587_D013449_6_926_938_Sulfonamides_D001017_6_1100_1124_coarctation of the aorta	Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).
CID	19884587_D013449_6_926_938_Sulfonamides_D002754_6_1155_1170_choanal atresia	Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).
CID	19884587_D013449_6_926_938_Sulfonamides_D006548_6_1263_1283_diaphragmatic hernia	Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).
CID	19884587_D013449_6_926_938_Sulfonamides_D017880_6_1202_1228_transverse limb deficiency	Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).
CID	19884587_D013449_6_926_938_Sulfonamides_D018636_6_1038_1069_hypoplastic left heart syndrome	Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).
CID	19893084_D005839_1_128_138_gentamicin_D058186_1_97_116_acute renal failure	In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.
CID	19917396_D016559_3_317_327_tacrolimus_D006332_3_283_305_myocardial hypertrophy	Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.
CID	19917396_D016559_0_45_55_tacrolimus_D006332_0_11_33_myocardial hypertrophy	Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.
CID	19917396_D016559_7_911_921_tacrolimus_D006332_7_826_848_Myocardial hypertrophy	Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.
CID	19917396_D016559_8_1020_1030_tacrolimus_D006332_8_1050_1072_myocardial hypertrophy	Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.
UN	19923525_D002118_18_2635_2642_calcium_D007022_18_2662_2673_hypotension	The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.
CID	19923525_D005996_0_48_61_nitroglycerin_D007022_0_70_81_hypotension	Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.
CID	19923525_D005996_2_327_330_NTG_D007022_2_340_351_hypotension	We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.
CID	19923525_D005996_17_2494_2497_NTG_D007022_17_2544_2555_hypotension	NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.
CID	19923525_D005996_0_48_61_nitroglycerin_D008569_0_20_37_memory impairment	Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.
UN	19923525_D009553_0_0_10_Nimodipine_D007022_0_70_81_hypotension	Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.
UN	19923525_D009553_0_0_10_Nimodipine_D008569_0_20_37_memory impairment	Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.
CID	1992636_D009853_0_44_54_omeprazole_D000743_0_0_16_Hemolytic anemia	Hemolytic anemia associated with the use of omeprazole.
CID	1992636_D009853_8_987_997_omeprazole_D000743_8_1019_1035_hemolytic anemia	The mechanism by which omeprazole caused the patient's hemolytic anemia is uncertain, but physicians should be alerted to this possible adverse effect.
CID	1992636_D009853_5_669_679_omeprazole_D004417_5_614_633_shortness of breath	The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.
CID	1992636_D009853_5_669_679_omeprazole_D053609_5_600_608_lethargy	The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.
UN	19940105_C507346_4_765_771_AMN082_D002375_4_801_810_catalepsy	Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.
UN	19940105_C507346_7_1148_1154_AMN082_D002375_7_1199_1208_catalepsy	In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.
UN	19940105_C507346_3_503_554_N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride_D010300_3_673_675_PD	The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.
UN	19940105_C507346_6_1036_1042_AMN082_D010300_6_1015_1017_PD	In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.
UN	19940105_C507346_8_1313_1319_AMN082_D010300_8_1380_1382_PD	Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.
UN	19940105_C507346_6_1036_1042_AMN082_D018476_6_994_1002_akinetic	In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.
CID	19940105_D006220_4_781_792_haloperidol_D002375_4_801_810_catalepsy	Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.
CID	19940105_D006220_7_1179_1190_haloperidol_D002375_7_1199_1208_catalepsy	In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.
UN	19940105_D016627_6_1113_1119_6-OHDA_D010300_6_1015_1017_PD	In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.
UN	19940105_D016627_6_1113_1119_6-OHDA_D018476_6_994_1002_akinetic	In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.
UN	19940105_D018698_1_121_130_glutamate_D010300_1_282_301_Parkinson's disease	Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).
UN	19940105_D018698_0_13_22_glutamate_D010300_0_87_106_Parkinson's disease	Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.
CID	19944333_C471405_0_0_9_Sorafenib_D003329_0_53_74_coronary artery spasm	Sorafenib-induced acute myocardial infarction due to coronary artery spasm.
CID	19944333_C471405_9_818_827_sorafenib_D003329_9_836_857_coronary artery spasm	We report the first case of sorafenib-induced coronary artery spasm.
UN	19944333_C471405_0_0_9_Sorafenib_D009203_0_24_45_myocardial infarction	Sorafenib-induced acute myocardial infarction due to coronary artery spasm.
UN	19944333_D020108_8_721_731_nicorandil_D060050_8_768_781_stable angina	Addition of oral nicorandil reduced his symptoms and maintained stable angina status.
UN	19944736_D008094_8_1553_1560_lithium_D004827_8_1570_1578_epilepsy	In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine-lithium model of epilepsy in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo.
CID	19944736_D013619_6_1138_1145_tacrine_D001930_6_1190_1214_damage of neuronal cells	In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.
CID	19944736_D013619_3_539_546_Tacrine_D012640_3_617_625_seizures	Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.
CID	19944736_D018021_3_564_568_LiCl_D001930_3_638_656_hippocampal damage	Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.
CID	19944736_D018021_3_564_568_LiCl_D012640_3_617_625_seizures	Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.
UN	19957053_D004809_0_22_31_ephedrine_D002534_0_32_64_reduces frontal lobe oxygenation	Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.
UN	19957053_D004809_0_22_31_ephedrine_D007022_0_94_105_hypotension	Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.
CID	19957053_D010656_0_0_13_Phenylephrine_D002534_0_32_64_reduces frontal lobe oxygenation	Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.
UN	19957053_D010656_9_1276_1289_phenylephrine_D007022_9_1301_1312_hypotension	CONCLUSIONS: The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.
CID	19996135_D014148_3_585_588_TXA_D012640_3_599_607_seizures	The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery.
CID	19996135_D014148_0_10_25_tranexamic Acid_D012640_0_66_74_seizures	High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
CID	19996135_D014148_8_1183_1186_TXA_D012640_8_1151_1159_seizures	All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.
UN	20003049_C031942_8_1776_1786_argatroban_D001778_8_1836_1848_coagulopathy	This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy.
UN	20003049_C031942_6_1468_1478_argatroban_D001778_6_1526_1538_coagulopathy	CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.
UN	20003049_C031942_5_1144_1154_argatroban_D008107_5_1274_1292_hepatic impairment	RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).
UN	20003049_C031942_2_499_509_argatroban_D013921_2_477_481_HITT	In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.
UN	20003049_C031942_2_499_509_argatroban_D013927_2_477_481_HITT	In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.
UN	20003049_C031942_2_499_509_argatroban_D016638_2_426_440_critically ill	In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.
UN	20003049_D006493_1_277_284_heparin_D013921_1_293_309_thrombocytopenia	BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).
UN	20003049_D006493_0_101_108_heparin_D013921_0_117_133_thrombocytopenia	Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.
UN	20003049_D006493_0_101_108_heparin_D013927_0_139_149_thrombosis	Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.
UN	20003049_D006493_1_277_284_heparin_D013927_1_328_338_thrombosis	BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).
CID	2004_D000639_4_579_592_amitriptyline_D002037_4_608_632_left bundle branch block	Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
UN	2004_D002746_3_515_524_Thorazine_D013617_3_451_479_Supraventricular tachycardia	Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
UN	2004_D008012_6_807_816_lidocaine_D001145_6_740_763_ventricular arrhythmias	The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.
CID	2004_D009661_4_552_565_nortriptyline_D002037_4_608_632_left bundle branch block	Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
UN	2004_D010640_10_1464_1478_phenothiazines_D005117_10_1420_1441_cardiac complications	A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.
UN	2004_D011433_6_939_950_propranolol_D001145_6_740_763_ventricular arrhythmias	The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.
CID	2004_D013881_2_320_332_thioridazine_D017180_2_379_402_ventricular tachycardia	Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.
UN	2004015_C030299_9_1387_1390_PHZ_D000740_9_1428_1435_anaemia	The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.
UN	2004015_C030299_8_1246_1261_phenylhydrazine_D000740_8_1210_1217_anaemia	The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.
UN	2004015_D015215_0_66_80_azidothymidine_C565469_0_89_104_immunodeficient	Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.
UN	2004015_D015215_2_319_322_AZT_D000163_2_221_225_AIDS	We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).
CID	2004015_D015215_1_134_161_3'-azido-3'dideoxythymidine_D000740_1_115_122_anaemia	The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.
CID	2004015_D015215_10_1518_1521_AZT_D000740_10_1498_1505_anaemia	However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.
CID	2004015_D015215_2_319_322_AZT_D000740_2_331_338_anaemia	We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).
CID	2004015_D015215_4_554_557_AZT_D000740_4_567_574_anaemia	AZT produced anaemia in both groups, in a dose-dependent fashion.
CID	2004015_D015215_9_1379_1382_AZT_D000740_9_1428_1435_anaemia	The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.
CID	2004015_D015215_8_1158_1161_AZT_D000740_8_1210_1217_anaemia	The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.
CID	2004015_D015215_11_1545_1548_AZT_D000740_11_1568_1575_anaemia	AZT-induced peripheral anaemia in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.
UN	2004015_D015215_2_319_322_AZT_D007239_2_227_236_infection	We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).
UN	2004015_D015215_2_319_322_AZT_D007938_2_279_288_leukaemia	We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).
UN	2004015_D015215_10_1518_1521_AZT_D045262_10_1446_1461_reticulocytosis	However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.
CID	20042557_D015742_8_1619_1627_propofol_D003693_8_1665_1687_postoperative delirium	CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.
UN	20042557_D015742_2_589_597_propofol_D003704_2_517_525_dementia	PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.
UN	20042557_D015742_2_589_597_propofol_D006620_2_540_552_hip fracture	PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.
CID	20042557_D015742_8_1619_1627_propofol_D011183_8_1665_1687_postoperative delirium	CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.
UN	20067456_D016642_1_238_247_bupropion_D012735_1_279_297_sexual dysfunction	OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.
UN	20067456_D016642_0_30_39_bupropion_D012735_0_48_66_sexual dysfunction	The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.
UN	20067456_D016642_12_1858_1867_Bupropion_D012735_12_1903_1905_SD	CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.
CID	20080419_D010862_1_283_294_pilocarpine_D004827_1_263_271_epilepsy	In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of epilepsy induced by pilocarpine in rats.
UN	20080983_C048833_1_157_166_modafinil_D012893_1_180_198_daytime sleepiness	OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.
CID	20080983_D003042_11_1829_1836_cocaine_D012893_11_1797_1815_daytime sleepiness	CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.
CID	20080983_D003042_1_210_217_cocaine_D012893_1_180_198_daytime sleepiness	OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.
UN	20084309_D008874_9_1291_1293_MZ_D000402_9_1212_1230_airway obstruction	Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.
CID	20084309_D008874_9_1291_1293_MZ_D000860_9_1273_1280_hypoxia	Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.
UN	20084309_D008874_5_811_813_MZ_D008944_5_799_801_MR	Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.
UN	20084309_D008874_11_1443_1445_MZ_D009202_11_1413_1415_MP	The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).
UN	20084309_D008874_5_811_813_MZ_D009202_5_734_748_myocardiopathy	Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.
UN	20084309_D008874_5_811_813_MZ_D020521_5_726_732_stroke	Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.
UN	2008831_D008755_1_158_174_methylergonovine_D000787_1_286_301_angina pectoris	The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).
UN	2008831_D008755_0_49_65_methylergonovine_D000788_0_95_109_variant angina	Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.
UN	2008831_D008755_1_158_174_methylergonovine_D000788_1_208_222_variant angina	The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).
UN	2008831_D008755_1_158_174_methylergonovine_D002637_1_253_263_chest pain	The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).
UN	2008831_D008755_7_967_983_methylergonovine_D013035_7_877_882_spasm	These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.
UN	20098969_D008694_2_226_241_Methamphetamine_D001145_2_369_389_cardiac dysrhythmias	BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.
UN	20098969_D008694_2_226_241_Methamphetamine_D001523_2_425_441_violent behavior	BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.
CID	20098969_D008694_7_990_1005_methamphetamine_D003731_7_1055_1071_carious episodes	She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug.
UN	20098969_D008694_2_226_241_Methamphetamine_D006212_2_405_419_hallucinations	BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.
UN	20098969_D008694_2_226_241_Methamphetamine_D006973_2_391_403_hypertension	BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.
UN	20098969_D008694_3_467_482_methamphetamine_D014987_3_519_529_xerostomia	Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries ("meth mouth"), and excessive tooth wear.
UN	20098969_D008694_3_467_482_methamphetamine_D057085_3_576_586_tooth wear	Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries ("meth mouth"), and excessive tooth wear.
UN	20103708_D010100_1_204_210_oxygen_D003928_1_87_107_Diabetic nephropathy	OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).
UN	20103708_D010100_1_204_210_oxygen_D051437_1_138_151_renal failure	OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).
CID	20103708_D013311_0_31_45_streptozotocin_D003928_0_54_74_diabetic nephropathy	The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.
CID	20103708_D013311_4_628_642_streptozotocin_D003928_4_651_671_diabetic nephropathy	RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.
UN	20103708_D013311_6_926_940_streptozotocin_D058186_6_949_961_renal damage	In the animal study, Nrf2 was demonstrated to be crucial in ameliorating streptozotocin-induced renal damage.
CID	20164825_D005839_4_582_592_gentamicin_D058186_4_602_621_acute renal failure	Metformin treatment fully blocked gentamicin-mediated acute renal failure.
UN	20164825_D008687_10_1379_1388_metformin_D007674_10_1411_1425_nephrotoxicity	Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.
UN	20164825_D008687_0_0_9_Metformin_D007674_0_51_62_nephropathy	Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway.
UN	20164825_D008687_7_953_962_metformin_D007674_7_910_928_kidney dysfunction	These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.
UN	20164825_D008687_1_122_131_metformin_D014652_1_216_236_vascular dysfunction	The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.
UN	20164825_D008687_4_548_557_Metformin_D058186_4_602_621_acute renal failure	Metformin treatment fully blocked gentamicin-mediated acute renal failure.
UN	20195852_C038192_2_523_532_iopromide_D003490_2_692_700_cyanosis	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
CID	20195852_C038192_2_523_532_iopromide_D007674_2_481_484_CIN	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
UN	20195852_D003287_2_669_671_CM_D003490_2_692_700_cyanosis	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
CID	20195852_D003287_2_502_516_contrast media_D007674_2_481_484_CIN	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
CID	20195852_D003287_1_169_183_contrast media_D007674_1_192_203_nephropathy	Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.
CID	20195852_D003287_0_50_64_contrast media_D007674_0_8_19_nephropathy	Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.
CID	20195852_D003287_8_1728_1730_CM_D007674_8_1688_1691_CIN	Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).
UN	20195852_D007472_2_537_544_iohexol_D003490_2_692_700_cyanosis	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
CID	20195852_D007472_2_537_544_iohexol_D007674_2_481_484_CIN	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
CID	20196116_D000995_1_112_128_Antituberculosis_D017114_1_154_173_acute liver failure	Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.
CID	20196116_D000995_0_0_16_Antituberculosis_D017114_0_33_52_acute liver failure	Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.
UN	20196116_D001663_14_1620_1629_bilirubin_D001927_14_1718_1732_encephalopathy	In multivariate analysis, three factors independently predicted mortality: serum bilirubin (>or=10.8 mg/dL), prothrombin time (PT) prolongation (>or=26 seconds), and grade III/IV encephalopathy at presentation.
CID	2021202_D007530_1_105_115_isoflurane_D007022_1_124_135_hypotension	The effect of isoflurane-induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects.
CID	2021202_D007530_0_49_59_isoflurane_D007022_0_68_79_hypotension	Renal function and hemodynamics during prolonged isoflurane-induced hypotension in humans.
CID	2021202_D007530_8_1027_1037_isoflurane_D007022_8_1046_1057_hypotension	We conclude that renal compensatory mechanisms are preserved during isoflurane-induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed.
UN	2024540_D000806_1_174_220_angiotensin converting enzyme (ACE) inhibitors_D006333_1_268_292_congestive heart failure	Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.
CID	2024540_D000806_2_426_439_ACE inhibitor_D007022_2_572_583_hypotension	To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment.
CID	2024540_D000806_1_174_220_angiotensin converting enzyme (ACE) inhibitors_D007022_1_310_321_hypotension	Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.
UN	2024540_D004656_0_51_60_enalapril_D006333_0_122_146_congestive heart failure	Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.
UN	2024540_D004656_5_790_799_enalapril_D007022_5_872_883_hypotension	Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension (5.2%) than the patients who received prazosin (12.9%).
UN	2024540_D011224_0_65_73_prazosin_D006333_0_122_146_congestive heart failure	Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.
CID	2024540_D011224_5_922_930_prazosin_D007022_5_872_883_hypotension	Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension (5.2%) than the patients who received prazosin (12.9%).
CID	2024540_D011224_2_477_485_prazosin_D007022_2_572_583_hypotension	To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment.
UN	20331935_D013739_7_1071_1083_testosterone_D006966_7_1153_1171_hyperprolactinemia	Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia.
CID	20331935_D018967_13_1946_1957_risperidone_D006966_13_1966_1984_hyperprolactinemia	CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.
CID	20331935_D018967_1_208_219_risperidone_D006966_1_228_246_hyperprolactinemia	OBJECTIVE: The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents.
UN	20331935_D018967_12_1810_1821_risperidone_D050723_12_1782_1791_fractures	Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.
CID	20394767_C015068_7_1178_1182_mCPP_D012021_7_1203_1210_startle	Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.
CID	20394767_D010433_7_1239_1242_PTZ_D012021_7_1263_1270_startle	Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.
CID	20394767_D015016_7_1113_1122_yohimbine_D012021_7_1142_1149_startle	Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.
CID	20466178_C117268_3_417_429_pimecrolimus_D003872_3_485_495_dermatitis	Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.
UN	20466178_D016559_0_47_57_tacrolimus_D003872_0_12_22_dermatitis	Rosaceiform dermatitis associated with topical tacrolimus treatment.
UN	20466178_D016559_1_173_183_tacrolimus_D003875_1_137_146_eruptions	We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.
UN	20466178_D016559_1_173_183_tacrolimus_D005148_1_197_214_facial dermatitis	We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.
UN	20466178_D016559_1_173_183_tacrolimus_D012393_1_113_120_rosacea	We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.
UN	20470218_D008727_6_1064_1076_methotrexate_D004833_6_1022_1044_temporal lobe epilepsy	CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).
UN	20470218_D008727_6_1064_1076_methotrexate_D007177_6_1107_1151_inappropriate antidiuretic hormone secretion	CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).
UN	20470218_D008727_6_1064_1076_methotrexate_D020521_6_1006_1012_stroke	CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).
UN	20470218_D008727_6_1064_1076_methotrexate_D056784_6_967_986_leukoencephalopathy	CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).
UN	20477932_C052342_0_134_144_topiramate_D007859_0_15_46_memory and learning impairments	Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.
UN	20477932_C052342_0_134_144_topiramate_D008569_0_15_46_memory and learning impairments	Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.
UN	20477932_C052342_3_677_687_topiramate_D019970_3_723_740_cocaine addiction	Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.
CID	20477932_D003042_0_0_7_Cocaine_D007859_0_15_46_memory and learning impairments	Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.
CID	20477932_D003042_0_0_7_Cocaine_D008569_0_15_46_memory and learning impairments	Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.
UN	20477932_D003042_3_785_792_cocaine_D019970_3_723_740_cocaine addiction	Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.
UN	20477932_D009569_3_585_597_nitric oxide_D019970_3_723_740_cocaine addiction	Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.
UN	20510337_C024989_5_952_964_coenzyme Q10_D007674_5_891_910_renal tissue damage	Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
UN	20510337_C024989_0_0_12_Coenzyme Q10_D007674_0_51_65_nephrotoxicity	Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.
UN	20510337_C024989_4_473_485_Coenzyme Q10_D009336_4_687_695_necrosis	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
UN	20510337_C024989_4_473_485_Coenzyme Q10_D009369_4_681_686_tumor	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
UN	20510337_C024989_1_106_118_coenzyme Q10_D058186_1_149_167_acute renal injury	The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p. injection of cisplatin (5 mg/kg).
UN	20510337_D002945_4_841_850_cisplatin_D009336_4_687_695_necrosis	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
UN	20510337_D002945_4_841_850_cisplatin_D009369_4_681_686_tumor	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
CID	20510337_D002945_1_206_215_cisplatin_D058186_1_149_167_acute renal injury	The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p. injection of cisplatin (5 mg/kg).
UN	20510337_D005978_4_560_579_reduced glutathione_D009336_4_687_695_necrosis	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
UN	20510337_D005978_4_560_579_reduced glutathione_D009369_4_681_686_tumor	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
UN	20510337_D009569_4_710_722_nitric oxide_D009336_4_687_695_necrosis	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
UN	20510337_D009569_4_710_722_nitric oxide_D009369_4_681_686_tumor	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
UN	20510337_D010984_4_727_735_platinum_D009336_4_687_695_necrosis	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
UN	20510337_D010984_4_727_735_platinum_D009369_4_681_686_tumor	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
UN	20510337_D012643_4_788_796_selenium_D009336_4_687_695_necrosis	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
UN	20510337_D012643_4_788_796_selenium_D009369_4_681_686_tumor	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
UN	20510337_D013481_4_590_600_superoxide_D009336_4_687_695_necrosis	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
UN	20510337_D013481_4_590_600_superoxide_D009369_4_681_686_tumor	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
UN	20510337_D015032_4_801_805_zinc_D009336_4_687_695_necrosis	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
UN	20510337_D015032_4_801_805_zinc_D009369_4_681_686_tumor	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
CID	2051906_D001379_0_55_67_azathioprine_D002779_0_28_44_bile duct injury	Reversible cholestasis with bile duct injury following azathioprine therapy.
CID	2051906_D001379_2_284_296_azathioprine_D002779_2_243_254_cholestasis	A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.
CID	2051906_D001379_5_592_604_azathioprine_D002779_5_613_624_cholestasis	It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.
UN	2051906_D001379_2_284_296_azathioprine_D008107_2_174_187_liver disease	A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.
UN	2051906_D001379_2_284_296_azathioprine_D017285_2_128_140_polymyositis	A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.
CID	20520283_C522667_8_1810_1819_asenapine_D001480_8_1884_1907_extrapyramidal symptoms	Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.
CID	20520283_C522667_6_1585_1594_asenapine_D001480_6_1500_1523_Extrapyramidal symptoms	Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.
UN	20520283_C522667_1_134_143_Asenapine_D001714_1_246_251_manic	Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.
UN	20520283_C522667_1_134_143_Asenapine_D011618_1_321_330_psychotic	Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.
UN	20520283_C522667_2_463_472_asenapine_D012559_2_397_410_schizophrenia	In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).
CID	20520283_D006220_8_1824_1835_haloperidol_D001480_8_1884_1907_extrapyramidal symptoms	Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.
UN	20520283_D006220_0_51_62_haloperidol_D012559_0_119_132_schizophrenia	Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.
CID	20528871_C104457_3_579_583_AraG_D006402_3_518_541_Haematological toxicity	Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.
CID	20528871_C104457_2_435_439_AraG_D009422_2_481_491_neuropathy	The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.
UN	20528871_C104457_1_168_178_nelarabine_D015458_1_356_384_T-cell leukaemia or lymphoma	A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.
UN	20528871_C104457_0_21_31_nelarabine_D015458_0_99_142_T-cell lymphoblastic leukaemia and lymphoma	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
UN	20528871_C104457_1_168_178_nelarabine_D016399_1_356_384_T-cell leukaemia or lymphoma	A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.
UN	20528871_C104457_0_21_31_nelarabine_D016399_0_99_142_T-cell lymphoblastic leukaemia and lymphoma	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
CID	20528871_C104457_2_435_439_AraG_D059352_2_496_516_musculoskeletal pain	The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.
UN	20528871_D003520_5_941_957_cyclophosphamide_D009422_5_968_989_neurological toxicity	Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.
UN	20528871_D003520_0_48_64_cyclophosphamide_D015458_0_99_142_T-cell lymphoblastic leukaemia and lymphoma	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
UN	20528871_D003520_0_48_64_cyclophosphamide_D016399_0_99_142_T-cell lymphoblastic leukaemia and lymphoma	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
UN	20528871_D005047_5_927_936_etoposide_D009422_5_968_989_neurological toxicity	Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.
UN	20528871_D005047_0_33_42_etoposide_D015458_0_99_142_T-cell lymphoblastic leukaemia and lymphoma	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
UN	20528871_D005047_1_198_207_etoposide_D015458_1_356_384_T-cell leukaemia or lymphoma	A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.
UN	20528871_D005047_1_198_207_etoposide_D016399_1_356_384_T-cell leukaemia or lymphoma	A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.
UN	20528871_D005047_0_33_42_etoposide_D016399_0_99_142_T-cell lymphoblastic leukaemia and lymphoma	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
UN	20533999_D004298_5_960_962_DA_D009461_5_993_1014_dopaminergic deficits	In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.
UN	20533999_D004298_4_789_791_DA_D020258_4_805_818_neurotoxicity	Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
UN	20533999_D004298_3_641_643_DA_D020258_3_644_657_neurotoxicity	Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.
UN	20533999_D004298_6_1250_1252_DA_D020258_6_1193_1206_neurotoxicity	Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.
UN	20533999_D007980_3_537_561_L-dihydroxyphenylalanine_D020258_3_644_657_neurotoxicity	Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.
UN	20533999_D008694_5_980_984_METH_D009461_5_993_1014_dopaminergic deficits	In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.
CID	20533999_D008694_0_49_64_methamphetamine_D020258_0_73_86_neurotoxicity	Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.
CID	20533999_D008694_4_800_804_METH_D020258_4_805_818_neurotoxicity	Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
CID	20533999_D008694_3_628_632_METH_D020258_3_644_657_neurotoxicity	Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.
CID	20533999_D008694_6_1167_1171_METH_D020258_6_1193_1206_neurotoxicity	Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.
UN	20533999_D019805_3_598_624_alpha-methyl-para-tyrosine_D020258_3_644_657_neurotoxicity	Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.
UN	2054792_D004317_0_10_20_adriamycin_D005334_0_46_58_hyperthermia	Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.
UN	2054792_D004317_7_983_993_Adriamycin_D005334_7_961_973_hyperthermia	Thus, while whole body hyperthermia enhances Adriamycin-mediated antitumor effect, normal tissue toxicity is also increased, and the potential therapeutic gain of the combined modality treatment is eroded.
UN	2054792_D004317_0_10_20_adriamycin_D009369_0_62_67_tumor	Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.
CID	20552622_D000420_0_55_65_salbutamol_D013617_0_19_41_atrial tachyarrhythmia	Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.
CID	20552622_D000420_10_1117_1127_Salbutamol_D013617_10_1172_1176_SIAT	CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.
UN	20552622_D001262_3_379_387_atenolol_D001145_3_340_350_arrhythmia	The arrhythmia resolved after therapy with atenolol, but recurred a year later.
UN	20552622_D001262_11_1450_1458_atenolol_D013610_11_1317_1328_tachycardia	Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.
UN	2055425_D000255_5_1084_1087_ATP_D003920_5_1048_1056_diabetic	Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol. 6.
UN	2055425_D000255_3_655_658_ATP_D003920_3_619_627_diabetic	Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol. 4.
CID	2055425_D013311_0_105_119_streptozotocin_D003920_0_128_145_diabetes mellitus	The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin-induced diabetes mellitus. 1.
CID	2055425_D013311_1_235_249_streptozotocin_D003920_1_250_258_diabetic	The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin-diabetic rats were investigated. 2.
CID	2055425_D013311_6_1147_1161_streptozotocin_D003920_6_1170_1178_diabetes	The data indicate that the effects of streptozotocin-induced diabetes on urinary bladder function are both prevented and reversed by insulin treatment.
UN	2055425_D018723_5_1093_1104_bethanechol_D003920_5_1048_1056_diabetic	Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol. 6.
UN	2055425_D018723_3_664_675_bethanechol_D003920_3_619_627_diabetic	Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol. 4.
UN	20558148_C031231_6_1211_1214_AP7_D002375_6_1291_1300_catalepsy	The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.
UN	20558148_D000596_4_694_704_amino acid_D002375_4_742_751_catalepsy	The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.
UN	20558148_D004298_4_767_775_dopamine_D002375_4_742_751_catalepsy	The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.
CID	20558148_D006220_8_1575_1586_haloperidol_D002375_8_1595_1604_catalepsy	These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced catalepsy and participate in the regulation of motor activity.
CID	20558148_D006220_5_857_868_Haloperidol_D002375_5_877_886_catalepsy	Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
CID	20558148_D006220_6_1250_1261_haloperidol_D002375_6_1291_1300_catalepsy	The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.
CID	20558148_D006220_4_793_804_haloperidol_D002375_4_742_751_catalepsy	The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.
CID	20558148_D006220_0_99_110_haloperidol_D002375_0_119_128_catalepsy	Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.
UN	20558148_D016202_5_958_962_NMDA_D002375_5_877_886_catalepsy	Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
UN	20558148_D016291_5_985_991_MK-801_D002375_5_877_886_catalepsy	Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
UN	20558148_D016291_6_1200_1206_MK-801_D002375_6_1291_1300_catalepsy	The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.
UN	20558148_D018698_5_948_957_glutamate_D002375_5_877_886_catalepsy	Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
CID	20588063_D011692_2_245_270_puromycin aminonucleoside_D009401_2_271_280_nephrosis	Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.
CID	20588063_D011692_0_109_134_puromycin aminonucleoside_D009401_0_135_144_nephrosis	Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.
CID	20619828_D002997_4_514_526_Clomipramine_D001008_4_631_638_anxiety	RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.
CID	20619828_D002997_4_514_526_Clomipramine_D008569_4_797_814_memory impairment	RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.
CID	20619828_D002997_4_514_526_Clomipramine_D060845_4_843_851_hoarding	RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.
CID	20621845_D002122_9_1708_1715_CaCl(2)_D017545_9_1682_1685_TAA	CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.
CID	20621845_D002122_0_89_94_CaCl2_D017545_0_103_127_thoracic aortic aneurysm	Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.
CID	20621845_D002122_1_239_255_calcium chloride_D017545_1_231_234_TAA	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.
CID	20633755_D009943_1_193_222_organophosphorus (OP) poisons_D001049_1_119_124_apnea	Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.
CID	20633755_D013390_0_0_13_Suxamethonium_D001049_0_32_37_apnea	Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.
CID	20633755_D013390_1_88_101_Suxamethonium_D001049_1_119_124_apnea	Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.
CID	20635749_D000638_0_43_53_amiodarone_D003128_0_70_84_myxedemic coma	Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.
CID	20635749_D000638_1_153_163_amiodarone_D003128_1_126_139_myxedema coma	This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).
CID	20635749_D000638_2_355_365_amiodarone_D003128_2_324_337_myxedema coma	To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy.
UN	20635749_D000638_1_153_163_amiodarone_D006333_1_212_236_congestive heart failure	This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).
UN	20635749_D000638_0_43_53_amiodarone_D006333_0_7_31_congestive heart failure	Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.
UN	20635749_D000638_6_850_860_amiodarone_D006333_6_867_870_CHF	This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.
UN	20635749_D000638_5_604_614_amiodarone_D006333_5_597_600_CHF	Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.
CID	20635749_D000638_1_153_163_amiodarone_D007037_1_172_186_hypothyroidism	This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).
CID	20635749_D000638_5_604_614_amiodarone_D007037_5_663_677_hypothyroidism	Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.
CID	20635749_D000638_2_355_365_amiodarone_D009230_2_324_337_myxedema coma	To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy.
CID	20635749_D000638_0_43_53_amiodarone_D009230_0_70_84_myxedemic coma	Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.
CID	20635749_D000638_1_153_163_amiodarone_D009230_1_126_139_myxedema coma	This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).
CID	20667451_D002220_4_593_606_carbamazepine_D003072_4_615_635_cognitive impairment	Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.
CID	20667451_D002220_12_1705_1718_carbamazepine_D003072_12_1607_1643_deterioration of cognitive functions	These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.
CID	20667451_D002220_9_1113_1126_carbamazepine_D003072_9_1159_1192_impairment of learning and memory	The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.
CID	20667451_D002220_13_1896_1909_carbamazepine_D003072_13_1932_1952_cognitive impairment	The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.
CID	20667451_D002220_1_163_176_carbamazepine_D003072_1_201_221_cognitive impairment	The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.
CID	20667451_D002220_0_86_99_carbamazepine_D003072_0_21_42_cognitive dysfunction	Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.
UN	20667451_D003474_4_546_554_curcumin_D003072_4_615_635_cognitive impairment	Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.
UN	20667451_D003474_10_1247_1255_curcumin_D003072_10_1285_1305_cognitive impairment	Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.
UN	20667451_D003474_12_1558_1566_curcumin_D003072_12_1607_1643_deterioration of cognitive functions	These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.
UN	20667451_D003474_0_0_8_Curcumin_D003072_0_21_42_cognitive dysfunction	Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.
CID	20667451_D010634_9_1094_1108_phenobarbitone_D003072_9_1159_1192_impairment of learning and memory	The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.
CID	20667451_D010634_12_1686_1700_phenobarbitone_D003072_12_1607_1643_deterioration of cognitive functions	These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.
CID	20667451_D010634_13_1877_1891_phenobarbitone_D003072_13_1932_1952_cognitive impairment	The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.
CID	20667451_D010634_1_144_158_phenobarbitone_D003072_1_201_221_cognitive impairment	The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.
CID	20667451_D010634_0_67_81_phenobarbitone_D003072_0_21_42_cognitive dysfunction	Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.
CID	20667451_D010634_4_573_587_phenobarbitone_D003072_4_615_635_cognitive impairment	Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.
UN	20683499_C029036_2_354_361_crocins_D000544_2_374_393_Alzheimer's disease	In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.
UN	20683499_C029036_0_53_59_crocin_D000544_0_102_121_Alzheimer's disease	Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.
UN	20683499_C029036_10_1580_1586_crocin_D003072_10_1618_1636_cognitive deficits	CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.
UN	20683499_C029036_9_1362_1368_crocin_D007859_9_1422_1452_learning and memory impairment	In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.
UN	20683499_C029036_9_1362_1368_crocin_D008569_9_1422_1452_learning and memory impairment	In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.
UN	20683499_C029036_10_1580_1586_crocin_D019636_10_1701_1727_neurodegenerative diseases	CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.
CID	20683499_D013311_2_435_447_streptozocin_D000544_2_374_393_Alzheimer's disease	In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.
CID	20683499_D013311_0_63_75_streptozocin_D000544_0_102_121_Alzheimer's disease	Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.
CID	20683499_D013311_10_1647_1650_STZ_D003072_10_1618_1636_cognitive deficits	CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.
UN	20683499_D013311_9_1464_1467_STZ_D007859_9_1422_1452_learning and memory impairment	In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.
UN	20683499_D013311_9_1464_1467_STZ_D008569_9_1422_1452_learning and memory impairment	In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.
UN	20698227_C100416_3_553_582_pegylated interferon alpha 2a_D019698_3_493_536_chronically infected with hepatitis C virus	METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.
CID	20698227_C471405_1_222_231_sorafenib_D006461_1_263_272_hemolysis	BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.
CID	20698227_C473478_1_208_217_sunitinib_D006461_1_263_272_hemolysis	BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.
UN	20698227_D012254_9_1279_1288_ribavirin_D000740_9_1297_1303_anemia	CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation.
UN	20698227_D012254_0_46_55_ribavirin_D000743_0_67_83_hemolytic anemia	Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?
UN	20698227_D012254_1_111_120_ribavirin_D006461_1_263_272_hemolysis	BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.
UN	20698227_D012254_3_587_596_ribavirin_D019698_3_493_536_chronically infected with hepatitis C virus	METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.
UN	20698227_D012254_9_1279_1288_ribavirin_D019698_9_1321_1332_hepatitis C	CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation.
CID	2070391_D008012_0_43_52_lidocaine_D010146_0_23_27_pain	Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization.
CID	2070391_D008012_1_182_191_lidocaine_D010146_1_144_148_pain	Previous reports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution.
CID	2070391_D008012_2_310_319_lidocaine_D010146_2_360_364_pain	To determine if the addition of a buffering solution to adjust the pH of lidocaine into the physiologic range would reduce pain during injection, we performed a blinded randomized study in patients undergoing cardiac catheterization.
CID	2070391_D008012_3_556_565_lidocaine_D010146_3_526_530_pain	Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area.
CID	2070391_D008012_4_672_681_lidocaine_D010146_4_648_652_pain	The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).
UN	20705401_C076029_2_379_389_olanzapine_D006948_2_417_430_hyperactivity	The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.
UN	20705401_D003024_2_365_374_clozapine_D006948_2_417_430_hyperactivity	The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.
UN	20705401_D003913_2_395_408_d-amphetamine_D006948_2_417_430_hyperactivity	The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.
CID	20705401_D008694_5_910_914_METH_D011605_5_924_933_psychosis	The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.
CID	20705401_D008694_7_1261_1265_METH_D011605_7_1274_1283_psychosis	METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.
CID	20705401_D008694_6_1072_1076_METH_D011605_6_1085_1094_psychosis	Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.
CID	20705401_D008694_9_1488_1492_METH_D011605_9_1501_1510_psychosis	RESULTS: rs6693503 was associated with METH-induced psychosis patients in the allele/genotype-wise analysis.
CID	20705401_D008694_12_1924_1928_METH_D011605_12_1937_1946_psychosis	CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.
CID	20705401_D008694_11_1807_1811_METH_D011605_11_1820_1829_psychosis	In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.
CID	20705401_D008694_0_45_60_methamphetamine_D011605_0_69_78_psychosis	Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.
UN	20705401_D008694_5_910_914_METH_D012563_5_958_985_paranoid type schizophrenia	The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.
UN	20705401_D012701_2_480_484_5-HT_D006948_2_417_430_hyperactivity	The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.
UN	20705401_D012701_6_1049_1053_5-HT_D011605_6_1085_1094_psychosis	Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.
UN	20705401_D012701_0_0_9_Serotonin_D011605_0_69_78_psychosis	Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.
UN	20705401_D012701_4_801_805_5-HT_D011605_4_856_875_psychotic disorders	These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.
UN	20705401_D012701_4_801_805_5-HT_D012559_4_741_754_schizophrenia	These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.
UN	2071257_D005997_0_10_44_L-alpha-glyceryl-phosphorylcholine_D000647_0_48_55_amnesia	Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine.
UN	2071257_D005997_1_171_182_L-alpha-GFC_D008569_1_187_204_memory impairment	The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.
UN	2071257_D012601_0_66_77_scopolamine_D000647_0_48_55_amnesia	Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine.
CID	2071257_D012601_4_684_695_scopolamine_D008569_4_638_672_impairment of attention and memory	The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by scopolamine.
CID	2071257_D012601_1_216_227_scopolamine_D008569_1_187_204_memory impairment	The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.
CID	20722491_C110904_7_1044_1056_capecitabine_D003967_7_1061_1069_diarrhea	The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.
UN	20722491_C110904_3_467_479_capecitabine_D007674_3_539_563_renal and kidney disease	WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.
UN	20722491_C110904_8_1124_1136_Capecitabine_D007674_8_1230_1260_hepatic and renal dysfunctions	Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.
UN	20722491_C110904_8_1124_1136_Capecitabine_D008107_8_1230_1260_hepatic and renal dysfunctions	Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.
CID	20722491_C110904_7_1044_1056_capecitabine_D009325_7_1071_1077_nausea	The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.
CID	20722491_C110904_7_1044_1056_capecitabine_D013280_7_1089_1099_stomatitis	The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.
CID	20722491_C110904_7_1044_1056_capecitabine_D014839_7_1079_1087_vomiting	The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.
CID	20722491_C110904_7_1044_1056_capecitabine_D060831_7_1104_1122_hand-foot syndrome	The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.
UN	20722491_D005472_1_92_106_5-fluorouracil_D001943_1_187_231_colorectal, breast and head and neck cancers	IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.
UN	20722491_D005472_1_92_106_5-fluorouracil_D006258_1_187_231_colorectal, breast and head and neck cancers	IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.
UN	20722491_D005472_1_92_106_5-fluorouracil_D009369_1_169_175_tumors	IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.
UN	20722491_D005472_1_92_106_5-fluorouracil_D015179_1_187_231_colorectal, breast and head and neck cancers	IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.
CID	20727411_D007649_7_1000_1008_Ketamine_D011605_7_1018_1027_psychosis	Ketamine elicited psychosis like psychopathology.
UN	20727411_D007649_2_311_319_ketamine_D012559_2_386_399_schizophrenia	Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.
UN	20727411_D007649_3_433_441_ketamine_D018754_3_515_540_glutamatergic dysfunction	In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.
UN	20727411_D016202_1_130_134_NMDA_D012559_1_191_204_schizophrenia	The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.
UN	20727411_D016202_11_1657_1661_NMDA_D012559_11_1709_1722_schizophrenia	Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia.
CID	20735774_D000082_6_774_785_paracetamol_D017114_6_821_840_acute liver failure	On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.
CID	20735774_D000082_9_1305_1316_Paracetamol_D017114_9_1325_1344_acute liver failure	CONCLUSIONS: Paracetamol-induced acute liver failure did not affect long-term mortality.
CID	20735774_D000082_0_53_64_paracetamol_D017114_0_73_92_acute liver failure	Long-term prognosis for transplant-free survivors of paracetamol-induced acute liver failure.
CID	20735774_D000082_1_153_164_paracetamol_D017114_1_173_192_acute liver failure	BACKGROUND: The prognosis for transplant-free survivors of paracetamol-induced acute liver failure remains unknown.
CID	20735774_D000082_2_234_245_paracetamol_D017114_2_254_273_acute liver failure	AIM: To examine whether paracetamol-induced acute liver failure increases long-term mortality.
UN	20735774_D000082_6_774_785_paracetamol_D056486_6_794_806_liver injury	On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.
UN	20735774_D000082_3_362_373_paracetamol_D056486_3_382_400_acute liver injury	METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004.
UN	20880751_D004298_2_214_222_dopamine_D004409_2_285_296_dyskinesias	However, the long-term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias.
CID	20880751_D007980_5_1040_1048_levodopa_D004409_5_1057_1068_dyskinesias	Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.
CID	20880751_D007980_3_436_444_levodopa_D004409_3_453_464_dyskinesias	Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa-induced dyskinesias, their pathogenesis is still unclear.
CID	20880751_D007980_0_0_8_Levodopa_D004409_0_17_28_dyskinesias	Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.
UN	20880751_D007980_0_0_8_Levodopa_D010300_0_46_65_Parkinson's disease	Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.
UN	20880751_D007980_1_101_109_Levodopa_D010300_1_158_177_Parkinson's disease	Levodopa is the most effective drug for the treatment of Parkinson's disease.
UN	20880751_D018698_5_947_956_glutamate_D004409_5_1057_1068_dyskinesias	Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.
CID	20882060_D006220_5_711_722_haloperidol_D002375_5_731_753_parkinsonian catalepsy	RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.
CID	20882060_D006220_0_35_46_haloperidol_D002375_0_55_77_parkinsonian catalepsy	Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.
UN	20882060_D006220_3_485_496_haloperidol_D010302_3_505_526_parkinsonian symptoms	The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced parkinsonian symptoms.
UN	20882060_D009496_5_665_676_neurotensin_D002375_5_731_753_parkinsonian catalepsy	RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.
UN	20882060_D009496_0_20_31_neurotensin_D002375_0_55_77_parkinsonian catalepsy	Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.
UN	20882060_D009496_3_470_481_neurotensin_D010302_3_505_526_parkinsonian symptoms	The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced parkinsonian symptoms.
UN	2096243_C017367_5_608_616_carmofur_D010554_5_670_698_organic personality syndrome	Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.
CID	2096243_C017367_0_0_8_Carmofur_D019965_0_17_41_organic mental disorders	Carmofur-induced organic mental disorders.
CID	2096243_C017367_5_608_616_carmofur_D056784_5_625_644_leukoencephalopathy	Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.
CID	2096243_C017367_1_148_156_carmofur_D056784_1_165_184_leukoencephalopathy	Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.
CID	20973483_D006220_3_670_681_haloperidol_D002375_3_690_699_catalepsy	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
UN	20973483_D006220_3_670_681_haloperidol_D004409_3_734_742_akinesia	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
UN	20973483_D006220_3_670_681_haloperidol_D010300_3_616_635_Parkinson's disease	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
UN	20973483_D012110_3_716_725_reserpine_D002375_3_690_699_catalepsy	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
CID	20973483_D012110_3_716_725_reserpine_D004409_3_734_742_akinesia	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
UN	20973483_D012110_3_716_725_reserpine_D010300_3_616_635_Parkinson's disease	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
UN	20973483_D015632_3_818_822_MPTP_D002375_3_690_699_catalepsy	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
UN	20973483_D015632_3_818_822_MPTP_D004409_3_734_742_akinesia	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
UN	20973483_D015632_3_818_822_MPTP_D010300_3_616_635_Parkinson's disease	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
UN	20973483_D016627_3_748_765_6-hydroxydopamine_D002375_3_690_699_catalepsy	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
UN	20973483_D016627_3_748_765_6-hydroxydopamine_D004409_3_734_742_akinesia	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
UN	20973483_D016627_3_748_765_6-hydroxydopamine_D010300_3_616_635_Parkinson's disease	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
UN	20973483_D058915_0_35_71_adenosine A2A/A1 receptor antagonist_D010300_0_92_111_Parkinson's disease	In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
UN	20973483_D058915_1_152_192_adenosine A(2A)/A(1) receptor antagonist_D010300_1_221_240_Parkinson's disease	The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.
CID	21029050_D013390_0_76_91_succinylcholine_D001049_0_64_69_apnea	Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy.
UN	21418164_D008130_4_554_558_CCNU_D001932_4_630_642_brain tumour	CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.
CID	21418164_D008130_1_204_248_1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_D005767_1_108_170_haematological, renal, hepatic and gastrointestinal toxicities	OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).
CID	21418164_D008130_1_204_248_1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_D007674_1_108_170_haematological, renal, hepatic and gastrointestinal toxicities	OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).
UN	21418164_D008130_4_554_558_CCNU_D008223_4_602_610_lymphoma	CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.
UN	21418164_D008130_4_554_558_CCNU_D015620_4_644_663_histiocytic tumours	CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.
UN	21418164_D008130_4_554_558_CCNU_D034801_4_612_628_mast cell tumour	CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.
UN	21418164_D008130_1_204_248_1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_D056486_1_108_170_haematological, renal, hepatic and gastrointestinal toxicities	OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).
UN	220563_C023470_1_118_137_perhexiline maleate_D000787_1_248_263_angina pectoris	Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.
CID	220563_C023470_1_118_137_perhexiline maleate_D010523_1_47_68_Peripheral neuropathy	Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.
CID	220563_C023470_0_0_19_Perhexiline maleate_D010523_0_24_45_peripheral neuropathy	Perhexiline maleate and peripheral neuropathy.
UN	2220369_C015173_1_210_231_dipivalyl epinephrine_D005901_1_245_253_glaucoma	A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.
CID	2220369_C015173_0_36_57_dipivalyl epinephrine_D020246_0_8_23_vein thrombosis	Central vein thrombosis and topical dipivalyl epinephrine.
UN	2224762_C027260_2_139_171_4'-0-tetrahydropyranyladriamycin_D009369_2_253_259_tumors	A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.
CID	2234245_D003676_0_64_79_desferrioxamine_D014786_0_0_28_Ocular and auditory toxicity	Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.
CID	2234245_D003676_7_1234_1249_desferrioxamine_D014786_7_1144_1164_audiovisual toxicity	The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.
UN	2257294_C034753_4_892_895_BAU_D000740_4_947_953_anemia	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.
UN	2257294_C034753_2_491_510_benzylacyclouridine_D000740_2_549_555_anemia	Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.
UN	2257294_C034753_5_1186_1189_BAU_D001855_5_1210_1225_marrow toxicity	When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.
UN	2257294_C034753_0_0_19_Benzylacyclouridine_D001855_0_52_70_marrow suppression	Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.
UN	2257294_C034753_0_0_19_Benzylacyclouridine_D007153_0_104_120_immunodeficiency	Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.
UN	2257294_C034753_4_892_895_BAU_D007970_4_958_968_leukopenia	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.
UN	2257294_C034753_2_491_510_benzylacyclouridine_D007970_2_560_570_leukopenia	Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.
UN	2257294_D014529_2_456_459_Urd_D000740_2_549_555_anemia	Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.
UN	2257294_D014529_1_179_186_uridine_D007153_1_358_374_immunodeficiency	Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.
UN	2257294_D014529_2_456_459_Urd_D007970_2_560_570_leukopenia	Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.
CID	2257294_D015215_2_537_540_AZT_D000740_2_549_555_anemia	Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.
CID	2257294_D015215_4_935_938_AZT_D000740_4_947_953_anemia	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.
CID	2257294_D015215_5_1198_1201_AZT_D001855_5_1210_1225_marrow toxicity	When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.
CID	2257294_D015215_0_29_43_azidothymidine_D001855_0_52_70_marrow suppression	Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.
UN	2257294_D015215_1_233_247_azidothymidine_D007153_1_358_374_immunodeficiency	Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.
UN	2257294_D015215_0_29_43_azidothymidine_D007153_0_104_120_immunodeficiency	Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.
CID	2257294_D015215_2_537_540_AZT_D007970_2_560_570_leukopenia	Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.
CID	2257294_D015215_4_798_801_AZT_D007970_4_762_772_leukopenic	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.
CID	2257294_D015215_4_935_938_AZT_D007970_4_958_968_leukopenia	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.
UN	2265898_C009265_1_294_312_carbidopa/levodopa_D001523_1_352_364_hallucinosis	Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.
CID	2265898_C009265_0_26_44_levodopa/carbidopa_D004827_0_7_15_epilepsy	Serial epilepsy caused by levodopa/carbidopa administration in two patients on hemodialysis.
UN	2265898_C009265_1_294_312_carbidopa/levodopa_D007676_1_170_191_chronic renal failure	Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.
UN	2265898_C009265_1_294_312_carbidopa/levodopa_D012640_1_379_387_seizures	Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.
CID	2266990_D008454_6_725_733_mazindol_D001068_6_743_761_decreased appetite	Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.
CID	2266990_D008454_6_848_856_mazindol_D012817_6_815_840_gastrointestinal symptoms	Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.
CID	2266990_D008454_6_725_733_mazindol_D014987_6_769_778_dry mouth	Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.
UN	2266990_D008454_9_1251_1259_Mazindol_D018908_9_1294_1302_weakness	Mazindol doses not slow the progression of weakness in Duchenne dystrophy.
UN	2266990_D008454_9_1251_1259_Mazindol_D020388_9_1306_1324_Duchenne dystrophy	Mazindol doses not slow the progression of weakness in Duchenne dystrophy.
UN	2266990_D008454_0_34_42_mazindol_D020388_0_46_64_Duchenne dystrophy	Randomized, double-blind trial of mazindol in Duchenne dystrophy.
CID	2273650_D003513_2_548_561_cycloheximide_D000647_2_570_577_amnesia	Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.
CID	2273650_D003513_1_181_194_cycloheximide_D000647_1_145_152_Amnesia	Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.
UN	2273650_D009020_1_212_220_morphine_D000647_1_145_152_Amnesia	Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.
UN	2273650_D009270_1_356_364_naloxone_D000647_1_145_152_Amnesia	Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.
CID	2273650_D012601_2_447_458_scopolamine_D000647_2_467_474_amnesia	Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.
CID	2273650_D012601_1_165_176_scopolamine_D000647_1_145_152_Amnesia	Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.
UN	227508_D003000_4_487_496_clonidine_D006973_4_469_481_hypertensive	In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).
CID	227508_D008750_2_306_322_alpha-methyldopa_D007022_2_274_285_hypotensive	The hypotensive effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone.
UN	227508_D009270_4_589_597_naloxone_D006973_4_469_481_hypertensive	In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).
UN	227508_D009270_2_354_362_naloxone_D007022_2_274_285_hypotensive	The hypotensive effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone.
UN	230316_D006912_0_17_46_halogenated hydroxyquinolines_D020258_0_0_13_Neurotoxicity	Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.
UN	230316_D006912_1_173_202_halogenated hydroxyquinolines_D020258_1_149_159_neurotoxic	An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan.
UN	230316_D007464_6_835_845_clioquinol_C538178_6_863_891_acrodermatitis enteropathica	This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica.
CID	230316_D007464_4_644_654_clioquinol_D001927_4_578_592_encephalopathy	In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.
CID	2304736_D011224_7_817_825_prazosin_D014550_7_784_803_stress incontinence	Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery, because their incontinence may resolve spontaneously with a change in drug therapy.
CID	2304736_D011224_1_83_91_prazosin_D014550_1_56_75_stress incontinence	A case of genuine stress incontinence due to prazosin, a common antihypertensive drug, is presented.
CID	2304736_D011224_0_0_8_Prazosin_D014550_0_17_36_stress incontinence	Prazosin-induced stress incontinence.
CID	2312209_D007548_1_221_241_isosorbide dinitrate_D009203_1_146_167_myocardial infarction	A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.
CID	2312209_D007548_0_61_81_isosorbide dinitrate_D009203_0_0_21_Myocardial infarction	Myocardial infarction following sublingual administration of isosorbide dinitrate.
UN	2312209_D007548_1_221_241_isosorbide dinitrate_D009336_1_116_124_necrosis	A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.
UN	2320800_D002945_1_197_206_cisplatin_D001002_1_260_266_anuria	A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.
UN	2320800_D002945_1_197_206_cisplatin_D001943_1_158_171_breast cancer	A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.
UN	2320800_D002945_6_786_795_cisplatin_D007022_6_857_868_hypotension	We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.
UN	2320800_D002945_1_197_206_cisplatin_D051437_1_241_254_renal failure	A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.
CID	2320800_D007069_0_37_47_ifosfamide_D001002_0_7_13_anuria	Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.
CID	2320800_D007069_6_726_736_ifosfamide_D001002_6_701_707_anuria	We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.
UN	2320800_D007069_0_37_47_ifosfamide_D001943_0_66_79_breast cancer	Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.
UN	2320800_D007069_6_726_736_ifosfamide_D007022_6_857_868_hypotension	We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.
CID	2320800_D007069_5_592_602_Ifosfamide_D007674_5_614_625_nephrotoxic	Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.
CID	2320800_D007069_0_37_47_ifosfamide_D007674_0_96_119_impaired renal function	Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.
CID	2320800_D007069_7_898_908_ifosfamide_D007674_7_937_948_nephrotoxic	We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion.
UN	2320800_D007069_1_295_305_ifosfamide_D051437_1_241_254_renal failure	A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.
UN	2322844_C053876_6_887_893_AH6809_D006930_6_859_871_hyperalgesia	Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.
UN	2322844_D011453_1_159_173_prostaglandins_D010146_1_177_181_pain	The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.
CID	2322844_D015230_5_648_664_prostaglandin D2_D006930_5_625_637_hyperalgesic	The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.
CID	2322844_D015230_8_1063_1079_prostaglandin D2_D006930_8_1107_1119_hyperalgesia	These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.
CID	2322844_D015232_8_1084_1100_prostaglandin E2_D006930_8_1107_1119_hyperalgesia	These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.
CID	2322844_D015232_6_834_850_prostaglandin E2_D006930_6_859_871_hyperalgesia	Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.
CID	2322844_D015232_3_409_425_Prostaglandin E2_D006930_3_435_447_hyperalgesic	Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.
UN	2322844_D015237_7_967_989_Prostaglandin F2 alpha_D010146_7_1011_1015_pain	Prostaglandin F2 alpha had little effect on pain responses.
UN	2322844_D019342_1_248_259_acetic acid_D010146_1_177_181_pain	The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.
CID	2334179_D010396_8_928_943_D-Penicillamine_D009404_8_951_969_nephrotic syndrome	D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.
CID	2334179_D010396_8_928_943_D-Penicillamine_D011507_8_1005_1016_proteinuria	D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.
UN	2334179_D010396_3_387_402_D-penicillamine_D012594_3_343_364_localized scleroderma	Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.
UN	2334179_D010396_0_0_15_D-penicillamine_D012594_0_36_57_localized scleroderma	D-penicillamine in the treatment of localized scleroderma.
UN	2334179_D010396_9_1098_1113_D-penicillamine_D012594_9_1150_1171_localized scleroderma	These data suggest that D-penicillamine may be effective in severe cases of localized scleroderma.
UN	2334179_D010396_8_928_943_D-Penicillamine_D051437_8_1053_1072_renal insufficiency	D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.
UN	2334618_D002045_1_331_342_bupivacaine_D001049_1_155_161_apnoea	The incidence of postoperative respiratory apnoea was compared between five patients receiving a continuous i.v. infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.
UN	2334618_D009020_4_881_889_morphine_D013610_4_789_805_tachyarrhythmias	There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.
CID	2334618_D009020_4_881_889_morphine_D018879_4_829_854_ventricular ectopic beats	There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.
CID	2334618_D009020_3_733_741_morphine_D020181_3_617_666_obstructive (P less than 0.05) and central apnoea	Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.
CID	2334618_D009020_3_733_741_morphine_D020182_3_617_666_obstructive (P less than 0.05) and central apnoea	Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.
UN	2339463_D015119_1_221_246_epsilon-aminocaproic acid_D008595_1_259_270_menorrhagia	We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.
CID	2339463_D015119_1_221_246_epsilon-aminocaproic acid_D020225_1_149_194_sagittal and left transverse sinus thrombosis	We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.
UN	2339463_D015119_1_221_246_epsilon-aminocaproic acid_D020227_1_149_194_sagittal and left transverse sinus thrombosis	We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.
UN	2343592_C044650_1_247_266_imipenem/cilastatin_D006259_1_150_161_head trauma	Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.
UN	2343592_C044650_1_247_266_imipenem/cilastatin_D007674_1_181_194_renal disease	Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.
CID	2343592_C044650_1_247_266_imipenem/cilastatin_D012640_1_205_213_seizures	Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.
UN	2343592_C044650_1_247_266_imipenem/cilastatin_D020521_1_114_140_cerebral vascular accident	Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.
UN	2343592_D010672_3_436_445_phenytoin_D012640_3_385_393_seizures	All seizures were controlled with therapeutic doses of phenytoin.
UN	2343592_D015378_0_22_30_imipenem_D012640_0_0_7_Seizure	Seizure activity with imipenem therapy: incidence and risk factors.
UN	2343592_D047090_4_497_508_beta-lactam_D012640_4_541_548_seizure	Both patients had received maximum doses of other beta-lactam antibiotics without evidence of seizure activity.
UN	234669_C093415_5_903_906_PO2_D014693_5_780_804_ventricular fibrillation	During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.
UN	234669_D000628_6_1095_1108_aminophylline_D007040_6_1006_1021_hypoventilation	When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.
UN	234669_D000628_0_11_24_aminophylline_D012131_0_89_108_respiratory failure	Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.
CID	234669_D000628_3_377_390_aminophylline_D014693_3_398_422_ventricular fibrillation	The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.
CID	234669_D000628_0_11_24_aminophylline_D014693_0_57_81_ventricular fibrillation	Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.
CID	234669_D000628_6_1095_1108_aminophylline_D014693_6_1149_1173_ventricular fibrillation	When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.
UN	234669_D002245_5_912_926_carbon dioxide_D014693_5_780_804_ventricular fibrillation	During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.
UN	234669_D010100_5_895_901_oxygen_D014693_5_780_804_ventricular fibrillation	During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.
UN	2348231_C008514_3_486_501_methylxanthines_D006940_3_465_474_hyperemia	Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.
UN	2348231_C008514_2_332_346_methylxanthine_D007383_2_376_401_intermittent claudication	Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.
CID	2348231_D004176_0_42_54_dipyridamole_D006940_0_72_81_hyperemia	Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.
CID	2348231_D004176_3_435_447_dipyridamole_D006940_3_465_474_hyperemia	Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.
CID	2348231_D004176_7_1088_1100_dipyridamole_D006940_7_1109_1118_hyperemia	Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).
CID	2348231_D004176_8_1264_1276_dipyridamole_D006940_8_1294_1303_hyperemia	We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.
UN	2348231_D004176_1_146_158_Dipyridamole_D016491_1_241_268_peripheral vascular disease	Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of peripheral vascular disease.
UN	2348231_D010431_3_411_425_pentoxifylline_D006940_3_465_474_hyperemia	Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.
UN	2348231_D010431_7_1045_1059_pentoxifylline_D006940_7_1109_1118_hyperemia	Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).
UN	2348231_D010431_8_1231_1246_pentoxyifylline_D006940_8_1294_1303_hyperemia	We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.
UN	2348231_D010431_0_16_23_Trental_D006940_0_72_81_hyperemia	Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.
CID	2348231_D010431_2_320_327_Trental_D007383_2_376_401_intermittent claudication	Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.
UN	2348231_D013793_3_567_575_thallium_D006940_3_465_474_hyperemia	Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.
UN	2348231_D013793_0_113_121_thallium_D006940_0_72_81_hyperemia	Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.
UN	2348231_D013793_1_159_167_thallium_D016491_1_241_268_peripheral vascular disease	Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of peripheral vascular disease.
UN	2348231_D013806_3_510_522_theophylline_D006940_3_465_474_hyperemia	Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.
UN	2355241_D007980_4_856_864_levodopa_D002543_4_740_760_cerebral haemorrhage	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.
UN	2355241_D007980_4_856_864_levodopa_D003643_4_775_780_death	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.
CID	2355241_D007980_4_856_864_levodopa_D007022_4_834_845_hypotensive	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.
CID	2355241_D007980_4_856_864_levodopa_D007022_4_871_882_hypotensive	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.
UN	2355241_D007980_4_856_864_levodopa_D010300_4_798_817_Parkinson's disease	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.
UN	2355241_D009638_4_908_921_noradrenaline_D002543_4_740_760_cerebral haemorrhage	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.
UN	2355241_D009638_4_908_921_noradrenaline_D003643_4_775_780_death	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.
UN	2355241_D009638_4_908_921_noradrenaline_D007022_4_871_882_hypotensive	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.
UN	2355241_D009638_4_908_921_noradrenaline_D010300_4_936_948_parkinsonian	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.
UN	2375138_D008874_0_23_32_midazolam_D003643_0_73_78_death	Possible intramuscular midazolam-associated cardiorespiratory arrest and death.
UN	2375138_D008874_3_441_450_midazolam_D003643_3_387_392_death	This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.
CID	2375138_D008874_0_23_32_midazolam_D006323_0_44_68_cardiorespiratory arrest	Possible intramuscular midazolam-associated cardiorespiratory arrest and death.
CID	2375138_D008874_3_441_450_midazolam_D006323_3_358_382_cardiorespiratory arrest	This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.
CID	2385256_D008274_7_777_786_magnesium_D009157_7_844_861_myasthenia gravis	Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.
CID	2385256_D008274_0_47_56_magnesium_D009157_0_0_17_Myasthenia gravis	Myasthenia gravis presenting as weakness after magnesium administration.
UN	2385256_D008274_7_777_786_magnesium_D010243_7_761_770_paralysis	Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.
UN	2385256_D008274_1_192_201_magnesium_D011225_1_221_233_preeclampsia	We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.
UN	2385256_D008274_1_192_201_magnesium_D011782_1_162_174_quadriplegic	We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.
CID	2396046_D002794_3_508_515_choline_D006528_3_450_475_hepatocellular carcinomas	No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.
UN	2396046_D010634_3_650_663_phenobarbital_D006528_3_574_598_hepatocellular carcinoma	No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.
UN	2422478_D008750_3_568_578_methyldopa_D006973_3_517_529_hypertensive	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
CID	2422478_D008750_6_1366_1376_methyldopa_D007022_6_1385_1396_hypotension	It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.
CID	2422478_D008750_6_1511_1521_methyldopa_D007022_6_1489_1500_hypotensive	It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.
CID	2422478_D008750_0_81_91_methyldopa_D007022_0_59_70_hypotensive	Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.
UN	2422478_D008750_3_568_578_methyldopa_D020521_3_531_537_stroke	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
UN	2422478_D012701_3_611_620_serotonin_D006973_3_517_529_hypertensive	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
UN	2422478_D012701_0_11_20_serotonin_D007022_0_59_70_hypotensive	Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.
UN	2422478_D012701_1_217_226_serotonin_D007022_1_260_271_hypotensive	Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.
UN	2422478_D012701_3_611_620_serotonin_D007022_3_671_682_hypotension	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
UN	2422478_D012701_4_956_965_serotonin_D007022_4_1017_1028_hypotension	However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.
UN	2422478_D012701_6_1437_1446_serotonin_D007022_6_1489_1500_hypotensive	It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.
UN	2422478_D012701_3_611_620_serotonin_D020521_3_531_537_stroke	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
UN	2422478_D015116_3_790_813_5,7-dihydroxytryptamine_D006973_3_517_529_hypertensive	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
UN	2422478_D015116_4_894_901_5,7-DHT_D007022_4_1017_1028_hypotension	However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.
UN	2422478_D015116_3_790_813_5,7-dihydroxytryptamine_D007022_3_671_682_hypotension	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
UN	2422478_D015116_3_790_813_5,7-dihydroxytryptamine_D020521_3_531_537_stroke	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
CID	2425813_D011239_1_218_230_prednisolone_D006529_1_112_129_Liver enlargement	Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.
CID	2425813_D011239_1_218_230_prednisolone_D009133_1_134_148_muscle wastage	Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.
UN	2435991_C032151_0_40_51_cibenzoline_D001145_0_62_85_ventricular arrhythmias	Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.
UN	2435991_C032151_2_331_342_Cibenzoline_D001145_2_362_373_arrhythmias	Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).
UN	2435991_C032151_5_991_1002_cibenzoline_D003866_5_1044_1054_depressive	Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.
UN	2435991_C032151_5_991_1002_cibenzoline_D007022_5_1017_1028_hypotensive	Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.
CID	2435991_D004071_1_123_132_digitalis_D001145_1_165_188_ventricular arrhythmias	Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.
CID	2435991_D004837_1_139_149_adrenaline_D001145_1_165_188_ventricular arrhythmias	Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.
CID	2435991_D004837_3_731_741_adrenaline_D001145_3_750_760_arrhythmia	The concentration for adrenaline-induced arrhythmia was significantly higher than those for the other types of arrhythmias.
CID	2440413_C034818_4_932_986_methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate_D012640_4_857_864_seizure	Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.
UN	2440413_D001556_1_375_384_gamma-HCH_D012640_1_343_351_seizures	Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).
UN	2440413_D001556_8_1657_1666_gamma-HCH_D012640_8_1629_1636_seizure	The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.
UN	2440413_D001556_7_1471_1480_gamma-HCH_D012640_7_1420_1427_seizure	The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.
UN	2440413_D001556_0_53_60_lindane_D012640_0_91_99_seizures	Differential effects of gamma-hexachlorocyclohexane (lindane) on pharmacologically-induced seizures.
CID	2440413_D001640_4_913_924_bicuculline_D012640_4_857_864_seizure	Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.
UN	2440413_D005680_8_1678_1682_GABA_D012640_8_1629_1636_seizure	The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.
CID	2440413_D010433_4_794_797_PTZ_D012640_4_770_777_Seizure	Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.
CID	2440413_D010433_1_331_334_PTZ_D012640_1_343_351_seizures	Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).
CID	2440413_D010433_7_1448_1451_PTZ_D012640_7_1420_1427_seizure	The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.
CID	2440413_D010852_4_802_812_picrotoxin_D012640_4_770_777_Seizure	Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.
CID	2440413_D010852_7_1456_1459_PTX_D012640_7_1420_1427_seizure	The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.
CID	2440413_D013331_4_998_1008_strychnine_D012640_4_857_864_seizure	Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.
CID	2440413_D015097_4_881_905_3-mercaptopropionic acid_D012640_4_857_864_seizure	Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.
CID	2445283_D012254_5_479_488_ribavirin_D000740_5_548_554_anemia	From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.
UN	2445283_D012254_6_651_660_ribavirin_D006478_6_688_691_AHF	The possible beneficial effect of ribavirin during the initial days of AHF is discussed.
UN	2445283_D012254_0_34_43_ribavirin_D006478_0_61_88_Argentine hemorrhagic fever	Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.
UN	2445283_D012254_1_124_133_ribavirin_D006478_1_165_192_Argentine hemorrhagic fever	Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.
UN	2445283_D012254_5_479_488_ribavirin_D006478_5_534_537_AHF	From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.
UN	2445283_D012254_2_251_260_ribavirin_D014766_2_293_300_viremia	Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.
CID	2466960_D005472_4_618_622_5-FU_D000787_4_603_609_angina	Anginal episodes were rare: only one patient had angina (during 5-FU infusion).
UN	2466960_D005472_9_1348_1352_5-FU_D003324_9_1492_1515_coronary artery disease	We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.
CID	2466960_D005472_6_921_925_5-FU_D007511_6_855_863_ischemic	The incidence of ischemic episodes per patient per hour was 0.05 +/- 0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).
CID	2466960_D005472_9_1348_1352_5-FU_D007511_9_1449_1457_ischemia	We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.
CID	2466960_D005472_2_347_351_5-FU_D007511_2_427_435_ischemic	We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.
UN	2466960_D005472_2_347_351_5-FU_D009369_2_384_390_tumors	We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.
UN	2466960_D005472_1_166_178_fluorouracil_D066126_1_133_149_cardiac toxicity	Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.
CID	2476560_D001556_3_361_368_lindane_D000741_3_439_455_aplastic anaemia	Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.
CID	2476560_D001556_3_361_368_lindane_D002493_3_376_411_toxic to the central nervous system	Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.
UN	2476560_D001556_1_122_129_lindane_D012532_1_53_60_scabies	Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.
UN	2484011_D000547_4_502_512_amantadine_D003866_4_513_522_depressed	The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive.
CID	2484011_D000547_12_2047_2057_amantadine_D011596_12_2015_2036_behavioral depression	The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.
UN	2484011_D000588_12_1803_1809_amines_D011596_12_2015_2036_behavioral depression	The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.
UN	2484011_D002395_12_1864_1877_catecholamine_D011596_12_2015_2036_behavioral depression	The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.
UN	2484011_D009638_12_1976_1990_norepinephrine_D011596_12_2015_2036_behavioral depression	The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.
CID	2505783_C004656_2_349_352_CAA_D003556_2_375_395_hemorrhagic cystitis	Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.
CID	2505783_C004656_2_349_352_CAA_D006470_2_375_395_hemorrhagic cystitis	Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.
CID	2515254_D005996_5_617_630_nitroglycerin_D008881_5_589_597_migraine	Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.
CID	2515254_D005996_2_288_301_nitroglycerin_D008881_2_255_263_migraine	Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group.
CID	2515254_D005996_1_156_169_nitroglycerin_D008881_1_87_95_migraine	Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.
UN	2515254_D005996_5_617_630_nitroglycerin_D010146_5_693_697_pain	Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.
CID	2522601_D002220_1_167_180_carbamazepine_D003873_1_208_220_erythroderma	We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.
CID	2522601_D002220_1_167_180_carbamazepine_D004342_1_147_163_hypersensitivity	We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.
CID	2522601_D002220_0_20_33_carbamazepine_D004342_0_0_16_Hypersensitivity	Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.
UN	2522601_D002220_0_20_33_carbamazepine_D004802_0_72_84_eosinophilia	Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.
CID	2522601_D002220_1_167_180_carbamazepine_D007010_1_265_277_hyponatremia	We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.
CID	2522601_D002220_0_20_33_carbamazepine_D007955_0_52_70_leukemoid reaction	Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.
CID	2522601_D002220_1_167_180_carbamazepine_D051437_1_283_296_renal failure	We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.
CID	2522601_D002220_0_20_33_carbamazepine_D051437_0_104_117_renal failure	Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.
UN	2533791_D017325_3_553_572_hepatitis B vaccine_D006509_3_470_481_hepatitis B	These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.
UN	2549018_D000928_5_972_986_antidepressant_D017109_5_948_957_akathisia	The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced "jitteriness" may be identical.
UN	2549018_D005473_2_208_218_fluoxetine_D001008_2_325_332_anxiety	The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.
UN	2549018_D005473_1_93_103_fluoxetine_D003865_1_158_174_major depression	Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.
UN	2549018_D005473_1_93_103_fluoxetine_D009771_1_125_154_obsessive compulsive disorder	Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.
CID	2549018_D005473_3_508_518_fluoxetine_D017109_3_527_536_akathisia	Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.
CID	2549018_D005473_4_628_638_fluoxetine_D017109_4_579_588_Akathisia	Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.
CID	2549018_D005473_5_780_790_fluoxetine_D017109_5_799_808_akathisia	The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced "jitteriness" may be identical.
CID	2549018_D005473_5_929_939_fluoxetine_D017109_5_948_957_akathisia	The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced "jitteriness" may be identical.
CID	2549018_D005473_0_0_10_Fluoxetine_D017109_0_19_28_akathisia	Fluoxetine-induced akathisia: clinical and theoretical implications.
UN	2549018_D011433_4_717_728_propranolol_D017109_4_579_588_Akathisia	Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.
UN	2557556_D009020_4_738_746_Morphine_D006930_4_775_787_hyperalgesia	Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.
CID	2557556_D015124_4_799_837_8-bromo cyclic adenosine monophosphate_D006930_4_775_787_hyperalgesia	Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.
CID	2557556_D015232_2_556_572_prostaglandin E2_D006930_2_581_593_hyperalgesia	Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
CID	2559236_D004317_2_257_267_adriamycin_D000419_2_325_336_albuminuria	Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration.
CID	2559236_D004317_1_202_212_adriamycin_D009401_1_213_222_nephrosis	The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.
CID	2559236_D004317_6_986_996_adriamycin_D009401_6_997_1006_nephrosis	Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.
UN	2559236_D004656_7_1016_1025_enalapril_D000419_7_1076_1087_albuminuria	Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4.
UN	2559236_D004656_6_942_951_enalapril_D007674_6_970_982_renal injury	Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.
UN	2559236_D004656_6_942_951_enalapril_D009401_6_997_1006_nephrosis	Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.
CID	2564649_D005283_6_1164_1172_fentanyl_D009127_6_1143_1160_muscular rigidity	It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.
CID	2564649_D005283_0_70_78_fentanyl_D009127_0_87_104_muscular rigidity	Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat.
UN	2564649_D011224_4_938_946_prazosin_D009127_4_746_763_muscular rigidity	Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.
CID	2569282_D015760_9_1447_1457_alfentanil_D009127_9_1466_1481_muscle rigidity	In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.
CID	2569282_D015760_4_623_633_alfentanil_D009127_4_587_602_muscle rigidity	In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.
UN	2569282_D020927_1_180_185_D-MED_D009123_1_210_227_muscle flaccidity	The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.
UN	2569282_D020927_4_568_573_D-MED_D009127_4_587_602_muscle rigidity	In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.
UN	2569282_D020927_9_1431_1436_D-MED_D009127_9_1466_1481_muscle rigidity	In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.
UN	2569282_D020927_11_1682_1687_D-MED_D012021_11_1733_1740_startle	The high-dose D-MED animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)
UN	2569282_D020927_11_1682_1687_D-MED_D018476_11_1710_1718_akinetic	The high-dose D-MED animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)
UN	2572625_C013295_1_200_215_thienodiazepine_D047508_1_104_137_extensive hepatocellular necrosis	We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.
UN	2572625_C013295_1_200_215_thienodiazepine_D056486_1_89_98_hepatitis	We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.
UN	2572625_C084599_1_185_196_clotiazepam_D047508_1_104_137_extensive hepatocellular necrosis	We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.
CID	2572625_C084599_4_569_580_clotiazepam_D056486_4_546_560_hepatotoxicity	This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.
CID	2572625_C084599_0_0_11_Clotiazepam_D056486_0_26_35_hepatitis	Clotiazepam-induced acute hepatitis.
UN	2572625_D001569_4_593_608_benzodiazepines_D056486_4_546_560_hepatotoxicity	This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.
CID	2576810_D000661_2_396_407_amphetamine_D006948_2_416_429_hyperactivity	A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced hyperactivity.
CID	2576810_D009627_3_460_471_nomifensine_D006948_3_435_448_hyperactivity	The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.
CID	2576810_D016666_3_503_514_fluvoxamine_D006948_3_435_448_hyperactivity	The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.
CID	2578334_D001374_0_0_13_5-azacytidine_D011230_0_26_59_initiation induced by carcinogens	5-azacytidine potentiates initiation induced by carcinogens in rat liver.
CID	2578334_D001564_1_364_379_benzo[a]-pyrene_D011230_1_172_206_initiation of carcinogenic process	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).
CID	2578334_D008770_1_393_415_N-methyl-N-nitrosourea_D011230_1_172_206_initiation of carcinogenic process	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).
CID	2578334_D019813_1_431_452_1,2-dimethylhydrazine_D011230_1_172_206_initiation of carcinogenic process	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).
UN	2594614_C045856_2_448_456_BN 52021_D001919_2_545_567_decrease of MBP and HR	Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.
UN	2594614_C045856_4_719_727_BN 52021_D001919_4_825_847_decrease of MBP and HR	When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.
UN	2594614_C045856_0_71_79_BN 52021_D002318_0_104_130_cardiovascular impairments	Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.
UN	2594614_C045856_2_448_456_BN 52021_D007022_2_545_567_decrease of MBP and HR	Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.
UN	2594614_C045856_4_719_727_BN 52021_D007022_4_825_847_decrease of MBP and HR	When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.
CID	2594614_D002045_1_180_191_bupivacaine_D001919_1_241_307_decrease of mean arterial blood pressure (MBP) and heart rate (HR)	Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals respectively).
CID	2594614_D002045_2_483_494_bupivacaine_D001919_2_545_567_decrease of MBP and HR	Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.
CID	2594614_D002045_4_775_786_bupivacaine_D001919_4_825_847_decrease of MBP and HR	When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.
CID	2594614_D002045_2_483_494_bupivacaine_D007022_2_545_567_decrease of MBP and HR	Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.
CID	2594614_D002045_1_180_191_bupivacaine_D007022_1_241_307_decrease of mean arterial blood pressure (MBP) and heart rate (HR)	Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals respectively).
CID	2594614_D002045_4_775_786_bupivacaine_D007022_4_825_847_decrease of MBP and HR	When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.
UN	2594614_D002045_7_1373_1384_bupivacaine_D018376_7_1393_1419_cardiovascular alterations	Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced cardiovascular alterations.
UN	2598570_D000431_5_986_993_alcohol_D001249_5_769_775_asthma	Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).
UN	2598570_D000431_5_986_993_alcohol_D006255_5_755_764_hay fever	Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).
UN	2598570_D007052_6_1143_1152_ibuprofen_D006073_6_1223_1227_gout	Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.
UN	2598570_D007052_6_1143_1152_ibuprofen_D007669_6_1195_1208_kidney stones	Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.
UN	2598570_D007052_6_1143_1152_ibuprofen_D007674_6_1167_1180_renal disease	Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.
CID	2598570_D013496_0_55_63_suprofen_D021501_0_30_40_flank pain	The epidemiology of the acute flank pain syndrome from suprofen.
CID	26094_D008750_4_567_578_methyl dopa_D003866_4_542_553_depressions	This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.
UN	2611118_D004008_3_436_453_diclofenac sodium_D006521_3_381_405_chronic active hepatitis	The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.
UN	2611118_D004008_0_41_58_diclofenac sodium_D006521_0_0_24_Chronic active hepatitis	Chronic active hepatitis associated with diclofenac sodium therapy.
CID	2611118_D004008_2_337_347_diclofenac_D056486_2_316_325_hepatitis	Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.
UN	2632720_D006854_2_246_254_cortisol_D006973_2_366_378_hypertension	In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.
UN	2632720_D007654_1_154_166_ketoconazole_D003480_1_101_119_Cushing's syndrome	Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.
CID	2632720_D007654_1_154_166_ketoconazole_D006973_1_187_199_hypertension	Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.
CID	2632720_D007654_0_53_65_ketoconazole_D006973_0_9_21_hypertension	Arterial hypertension as a complication of prolonged ketoconazole treatment.
CID	2632720_D007654_5_770_782_ketoconazole_D006973_5_847_859_hypertension	Our findings show that long-term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid-related hypertension.
UN	2670794_D000809_0_27_38_angiotensin_D004211_0_113_138_intravascular coagulation	Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.
UN	2670794_D000809_0_27_38_angiotensin_D011665_0_72_105_pulmonary and renal insufficiency	Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.
UN	2670794_D000809_0_27_38_angiotensin_D051437_0_72_105_pulmonary and renal insufficiency	Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.
UN	2670794_D002216_0_58_67_Captopril_D004211_0_113_138_intravascular coagulation	Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.
UN	2670794_D002216_8_1228_1237_Captopril_D007674_8_1504_1517_kidney damage	Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less kidney damage will be produced.
UN	2670794_D002216_5_856_865_Captopril_D007674_5_763_775_Renal damage	Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.
UN	2670794_D002216_0_58_67_Captopril_D011665_0_72_105_pulmonary and renal insufficiency	Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.
UN	2670794_D002216_0_58_67_Captopril_D051437_0_72_105_pulmonary and renal insufficiency	Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.
CID	2670794_D014148_1_250_265_tranexamic acid_D004211_1_164_189_intravascular coagulation	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.
UN	2670794_D014148_1_267_271_AMCA_D011665_1_298_331_pulmonary and renal insufficiency	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.
UN	2670794_D014148_1_250_265_tranexamic acid_D014947_1_364_370_trauma	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.
UN	2670794_D014148_1_250_265_tranexamic acid_D018805_1_374_380_sepsis	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.
UN	2670794_D014148_1_267_271_AMCA_D051437_1_298_331_pulmonary and renal insufficiency	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.
UN	2670794_D014508_5_813_817_urea_D007674_5_763_775_Renal damage	Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.
UN	2673163_D003042_6_880_887_cocaine_D001165_6_949_976_arteriovenous malformations	These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.
UN	2673163_D003042_6_880_887_cocaine_D002532_6_922_944_intracranial aneurysms	These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.
CID	2673163_D003042_6_989_996_cocaine_D002544_6_1073_1092_cerebral infarction	These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.
CID	2696505_D007741_1_103_112_labetalol_D007022_1_121_132_hypotension	In a randomized study, labetalol-induced hypotension and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.
CID	2696505_D007741_0_27_36_labetalol_D007022_0_67_78_hypotension	A randomized comparison of labetalol and nitroprusside for induced hypotension.
UN	2696505_D009599_3_611_624_nitroprusside_D006973_3_542_554_hypertension	Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.
CID	2696505_D009599_0_41_54_nitroprusside_D007022_0_67_78_hypotension	A randomized comparison of labetalol and nitroprusside for induced hypotension.
CID	2696505_D009599_1_137_150_nitroprusside_D007022_1_121_132_hypotension	In a randomized study, labetalol-induced hypotension and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.
CID	2696505_D009599_3_611_624_nitroprusside_D016534_3_491_532_increase in heart rate and cardiac output	Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.
UN	2709684_D005839_5_848_858_gentamicin_D003920_5_843_845_DM	Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).
UN	2709684_D005839_2_350_360_gentamicin_D003920_2_395_403_diabetic	The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).
UN	2709684_D005839_0_46_56_gentamicin_D006029_0_18_28_glycosuria	Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.
UN	2709684_D005839_8_1288_1298_gentamicin_D009956_8_1412_1428_tubular necrosis	In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).
CID	2709684_D005839_1_284_294_gentamicin_D058186_1_303_322_acute renal failure	Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).
CID	2709684_D005839_8_1288_1298_gentamicin_D058186_8_1299_1302_ARF	In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).
UN	2709684_D005947_2_469_476_glucose_D003920_2_395_403_diabetic	The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).
UN	2709684_D005947_2_469_476_glucose_D007674_2_361_375_nephrotoxicity	The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).
UN	2709684_D010695_2_495_504_phlorizin_D003920_2_395_403_diabetic	The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).
UN	2709684_D010695_7_1012_1013_P_D006029_7_1044_1054_glycosuria	In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).
UN	2709684_D010695_3_573_574_P_D006029_3_528_538_glycosuria	DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.
UN	2709684_D010695_0_0_9_Phlorizin_D006029_0_18_28_glycosuria	Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.
UN	2709684_D010695_0_0_9_Phlorizin_D007674_0_57_71_nephrotoxicity	Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.
UN	2709684_D010695_8_1342_1343_P_D009956_8_1412_1428_tubular necrosis	In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).
UN	2709684_D010695_7_1012_1013_P_D009956_7_1214_1230_tubular necrosis	In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).
UN	2709684_D010695_9_1536_1537_P_D009956_9_1598_1614_tubular necrosis	These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)
UN	2709684_D010695_8_1270_1271_P_D058186_8_1299_1302_ARF	In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).
CID	2709684_D013311_1_99_113_streptozotocin_D003920_1_122_139_diabetes mellitus	Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).
UN	2709684_D013311_1_99_113_streptozotocin_D006029_1_174_184_glycosuria	Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).
UN	2709684_D013311_1_99_113_streptozotocin_D058186_1_303_322_acute renal failure	Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).
UN	2716967_D007649_1_168_176_ketamine_D000699_1_198_207_analgesia	Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.
CID	2716967_D007649_2_369_377_ketamine_D002375_2_403_413_cataleptic	Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.
CID	2716967_D007649_0_37_45_ketamine_D002375_0_0_9_Catalepsy	Catalepsy induced by combinations of ketamine and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat.
CID	2716967_D007649_1_168_176_ketamine_D002375_1_212_221_catalepsy	Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.
UN	2716967_D007649_5_939_947_ketamine_D009127_5_865_873_rigidity	Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination.
UN	2716967_D009020_1_181_189_morphine_D000699_1_198_207_analgesia	Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.
CID	2716967_D009020_1_181_189_morphine_D002375_1_212_221_catalepsy	Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.
CID	2716967_D009020_0_50_58_morphine_D002375_0_0_9_Catalepsy	Catalepsy induced by combinations of ketamine and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat.
UN	2716967_D009020_5_951_959_morphine_D009127_5_865_873_rigidity	Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination.
UN	2716967_D009270_6_981_989_Naloxone_D002375_6_1012_1022_cataleptic	Naloxone inhibited the induced cataleptic effects.
UN	2716967_D009270_9_1649_1657_naloxone_D009127_9_1565_1573_rigidity	While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.
CID	2722224_D006854_0_0_14_Hydrocortisone_D006973_0_23_35_hypertension	Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function.
CID	2722224_D006854_9_1722_1736_hydrocortisone_D006973_9_1686_1716_rise in resting blood pressure	The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS)
UN	2722224_D006854_9_1722_1736_hydrocortisone_D016534_9_1759_1783_increased cardiac output	The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS)
CID	2750819_D008278_0_28_45_magnesium sulfate_D020879_0_0_22_Neuromuscular blockade	Neuromuscular blockade with magnesium sulfate and nifedipine.
CID	2750819_D008278_1_160_177_magnesium sulfate_D020879_1_121_143_neuromuscular blockade	A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.
CID	2750819_D009543_0_50_60_nifedipine_D020879_0_0_22_Neuromuscular blockade	Neuromuscular blockade with magnesium sulfate and nifedipine.
CID	2750819_D009543_1_100_110_nifedipine_D020879_1_121_143_neuromuscular blockade	A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.
UN	2790457_D002220_6_862_865_CBZ_D012640_6_890_897_seizure	The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.
UN	2790457_D002220_0_8_21_carbamazepine_D012640_0_67_75_seizures	Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.
UN	2790457_D002220_1_140_143_CBZ_D012640_1_183_191_seizures	The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.
UN	2790457_D002220_3_488_491_CBZ_D012640_3_524_531_seizure	Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.
CID	2790457_D003042_0_87_94_cocaine_D012640_0_67_75_seizures	Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.
CID	2790457_D003042_5_808_815_cocaine_D012640_5_824_832_seizures	Repeated i.p. injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.
CID	2790457_D003042_3_557_564_cocaine_D012640_3_524_531_seizure	Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.
CID	2790457_D003042_4_680_687_cocaine_D012640_4_696_704_seizures	Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.
CID	2790457_D003042_2_382_389_cocaine_D012640_2_398_406_seizures	Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.
CID	2790457_D008012_2_367_376_lidocaine_D012640_2_398_406_seizures	Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.
CID	2790457_D008012_0_99_108_lidocaine_D012640_0_67_75_seizures	Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.
CID	2790457_D008012_5_794_803_lidocaine_D012640_5_824_832_seizures	Repeated i.p. injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.
CID	2790457_D008012_4_653_662_lidocaine_D012640_4_696_704_seizures	Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.
CID	2802551_D000666_0_33_47_amphotericin B_D007674_0_48_62_nephrotoxicity	Sodium status influences chronic amphotericin B nephrotoxicity in rats.
CID	2802551_D000666_1_101_115_amphotericin B_D007674_1_76_87_nephrotoxic	The nephrotoxic potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been investigated in salt-depleted, normal-salt, and salt-loaded rats.
UN	2802551_D012964_0_0_6_Sodium_D007674_0_48_62_nephrotoxicity	Sodium status influences chronic amphotericin B nephrotoxicity in rats.
UN	2826064_D010096_2_278_288_oxprenolol_D007008_2_310_321_hypokalemia	Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.
UN	2826064_D010096_0_64_74_oxprenolol_D007008_0_29_40_hypokalemia	Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.
CID	2826064_D013726_1_133_144_terbutaline_D007008_1_153_164_hypokalemia	The time course and concentration-effect relationship of terbutaline-induced hypokalemia was studied, using computer-aided pharmacokinetic-dynamic modeling.
UN	2840807_D000324_3_580_584_ACTH_D003866_3_788_798_depression	However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.
CID	2840807_D000324_0_49_53_ACTH_D004421_0_2_10_dystonia	A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.
UN	2840807_D000324_3_580_584_ACTH_D009069_3_900_917_movement disorder	However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.
CID	2840807_D009074_0_45_48_MSH_D004421_0_2_10_dystonia	A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.
UN	2870085_C047847_10_1197_1206_flestolol_D000789_10_1180_1195_unstable angina	In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.
UN	2870085_C047847_10_1197_1206_flestolol_D002637_10_1266_1276_chest pain	In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.
UN	2870085_C047847_6_726_735_Flestolol_D013610_6_799_810_tachycardia	Flestolol produced a dose-dependent attenuation of isoproterenol-induced tachycardia.
UN	2870085_C047847_9_1071_1080_Flestolol_D013617_9_1129_1161_supraventricular tachyarrhythmia	Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.
CID	2870085_D007545_6_777_790_isoproterenol_D013610_6_799_810_tachycardia	Flestolol produced a dose-dependent attenuation of isoproterenol-induced tachycardia.
CID	2886572_D004837_0_55_66_epinephrine_D006973_0_75_87_hypertensive	Enhanced stimulus-induced neurotransmitter overflow in epinephrine-induced hypertensive rats is not mediated by prejunctional beta-adrenoceptor activation.
UN	2887062_D001971_9_1524_1537_bromocriptine_D000236_9_1555_1562_adenoma	However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.
UN	2887062_D001971_1_162_175_bromocriptine_D015175_1_179_191_prolactinoma	To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).
UN	2887062_D001971_0_111_124_bromocriptine_D015175_0_91_104_prolactinomas	Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.
CID	2887062_D004967_1_288_296_estrogen_D015175_1_309_321_prolactinoma	To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).
CID	2887062_D004967_0_70_78_estrogen_D015175_0_91_104_prolactinomas	Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.
UN	2893236_C005151_3_541_558_thiosemicarbazide_D012131_3_701_719_respiratory arrest	Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental. 50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.
UN	2893236_D000596_3_836_847_amino acids_D012131_3_701_719_respiratory arrest	Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental. 50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.
UN	2893236_D001224_2_436_445_aspartate_D012133_2_244_265_respiratory paralysis	In this study naloxone reversed respiratory paralysis induced by thiopental in rats. 25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.
UN	2893236_D005680_3_745_749_GABA_D012131_3_701_719_respiratory arrest	Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental. 50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.
UN	2893236_D005680_0_0_4_GABA_D012133_0_49_70_respiratory paralysis	GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.
UN	2893236_D005680_5_1151_1155_GABA_D012133_5_1093_1114_respiratory paralysis	These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.
UN	2893236_D005998_2_449_456_glycine_D012133_2_244_265_respiratory paralysis	In this study naloxone reversed respiratory paralysis induced by thiopental in rats. 25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.
UN	2893236_D009270_5_1075_1083_naloxone_D012133_5_1093_1114_respiratory paralysis	These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.
UN	2893236_D009270_2_226_234_naloxone_D012133_2_244_265_respiratory paralysis	In this study naloxone reversed respiratory paralysis induced by thiopental in rats. 25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.
UN	2893236_D009270_0_20_28_naloxone_D012133_0_49_70_respiratory paralysis	GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.
CID	2893236_D013874_5_1127_1137_thiopental_D012133_5_1093_1114_respiratory paralysis	These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.
CID	2893236_D013874_0_83_93_thiopental_D012133_0_49_70_respiratory paralysis	GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.
CID	2893236_D013874_2_277_287_thiopental_D012133_2_244_265_respiratory paralysis	In this study naloxone reversed respiratory paralysis induced by thiopental in rats. 25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.
UN	2893236_D018698_3_766_775_glutamate_D012131_3_701_719_respiratory arrest	Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental. 50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.
UN	2893236_D018698_4_945_954_glutamate_D012133_4_922_943_respiratory paralysis	Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.
UN	2894433_D002712_6_935_943_chloride_D001919_6_1030_1041_bradycardia	The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.
CID	2894433_D003975_5_588_596_diazepam_D001919_5_638_649_bradycardia	However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).
CID	2894433_D003975_0_0_8_Diazepam_D001919_0_28_39_bradycardia	Diazepam facilitates reflex bradycardia in conscious rats.
CID	2894433_D004837_3_360_370_adrenaline_D001919_3_300_311_bradycardia	Also, reflex bradycardia was produced in rats by intravenous infusion of adrenaline (1.25-2.5 micrograms kg-1).
CID	2894433_D004837_4_536_546_adrenaline_D001919_4_562_573_bradycardia	Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.
CID	2894433_D004837_5_612_622_adrenaline_D001919_5_638_649_bradycardia	However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).
UN	2894433_D005680_6_930_934_GABA_D001919_6_1030_1041_bradycardia	The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.
UN	2894433_D010852_5_718_728_picrotoxin_D001919_5_638_649_bradycardia	However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).
CID	2894766_D012460_1_222_235_sulfasalazine_D002305_1_115_132_cardiac tamponade	Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.
UN	2894766_D012460_1_222_235_sulfasalazine_D003093_1_256_274_ulcerative colitis	Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.
CID	2894766_D012460_0_0_13_Sulfasalazine_D008180_0_22_41_lupus erythematosus	Sulfasalazine-induced lupus erythematosus.
CID	2894766_D012460_4_715_728_sulfasalazine_D008180_4_737_751_lupus syndrome	Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.
CID	2894766_D012460_3_467_480_sulfasalazine_D008180_3_489_494_lupus	It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.
CID	2894766_D012460_1_222_235_sulfasalazine_D010996_1_66_83_pleural effusions	Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.
CID	2894766_D012460_1_222_235_sulfasalazine_D011014_1_43_54_Pneumonitis	Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.
UN	2894766_D012460_3_467_480_sulfasalazine_D012700_3_518_527_serositis	It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.
UN	2894766_D012460_4_619_632_sulfasalazine_D015212_4_656_682_inflammatory bowel disease	Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.
UN	28952_D002752_0_47_61_chlorthalidone_D006973_0_104_116_hypertension	Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.
CID	28952_D002752_0_47_61_chlorthalidone_D007008_0_27_39_hypokalaemia	Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.
UN	28952_D011188_0_8_17_potassium_D006973_0_104_116_hypertension	Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.
UN	28952_D011188_1_190_199_potassium_D006973_1_356_368_hypertension	To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.
UN	28952_D011188_1_190_199_potassium_D007008_1_224_236_hypokalaemia	To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.
UN	28952_D011188_0_8_17_potassium_D007008_0_27_39_hypokalaemia	Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.
UN	28952_D012964_0_143_149_sodium_D006973_0_104_116_hypertension	Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.
UN	28952_D012964_0_143_149_sodium_D007008_0_27_39_hypokalaemia	Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.
UN	2907585_D002065_1_112_121_buspirone_D002375_1_132_141_catalepsy	The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.
UN	2907585_D002065_2_207_216_buspirone_D002375_2_321_330_catalepsy	A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.
CID	2907585_D006220_2_301_312_haloperidol_D002375_2_321_330_catalepsy	A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.
CID	2907585_D006220_1_153_164_haloperidol_D002375_1_132_141_catalepsy	The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.
UN	2907585_D012701_5_549_553_5-HT_D002375_5_610_619_catalepsy	However, inhibition of postsynaptic 5-HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect.
UN	2907585_D012701_3_369_388_5-hydroxytryptamine_D002375_3_422_431_catalepsy	Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse catalepsy.
UN	2907585_D058825_2_227_259_5-hydroxytryptaminergic agonists_D002375_2_321_330_catalepsy	A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.
CID	2917114_D004491_4_660_671_edrophonium_D001919_4_680_692_bradycardias	Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.
UN	2917114_D006024_4_510_524_glycopyrronium_D001919_4_680_692_bradycardias	Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.
UN	2924746_D002220_5_716_719_CBZ_D012640_5_725_733_seizures	Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).
UN	2924746_D002220_6_796_799_CBZ_D015430_6_955_966_weight gain	Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.
CID	2924746_D005481_5_621_644_hexafluorodiethyl ether_D012640_5_601_609_Seizures	Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).
CID	2924746_D005481_6_894_898_HFDE_D012640_6_907_915_seizures	Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.
UN	2924746_D005481_6_894_898_HFDE_D015430_6_955_966_weight gain	Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.
UN	2924746_D019946_4_463_479_propylene glycol_D012640_4_565_573_seizures	In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.
UN	2924746_D019946_4_463_479_propylene glycol_D015430_4_588_599_weight gain	In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.
CID	2950248_D004176_1_129_141_dipyridamole_D000787_1_42_48_Angina	Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.
UN	2950248_D004176_2_336_348_dipyridamole_D003324_2_435_458_coronary artery disease	To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.
UN	2950248_D004176_3_597_609_dipyridamole_D007511_3_618_626_ischemia	Epicardial coronary collateral vessels were demonstrated in all four patients; a coronary "steal" phenomenon may be the mechanism of the dipyridamole-induced ischemia observed.
CID	2951327_D005996_2_772_785_nitroglycerin_D007022_2_734_745_hypotension	Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.
UN	2951327_D005996_2_772_785_nitroglycerin_D013610_2_588_599_tachycardia	Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.
CID	2951327_D006830_2_757_768_hydralazine_D007022_2_734_745_hypotension	Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.
UN	2951327_D006830_2_757_768_hydralazine_D013610_2_588_599_tachycardia	Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.
UN	2951327_D009638_2_627_641_norepinephrine_D007022_2_734_745_hypotension	Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.
UN	2951327_D009638_2_627_641_norepinephrine_D013610_2_588_599_tachycardia	Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.
UN	2980315_C053571_4_508_516_iopentol_D014693_4_433_457_ventricular fibrillation	Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).
UN	2980315_D007472_4_526_533_iohexol_D014693_4_433_457_ventricular fibrillation	Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).
CID	2980315_D008794_4_550_560_metrizoate_D014693_4_433_457_ventricular fibrillation	Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).
CID	3001299_D008094_1_232_239_lithium_D007037_1_210_224_hypothyroidism	It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.
CID	3001299_D008094_3_454_461_lithium_D007037_3_388_402_Hypothyroidism	Hypothyroidism developed in eight patients while they were taking lithium.
UN	3001299_D008094_1_232_239_lithium_D018500_1_175_205_nephrogenic diabetes insipidus	It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.
CID	3015327_D007538_1_122_131_isoniazid_D009422_1_84_94_neuropathy	The neuropathy caused by a single dose of isoniazid in rats was studied with a computer-assisted morphometric method.
CID	3015327_D007538_0_47_56_isoniazid_D009422_0_57_67_neuropathy	Remodelling of nerve structure in experimental isoniazid neuropathy in the rat.
UN	3015567_D003345_5_1048_1062_corticosterone_D007022_5_1001_1012_hypotension	Suppression of irCRF secretion in response to nitroprusside-induced hypotension is observed and occurs at a plasma corticosterone level between 8-12 micrograms/dl.
CID	3015567_D009599_1_146_159_Nitroprusside_D007022_1_168_179_hypotension	Nitroprusside-induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation.
CID	3015567_D009599_5_979_992_nitroprusside_D007022_5_1001_1012_hypotension	Suppression of irCRF secretion in response to nitroprusside-induced hypotension is observed and occurs at a plasma corticosterone level between 8-12 micrograms/dl.
CID	3031535_D006220_4_984_995_haloperidol_D002375_4_963_972_catalepsy	These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.
CID	3031535_D013759_4_912_915_THC_D002375_4_891_900_catalepsy	These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.
CID	3031535_D013759_0_50_78_delta 9-tetrahydrocannabinol_D002375_0_29_38_catalepsy	Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.
UN	3057041_C020976_0_87_97_azelastine_D006255_0_149_173_spring allergic rhinitis	Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.
UN	3057041_C020976_14_2132_2142_Azelastine_D006255_14_2192_2218_seasonal allergic rhinitis	Azelastine appears to be a safe, efficacious medication for seasonal allergic rhinitis.
CID	3057041_C020976_13_2114_2124_azelastine_D006970_13_2010_2020_Drowsiness	Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.
CID	3057041_C020976_13_2114_2124_azelastine_D013651_13_2025_2049_altered taste perception	Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.
UN	3057041_D002744_0_99_115_chlorpheniramine_D006255_0_149_173_spring allergic rhinitis	Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.
UN	3057041_D002744_1_238_262_chlorpheniramine maleate_D006255_1_319_343_spring allergic rhinitis	Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.
UN	3070035_D002216_1_294_303_captopril_D006973_1_151_163_hypertension	We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.
UN	3070035_D002216_0_17_26_captopril_D006978_0_97_122_renovascular hypertension	Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.
CID	3070035_D002216_1_294_303_captopril_D058186_1_230_268_sudden deterioration of renal function	We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.
CID	3076126_D008148_12_1445_1455_lovastatin_D009212_12_1355_1368_myoglobinuria	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.
CID	3076126_D008148_12_1445_1455_lovastatin_D051437_12_1400_1413_renal failure	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.
CID	3076126_D009525_12_1535_1541_niacin_D009135_12_1315_1323_Myopathy	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.
UN	3076126_D009525_12_1535_1541_niacin_D009212_12_1355_1368_myoglobinuria	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.
UN	3076126_D009525_12_1535_1541_niacin_D051437_12_1400_1413_renal failure	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.
CID	3076126_D015248_12_1520_1531_gemfibrozil_D009135_12_1315_1323_Myopathy	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.
UN	3076126_D015248_12_1520_1531_gemfibrozil_D009212_12_1355_1368_myoglobinuria	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.
UN	3076126_D015248_12_1520_1531_gemfibrozil_D051437_12_1400_1413_renal failure	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.
CID	3076126_D016572_12_1507_1518_cyclosporin_D009135_12_1315_1323_Myopathy	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.
UN	3076126_D016572_12_1507_1518_cyclosporin_D009212_12_1355_1368_myoglobinuria	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.
UN	3076126_D016572_12_1507_1518_cyclosporin_D051437_12_1400_1413_renal failure	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.
CID	3084782_D006046_3_499_503_gold_D003872_3_481_491_dermatitis	A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.
UN	3084782_D006046_3_499_503_gold_D009393_3_363_372_nephritis	A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.
UN	3084782_D008625_4_625_634_Tiopronin_D001172_4_607_609_RA	Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.
CID	3084782_D008625_3_395_404_Tiopronin_D003872_3_377_387_dermatitis	A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.
CID	3084782_D008625_4_625_634_Tiopronin_D009393_4_643_652_nephritis	Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.
CID	3084782_D008625_3_395_404_Tiopronin_D009393_3_363_372_nephritis	A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.
UN	3084782_D010396_3_408_423_D-Penicillamine_D003872_3_377_387_dermatitis	A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.
UN	3084782_D010396_3_408_423_D-Penicillamine_D009393_3_363_372_nephritis	A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.
CID	3088349_D000661_2_468_479_amphetamine_D009069_2_488_507_rotational behavior	In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.
CID	3088349_D000661_6_1115_1126_amphetamine_D009069_6_1135_1143_rotation	However, regardless of the duration of recovery (and irrespective of either lesion volume, amphetamine dose, or post-lesion motor exercise), amphetamine-induced rotation tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further amphetamine injections.
UN	3088349_D016627_1_181_187_6-OHDA_D009069_1_229_251_contralateral rotation	Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.
UN	3101906_D007654_13_1396_1408_ketoconazole_D003643_13_1364_1370_deaths	In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.
CID	3101906_D007654_13_1396_1408_ketoconazole_D007565_13_1466_1474_jaundice	In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.
CID	3101906_D007654_14_1634_1646_ketoconazole_D056486_14_1675_1689_hepatic injury	Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.
UN	3107448_D005905_3_340_349_glyburide_D003924_3_246_271_type II diabetes mellitus	Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.
CID	3107448_D005905_3_340_349_glyburide_D056486_3_285_314_acute hepatitis-like syndrome	Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.
CID	3107448_D005905_6_627_636_Glyburide_D056486_6_652_680_acute hepatitis-like illness	Glyburide can produce an acute hepatitis-like illness in some persons.
CID	3107448_D005905_0_0_9_Glyburide_D056486_0_18_27_hepatitis	Glyburide-induced hepatitis.
CID	3108839_D016685_1_50_61_Mitomycin C_D006463_1_73_98_Hemolytic Uremic Syndrome	Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.
CID	3108839_D016685_0_0_11_Mitomycin C_D006463_0_23_48_hemolytic uremic syndrome	Mitomycin C associated hemolytic uremic syndrome.
UN	3108839_D016685_6_1038_1049_mitomycin C_D011654_6_1062_1077_pulmonary edema	We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.
UN	3108839_D016685_6_1038_1049_mitomycin C_D013274_6_942_964_gastric adenocarcinoma	We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.
CID	3108839_D016685_2_299_310_mitomycin C_D051437_2_269_282_renal failure	It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.
CID	3108839_D016685_3_445_456_mitomycin C_D051437_3_511_524_renal failure	The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.
CID	3108839_D016685_6_1038_1049_mitomycin C_D051437_6_979_992_renal failure	We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.
UN	3115150_D002707_4_646_662_Chlordiazepoxide_D009127_4_725_733_rigidity	Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.
UN	3115150_D007650_0_0_10_Ketanserin_D009127_0_52_67_muscle rigidity	Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.
UN	3115150_D012701_8_1402_1411_serotonin_D002318_8_1584_1626_cardiovascular, and respiratory depression	Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.
UN	3115150_D012701_8_1402_1411_serotonin_D009127_8_1479_1487_rigidity	Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.
UN	3115150_D012701_1_137_146_serotonin_D009127_1_197_212_muscle rigidity	Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.
UN	3115150_D012701_8_1402_1411_serotonin_D012131_8_1584_1626_cardiovascular, and respiratory depression	Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.
CID	3115150_D015760_0_33_43_alfentanil_D009127_0_52_67_muscle rigidity	Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.
CID	3115150_D015760_4_746_756_alfentanil_D009127_4_725_733_rigidity	Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.
CID	3123611_D000661_3_278_289_amphetamine_D002819_3_298_304_chorea	The third patient had acute amphetamine-induced chorea after prolonged oral contraception.
CID	3123611_D003276_3_321_339_oral contraception_D002819_3_298_304_chorea	The third patient had acute amphetamine-induced chorea after prolonged oral contraception.
CID	3123611_D003276_0_23_41_oral contraception_D002819_0_0_6_Chorea	Chorea associated with oral contraception.
CID	3123611_D003276_1_91_110_oral contraceptives_D002819_1_68_74_chorea	Three patients developed chorea while receiving oral contraceptives.
UN	3125768_C032943_6_728_738_metocurine_D009127_6_700_708_rigidity	These variables returned to baseline when rigidity was abolished with metocurine.
CID	3125768_D015760_0_39_49_alfentanil_D009127_0_58_66_rigidity	Intracranial pressure increases during alfentanil-induced rigidity.
CID	3125768_D015760_1_116_126_alfentanil_D009127_1_135_143_rigidity	Intracranial pressure (ICP) was measured during alfentanil-induced rigidity in rats.
CID	3125768_D015760_8_895_905_alfentanil_D009127_8_861_869_rigidity	These observations suggest that rigidity should be prevented when alfentanil, and, presumably, other opiates, are used in the anesthetic management of patients with ICP problems.
UN	3131282_C009166_3_830_832_RA_D002277_3_800_809_carcinoma	In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.
UN	3131282_C009166_5_1090_1092_RA_D009369_5_1026_1032_Tumors	Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.
UN	3131282_C009166_5_1090_1092_RA_D010212_5_1038_1048_papillomas	Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.
UN	3131282_C009166_7_1241_1243_RA_D013274_7_1280_1306_forestomach carcinogenesis	These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.
UN	3131282_C009166_0_26_41_retinyl acetate_D013274_0_45_71_forestomach carcinogenesis	Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.
UN	3131282_C009166_4_867_869_RA_D017573_4_1002_1024_epithelial hyperplasia	In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.
UN	3131282_C009166_0_26_41_retinyl acetate_D063646_0_3_15_carcinogenic	Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.
UN	3131282_D002083_3_483_486_BHA_D002277_3_723_732_carcinoma	In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.
UN	3131282_D002083_3_483_486_BHA_D010212_3_695_718_squamous cell papilloma	In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.
CID	3131282_D002083_0_103_127_butylated hydroxyanisole_D013274_0_45_71_forestomach carcinogenesis	Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.
CID	3131282_D002083_7_1276_1279_BHA_D013274_7_1280_1306_forestomach carcinogenesis	These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.
CID	3131282_D002083_1_213_216_BHA_D013274_1_230_255_forestomach tumorigenesis	The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.
UN	3131282_D002083_4_990_993_BHA_D017573_4_1002_1024_epithelial hyperplasia	In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.
UN	3131282_D002083_0_103_127_butylated hydroxyanisole_D063646_0_3_15_carcinogenic	Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.
CID	3137399_D004317_7_772_783_doxorubicin_D006333_7_716_731_cardiac failure	One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.
UN	3137399_D004317_1_201_212_doxorubicin_D066126_1_139_150_cardiotoxic	Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.
CID	3137399_D016685_7_748_751_MMC_D006333_7_716_731_cardiac failure	One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.
UN	3137399_D016685_1_109_112_MMC_D066126_1_139_150_cardiotoxic	Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.
UN	3137399_D016685_0_72_83_mitomycin C_D066126_0_46_60_cardiotoxicity	A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.
UN	3137399_D016685_11_1111_1114_MMC_D066126_11_1123_1137_cardiotoxicity	Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.
UN	3173179_D002216_3_465_474_captopril_D006973_3_554_566_hypertension	We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.
UN	3173179_D002216_3_465_474_captopril_D009203_3_408_429_myocardial infarction	We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.
UN	3173179_D014700_3_497_506_verapamil_D006973_3_554_566_hypertension	We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.
CID	3173179_D014700_0_0_9_Verapamil_D009203_0_44_65_myocardial infarction	Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.
CID	3173180_D008795_0_49_62_metronidazole_D006463_0_0_27_Haemolytic-uraemic syndrome	Haemolytic-uraemic syndrome after treatment with metronidazole.
CID	3173180_D008795_1_190_203_metronidazole_D006463_1_141_168_haemolytic-uraemic syndrome	This paper describes the clinical features of six children who developed the haemolytic-uraemic syndrome after treatment with metronidazole.
CID	3173180_D008795_3_361_374_metronidazole_D006463_3_399_426_haemolytic-uraemic syndrome	While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.
CID	3173180_D008795_3_635_648_metronidazole_D006463_3_575_602_haemolytic-uraemic syndrome	While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.
CID	3183120_C033706_0_44_54_tiazofurin_D001927_0_11_27_cerebral lesions	Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.
CID	3187073_D005472_12_1314_1318_5-FU_D002637_12_1412_1422_chest pain	It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.
UN	3187073_D005472_12_1314_1318_5-FU_D013610_12_1426_1441_tachyarrhythmia	It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.
UN	3220106_D004298_8_1574_1576_DA_D006948_8_1452_1475_locomotor hyperactivity	These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.
CID	3220106_D009538_8_1491_1499_nicotine_D006948_8_1452_1475_locomotor hyperactivity	These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.
CID	3220106_D009538_0_23_31_nicotine_D006948_0_40_63_locomotor hyperactivity	Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats.
CID	3220106_D009538_0_75_83_nicotine_D006948_0_40_63_locomotor hyperactivity	Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats.
UN	322550_D009599_3_580_593_nitroprusside_D002303_3_701_725_decreased cardiac output	Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.
UN	322550_D009599_8_1258_1271_nitroprusside_D002303_8_1423_1478_decreases in arterial blood pressure and cardiac output	During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.
CID	322550_D009599_0_60_73_nitroprusside_D007022_0_82_93_hypotension	Pulmonary shunt and cardiovascular responses to CPAP during nitroprusside-induced hypotension.
CID	322550_D009599_4_737_750_Nitroprusside_D007022_4_770_806_decreases in arterial blood pressure	Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.
CID	322550_D009599_3_580_593_nitroprusside_D007022_3_622_657_decrease in arterial blood pressure	Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.
UN	322550_D014867_3_564_567_H2O_D002303_3_701_725_decreased cardiac output	Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.
UN	322550_D014867_3_564_567_H2O_D007022_3_622_657_decrease in arterial blood pressure	Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.
CID	326460_D001539_0_16_30_bendrofluazide_D007008_0_39_50_hypokalemia	Amelioration of bendrofluazide-induced hypokalemia by timolol.
CID	326460_D001539_1_155_169_bendrofluazide_D007008_1_129_140_hypokalemia	The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.
UN	326460_D013999_0_54_61_timolol_D007008_0_39_50_hypokalemia	Amelioration of bendrofluazide-induced hypokalemia by timolol.
UN	3300918_D002118_4_518_525_calcium_D004881_4_668_686_St. Anthony's fire	Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.
UN	3300918_D002118_4_518_525_calcium_D008881_4_628_636_migraine	Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.
UN	3300918_D004876_4_576_581_ergot_D004881_4_668_686_St. Anthony's fire	Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.
UN	3300918_D004876_3_325_330_ergot_D005734_3_381_389_gangrene	A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.
CID	3300918_D004876_4_576_581_ergot_D008881_4_628_636_migraine	Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.
CID	3300918_D008784_1_193_205_methysergide_D014652_1_93_102_vasospasm	A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.
CID	3311455_D016572_5_834_846_cyclosporine_D007674_5_783_797_nephrotoxicity	Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.
CID	3311455_D016572_7_993_1005_cyclosporine_D007674_7_1024_1038_nephrotoxicity	We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.
UN	3341566_D009599_0_69_89_sodium nitroprusside_D006470_0_46_56_hemorrhage	Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside-induced hypotension in ventilated dogs.
UN	3341566_D009599_7_1184_1187_SNP_D006470_7_1176_1179_HEM	The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).
CID	3341566_D009599_0_69_89_sodium nitroprusside_D007022_0_98_109_hypotension	Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside-induced hypotension in ventilated dogs.
UN	3358181_D010656_6_805_818_phenylephrine_D007022_6_828_839_hypotensive	After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat hypotensive patients with tachycardia.
UN	3358181_D010656_6_805_818_phenylephrine_D013610_6_854_865_tachycardia	After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat hypotensive patients with tachycardia.
UN	3358181_D012312_1_154_163_ritodrine_D007752_1_168_181_preterm labor	This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.
CID	3358181_D012312_0_59_68_ritodrine_D014693_0_0_28_Ventricular tachyarrhythmias	Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.
UN	3371379_D002118_2_219_226_calcium_D020258_2_111_124_neurotoxicity	Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.
CID	3371379_D002220_2_97_110_carbamazepine_D020258_2_111_124_neurotoxicity	Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.
CID	3371379_D002220_0_18_31_carbamazepine_D020258_0_32_45_neurotoxicity	Verapamil-induced carbamazepine neurotoxicity.
CID	3371379_D014700_0_0_9_Verapamil_D020258_0_32_45_neurotoxicity	Verapamil-induced carbamazepine neurotoxicity.
CID	3371379_D014700_2_155_164_verapamil_D020258_2_111_124_neurotoxicity	Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.
CID	33969_C017610_1_183_205_fluphenazine enanthate_D010302_1_159_171_parkinsonism	In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.
UN	33969_C017610_1_183_205_fluphenazine enanthate_D012559_1_212_225_schizophrenic	In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.
UN	33969_C084820_3_618_631_ethopropazine_D001008_3_590_597_anxiety	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.
UN	33969_C084820_3_618_631_ethopropazine_D003866_3_602_612_depression	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.
UN	33969_C084820_3_618_631_ethopropazine_D004409_3_488_506_tardive dyskinesia	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.
UN	33969_C084820_0_0_13_Ethopropazine_D010302_0_53_65_parkinsonism	Ethopropazine and benztropine in neuroleptic-induced parkinsonism.
UN	33969_C084820_1_97_110_ethopropazine_D010302_1_159_171_parkinsonism	In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.
UN	33969_C084820_1_97_110_ethopropazine_D012559_1_212_225_schizophrenic	In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.
CID	33969_D001590_3_429_440_benztropine_D001008_3_590_597_anxiety	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.
CID	33969_D001590_3_429_440_benztropine_D003866_3_602_612_depression	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.
CID	33969_D001590_3_429_440_benztropine_D004409_3_488_506_tardive dyskinesia	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.
UN	33969_D001590_1_127_138_benztropine_D010302_1_159_171_parkinsonism	In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.
UN	33969_D001590_0_18_29_benztropine_D010302_0_53_65_parkinsonism	Ethopropazine and benztropine in neuroleptic-induced parkinsonism.
UN	33969_D001590_2_257_268_benztropine_D010302_2_319_340_parkinsonian symptoms	Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
UN	33969_D001590_1_127_138_benztropine_D012559_1_212_225_schizophrenic	In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.
UN	33969_D011352_3_542_555_procyclindine_D001008_3_590_597_anxiety	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.
UN	33969_D011352_3_542_555_procyclindine_D003866_3_602_612_depression	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.
UN	33969_D011352_3_542_555_procyclindine_D004409_3_488_506_tardive dyskinesia	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.
UN	33969_D011352_2_368_380_procyclidine_D010302_2_319_340_parkinsonian symptoms	Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
CID	3403780_D000082_1_156_167_paracetamol_D000138_1_86_104_metabolic acidosis	A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.
CID	3403780_D000082_0_0_11_Paracetamol_D000138_0_29_47_metabolic acidosis	Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.
UN	3403780_D000082_0_0_11_Paracetamol_D003128_0_23_27_coma	Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.
CID	3403780_D000082_1_156_167_paracetamol_D017114_1_106_145_acute renal failure and hepatic failure	A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.
CID	3403780_D000082_1_156_167_paracetamol_D058186_1_106_145_acute renal failure and hepatic failure	A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.
CID	3409645_D008727_4_642_654_methotrexate_D007172_4_515_524_Impotence	Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.
CID	3411101_C033457_0_0_32_Quinidine phenylethylbarbiturate_D056486_0_51_60_hepatitis	Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.
CID	3411101_C033457_5_458_480_phenylethylbarbiturate_D056486_5_514_523_hepatitis	Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.
UN	3411101_D011802_5_438_447_Quinidine_D056486_5_514_523_hepatitis	Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.
UN	3412544_D000082_1_219_230_paracetamol_D001749_1_121_166_cancer of the renal pelvis, ureter or bladder	The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.
UN	3412544_D000082_1_219_230_paracetamol_D007680_1_121_166_cancer of the renal pelvis, ureter or bladder	The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.
UN	3412544_D000082_3_580_591_paracetamol_D007681_3_608_632_renal papillary necrosis	By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.
UN	3412544_D000082_0_5_16_paracetamol_D007681_0_44_68_renal papillary necrosis	Does paracetamol cause urothelial cancer or renal papillary necrosis?
UN	3412544_D000082_3_580_591_paracetamol_D009369_3_649_656_cancers	By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.
UN	3412544_D000082_1_219_230_paracetamol_D014516_1_121_166_cancer of the renal pelvis, ureter or bladder	The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.
UN	3412544_D000082_0_5_16_paracetamol_D014523_0_23_40_urothelial cancer	Does paracetamol cause urothelial cancer or renal papillary necrosis?
CID	3412544_D010615_1_205_215_phenacetin_D001749_1_121_166_cancer of the renal pelvis, ureter or bladder	The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.
CID	3412544_D010615_1_205_215_phenacetin_D007680_1_121_166_cancer of the renal pelvis, ureter or bladder	The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.
CID	3412544_D010615_2_399_409_phenacetin_D007681_2_327_351_renal papillary necrosis	The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.
UN	3412544_D010615_1_205_215_phenacetin_D014516_1_121_166_cancer of the renal pelvis, ureter or bladder	The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.
UN	3413271_D004837_3_370_381_epinephrine_D000787_3_466_472_angina	Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.
UN	3413271_D004837_1_113_124_epinephrine_D003324_1_188_211_coronary artery disease	The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.
UN	3413271_D004837_3_370_381_epinephrine_D003866_3_451_461_depression	Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.
UN	3413271_D004837_2_315_326_epinephrine_D007511_2_232_240_ischemia	Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.
UN	3413271_D004837_5_766_777_epinephrine_D007511_5_786_794_ischemia	Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.
UN	3413271_D004837_6_973_984_epinephrine_D007511_6_952_960_ischemia	These findings indicate that ischemia produced by epinephrine, as may occur during states of emotional distress, has a mechanism distinct from that due to physical exertion.
CID	3413271_D004837_4_532_543_epinephrine_D017202_4_501_520_myocardial ischemia	However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.
CID	3413271_D004837_0_45_56_epinephrine_D017202_0_14_33_myocardial ischemia	Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.
CID	3413271_D004837_1_113_124_epinephrine_D017202_1_138_157_myocardial ischemia	The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.
CID	3413271_D004837_3_370_381_epinephrine_D017202_3_404_423_myocardial ischemia	Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.
UN	3413271_D010100_2_275_281_oxygen_D007511_2_232_240_ischemia	Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.
CID	3425586_D003622_6_897_904_dapsone_D000743_6_920_936_hemolytic anemia	Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.
CID	3425586_D003622_0_0_7_Dapsone_D000743_0_30_46_hemolytic anemia	Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.
CID	3425586_D003622_1_215_222_dapsone_D000743_1_175_191_hemolytic anemia	A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.
UN	3425586_D003622_1_215_222_dapsone_D006461_1_272_281_hemolysis	A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.
UN	3425586_D003622_1_215_222_dapsone_D007918_1_144_151_leprosy	A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.
UN	3431591_C031662_5_917_924_CB 3717_D001943_5_952_965_breast cancer	In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.
UN	3431591_C031662_5_917_924_CB 3717_D006528_5_983_991_hepatoma	In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.
UN	3431591_C031662_5_917_924_CB 3717_D008654_5_997_1009_mesothelioma	In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.
UN	3431591_C031662_5_917_924_CB 3717_D010051_5_967_981_ovarian cancer	In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.
UN	343678_D006514_2_369_396_hepatitis B surface antigen_D006509_2_321_337_type B hepatitis	Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.
CID	3461217_D008770_0_85_107_N-nitroso-N-methylurea_D011471_0_28_43_prostate cancer	Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.
CID	3461217_D008770_1_258_280_N-nitroso-N-methylurea_D011471_1_227_230_PAs	More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.
CID	3461217_D043343_3_550_552_TP_D011471_3_524_526_PA	Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.
UN	347884_D006220_8_929_940_haloperidol_D019967_8_1012_1082_psychotic syndromes belonging predominantly to the schizophrenia group	In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.
CID	3496378_D014217_1_108_122_troleandomycin_D002779_1_177_188_cholestasis	We report the case of a patient in whom troleandomycin-induced hepatitis was followed by prolonged anicteric cholestasis.
CID	3496378_D014217_0_28_42_troleandomycin_D002779_0_10_21_cholestasis	Prolonged cholestasis after troleandomycin-induced acute hepatitis.
CID	3496378_D014217_5_681_695_troleandomycin_D002779_5_658_669_cholestasis	This observation demonstrates that prolonged cholestasis can follow troleandomycin-induced acute hepatitis.
CID	3496378_D014217_2_232_246_troleandomycin_D004802_2_282_299_hypereosinophilia	Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.
CID	3496378_D014217_2_232_246_troleandomycin_D007565_2_190_198_Jaundice	Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.
CID	3496378_D014217_0_28_42_troleandomycin_D056486_0_57_66_hepatitis	Prolonged cholestasis after troleandomycin-induced acute hepatitis.
CID	3496378_D014217_1_108_122_troleandomycin_D056486_1_131_140_hepatitis	We report the case of a patient in whom troleandomycin-induced hepatitis was followed by prolonged anicteric cholestasis.
CID	3496378_D014217_5_681_695_troleandomycin_D056486_5_710_719_hepatitis	This observation demonstrates that prolonged cholestasis can follow troleandomycin-induced acute hepatitis.
UN	3503576_D003676_1_266_278_deferoxamine_D000740_1_193_199_anemia	Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.
CID	3503576_D003676_1_266_278_deferoxamine_D014786_1_85_118_Visual and auditory neurotoxicity	Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.
UN	3503576_D007501_1_219_223_iron_D000740_1_193_199_anemia	Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.
UN	3503576_D007501_1_219_223_iron_D006311_1_85_118_Visual and auditory neurotoxicity	Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.
UN	3503576_D007501_1_219_223_iron_D014786_1_85_118_Visual and auditory neurotoxicity	Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.
CID	3535719_D009428_7_1207_1217_netilmicin_D006311_7_1148_1159_ototoxicity	We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.
UN	3535719_D009428_1_135_153_netilmicin sulfate_D007239_1_271_281_infections	We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.
CID	3535719_D009428_3_409_419_netilmicin_D007674_3_336_350_Nephrotoxicity	Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).
CID	3535719_D010878_4_506_518_piperacillin_D006311_4_449_460_Ototoxicity	Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.
UN	3535719_D010878_1_196_215_piperacillin sodium_D007239_1_271_281_infections	We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.
CID	3535719_D014031_7_1228_1238_tobramycin_D006311_7_1148_1159_ototoxicity	We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.
CID	3535719_D014031_4_541_551_tobramycin_D006311_4_449_460_Ototoxicity	Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.
UN	3535719_D014031_1_157_175_tobramycin sulfate_D007239_1_271_281_infections	We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.
CID	3535719_D014031_3_424_434_tobramycin_D007674_3_336_350_Nephrotoxicity	Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).
UN	354896_D008012_2_409_418_lidocaine_D001919_2_331_347_bradyarrhythmias	The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias; and, thus, this probably represented a true idiosyncrasy to lidocaine.
UN	354896_D008012_1_90_99_lidocaine_D003866_1_142_152_depression	Intravenous administration of a single 50-mg bolus of lidocaine in a 67-year-old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers.
CID	354896_D008012_0_0_9_Lidocaine_D006323_0_18_34_cardiac asystole	Lidocaine-induced cardiac asystole.
UN	3560095_D005480_1_143_155_flurbiprofen_D001168_1_249_258_arthritis	Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.
UN	3560095_D005480_0_0_12_Flurbiprofen_D001171_0_33_62_juvenile rheumatoid arthritis	Flurbiprofen in the treatment of juvenile rheumatoid arthritis.
CID	3560096_D007213_1_163_175_indomethacin_D006947_1_47_59_Hyperkalemia	Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.
UN	3560096_D011188_5_594_603_potassium_D006947_5_726_738_hyperkalemia	As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between sulindac and hyperkalemia.
CID	3560096_D013467_5_713_721_sulindac_D006947_5_726_738_hyperkalemia	As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between sulindac and hyperkalemia.
CID	3560096_D013467_0_29_37_sulindac_D006947_0_0_12_Hyperkalemia	Hyperkalemia associated with sulindac therapy.
UN	3564823_D008012_0_40_49_lidocaine_D013035_0_22_27_spasm	Drug-induced arterial spasm relieved by lidocaine.
UN	3564823_D008012_4_346_355_lidocaine_D020301_4_442_451_vasospasm	Since the cranial condition precluded use of more usual methods, lidocaine was given intra-arterially, with careful cardiovascular monitoring, to counteract the vasospasm.
UN	3564823_D013874_2_123_139_sodium pentothal_D002545_2_178_196_cerebral ischaemia	Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.
CID	3615541_D000661_0_43_54_amphetamine_D006948_0_63_76_hyperactivity	Regional localization of the antagonism of amphetamine-induced hyperactivity by intracerebral calcitonin injections.
UN	3615541_D002116_0_94_104_calcitonin_D006948_0_63_76_hyperactivity	Regional localization of the antagonism of amphetamine-induced hyperactivity by intracerebral calcitonin injections.
CID	3629586_C021341_3_453_463_cefazedone_D000740_3_516_522_anemia	In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.
CID	3629586_C021341_4_751_761_cefazedone_D000740_4_607_613_anemia	A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.
CID	3629586_C021341_3_453_463_cefazedone_D009503_3_524_535_neutropenia	In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.
CID	3629586_C021341_3_453_463_cefazedone_D013921_3_541_557_thrombocytopenia	In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.
UN	3629586_D002511_0_85_98_cephalosporin_D006402_0_99_113_hematotoxicity	The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.
UN	3629586_D002511_1_122_135_Cephalosporin_D006402_1_167_191_hematologic disturbances	Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.
UN	3629586_D002511_8_1667_1680_cephalosporin_D006402_8_1689_1705_blood dyscrasias	We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.
CID	3629586_D015790_4_724_733_cefonicid_D000740_4_607_613_anemia	A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.
CID	3629586_D015790_3_440_449_cefonicid_D000740_3_516_522_anemia	In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.
CID	3629586_D015790_3_440_449_cefonicid_D009503_3_524_535_neutropenia	In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.
CID	3629586_D015790_3_440_449_cefonicid_D013921_3_541_557_thrombocytopenia	In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.
CID	3653576_C001335_1_244_268_hexachloro-1:3-butadiene_D058186_1_97_138_Acute experimental models of renal damage	Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.
CID	3653576_C004504_1_314_331_2-bromoethylamine_D058186_1_97_138_Acute experimental models of renal damage	Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.
CID	3653576_D011692_1_277_302_puromycin aminonucleoside_D058186_1_97_138_Acute experimental models of renal damage	Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.
CID	3670965_D001241_8_1282_1289_aspirin_D012202_8_1177_1190_Reye syndrome	Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.
UN	3676049_D007530_5_1038_1048_isoflurane_D000783_5_1025_1033_aneurysm	After the clipping of the aneurysm the isoflurane concentration was reduced to 0.75%.
UN	3676049_D007530_0_42_52_isoflurane_D002532_0_110_128_cerebral aneurysms	Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.
CID	3676049_D007530_1_210_220_isoflurane_D007022_1_229_240_hypotension	Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.
CID	3676049_D007530_0_42_52_isoflurane_D007022_0_61_72_hypotension	Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.
UN	3676049_D007530_2_519_529_isoflurane_D013345_2_371_395_subarachnoid haemorrhage	Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v. Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).
UN	3676049_D008628_3_776_778_Hg_D007022_3_734_745_hypotension	Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.
UN	3676049_D009609_2_563_576_nitrous oxide_D013345_2_371_395_subarachnoid haemorrhage	Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v. Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).
UN	3676049_D010100_1_182_188_oxygen_D002532_1_298_315_cerebral aneurysm	Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.
UN	3676049_D010100_1_182_188_oxygen_D007022_1_229_240_hypotension	Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.
UN	3676049_D010100_2_580_586_oxygen_D013345_2_371_395_subarachnoid haemorrhage	Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v. Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).
UN	3676049_D014978_2_460_465_xenon_D013345_2_371_395_subarachnoid haemorrhage	Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v. Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).
UN	3686155_D001971_1_160_173_bromocriptine_D007775_1_178_201_inhibition of lactation	Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.
UN	3686155_D001971_2_203_216_Bromocriptine_D010300_2_307_326_Parkinson's disease	Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.
CID	3686155_D001971_2_203_216_Bromocriptine_D011605_2_262_271_psychosis	Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.
CID	3686155_D001971_3_357_370_bromocriptine_D011605_3_381_390_psychosis	These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.
CID	3686155_D001971_0_32_45_bromocriptine_D011605_0_11_20_psychosis	Postpartum psychosis induced by bromocriptine.
CID	3693336_D014229_3_302_311_triazolam_D001714_3_239_244_Manic	Manic excitement was coincident with the duration of action of triazolam.
CID	3693336_D014229_1_91_100_triazolam_D001714_1_138_143_mania	Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.
CID	3693336_D014229_0_0_9_Triazolam_D001714_0_46_51_mania	Triazolam-induced brief episodes of secondary mania in a depressed patient.
UN	3693336_D014229_0_0_9_Triazolam_D003866_0_57_66_depressed	Triazolam-induced brief episodes of secondary mania in a depressed patient.
UN	3693336_D014229_1_91_100_triazolam_D003866_1_149_158_depressed	Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.
UN	3703509_D011241_2_213_223_prednisone_D006963_2_290_300_polyphagia	Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.
UN	3703509_D011241_2_213_223_prednisone_D006970_2_266_276_somnolence	Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.
UN	3703509_D011241_2_213_223_prednisone_D011141_2_306_314_polyuria	Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.
UN	3703509_D011241_2_213_223_prednisone_D053609_2_245_253_lethargy	Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.
UN	3703509_D011241_2_213_223_prednisone_D059606_2_278_288_polydipsia	Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.
UN	3703509_D019344_4_502_509_lactate_D000140_4_433_448_lactic acidosis	Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
UN	3703509_D019344_4_502_509_lactate_D007662_4_472_479_ketosis	Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
UN	3708922_D000666_3_493_508_amphothericin B_D007674_3_427_438_nephrotoxic	The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.
UN	3708922_D005839_3_458_468_gentamicin_D007674_3_427_438_nephrotoxic	The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.
UN	3708922_D005839_4_644_654_Gentamicin_D007674_4_694_708_nephrotoxicity	Gentamicin at toxic doses, however, increased CSA nephrotoxicity.
UN	3708922_D007654_3_513_525_ketoconazole_D007674_3_427_438_nephrotoxic	The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.
CID	3708922_D016572_0_13_25_cyclosporine_D007674_0_26_40_nephrotoxicity	Experimental cyclosporine nephrotoxicity: risk of concomitant chemotherapy.
CID	3708922_D016572_5_746_749_CSA_D007674_5_720_734_nephrotoxicity	Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.
CID	3708922_D016572_3_381_384_CSA_D007674_3_427_438_nephrotoxic	The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.
CID	3708922_D016572_4_690_693_CSA_D007674_4_694_708_nephrotoxicity	Gentamicin at toxic doses, however, increased CSA nephrotoxicity.
CID	3714122_C005238_5_939_946_Mipafox_D013118_5_1114_1125_cord damage	In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.
UN	3714122_C005238_0_59_66_mipafox_D020258_0_24_34_neurotoxic	The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.
UN	3714122_D010755_1_326_341_organophosphate_D009422_1_187_197_neuropathy	The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.
UN	3714122_D010755_1_326_341_organophosphate_D020258_1_315_325_neurotoxic	The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.
UN	3719553_D002945_1_231_240_cisplatin_D000799_1_81_100_angioneurotic edema	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.
UN	3719553_D002945_1_231_240_cisplatin_D004342_1_49_66_allergic reaction	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.
UN	3719553_D002945_1_231_240_cisplatin_D005355_1_216_225_cirrhosis	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.
UN	3719553_D002945_1_231_240_cisplatin_D007674_1_249_272_impaired renal function	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.
UN	3719553_D002945_1_231_240_cisplatin_D009062_1_186_214_carcinoma of the oral cavity	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.
UN	3719553_D004155_3_367_382_diphenhydramine_D004342_3_451_468_allergic reaction	Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.
CID	3719553_D005472_1_134_148_5-fluorouracil_D000799_1_81_100_angioneurotic edema	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.
UN	3719553_D005472_1_134_148_5-fluorouracil_D004342_1_49_66_allergic reaction	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.
UN	3719553_D005472_0_21_35_5-fluorouracil_D004342_0_0_17_Allergic reaction	Allergic reaction to 5-fluorouracil infusion.
UN	3719553_D005472_1_134_148_5-fluorouracil_D005355_1_216_225_cirrhosis	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.
UN	3719553_D005472_1_134_148_5-fluorouracil_D007674_1_249_272_impaired renal function	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.
UN	3719553_D005472_1_134_148_5-fluorouracil_D009062_1_186_214_carcinoma of the oral cavity	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.
UN	3719553_D011241_3_387_397_prednisone_D004342_3_451_468_allergic reaction	Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.
UN	3732088_D000584_3_470_479_amiloride_D003324_3_381_404_coronary artery disease	Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.
UN	3732088_D000584_3_470_479_amiloride_D006973_3_358_370_hypertension	Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.
UN	3732088_D000584_6_866_875_amiloride_D018879_6_958_983_ventricular ectopic beats	Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.
UN	3732088_D002752_3_534_548_chlorthalidone_D003324_3_381_404_coronary artery disease	Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.
UN	3732088_D002752_3_534_548_chlorthalidone_D006973_3_358_370_hypertension	Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.
CID	3732088_D002752_6_891_905_chlorthalidone_D018879_6_958_983_ventricular ectopic beats	Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.
UN	3732088_D011188_1_122_131_potassium_D001145_1_163_182_cardiac arrhythmias	It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.
UN	3732088_D011188_0_11_20_potassium_D001145_0_25_36_arrhythmias	Diuretics, potassium and arrhythmias in hypertensive coronary disease.
UN	3732088_D011188_3_439_448_potassium_D003324_3_381_404_coronary artery disease	Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.
UN	3732088_D011188_0_11_20_potassium_D003327_0_53_69_coronary disease	Diuretics, potassium and arrhythmias in hypertensive coronary disease.
UN	3732088_D011188_0_11_20_potassium_D006973_0_40_52_hypertensive	Diuretics, potassium and arrhythmias in hypertensive coronary disease.
UN	3732088_D011188_7_1428_1437_potassium_D017202_7_1376_1399_ischaemic heart disease	The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.
UN	3750012_D002738_1_205_216_chloroquine_D001172_1_229_249_rheumatoid arthritis	We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.
UN	3750012_D002738_0_46_57_chloroquine_D001172_0_70_90_rheumatoid arthritis	Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.
CID	3750012_D002738_1_205_216_chloroquine_D009157_1_163_180_myasthenia gravis	We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.
CID	3750012_D002738_0_46_57_chloroquine_D009157_0_0_17_Myasthenia gravis	Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.
UN	3750012_D010396_1_187_200_penicillamine_D001172_1_229_249_rheumatoid arthritis	We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.
UN	3750012_D010396_0_28_41_penicillamine_D001172_0_70_90_rheumatoid arthritis	Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.
CID	3750012_D010396_1_187_200_penicillamine_D009157_1_163_180_myasthenia gravis	We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.
CID	3750012_D010396_0_28_41_penicillamine_D009157_0_0_17_Myasthenia gravis	Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.
UN	3762968_D013831_1_88_96_thiamine_D003920_1_152_160_diabetic	We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.
UN	3762968_D013831_1_88_96_thiamine_D014899_1_183_208_Wernicke's encephalopathy	We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.
UN	3762968_D013831_1_88_96_thiamine_D020915_1_396_423_Wernicke-Korsakoff syndrome	We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.
UN	3762968_D013835_3_766_769_TPP_D003920_3_648_656_diabetic	We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.
UN	3762968_D013835_1_325_347_thiamine pyrophosphate_D003920_1_152_160_diabetic	We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.
UN	3762968_D013835_3_766_769_TPP_D014899_3_685_710_Wernicke's encephalopathy	We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.
UN	3762968_D013835_1_349_352_TPP_D020915_1_396_423_Wernicke-Korsakoff syndrome	We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.
UN	3762968_D014042_1_227_237_tolazamide_D003920_1_152_160_diabetic	We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.
CID	3762968_D014042_0_29_39_tolazamide_D014899_0_48_73_Wernicke's encephalopathy	Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.
CID	3762968_D014042_1_227_237_tolazamide_D014899_1_183_208_Wernicke's encephalopathy	We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.
CID	3762968_D014042_4_874_884_tolazamide_D014899_4_893_918_Wernicke's encephalopathy	These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.
UN	3762968_D014042_4_874_884_tolazamide_D020915_4_825_852_Wernicke-Korsakoff syndrome	These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.
CID	3769769_D014282_0_19_48_trihexyphenidyl hydrochloride_D001919_0_0_11_Bradycardia	Bradycardia due to trihexyphenidyl hydrochloride.
UN	3769769_D014282_1_124_153_trihexyphenidyl hydrochloride_D012559_1_60_73_schizophrenic	A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.
CID	3780697_D005283_0_30_38_fentanyl_D009127_0_15_23_rigidity	Post-operative rigidity after fentanyl administration.
UN	3780697_D005283_1_219_227_fentanyl_D012131_1_103_122_respiratory failure	A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.
CID	3780814_D004052_3_622_625_DEN_D011230_3_539_557_preneoplastic foci	After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.
UN	3780814_D004052_0_68_86_diethylnitrosamine_D063646_0_5_17_carcinogenic	Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.
UN	3780814_D004052_1_282_300_diethylnitrosamine_D063646_1_223_237_carcinogenesis	The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).
UN	3780814_D004052_7_1155_1158_DEN_D063646_7_1112_1126_carcinogenesis	It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.
UN	3780814_D010634_6_942_944_PB_D009369_6_994_999_tumor	In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.
UN	3780814_D010634_3_589_591_PB_D011230_3_539_557_preneoplastic foci	After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.
UN	3780814_D010634_0_28_41_phenobarbital_D063646_0_5_17_carcinogenic	Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.
CID	3780846_D006220_7_1164_1175_Haloperidol_D009127_7_1189_1197_rigidity	Haloperidol enhanced the rigidity in the A group.
CID	3780846_D009020_3_537_545_morphine_D009127_3_505_513_rigidity	Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).
CID	3780846_D009020_1_171_179_morphine_D009127_1_141_158_muscular rigidity	The development of tolerance to the muscular rigidity produced by morphine was studied in rats.
CID	3780846_D009020_0_87_95_morphine_D009127_0_57_74_muscular rigidity	On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats.
CID	3780846_D009020_3_537_545_morphine_D018476_3_608_616_akinetic	Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).
CID	3782049_D008972_0_43_52_molindone_D012206_0_18_32_rhabdomyolysis	A case of massive rhabdomyolysis following molindone administration.
CID	3782049_D008972_3_415_424_molindone_D012206_3_355_369_rhabdomyolysis	The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.
UN	3782049_D008972_3_415_424_molindone_D012559_3_299_312_schizophrenic	The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.
CID	3782049_D008972_3_415_424_molindone_D058186_3_385_404_acute renal failure	The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.
CID	3800626_D010423_0_50_61_pentazocine_D005355_0_70_86_fibrous myopathy	Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.
CID	3800626_D010423_3_345_356_pentazocine_D005355_3_365_381_fibrous myopathy	In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.
CID	3800626_D010423_0_50_61_pentazocine_D009135_0_70_86_fibrous myopathy	Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.
CID	3800626_D010423_2_243_254_pentazocine_D009135_2_263_271_myopathy	However, compression neuropathy due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.
CID	3800626_D010423_3_345_356_pentazocine_D009135_3_365_381_fibrous myopathy	In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.
CID	3800626_D010423_0_50_61_pentazocine_D009408_0_0_42_Compression neuropathy of the radial nerve	Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.
CID	3800626_D010423_2_243_254_pentazocine_D009408_2_185_207_compression neuropathy	However, compression neuropathy due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.
CID	3800626_D010423_0_50_61_pentazocine_D020425_0_0_42_Compression neuropathy of the radial nerve	Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.
UN	3827439_D000666_1_203_217_amphotericin B_D005355_1_87_96_cirrhosis	A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.
UN	3827439_D000666_1_203_217_amphotericin B_D013174_1_114_128_sporotrichosis	A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.
CID	3827439_D000666_1_203_217_amphotericin B_D058186_1_139_158_acute renal failure	A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.
CID	3827439_D000666_0_46_58_amphotericin_D058186_0_21_40_acute renal failure	Recurrent reversible acute renal failure from amphotericin.
CID	3828020_D010665_0_47_66_phenylpropanolamine_D002544_0_0_19_Cerebral infarction	Cerebral infarction with a single oral dose of phenylpropanolamine.
CID	3828020_D010665_3_518_521_PPA_D002544_3_463_482_cerebral infarction	We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.
CID	384871_D004977_0_43_53_ethambutol_D009901_0_0_26_Bilateral optic neuropathy	Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.
CID	384871_D007538_0_58_67_isoniazid_D009901_0_0_26_Bilateral optic neuropathy	Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.
UN	3856631_D001663_6_1114_1123_bilirubin_D009503_6_1136_1147_neutropenia	The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.
UN	3856631_D001663_6_1114_1123_bilirubin_D052016_6_1153_1162_mucositis	The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.
UN	3856631_D008727_0_69_81_methotrexate_D008577_0_23_41_meningeal leukemia	Remission induction of meningeal leukemia with high-dose intravenous methotrexate.
UN	3856631_D008727_1_207_219_methotrexate_D054198_1_104_132_acute lymphoblastic leukemia	Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.
UN	3856631_D008727_8_1269_1281_methotrexate_D054198_8_1366_1394_acute lymphoblastic leukemia	High-dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia.
UN	3865016_D005047_2_215_224_etoposide_D017254_2_290_311_leukemic infiltration	The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.
UN	3865016_D005047_1_81_90_etoposide_D054218_1_140_168_acute T-lymphocytic leukemia	A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.
UN	3865016_D016572_2_229_242_cyclosporin A_D017254_2_290_311_leukemic infiltration	The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.
UN	3865016_D016572_1_95_108_cyclosporin A_D054218_1_140_168_acute T-lymphocytic leukemia	A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.
UN	3934126_D000617_5_725_739_aminoglycoside_D006311_5_674_685_ototoxicity	Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.
UN	3934126_D000617_5_725_739_aminoglycoside_D007674_5_655_669_nephrotoxicity	Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.
UN	3934126_D000617_5_725_739_aminoglycoside_D013924_5_581_597_Thrombophlebitis	Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.
CID	3934126_D014640_5_745_755_vancomycin_D006311_5_674_685_ototoxicity	Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.
UN	3934126_D014640_2_208_218_Vancomycin_D007239_2_266_275_infection	Vancomycin was curative in 95% of 43 patients with proven infection.
UN	3934126_D014640_6_774_784_vancomycin_D007239_6_854_864_infections	We conclude that vancomycin, administered appropriately, constitutes safe, effective therapy for infections caused by susceptible bacteria.
UN	3934126_D014640_5_745_755_vancomycin_D007674_5_655_669_nephrotoxicity	Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.
CID	3934126_D014640_5_745_755_vancomycin_D013924_5_581_597_Thrombophlebitis	Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.
CID	3950060_D000583_1_127_135_amikacin_D007674_1_178_192_nephrotoxicity	Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.
CID	3950060_D000583_0_82_90_amikacin_D007674_0_24_38_nephrotoxicity	Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.
UN	3952818_D002118_4_456_463_calcium_D003329_4_384_398_coronary spasm	These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.
UN	3952818_D002118_4_456_463_calcium_D066126_4_419_433_cardiotoxicity	These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.
CID	3952818_D005472_2_179_193_5-fluorouracil_D002637_2_162_172_chest pain	We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.
UN	3952818_D005472_2_179_193_5-fluorouracil_D003110_2_111_126_colon carcinoma	We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.
UN	3952818_D005472_4_441_445_5-FU_D003329_4_384_398_coronary spasm	These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.
UN	3952818_D005472_2_179_193_5-fluorouracil_D009362_2_137_147_metastasis	We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.
UN	3952818_D005472_0_20_34_5-fluorouracil_D066126_0_0_16_Cardiac toxicity	Cardiac toxicity of 5-fluorouracil.
UN	3952818_D005472_4_531_535_5-FU_D066126_4_536_550_cardiotoxicity	These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.
UN	3952818_D009543_3_348_358_nifedipine_D000788_3_289_308_Prinzmetal's angina	Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.
UN	3952818_D009543_3_348_358_nifedipine_D002637_3_314_324_chest pain	Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.
CID	3961813_C025541_6_1128_1132_TOTP_D009410_6_1019_1049_Degenerating myelinated fibers	Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.
CID	3961813_C025541_3_569_573_TOTP_D009422_3_582_592_neuropathy	Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.
UN	3961813_C025541_4_735_739_TOTP_D020258_4_692_702_Neurotoxic	Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.
UN	3961813_D003345_0_55_69_corticosterone_D009422_0_106_116_neuropathy	Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed neuropathy in chickens.
UN	3961813_D003345_3_528_542_corticosterone_D009422_3_582_592_neuropathy	Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.
CID	3961813_D007531_6_1136_1139_DFP_D009410_6_1019_1049_Degenerating myelinated fibers	Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.
CID	3961813_D007531_3_687_690_DFP_D009422_3_582_592_neuropathy	Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.
UN	3961813_D007531_4_743_746_DFP_D020258_4_692_702_Neurotoxic	Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.
UN	3961813_D010755_0_73_89_organophosphorus_D009422_0_106_116_neuropathy	Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed neuropathy in chickens.
UN	3961813_D010755_4_807_824_organophosphorous_D020258_4_692_702_Neurotoxic	Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.
CID	3962737_D000638_3_259_269_amiodarone_D002779_3_230_251_cholestatic hepatitis	A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.
CID	3962737_D000638_4_426_436_amiodarone_D005234_4_458_467_steatosis	It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.
UN	3962737_D000638_4_426_436_amiodarone_D006519_4_492_511_alcoholic hepatitis	It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.
CID	3962737_D000638_4_426_436_amiodarone_D008103_4_552_574_cirrhosis of the liver	It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.
UN	3962737_D000638_1_30_40_Amiodarone_D013610_1_115_131_tachyarrhythmias	Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias.
CID	3962737_D000638_3_337_347_amiodarone_D056486_3_319_333_hepatotoxicity	A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.
CID	3962737_D000638_4_426_436_amiodarone_D056486_4_404_418_hepatic injury	It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.
CID	3962737_D000638_0_18_28_amiodarone_D056486_0_0_14_Hepatotoxicity	Hepatotoxicity of amiodarone.
CID	3969369_D013739_3_546_558_testosterone_D011471_3_666_681_prostate cancer	Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.
CID	3969369_D013739_2_317_329_testosterone_D011471_2_379_394_prostate cancer	Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.
CID	3969369_D013739_5_850_862_testosterone_D011472_5_878_889_prostatitis	Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.
UN	3969369_D013739_0_23_35_testosterone_D063646_0_64_78_carcinogenesis	Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.
UN	3970039_D000477_9_1484_1501_alkylating agents_D001172_9_1523_1543_rheumatoid arthritis	Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.
CID	3970039_D000477_6_926_943_alkylating agents_D008228_6_1000_1022_non-Hodgkin's lymphoma	Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.
CID	3970039_D000477_6_827_844_alkylating agents_D015470_6_886_915_acute nonlymphocytic leukemia	Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.
UN	3970039_D001379_8_1190_1202_azathioprine_D001172_8_1156_1176_rheumatoid arthritis	There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.
CID	3970039_D001379_6_948_960_azathioprine_D008228_6_1000_1022_non-Hodgkin's lymphoma	Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.
UN	3970039_D001379_6_948_960_azathioprine_D015470_6_886_915_acute nonlymphocytic leukemia	Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.
UN	3970039_D003520_8_1207_1223_cyclophosphamide_D001172_8_1156_1176_rheumatoid arthritis	There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.
CID	3970039_D003520_7_1024_1040_Cyclophosphamide_D001749_7_1071_1095_carcinoma of the bladder	Cyclophosphamide therapy increases the risk of carcinoma of the bladder.
CID	3970039_D003520_7_1024_1040_Cyclophosphamide_D002277_7_1071_1095_carcinoma of the bladder	Cyclophosphamide therapy increases the risk of carcinoma of the bladder.
UN	3985451_D014859_3_488_496_warfarin_D003286_3_648_659_contracture	Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.
UN	3985451_D014859_1_127_135_warfarin_D003286_1_222_233_contracture	We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.
CID	3985451_D014859_1_127_135_warfarin_D009135_1_166_177_muscle tear	We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.
UN	3985451_D014859_3_488_496_warfarin_D010146_3_558_562_pain	Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.
UN	3985451_D014859_1_127_135_warfarin_D010146_1_203_207_pain	We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.
UN	3985451_D014859_3_488_496_warfarin_D015417_3_606_634_motor and sensory impairment	Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.
CID	3985451_D014859_0_0_8_Warfarin_D020428_0_54_73_femoral nerve palsy	Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.
CID	3985451_D014859_3_488_496_warfarin_D020428_3_433_452_femoral nerve palsy	Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.
CID	3997294_D000638_0_72_82_amiodarone_D010490_0_17_49_pleural and pericardial effusion	Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.
CID	3997294_D000638_0_72_82_amiodarone_D010996_0_17_49_pleural and pericardial effusion	Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.
CID	3997294_D000638_4_593_603_amiodarone_D011014_4_604_615_pneumonitis	Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.
UN	3997294_D000638_1_167_177_amiodarone_D013617_1_262_295_supraventricular tachyarrhythmias	A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.
UN	3997294_D013256_4_678_685_steroid_D011014_4_604_615_pneumonitis	Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.
UN	4008111_D000638_1_81_91_amiodarone_D009202_1_132_154_primary cardiomyopathy	We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.
UN	4008111_D000638_2_248_258_amiodarone_D012804_2_349_366_sinus bradycardia	Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.
CID	4008111_D000638_2_248_258_amiodarone_D012848_2_296_312_sinoatrial block	Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.
CID	4008111_D000638_1_81_91_amiodarone_D012848_1_49_65_sinoatrial block	We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.
CID	4008111_D000638_0_0_10_Amiodarone_D012848_0_19_35_sinoatrial block	Amiodarone-induced sinoatrial block.
UN	4008111_D000638_1_81_91_amiodarone_D013617_1_191_219_supraventricular tachycardia	We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.
UN	4008111_D000638_1_81_91_amiodarone_D014927_1_156_186_Wolff-Parkinson-White syndrome	We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.
CID	4027862_D003891_0_0_11_Desipramine_D003693_0_20_28_delirium	Desipramine-induced delirium at "subtherapeutic" concentrations: a case report.
CID	4027862_D003891_1_121_132_Desipramine_D003693_1_145_153_delirium	An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the "subtherapeutic" range.
UN	4038130_D004837_6_670_681_epinephrine_D009135_6_546_559_muscle damage	In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.
CID	4038130_D008012_6_655_664_lidocaine_D009135_6_546_559_muscle damage	In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.
CID	4038130_D008619_6_639_650_mepivacaine_D009135_6_546_559_muscle damage	In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.
UN	4069770_D005839_2_207_217_gentamicin_D001002_2_262_268_anuria	The serum gentamicin concentration had reached toxic levels when anuria developed.
CID	4069770_D005839_1_142_152_gentamicin_D058186_1_103_122_acute renal failure	The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.
UN	4069770_D010406_1_171_181_penicillin_D058186_1_103_122_acute renal failure	The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.
CID	4071154_D007213_1_205_217_indomethacin_D001201_1_172_179_ascites	We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.
CID	4071154_D007213_1_205_217_indomethacin_D005355_1_161_170_cirrhosis	We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.
CID	4071154_D007213_1_205_217_indomethacin_D006947_1_130_142_hyperkalemia	We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.
CID	4071154_D007213_2_328_340_indomethacin_D009846_2_379_387_oliguria	Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.
CID	4071154_D007213_1_205_217_indomethacin_D011660_1_185_198_cor pulmonale	We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.
UN	4090988_D000082_7_825_836_paracetamol_D001744_7_945_960_bladder calculi	Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.
CID	4090988_D000082_0_13_24_paracetamol_D001749_0_28_53_bladder and liver tumours	Induction by paracetamol of bladder and liver tumours in the rat.
CID	4090988_D000082_7_825_836_paracetamol_D006965_7_860_871_hyperplasia	Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.
CID	4090988_D000082_0_13_24_paracetamol_D008113_0_28_53_bladder and liver tumours	Induction by paracetamol of bladder and liver tumours in the rat.
UN	4090988_D000082_5_617_628_paracetamol_D010212_5_543_553_Papillomas	Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.
UN	424937_D008750_7_1075_1085_methyldopa_D017093_7_1025_1040_hepatic failure	One patient died, having presented in hepatic failure, and another, who had been taking methyldopa for 7 years, showed slower clinical and biochemical resolution over a period of several months.
UN	424937_D008750_8_1323_1333_methyldopa_D017114_8_1228_1247_fulminant hepatitis	The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.
CID	424937_D008750_9_1426_1436_methyldopa_D056486_9_1495_1504_hepatitis	In this latter patient, and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.
CID	424937_D008750_8_1323_1333_methyldopa_D056486_8_1342_1351_hepatitis	The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.
CID	424937_D008750_0_38_48_methyldopa_D056486_0_12_26_hepatic injury	Patterns of hepatic injury induced by methyldopa.
CID	430165_D010672_2_129_146_diphenylhydantoin_D002526_2_227_249_cerebellar dysfunction	Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.
CID	430165_D010672_4_410_413_DPH_D010291_4_391_402_hemiparesis	Two patients are presented who suffered progressive hemiparesis due to DPH overdose.
CID	430165_D010672_4_410_413_DPH_D062787_4_414_422_overdose	Two patients are presented who suffered progressive hemiparesis due to DPH overdose.
CID	430165_D010672_2_148_151_DPH_D062787_2_153_161_overdose	Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.
CID	435349_D013390_0_0_13_Suxamethonium_D005207_0_41_55_fasciculations	Suxamethonium infusion rate and observed fasciculations.
UN	435349_D013390_3_312_315_Sch_D013746_3_265_272_tetanic	The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.
UN	458486_C037689_1_76_85_benzamide_D004409_1_167_188_involuntary movements	Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.
UN	458486_C037689_1_76_85_benzamide_D010300_1_209_239_idiopathic Parkinson's disease	Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.
UN	458486_D004298_4_606_614_dopamine_D004409_4_541_552_dyskinesias	These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors.
CID	458486_D007980_0_12_20_levodopa_D004409_0_29_50_involuntary movements	Tiapride in levodopa-induced involuntary movements.
CID	458486_D007980_4_524_532_levodopa_D004409_4_541_552_dyskinesias	These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors.
CID	458486_D007980_1_140_148_levodopa_D004409_1_167_188_involuntary movements	Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.
UN	458486_D007980_3_411_419_levodopa_D004421_3_468_476_dystonia	Tiapride had no effect on levodopa-induced early morning of "off-period" segmental dystonia.
UN	458486_D007980_1_140_148_levodopa_D010300_1_209_239_idiopathic Parkinson's disease	Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.
UN	458486_D008787_1_116_130_metoclopramide_D004409_1_167_188_involuntary movements	Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.
UN	458486_D008787_1_116_130_metoclopramide_D010300_1_209_239_idiopathic Parkinson's disease	Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.
UN	458486_D063325_0_0_8_Tiapride_D004409_0_29_50_involuntary movements	Tiapride in levodopa-induced involuntary movements.
UN	458486_D063325_3_385_393_Tiapride_D004421_3_468_476_dystonia	Tiapride had no effect on levodopa-induced early morning of "off-period" segmental dystonia.
UN	458486_D063325_1_52_60_Tiapride_D010300_1_209_239_idiopathic Parkinson's disease	Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.
UN	4812392_D001379_0_28_40_azathioprine_D011565_0_13_22_psoriasis	Treatment of psoriasis with azathioprine.
UN	4812392_D001379_4_406_418_azathioprine_D056486_4_459_471_liver damage	Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage.
CID	48362_D011802_0_0_9_Quinidine_D056486_0_10_19_hepatitis	Quinidine hepatitis.
CID	48362_D011802_5_486_495_quinidine_D056486_5_496_510_hepatotoxicity	We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.
UN	567256_D004054_1_198_216_diethylstilbestrol_D000230_1_165_192_adenocarcinoma of the liver	Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.
CID	567256_D004054_0_42_60_diethylstilbestrol_D006394_0_0_25_Angiosarcoma of the liver	Angiosarcoma of the liver associated with diethylstilbestrol.
CID	567256_D004054_1_198_216_diethylstilbestrol_D008113_1_165_192_adenocarcinoma of the liver	Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.
CID	567256_D004054_0_42_60_diethylstilbestrol_D008113_0_0_25_Angiosarcoma of the liver	Angiosarcoma of the liver associated with diethylstilbestrol.
CID	591536_D006493_2_374_381_heparin_D001157_2_253_271_arterial occlusion	Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.
UN	591536_D006493_2_374_381_heparin_D007511_2_311_319_ischemia	Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.
CID	591536_D006493_5_872_879_heparin_D013921_5_852_868_thrombocytopenia	The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.
CID	591536_D006493_0_104_111_heparin_D013921_0_120_136_thrombocytopenia	Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.
UN	591536_D006493_5_872_879_heparin_D013923_5_832_847_thromboembolism	The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.
UN	591536_D006493_0_56_63_heparin_D013923_0_9_24_thromboembolism	Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.
UN	591536_D006493_1_204_211_heparin_D013923_1_147_162_thromboembolism	Arterial thromboembolism is a recognized complication of systemic heparin therapy.
UN	591536_D006493_2_374_381_heparin_D013927_2_291_298_thrombi	Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.
UN	603022_D005702_1_135_160_Galanthamine hydrobromide_D062787_1_315_325_overdosage	Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.
CID	603022_D012601_1_305_313_hyoscine_D062787_1_315_325_overdosage	Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.
CID	6103707_D005445_6_744_757_flunitrazepam_D010146_6_718_722_pain	There was pain on i.m. injection of flunitrazepam significantly more often than with isotonic saline.
CID	6111982_D010042_2_308_315_ouabain_D001145_2_316_326_arrhythmia	Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.
UN	6111982_D010869_2_284_292_pindolol_D001145_2_316_326_arrhythmia	Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.
UN	6111982_D011433_2_268_279_propranolol_D001145_2_316_326_arrhythmia	Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.
UN	6115999_D001539_5_855_869_bendrofluazide_D004417_5_910_918_dyspnoea	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
CID	6115999_D001539_5_855_869_bendrofluazide_D006073_5_826_830_gout	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
UN	6115999_D001539_0_21_35_bendrofluazide_D006973_0_78_90_hypertension	Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.
CID	6115999_D001539_4_561_575_bendrofluazide_D007172_4_590_599_impotence	The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.
UN	6115999_D001539_5_855_869_bendrofluazide_D011928_5_885_905_Raynaud's phenomenon	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
CID	6115999_D001539_5_855_869_bendrofluazide_D018149_5_778_804_impaired glucose tolerance	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
UN	6115999_D011433_6_1008_1019_propranolol_D003316_6_959_974_corneal disease	No corneal disease is known to have occurred in the propranolol group.
CID	6115999_D011433_5_943_954_propranolol_D004417_5_910_918_dyspnoea	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
UN	6115999_D011433_5_943_954_propranolol_D006073_5_826_830_gout	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
UN	6115999_D011433_0_40_51_propranolol_D006973_0_78_90_hypertension	Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.
CID	6115999_D011433_4_664_675_propranolol_D007172_4_605_614_impotence	The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.
CID	6115999_D011433_5_943_954_propranolol_D011928_5_885_905_Raynaud's phenomenon	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
UN	6115999_D011433_5_943_954_propranolol_D018149_5_778_804_impaired glucose tolerance	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
UN	6118280_C014896_9_1336_1342_MK-212_D009207_9_1390_1399_myoclonus	Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.
UN	6118280_D001418_0_40_48_baclofen_D009207_0_72_87_myoclonic jerks	Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.
UN	6118280_D001418_9_1351_1359_baclofen_D009207_9_1390_1399_myoclonus	Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.
UN	6118280_D001569_0_20_35_benzodiazepines_D009207_0_72_87_myoclonic jerks	Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.
UN	6118280_D002998_6_740_750_clonazepam_D009207_6_852_867_myoclonic jerks	Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.
UN	6118280_D003975_6_813_821_diazepam_D009207_6_852_867_myoclonic jerks	Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.
UN	6118280_D006916_8_1026_1031_5-HTP_D009207_8_1119_1128_myoclonus	Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.
CID	6118280_D009118_1_129_137_muscimol_D009207_1_147_162_myoclonic jerks	In male Swiss mice, muscimol produced myoclonic jerks.
CID	6118280_D009118_0_55_63_muscimol_D009207_0_72_87_myoclonic jerks	Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.
CID	6118280_D009118_8_1134_1142_muscimol_D009207_8_1151_1160_myoclonus	Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.
CID	6127992_D000319_1_248_278_beta-adrenergic blocking drugs_D001919_1_193_204_bradycardia	Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.
CID	6127992_D000319_1_248_278_beta-adrenergic blocking drugs_D006333_1_160_175_cardiac failure	Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.
CID	6127992_D000319_1_248_278_beta-adrenergic blocking drugs_D007022_1_177_188_hypotension	Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.
UN	6127992_D000319_1_248_278_beta-adrenergic blocking drugs_D017202_1_117_140_ischaemic heart disease	Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.
CID	6127992_D014700_1_234_243_verapamil_D001919_1_193_204_bradycardia	Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.
CID	6127992_D014700_1_234_243_verapamil_D006333_1_160_175_cardiac failure	Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.
CID	6127992_D014700_1_234_243_verapamil_D007022_1_177_188_hypotension	Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.
UN	6127992_D014700_1_234_243_verapamil_D017202_1_117_140_ischaemic heart disease	Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.
UN	6133211_D012460_1_138_152_sulphasalazine_D015212_1_83_109_inflammatory bowel disease	Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.
UN	6150641_D002927_7_1476_1486_cimetidine_D006402_7_1293_1324_hepatic or hematologic toxicity	Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.
CID	6150641_D002927_6_1041_1051_cimetidine_D007172_6_1018_1027_impotence	Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.
UN	6150641_D002927_7_1476_1486_cimetidine_D056486_7_1293_1324_hepatic or hematologic toxicity	Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.
UN	6150641_D003404_7_1444_1454_creatinine_D006402_7_1293_1324_hepatic or hematologic toxicity	Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.
UN	6150641_D003404_7_1444_1454_creatinine_D056486_7_1293_1324_hepatic or hematologic toxicity	Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.
UN	6150641_D011899_7_1377_1387_ranitidine_D006402_7_1293_1324_hepatic or hematologic toxicity	Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.
UN	6150641_D011899_6_1127_1137_ranitidine_D007172_6_1018_1027_impotence	Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.
UN	6150641_D011899_7_1377_1387_ranitidine_D056486_7_1293_1324_hepatic or hematologic toxicity	Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.
CID	6153967_D004737_5_544_553_enflurane_D012640_5_603_610_seizure	Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure-free.
UN	6203452_D001761_1_292_301_bleomycin_D002277_1_109_118_carcinoma	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.
UN	6203452_D001761_1_292_301_bleomycin_D051437_1_174_193_renal insufficiency	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.
UN	6203452_D002945_5_972_981_cisplatin_D001855_5_1049_1072_bone marrow suppression	Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.
UN	6203452_D002945_1_281_290_cisplatin_D002277_1_109_118_carcinoma	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.
CID	6203452_D002945_5_972_981_cisplatin_D007674_5_982_996_nephrotoxicity	Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.
UN	6203452_D002945_5_972_981_cisplatin_D051437_5_939_952_renal failure	Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.
UN	6203452_D014748_1_309_323_vinca alkaloid_D002277_1_109_118_carcinoma	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.
UN	6203452_D014748_1_309_323_vinca alkaloid_D051437_1_174_193_renal insufficiency	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.
CID	6203632_D007545_0_15_28_isoproterenol_D006332_0_37_56_cardiac hypertrophy	Development of isoproterenol-induced cardiac hypertrophy.
UN	6209318_D008801_0_14_24_mexiletine_D001145_0_81_91_arrhythmia	International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings.
UN	6209318_D008801_6_1110_1120_mexiletine_D003643_6_1096_1102_deaths	There were more deaths in the mexiletine group (7.6%) than in the placebo group (4.8%); the difference was not statistically significant.
UN	6209318_D008801_2_195_205_mexiletine_D009203_2_313_334_myocardial infarction	The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.
CID	6209318_D008801_8_1392_1402_mexiletine_D012817_8_1339_1364_gastrointestinal problems	Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.
CID	6209318_D008801_8_1392_1402_mexiletine_D014202_8_1328_1334_tremor	Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.
UN	6216862_D010396_3_534_547_penicillamine_C536202_3_362_393_elastosis perforans serpiginosa	The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.
UN	6216862_D010396_1_223_236_penicillamine_D001172_1_262_282_rheumatoid arthritis	Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.
UN	6216862_D010396_0_25_38_penicillamine_D001172_0_67_87_rheumatoid arthritis	Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis.
UN	6216862_D010396_3_534_547_penicillamine_D001172_3_500_520_rheumatoid arthritis	The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.
CID	6216862_D010396_1_223_236_penicillamine_D005076_1_89_100_Skin rashes	Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.
UN	6216862_D010396_3_534_547_penicillamine_D006527_3_458_474_Wilson's disease	The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.
CID	6216862_D010396_1_223_236_penicillamine_D008180_1_115_143_systemic lupus erythematosus	Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.
CID	6216862_D010396_1_223_236_penicillamine_D009157_1_162_179_myasthenia gravis	Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.
CID	6216862_D010396_1_223_236_penicillamine_D011507_1_102_113_proteinuria	Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.
CID	6216862_D010396_1_223_236_penicillamine_D017285_1_145_157_polymyositis	Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.
UN	6229975_D013999_4_484_491_timolol_D001919_4_500_511_bradycardia	These differences may be caused by timolol-induced bradycardia and a compensatory increase in end-diastolic volume.
UN	6229975_D013999_7_856_863_timolol_D007238_7_772_782_infarction	After re-infarction, heart size increased in the placebo group and remained unchanged in the timolol group.
UN	6229975_D013999_1_110_117_timolol_D009203_1_148_169_myocardial infarction	The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).
UN	6229975_D013999_0_39_46_timolol_D009203_0_63_84_myocardial infarction	Changes in heart size during long-term timolol treatment after myocardial infarction.
CID	625456_D002119_1_184_202_calcium carbon-ate_D006934_1_63_77_hypercalcaemia	One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.
CID	625456_D002119_1_184_202_calcium carbon-ate_D053040_1_99_114_nephrolithiasis	One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.
CID	625456_D017693_1_203_221_sodium bicarbonate_D006934_1_63_77_hypercalcaemia	One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.
CID	625456_D017693_1_203_221_sodium bicarbonate_D053040_1_99_114_nephrolithiasis	One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.
CID	6286738_D002762_1_95_105_vitamin D3_D006934_1_138_151_hypercalcemia	Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.
UN	6286738_D002762_3_492_502_vitamin D3_D010319_3_519_529_milk fever	None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.
UN	6286738_D002762_6_1020_1030_vitamin D3_D010319_6_1044_1054_milk fever	Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.
CID	6286738_D002762_1_195_205_vitamin D3_D054559_1_153_170_hyperphosphatemia	Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.
CID	6287825_D012256_5_563_573_riboflavin_D010523_5_495_516_Peripheral neuropathy	Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.
UN	6287825_D012256_5_563_573_riboflavin_D044342_5_524_546_nutritional deficiency	Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.
CID	6287825_D013831_5_550_558_thiamine_D010523_5_495_516_Peripheral neuropathy	Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.
UN	6287825_D013831_5_550_558_thiamine_D044342_5_524_546_nutritional deficiency	Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.
CID	6292680_D004317_0_0_11_Doxorubicin_D009202_0_12_26_cardiomyopathy	Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.
UN	6292680_D004317_1_227_238_doxorubicin_D009369_1_190_195_tumor	Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.
UN	6292680_D004317_0_0_11_Doxorubicin_D009396_0_55_66_Wilms tumor	Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.
UN	6292680_D004317_3_469_480_doxorubicin_D009396_3_527_538_Wilms tumor	It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.
UN	6292680_D018943_1_136_149_anthracycline_D009369_1_190_195_tumor	Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.
UN	6292680_D018943_1_136_149_anthracycline_D009396_1_86_97_Wilms tumor	Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.
UN	6293644_D001058_2_380_391_apomorphine_D002375_2_342_351_catalepsy	Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.
CID	6293644_D001058_2_380_391_apomorphine_D006948_2_400_413_hyperactivity	Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.
CID	6293644_D006220_2_322_333_haloperidol_D002375_2_342_351_catalepsy	Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.
UN	6293644_D006220_2_322_333_haloperidol_D006948_2_400_413_hyperactivity	Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.
UN	6308277_D000082_3_784_797_acetaminophen_D012640_3_845_853_seizures	Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).
UN	6308277_D000082_4_1015_1028_acetaminophen_D012640_4_945_953_seizures	The frequency of sound-induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen.
UN	6308277_D000082_5_1058_1071_acetaminophen_D012640_5_1109_1117_seizures	In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).
CID	6308277_D002110_3_882_890_caffeine_D012640_3_845_853_seizures	Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).
CID	6308277_D002110_4_977_985_caffeine_D012640_4_945_953_seizures	The frequency of sound-induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen.
CID	6308277_D010433_5_1191_1208_pentylenetetrezol_D012640_5_1109_1117_seizures	In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).
UN	6308526_C024224_2_306_316_naloxazone_D000699_2_348_357_analgesia	Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.
UN	6308526_C024224_3_475_485_naloxazone_D001919_3_597_608_bradycardia	Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.
UN	6308526_C024224_2_306_316_naloxazone_D002375_2_359_368_catalepsy	Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.
UN	6308526_C024224_3_475_485_naloxazone_D007022_3_532_543_hypotension	Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.
UN	6308526_C024224_2_306_316_naloxazone_D007035_2_373_384_hypothermia	Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.
UN	6308526_C024224_3_475_485_naloxazone_D012131_3_548_570_respiratory depression	Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.
UN	6308526_D009020_2_339_347_morphine_D000699_2_348_357_analgesia	Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.
CID	6308526_D009020_3_580_588_morphine_D001919_3_597_608_bradycardia	Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.
CID	6308526_D009020_2_339_347_morphine_D002375_2_359_368_catalepsy	Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.
CID	6308526_D009020_3_515_523_morphine_D007022_3_532_543_hypotension	Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.
CID	6308526_D009020_2_339_347_morphine_D007035_2_373_384_hypothermia	Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.
UN	6308526_D009020_3_515_523_morphine_D012131_3_548_570_respiratory depression	Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.
UN	6323692_C018824_7_1044_1049_NH4Ac_D000699_7_1081_1090_analgesia	Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.
CID	6323692_C018824_1_251_256_NH4Ac_D001259_1_219_233_incoordination	Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.
CID	6323692_C018824_7_1044_1049_NH4Ac_D001259_7_1122_1136_incoordination	Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.
UN	6323692_C018824_4_842_847_NH4Ac_D003866_4_733_743_depression	Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
UN	6323692_D000079_4_810_822_acetaldehyde_D003866_4_733_743_depression	Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
UN	6323692_D000661_7_1153_1164_amphetamine_D000699_7_1081_1090_analgesia	Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.
UN	6323692_D000661_7_1153_1164_amphetamine_D001259_7_1122_1136_incoordination	Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.
UN	6323692_D002118_4_712_719_calcium_D003866_4_733_743_depression	Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
UN	6323692_D002118_8_1311_1318_calcium_D022124_8_1287_1301_hyperammonemia	The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.
UN	6323692_D002395_4_785_798_catecholamine_D003866_4_733_743_depression	Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
UN	6323692_D003975_7_1096_1104_diazepam_D000699_7_1081_1090_analgesia	Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.
CID	6323692_D003975_1_237_245_diazepam_D001259_1_219_233_incoordination	Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.
CID	6323692_D003975_7_1096_1104_diazepam_D001259_7_1122_1136_incoordination	Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.
UN	6323692_D009020_7_1072_1080_morphine_D000699_7_1081_1090_analgesia	Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.
UN	6323692_D009020_7_1072_1080_morphine_D001259_7_1122_1136_incoordination	Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.
UN	6323692_D010433_7_1255_1263_metrazol_D000699_7_1081_1090_analgesia	Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.
UN	6323692_D010433_7_1255_1263_metrazol_D001259_7_1122_1136_incoordination	Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.
UN	6323692_D014700_7_1014_1023_verapamil_D000699_7_1081_1090_analgesia	Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.
UN	6323692_D014700_7_1201_1210_verapamil_D001259_7_1122_1136_incoordination	Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.
CID	6381653_D007980_1_45_53_Levodopa_D004409_1_62_72_dyskinesia	Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.
CID	6381653_D007980_0_0_8_Levodopa_D004409_0_17_27_dyskinesia	Levodopa-induced dyskinesia and thalamotomy.
CID	6381653_D007980_2_395_403_levodopa_D004409_2_412_423_dyskinesias	Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.
UN	6381653_D007980_1_45_53_Levodopa_D010302_1_107_119_Parkinsonism	Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.
UN	6381653_D007980_2_395_403_levodopa_D010302_2_482_494_Parkinsonism	Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.
UN	6381653_D007980_2_395_403_levodopa_D013786_2_427_443_thalamic lesions	Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.
UN	6381653_D007980_1_45_53_Levodopa_D020821_1_153_161_dystonic	Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.
UN	6386793_D000639_6_836_849_amitriptyline_D003866_6_870_879_depressed	Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.
UN	6386793_D000639_2_286_299_amitriptyline_D003866_2_354_372_depressive illness	Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.
UN	6386793_D000639_1_187_200_amitriptyline_D003866_1_249_258_depressed	In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients.
CID	6386793_D000639_3_586_599_amitriptyline_D014786_3_495_509_blurred vision	The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.
CID	6386793_D000639_3_586_599_amitriptyline_D014987_3_511_520_dry mouth	The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.
UN	6386793_D000928_6_776_790_antidepressant_D003866_6_870_879_depressed	Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.
UN	6386793_D004308_0_51_74_dothiepin hydrochloride_D003866_0_101_120_depressive disorder	A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.
UN	6386793_D004308_3_566_575_dothiepin_D014786_3_495_509_blurred vision	The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.
UN	6386793_D004308_3_566_575_dothiepin_D014987_3_511_520_dry mouth	The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.
UN	6387529_D003975_0_22_30_diazepam_D000379_0_83_94_agoraphobia	Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.
CID	6387529_D003975_2_506_514_diazepam_D008569_2_442_472_impaired immediate free recall	Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.
UN	6387529_D003975_0_22_30_diazepam_D016584_0_64_78_panic disorder	Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.
UN	6387529_D011433_0_35_46_propranolol_D000379_0_83_94_agoraphobia	Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.
CID	6387529_D011433_2_520_531_propranolol_D008569_2_442_472_impaired immediate free recall	Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.
UN	6387529_D011433_0_35_46_propranolol_D016584_0_64_78_panic disorder	Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.
CID	6402369_D007069_0_13_23_ifosfamide_D001745_0_32_51_urothelial toxicity	Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
CID	6402369_D007069_1_311_321_ifosfamide_D001745_1_280_299_urothelial toxicity	The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.
UN	6402369_D007069_2_560_562_IF_D006417_2_753_763_haematuria	MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i. Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria.
UN	6402369_D007069_1_413_415_IF_D008175_1_380_391_lung cancer	The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.
UN	6402369_D013438_1_214_219_thiol_D001745_1_280_299_urothelial toxicity	The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.
UN	6402369_D013438_1_214_219_thiol_D008175_1_380_391_lung cancer	The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.
UN	6402369_D015080_1_265_270_MESNA_D001745_1_280_299_urothelial toxicity	The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.
UN	6402369_D015080_0_78_112_sodium 2-mercaptoethane sulphonate_D001745_0_32_51_urothelial toxicity	Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
UN	6402369_D015080_2_507_512_MESNA_D006417_2_753_763_haematuria	MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i. Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria.
UN	6402369_D015080_0_114_119_MESNA_D008175_0_149_160_lung cancer	Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
CID	6415512_D002220_0_65_78_carbamazepine_D004831_0_0_39_Myoclonic, atonic, and absence seizures	Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.
CID	6415512_D002220_0_65_78_carbamazepine_D004832_0_0_39_Myoclonic, atonic, and absence seizures	Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.
UN	6415512_D002220_2_330_343_carbamazepine_D012640_2_451_459_seizures	When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.
CID	6433367_D001640_3_735_746_bicuculline_D012640_3_755_766_convulsions	These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.
CID	6433367_D005481_1_241_250_flurothyl_D012640_1_218_229_convulsions	To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.
CID	6433367_D005481_3_656_665_fluorthyl_D012640_3_683_694_convulsions	These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.
CID	6433367_D010433_3_671_674_PTZ_D012640_3_683_694_convulsions	These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.
CID	6433367_D010852_1_252_262_picrotoxin_D012640_1_218_229_convulsions	To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.
CID	6433367_D010852_3_704_714_picrotoxin_D012640_3_683_694_convulsions	These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.
UN	6433367_D011453_0_10_23_prostaglandin_D012640_0_72_83_convulsions	Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats.
UN	6433367_D011453_1_144_147_PGs_D012640_1_152_159_seizure	To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.
CID	6436733_D000641_3_316_323_Ammonia_D006970_3_399_409_drowsiness	Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.
UN	6436733_D014635_1_103_106_VPA_D004827_1_124_133_epileptic	Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.
CID	6436733_D014635_3_483_486_VPA_D006970_3_399_409_drowsiness	Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.
UN	6454943_D002216_1_144_153_captopril_D006973_1_167_179_hypertensive	Proteinuria is a side effect of captopril treatment in hypertensive patients.
UN	6454943_D002216_2_253_262_captopril_D007674_2_230_247_renal abnormality	The possibility of reproducing the same renal abnormality with captopril was examined in SHR.
UN	6454943_D002216_4_401_410_captopril_D011507_4_479_490_proteinuria	Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.
UN	6454943_D002216_1_144_153_captopril_D011507_1_112_123_Proteinuria	Proteinuria is a side effect of captopril treatment in hypertensive patients.
UN	6454943_D002216_0_10_19_captopril_D011507_0_64_75_proteinuria	Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.
UN	6454943_D011692_0_40_55_aminonucleoside_D006973_0_93_105_hypertensive	Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.
CID	6454943_D011692_4_502_527_puromycin aminonucleoside_D011507_4_479_490_proteinuria	Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.
CID	6454943_D011692_0_40_55_aminonucleoside_D011507_0_64_75_proteinuria	Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.
UN	6466532_D001285_0_38_46_atropine_D001145_0_84_95_arrhythmias	Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.
UN	6466532_D001285_0_38_46_atropine_D001919_0_68_79_bradycardia	Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.
UN	6466532_D006024_0_19_33_glycopyrrolate_D001145_0_84_95_arrhythmias	Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.
UN	6466532_D006024_0_19_33_glycopyrrolate_D001919_0_68_79_bradycardia	Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.
CID	6466532_D013390_1_389_402_suxamethonium_D001919_1_349_360_bradycardia	The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children, was studied.
CID	6466532_D013390_0_124_137_suxamethonium_D001919_0_68_79_bradycardia	Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.
CID	6496797_D014196_0_48_57_trazodone_D006327_0_9_20_heart block	Complete heart block following a single dose of trazodone.
CID	6503301_D003606_1_147_158_dacarbazine_D006504_1_86_121_veno-occlusive disease of the liver	A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.
CID	6503301_D003606_0_35_46_dacarbazine_D006504_0_0_28_Veno-occlusive liver disease	Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.
UN	6503301_D003606_0_56_60_DTIC_D008545_0_66_74_melanoma	Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.
UN	6503301_D003606_1_160_164_DTIC_D008545_1_178_186_melanoma	A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.
CID	6504332_D010634_1_164_177_phenobarbital_D004409_1_133_143_dyskinesia	A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.
CID	6504332_D010634_0_0_13_Phenobarbital_D004409_0_22_32_dyskinesia	Phenobarbital-induced dyskinesia in a neurologically-impaired child.
UN	6504332_D010634_1_164_177_phenobarbital_D012640_1_190_198_seizures	A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.
CID	6518066_D008094_0_9_16_lithium_D004437_0_30_47_Ebstein's anomaly	Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography.
CID	6534871_D007545_1_130_143_isoproterenol_D009203_1_152_173_myocardial infarction	The effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of age.
UN	6538499_D004317_4_493_496_ADR_D002286_4_541_562_Ehrlich ascites tumor	Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.
UN	6538499_D004317_4_493_496_ADR_D007939_4_519_533_L1210 leukemia	Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.
CID	6538499_D004317_3_410_413_ADR_D009202_3_422_455_cardiac morphological alterations	Light microscopic analysis showed a significant protection against ADR-induced cardiac morphological alterations.
CID	6540303_D004298_2_340_348_dopamine_D002389_2_375_384_catatonia	In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.
CID	6540303_D007649_8_1332_1340_ketamine_D002389_8_1341_1350_catatonia	Furthermore, dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary.
CID	6540303_D007649_2_397_405_ketamine_D002389_2_375_384_catatonia	In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.
CID	6540303_D007649_1_198_206_ketamine_D002389_1_215_224_catatonia	The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.
CID	6540303_D007649_0_33_41_ketamine_D002389_0_42_51_catatonia	Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.
UN	6540303_D009638_2_429_443_norepinephrine_D002389_2_375_384_catatonia	In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.
CID	6615052_D006493_0_0_7_Heparin_D006470_0_50_60_hemorrhage	Heparin-induced thrombocytopenia, thrombosis, and hemorrhage.
CID	6615052_D006493_1_88_95_heparin_D013921_1_104_120_thrombocytopenia	Sixty-two patients with a heparin-induced thrombocytopenia are reported.
CID	6615052_D006493_0_0_7_Heparin_D013921_0_16_32_thrombocytopenia	Heparin-induced thrombocytopenia, thrombosis, and hemorrhage.
CID	6615052_D006493_2_260_267_heparin_D013923_2_216_230_thromboembolic	Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.
UN	663266_D003973_0_30_41_diatrizoate_D014693_0_0_24_Ventricular fibrillation	Ventricular fibrillation from diatrizoate with and without chelating agents.
UN	663266_D003974_3_430_440_Renografin_D014693_3_366_390_Ventricular fibrillation	Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.
UN	6634932_C002616_3_322_328_UM-272_D017180_3_339_362_ventricular tachycardia	Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.
CID	6634932_D010042_1_191_198_ouabain_D017180_1_207_231_ventricular tachycardias	UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.
UN	6637851_D000638_1_121_131_Amiodarone_D006323_1_240_254_cardiac arrest	Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.
UN	6637851_D000638_0_45_55_amiodarone_D014693_0_95_119_ventricular fibrillation	Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.
UN	6637851_D000638_3_467_477_amiodarone_D014693_3_521_545_ventricular fibrillation	Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).
UN	6637851_D000638_9_1587_1597_amiodarone_D014693_9_1551_1553_VF	However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.
UN	6637851_D000638_4_734_744_amiodarone_D017180_4_687_689_VT	Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.
UN	6637851_D000638_3_467_477_amiodarone_D017180_3_515_517_VT	Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).
UN	6637851_D000638_9_1587_1597_amiodarone_D017180_9_1545_1547_VT	However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.
UN	6637851_D000638_0_45_55_amiodarone_D017180_0_68_91_ventricular tachycardia	Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.
UN	6640832_D004317_0_15_25_adriamycin_D001749_0_41_58_bladder carcinoma	Early adjuvant adriamycin in superficial bladder carcinoma.
UN	6640832_D004317_0_15_25_adriamycin_D002277_0_41_58_bladder carcinoma	Early adjuvant adriamycin in superficial bladder carcinoma.
CID	6666578_D010396_0_0_15_D-penicillamine_D001018_0_24_34_angiopathy	D-penicillamine-induced angiopathy in rats.
CID	6674249_D015119_2_151_176_epsilon-aminocaproic acid_D009135_2_115_135_necrotizing myopathy	A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.
CID	6674249_D015119_0_35_39_EACA_D009135_0_48_56_myopathy	Why may epsilon-aminocaproic acid (EACA) induce myopathy in man?
CID	6674249_D015119_2_151_176_epsilon-aminocaproic acid_D009336_2_115_135_necrotizing myopathy	A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.
UN	6674249_D015119_2_151_176_epsilon-aminocaproic acid_D013345_2_224_248_subarachnoid haemorrhage	A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.
UN	6692345_D001241_1_176_183_aspirin_D001749_1_300_318_bladder carcinomas	The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.
UN	6692345_D001241_1_176_183_aspirin_D013274_1_350_368_forestomach tumors	The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.
UN	6692345_D001241_5_1069_1076_aspirin_D063646_5_1013_1027_carcinogenesis	The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.
CID	6692345_D005200_1_286_291_FANFT_D001749_1_300_318_bladder carcinomas	The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.
CID	6692345_D005200_1_286_291_FANFT_D013274_1_350_368_forestomach tumors	The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.
UN	6692345_D005200_5_1007_1012_FANFT_D063646_5_1013_1027_carcinogenesis	The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.
CID	6695415_D002110_0_76_84_caffeine_D002543_0_0_19_Cerebral hemorrhage	Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.
CID	6695415_D002110_6_755_763_caffeine_D002543_6_776_795_cerebral hemorrhage	These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.
CID	6695415_D002110_6_755_763_caffeine_D006973_6_810_822_hypertensive	These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.
CID	6695415_D002110_5_610_618_caffeine_D006973_5_660_672_hypertension	A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.
CID	6695415_D002110_3_300_308_caffeine_D006973_3_351_363_hypertensive	In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.
UN	6695415_D002110_3_300_308_caffeine_D020521_3_321_327_stroke	In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.
CID	6695415_D010665_6_751_754_PPA_D002543_6_776_795_cerebral hemorrhage	These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.
CID	6695415_D010665_0_36_55_phenylpropanolamine_D002543_0_0_19_Cerebral hemorrhage	Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.
CID	6695415_D010665_6_751_754_PPA_D006973_6_810_822_hypertensive	These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.
CID	6695415_D010665_3_296_299_PPA_D020521_3_321_327_stroke	In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.
UN	6699841_D005279_1_134_152_fenoprofen calcium_D001172_1_65_85_rheumatoid arthritis	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.
UN	6699841_D005279_1_134_152_fenoprofen calcium_D007681_1_202_226_renal papillary necrosis	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.
UN	6699841_D006046_1_180_184_gold_D001172_1_65_85_rheumatoid arthritis	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.
UN	6699841_D006046_1_180_184_gold_D007681_1_202_226_renal papillary necrosis	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.
UN	6699841_D009288_1_263_271_naproxen_D001172_1_65_85_rheumatoid arthritis	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.
CID	6699841_D009288_1_263_271_naproxen_D007681_1_228_231_RPN	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.
CID	6699841_D009288_0_32_40_naproxen_D007681_0_0_24_Renal papillary necrosis	Renal papillary necrosis due to naproxen.
UN	6699841_D012459_1_164_175_salicylates_D001172_1_65_85_rheumatoid arthritis	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.
UN	6699841_D012459_1_164_175_salicylates_D007681_1_202_226_renal papillary necrosis	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.
UN	6699841_D013467_1_124_132_sulindac_D001172_1_65_85_rheumatoid arthritis	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.
UN	6699841_D013467_4_550_558_sulindac_D007674_4_592_606_renal toxicity	We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.
UN	6699841_D013467_4_550_558_sulindac_D007681_4_482_485_RPN	We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.
CID	6727060_D008787_0_39_53_metoclopramide_D004409_0_10_28_tardive dyskinesia	A case of tardive dyskinesia caused by metoclopramide.
UN	6727060_D008787_1_178_192_metoclopramide_D005767_1_197_222_gastrointestinal disorder	Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.
CID	6732043_D000728_7_1039_1047_androgen_D020181_7_961_993_obstructive sleep apnea syndrome	Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.
CID	6732043_D000728_3_509_517_androgen_D020181_3_539_562_obstructive sleep apnea	A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.
CID	6732043_D000728_1_337_346_androgens_D020181_1_266_301_syndrome of obstructive sleep apnea	We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.
CID	6732043_D000728_0_74_82_androgen_D020181_0_17_49_obstructive sleep apnea syndrome	Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.
UN	6747681_D000431_11_1731_1738_ethanol_D014786_11_1678_1689_visual loss	The frequency of visual loss decreased after the concentration of the ethanol diluent was lowered.
UN	6747681_D002330_7_1334_1338_BCNU_D001254_7_1220_1232_astrocytomas	Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.
UN	6747681_D002330_0_15_19_BCNU_D005910_0_50_67_malignant gliomas	Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.
UN	6769133_D004317_1_552_562_adriamycin_D001768_1_377_395_myocardial lesions	Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy. 1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.
CID	6769133_D004317_0_261_271_adriamycin_D006333_0_211_235_congestive heart failure	Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates. 10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg). 8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.
UN	6769133_D004317_1_552_562_adriamycin_D009202_1_449_463_cardiomyopathy	Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy. 1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.
CID	6769133_D004317_1_552_562_adriamycin_D015470_1_495_522_acute myeloblastic leukemia	Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy. 1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.
UN	6769133_D004317_0_49_59_adriamycin_D066126_0_0_11_Cardiotoxic	Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates. 10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg). 8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.
UN	6769133_D018943_1_427_440_anthracycline_D001768_1_377_395_myocardial lesions	Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy. 1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.
UN	6769133_D018943_1_427_440_anthracycline_D009202_1_449_463_cardiomyopathy	Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy. 1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.
UN	6773726_D005996_2_404_417_nitroglycerin_D003920_2_449_457_diabetic	The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.
UN	6773726_D005996_0_39_52_nitroglycerin_D003929_0_56_85_diabetic autonomic neuropathy	Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?
CID	6773726_D005996_0_39_52_nitroglycerin_D007022_0_24_35_hypotension	Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?
UN	6773726_D005996_2_404_417_nitroglycerin_D009422_2_475_495_autonomic neuropathy	The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.
UN	6794356_D008094_1_189_196_lithium_D001282_1_130_144_atrial flutter	A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.
UN	6794356_D008094_2_386_393_lithium_D006331_2_345_360_cardiac disease	This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.
UN	6794356_D008094_1_189_196_lithium_D006333_1_146_170_congestive heart failure	A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.
UN	6794356_D008094_1_189_196_lithium_D014262_1_105_128_tricuspid regurgitation	A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.
UN	6794356_D008094_2_386_393_lithium_D014262_2_265_288_tricuspid regurgitation	This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.
UN	6794356_D016651_0_34_51_lithium carbonate_D014262_0_0_29_Tricuspid valve regurgitation	Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.
UN	6817363_C036466_1_114_124_aniracetam_D000647_1_567_574_amnesia	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
UN	6817363_C036466_2_1448_1458_aniracetam_D003072_2_1401_1429_impaired cognitive functions	These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
UN	6817363_C036466_1_138_163_1-anisoyl-2-pyrrolidinone_D003072_1_212_240_impaired cognitive functions	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
UN	6817363_C036466_1_114_124_aniracetam_D006935_1_424_435_hypercapnia	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
UN	6817363_C036466_0_42_52_Ro 13-5057_D007859_0_59_87_impaired learning and memory	Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.
UN	6817363_C036466_0_42_52_Ro 13-5057_D008569_0_59_87_impaired learning and memory	Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.
UN	6817363_D002701_1_881_896_chloramphenicol_D000647_1_637_644_amnesia	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
UN	6817363_D002701_1_881_896_chloramphenicol_D003072_1_212_240_impaired cognitive functions	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
UN	6817363_D002701_1_881_896_chloramphenicol_D006935_1_1278_1289_hypercapnia	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
UN	6817363_D003513_1_900_913_cycloheximide_D000647_1_637_644_amnesia	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
UN	6817363_D003513_1_900_913_cycloheximide_D003072_1_212_240_impaired cognitive functions	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
UN	6817363_D003513_1_1112_1125_cycloheximide_D006935_1_1278_1289_hypercapnia	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
CID	6817363_D012601_1_536_547_scopolamine_D000647_1_567_574_amnesia	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
UN	6817363_D012601_1_536_547_scopolamine_D003072_1_212_240_impaired cognitive functions	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
UN	6817363_D012601_1_536_547_scopolamine_D006935_1_424_435_hypercapnia	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
CID	6861444_D009638_2_346_359_noradrenaline_D006973_2_367_379_hypertension	Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously.
CID	6861444_D009638_4_740_753_noradrenaline_D006973_4_702_714_hypertension	These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism.
CID	6888657_D004054_1_161_179_diethylstilbestrol_D010911_1_85_101_Pituitary tumors	Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.
UN	6888657_D004967_0_20_28_estrogen_D010911_0_37_60_adenohypophyseal tumors	Characterization of estrogen-induced adenohypophyseal tumors in the Fischer 344 rat.
UN	6892185_D002122_4_738_754_calcium chloride_D004830_4_863_887_clonic-tonic convulsions	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.
UN	6892185_D002122_1_113_129_calcium chloride_D004830_1_354_378_clonic-tonic convulsions	The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.
UN	6892185_D002122_3_700_716_calcium chloride_D004830_3_609_633_clonic-tonic convulsions	On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.
UN	6892185_D002122_4_738_754_calcium chloride_D014202_4_852_858_tremor	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.
UN	6892185_D002122_1_113_129_calcium chloride_D014202_1_343_349_tremor	The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.
UN	6892185_D002122_3_700_716_calcium chloride_D014202_3_598_604_tremor	On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.
UN	6892185_D002122_1_113_129_calcium chloride_D015878_1_332_341_mydriasis	The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.
UN	6892185_D002122_3_700_716_calcium chloride_D015878_3_587_596_mydriasis	On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.
UN	6892185_D002122_4_738_754_calcium chloride_D015878_4_841_850_mydriasis	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.
CID	6892185_D002217_1_391_400_carbachol_D004830_1_354_378_clonic-tonic convulsions	The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.
CID	6892185_D002217_4_898_907_carbachol_D004830_4_863_887_clonic-tonic convulsions	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.
CID	6892185_D002217_3_644_653_carbachol_D004830_3_609_633_clonic-tonic convulsions	On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.
CID	6892185_D002217_1_391_400_carbachol_D014202_1_343_349_tremor	The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.
CID	6892185_D002217_4_898_907_carbachol_D014202_4_852_858_tremor	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.
CID	6892185_D002217_3_644_653_carbachol_D014202_3_598_604_tremor	On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.
CID	6892185_D002217_3_644_653_carbachol_D015878_3_587_596_mydriasis	On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.
CID	6892185_D002217_4_898_907_carbachol_D015878_4_841_850_mydriasis	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.
CID	6892185_D002217_1_391_400_carbachol_D015878_1_332_341_mydriasis	The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.
CID	6892185_D010830_1_405_412_eserine_D004830_1_354_378_clonic-tonic convulsions	The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.
CID	6892185_D010830_4_912_919_eserine_D004830_4_863_887_clonic-tonic convulsions	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.
CID	6892185_D010830_3_658_665_eserine_D004830_3_609_633_clonic-tonic convulsions	On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.
CID	6892185_D010830_1_405_412_eserine_D014202_1_343_349_tremor	The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.
CID	6892185_D010830_4_912_919_eserine_D014202_4_852_858_tremor	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.
CID	6892185_D010830_3_658_665_eserine_D014202_3_598_604_tremor	On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.
CID	6892185_D010830_3_658_665_eserine_D015878_3_587_596_mydriasis	On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.
CID	6892185_D010830_4_912_919_eserine_D015878_4_841_850_mydriasis	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.
CID	6892185_D010830_1_405_412_eserine_D015878_1_332_341_mydriasis	The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.
UN	6942642_D006852_3_341_360_hydrochlorothiazide_C563897_3_313_335_diastolic hypertension	We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.
UN	6942642_D011188_11_1475_1484_potassium_D007008_11_1441_1452_hypokalemia	In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.
UN	7007443_D000082_2_402_413_paracetamol_D006525_2_516_531_viral hepatitis	Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.
CID	7007443_D000082_2_402_413_paracetamol_D017114_2_370_395_fulminant hepatic failure	Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.
UN	7007443_D000082_2_402_413_paracetamol_D062787_2_414_422_overdose	Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.
CID	7053303_D002927_7_982_992_cimetidine_D003704_7_1027_1035_dementia	Thus, high cimetidine levels alone do not always induce dementia.
CID	7053303_D002927_6_793_803_cimetidine_D003704_6_768_776_dementia	There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.
UN	7053303_D002927_6_928_938_cimetidine_D007674_6_896_919_liver or kidney disease	There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.
UN	7053303_D002927_6_928_938_cimetidine_D008107_6_896_919_liver or kidney disease	There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.
CID	7053705_D013866_0_41_54_6-thioguanine_D006504_0_0_30_Hepatic veno-occlusive disease	Hepatic veno-occlusive disease caused by 6-thioguanine.
UN	7053705_D013866_1_221_234_6-thioguanine_D054198_1_150_176_acute lymphocytic leukemia	Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.
UN	7059267_D002747_1_100_114_chlorpropamide_D003924_1_66_86_adult-onset diabetes	A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.
CID	7059267_D002747_1_116_125_Diabenese_D009901_1_133_155_toxic optic neuropathy	A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.
CID	7059267_D002747_0_0_14_Chlorpropamide_D009901_0_23_39_optic neuropathy	Chlorpropamide-induced optic neuropathy.
UN	7066357_D002788_4_897_915_cholesteryl esters_D009404_4_785_794_nephrotic	In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.
UN	7066357_D005227_4_821_832_fatty acids_D009404_4_785_794_nephrotic	In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.
CID	7066357_D011692_0_110_135_puromycin aminonucleoside_D009404_0_69_87_nephrotic syndrome	Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.
CID	7066357_D011692_1_262_287_puromycin aminonucleoside_D009404_1_232_250_nephrotic syndrome	This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.
UN	7066357_D014280_4_834_849_triacylglycerol_D009404_4_785_794_nephrotic	In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.
CID	7072798_D002701_0_69_84_chloramphenicol_D000741_0_6_21_aplastic anemia	Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.
CID	7072798_D002701_3_395_410_chloramphenicol_D000741_3_330_345_aplastic anemia	The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.
CID	7072798_D002701_4_493_508_chloramphenicol_D000741_4_448_463_aplastic anemia	This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.
UN	7072798_D002701_1_223_238_chloramphenicol_D002386_1_168_176_cataract	A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.
UN	7072798_D002701_5_692_707_chloramphenicol_D005128_5_642_657_ocular toxicity	Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.
UN	7083920_D000638_3_441_451_amiodarone_D001282_3_500_514_atrial flutter	Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay.
CID	7083920_D000638_1_154_164_amiodarone_D006327_1_119_137_intra-Hisian block	A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.
UN	7083920_D000638_1_154_164_amiodarone_D006345_1_225_266_intraventricular conduction abnormalities	A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.
UN	7083920_D000638_1_154_164_amiodarone_D013617_1_179_197_atrial tachycardia	A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.
CID	7088431_D004054_1_195_213_diethylstilbestrol_D014625_1_98_137_clear cell adenocarcinoma of the vagina	Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in utero to diethylstilbestrol are reported.
CID	7088431_D004054_0_44_47_DES_D018262_0_15_40_clear cell adenocarcinoma	Development of clear cell adenocarcinoma in DES-exposed offspring under observation.
CID	7102237_D008874_1_415_424_midazolam_D001049_1_381_387_apnoea	In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.
UN	7102237_D009020_1_103_111_morphine_D001049_1_381_387_apnoea	In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.
UN	7102237_D009567_1_119_129_nitrazepam_D001049_1_381_387_apnoea	In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.
UN	7102237_D012601_1_89_100_scopolamine_D001049_1_381_387_apnoea	In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.
CID	7102237_D013874_1_255_266_thiopentone_D001049_1_381_387_apnoea	In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.
UN	7161250_D001569_5_563_577_benzodiazepine_D017109_5_531_540_Akathisia	Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.
CID	7161250_D006220_2_282_293_haloperidol_D010302_2_239_251_parkinsonism	The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients.
UN	7161250_D008140_5_578_587_lorazepam_D017109_5_531_540_Akathisia	Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.
CID	7189975_C004616_5_785_799_chloroprocaine_D012640_5_761_769_seizures	A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.
CID	7189975_D002045_5_741_752_bupivacaine_D012640_5_761_769_seizures	A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.
CID	7189975_D008012_5_824_833_lidocaine_D012640_5_761_769_seizures	A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.
CID	7197363_D001058_2_293_304_apomorphine_D001523_2_313_327_aggressiveness	Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.
CID	7197363_D001058_1_164_175_apomorphine_D001523_1_184_198_aggressiveness	The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.
UN	7197363_D001058_1_164_175_apomorphine_D009069_1_221_234_head twitches	The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.
UN	7197363_D001058_2_293_304_apomorphine_D012892_2_278_282_REMD	Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.
UN	7197363_D001058_1_164_175_apomorphine_D012892_1_155_159_REMD	The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.
UN	7197363_D011814_1_203_212_quipazine_D001523_1_184_198_aggressiveness	The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.
CID	7197363_D011814_1_203_212_quipazine_D009069_1_221_234_head twitches	The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.
CID	7197363_D011814_2_426_435_quipazine_D009069_2_444_457_head twitches	Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.
UN	7197363_D011814_1_203_212_quipazine_D012892_1_155_159_REMD	The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.
UN	7197363_D011814_2_426_435_quipazine_D012892_2_420_424_REMD	Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.
CID	7199841_C004616_4_679_698_2-chloroprocaine-CE_D010243_4_731_740_paralysis	Of the 20 animals that received subarachnoid injection of 2-chloroprocaine-CE seven (35%) developed hind-limb paralysis.
CID	7199841_C004616_6_925_944_2-chloroprocaine-CE_D013118_6_956_972_subpial necrosis	Of the 15 spinal cords of the animals that received 2-chloroprocaine-CE, 13 showed subpial necrosis; the nerve roots and subarachnoid vessels were normal.
UN	7199841_D002045_5_776_787_bupivacaine_D010243_5_862_871_paralysis	None of the animals that received bupivacaine, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb paralysis.
UN	7234705_D011342_3_366_378_procainamide_D001282_3_466_480_atrial flutter	In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.
UN	7234705_D011342_8_1032_1044_procainamide_D008133_8_1069_1091_prolonged Q-T syndrome	These seven cases demonstrate that procainamide can produce an acquired prolonged Q-T syndrome with polymorphous ventricular tachycardia.
CID	7234705_D011342_2_264_276_procainamide_D017180_2_308_331_ventricular tachycardia	In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.
CID	7234705_D011342_1_74_86_procainamide_D017180_1_108_131_ventricular tachycardia	Seven cases of procainamide-induced polymorphous ventricular tachycardia are presented.
CID	7234705_D011342_0_0_12_Procainamide_D017180_0_34_57_ventricular tachycardia	Procainamide-induced polymorphous ventricular tachycardia.
UN	7234705_D011342_3_366_378_procainamide_D018879_3_428_462_premature ventricular contractions	In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.
UN	7248170_D002251_1_405_425_carbon tetrachloride_D001201_1_236_243_ascites	The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.
UN	7248170_D002251_1_405_425_carbon tetrachloride_D001284_1_345_352_atrophy	The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.
UN	7248170_D002251_0_80_100_carbon tetrachloride_D005355_0_109_118_cirrhosis	Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.
UN	7248170_D002251_1_556_576_carbon tetrachloride_D006529_1_619_643_enlargement of the liver	The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.
CID	7248170_D002251_1_405_425_carbon tetrachloride_D008103_1_140_162_cirrhosis of the liver	The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.
UN	7248170_D002251_1_405_425_carbon tetrachloride_D013163_1_299_311_splenomegaly	The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.
UN	7248170_D010634_1_456_470_phenobarbitone_D001201_1_236_243_ascites	The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.
UN	7248170_D010634_1_456_470_phenobarbitone_D001284_1_345_352_atrophy	The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.
UN	7248170_D010634_0_0_14_Phenobarbitone_D005355_0_109_118_cirrhosis	Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.
CID	7248170_D010634_0_0_14_Phenobarbitone_D006529_0_23_47_enlargement of the liver	Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.
CID	7248170_D010634_1_596_610_phenobarbitone_D006529_1_619_643_enlargement of the liver	The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.
CID	7248170_D010634_1_456_470_phenobarbitone_D008103_1_140_162_cirrhosis of the liver	The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.
UN	7248170_D010634_1_456_470_phenobarbitone_D013163_1_299_311_splenomegaly	The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.
UN	7263204_D000493_2_331_342_allopurinol_D000741_2_273_288_aplastic anemia	A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.
CID	7263204_D007213_1_94_106_indomethacin_D000741_1_150_165_aplastic anemia	Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations, its role has not been definitely established.
CID	7263204_D007213_0_29_41_indomethacin_D000741_0_6_21_aplastic anemia	Fatal aplastic anemia due to indomethacin--lymphocyte transformation tests in vitro.
UN	7265370_C020743_1_134_165_hydrochlorothiazide-triamterene_D006973_1_178_190_hypertension	A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.
UN	7265370_C020743_1_134_165_hydrochlorothiazide-triamterene_D053040_1_80_95_nephrolithiasis	A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.
UN	7265370_C020743_0_41_48_dyazide_D053040_0_12_27_nephrolithiasis	Triamterene nephrolithiasis complicating dyazide therapy.
UN	7265370_D014223_1_68_79_triamterene_D006973_1_178_190_hypertension	A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.
CID	7265370_D014223_3_321_332_triamterene_D053040_3_333_348_nephrolithiasis	Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed.
CID	7265370_D014223_0_0_11_Triamterene_D053040_0_12_27_nephrolithiasis	Triamterene nephrolithiasis complicating dyazide therapy.
CID	7265370_D014223_1_68_79_triamterene_D053040_1_80_95_nephrolithiasis	A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.
UN	7269015_D002066_4_375_383_busulfan_D002277_4_414_423_carcinoma	In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites, periodic urinary cytology is suggested in patients on long-term therapy.
CID	7269015_D002066_0_0_8_Busulfan_D003556_0_17_37_hemorrhagic cystitis	Busulfan-induced hemorrhagic cystitis.
CID	7269015_D002066_1_51_59_busulfan_D003556_1_68_87_hemorrhage cystitis	A case of a busulfan-induced hemorrhage cystitis is reported.
CID	7269015_D002066_3_219_227_busulfan_D003556_3_228_236_cystitis	The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.
CID	7269015_D002066_0_0_8_Busulfan_D006470_0_17_37_hemorrhagic cystitis	Busulfan-induced hemorrhagic cystitis.
CID	7269015_D002066_1_51_59_busulfan_D006470_1_68_87_hemorrhage cystitis	A case of a busulfan-induced hemorrhage cystitis is reported.
UN	7269015_D003520_3_260_276_cyclophosphamide_D003556_3_285_293_cystitis	The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.
CID	7282516_D004317_6_983_986_DXR_D009202_6_987_989_CM	In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.
CID	7282516_D004317_0_52_63_doxorubicin_D009202_0_64_78_cardiomyopathy	Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.
CID	7282516_D004317_1_136_147_doxorubicin_D009202_1_100_102_CM	The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.
CID	7292072_D003891_1_120_131_desipramine_D017180_1_85_108_ventricular tachycardia	We report a case of variant ventricular tachycardia induced by desipramine toxicity.
CID	7292072_D003891_0_35_46_desipramine_D017180_0_8_31_ventricular tachycardia	Variant ventricular tachycardia in desipramine toxicity.
CID	7337133_D000082_0_68_81_acetaminophen_D001929_0_8_22_cerebral edema	Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.
CID	7337133_D000082_3_292_305_acetaminophen_D017093_3_314_339_fulminant hepatic failure	We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.
CID	7337133_D000082_0_68_81_acetaminophen_D017093_0_49_64_hepatic failure	Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.
UN	7337133_D000082_0_68_81_acetaminophen_D062787_0_82_90_overdose	Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.
UN	7352670_D000809_8_1292_1303_angiotensin_D007022_8_1340_1351_hypotensive	This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.
CID	7352670_D006221_1_166_175_halothane_D007022_1_226_237_hypotension	The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.
CID	7352670_D006221_8_1363_1372_halothane_D007022_8_1340_1351_hypotensive	This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.
UN	7352670_D009599_0_27_47_sodium nitroprusside_D006973_0_8_20_hypertensive	Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.
UN	7352670_D009599_5_735_738_SNP_D006973_5_795_821_increase in blood pressure	During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.
CID	7352670_D009599_1_213_216_SNP_D007022_1_226_237_hypotension	The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.
CID	7352670_D009599_8_1377_1380_SNP_D007022_8_1340_1351_hypotensive	This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.
UN	7352670_D012504_0_61_70_saralasin_D006973_0_8_20_hypertensive	Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.
UN	7416947_D004077_3_556_563_digoxin_D012214_3_667_690_rheumatic heart disease	The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.
CID	7416947_D004077_0_87_94_digoxin_D020018_0_25_43_sexual dysfunction	Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin.
UN	7420681_D005839_3_162_180_Gentamicin sulfate_D006311_3_228_239_ototoxicity	Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.
CID	7420681_D005839_6_784_794_gentamicin_D051437_6_816_829_renal failure	Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.
CID	7420681_D005839_7_837_847_gentamicin_D051437_7_868_881_renal failure	Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.
UN	7420681_D014031_3_185_203_tobramycin sulfate_D006311_3_228_239_ototoxicity	Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.
CID	7420681_D014031_7_920_930_tobramycin_D051437_7_868_881_renal failure	Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.
UN	7421734_D004967_2_270_279_estrogens_D006689_2_230_245_Hodgkin disease	She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.
UN	7421734_D004967_3_393_402_estrogens_D010049_3_407_422_ovarian failure	Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.
CID	7421734_D004967_3_393_402_estrogens_D016889_3_476_497_endometrial carcinoma	Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.
CID	7421734_D004967_2_270_279_estrogens_D016889_2_326_344_endometrial cancer	She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.
CID	7423039_D004317_0_25_35_adriamycin_D066126_0_36_50_cardiotoxicity	Metabolic involvement in adriamycin cardiotoxicity.
CID	7423039_D004317_1_79_89_adriamycin_D066126_1_56_67_cardiotoxic	The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system.
CID	7444978_D013307_3_588_600_streptomycin_D003638_3_336_344_deafness	Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.
CID	7444978_D013307_3_588_600_streptomycin_D004409_3_659_670_dyskinesias	Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.
UN	7449470_D004317_1_104_114_adriamycin_D066126_1_39_55_Cardiac toxicity	Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent.
UN	7449470_D004317_0_11_22_doxorubicin_D066126_0_23_37_cardiotoxicity	Late, late doxorubicin cardiotoxicity.
UN	7453952_D000584_5_870_879_amiloride_D003919_5_834_866_diabetes-insipidus-like syndrome	In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.
UN	7453952_D000584_0_71_80_amiloride_D003919_0_35_67_diabetes-insipidus-like syndrome	Attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats.
UN	7453952_D000584_6_1217_1226_amiloride_D011141_6_1165_1173_polyuria	It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.
UN	7453952_D000584_1_104_113_amiloride_D011141_1_148_156_polyuria	The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.
UN	7453952_D000584_1_104_113_amiloride_D059606_1_133_143_polydipsia	The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.
UN	7453952_D000584_6_1082_1091_amiloride_D059606_6_1150_1160_polydipsia	It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.
UN	7453952_D000584_6_1217_1226_amiloride_D059606_6_1150_1160_polydipsia	It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.
CID	7453952_D008094_5_818_825_lithium_D003919_5_834_866_diabetes-insipidus-like syndrome	In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.
CID	7453952_D008094_0_19_26_lithium_D003919_0_35_67_diabetes-insipidus-like syndrome	Attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats.
UN	7453952_D008094_6_1110_1117_lithium_D011141_6_1165_1173_polyuria	It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.
UN	7453952_D008094_1_168_175_lithium_D011141_1_148_156_polyuria	The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.
UN	7453952_D008094_6_1110_1117_lithium_D059606_6_1150_1160_polydipsia	It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.
UN	7453952_D008094_1_117_124_lithium_D059606_1_133_143_polydipsia	The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.
UN	7453952_D011188_5_1038_1047_potassium_D003919_5_834_866_diabetes-insipidus-like syndrome	In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.
UN	7453952_D018021_1_299_303_LiCl_D011141_1_148_156_polyuria	The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.
UN	7453952_D018021_1_299_303_LiCl_D059606_1_133_143_polydipsia	The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.
CID	7468724_D013726_1_169_180_terbutaline_D002318_1_93_121_cardiovascular complications	Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.
CID	7468724_D013726_0_45_56_terbutaline_D002318_0_0_28_Cardiovascular complications	Cardiovascular complications associated with terbutaline treatment for preterm labor.
UN	7468724_D013726_1_169_180_terbutaline_D007752_1_185_198_preterm labor	Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.
UN	7468724_D013726_0_45_56_terbutaline_D007752_0_71_84_preterm labor	Cardiovascular complications associated with terbutaline treatment for preterm labor.
UN	7504976_C019269_6_809_825_Benzylthiouracil_D056486_6_778_787_hepatitis	One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.
CID	7504976_D002231_5_702_713_carbimazole_D002779_5_655_666_cholestatic	Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.
CID	7504976_D002231_4_602_613_carbimazole_D002779_4_569_590_cholestatic hepatitis	Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).
CID	7504976_D002231_5_702_713_carbimazole_D056486_5_682_691_hepatitis	Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.
CID	7504976_D002231_4_602_613_carbimazole_D056486_4_569_590_cholestatic hepatitis	Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).
CID	7516729_D014700_6_943_952_verapamil_D001919_6_920_931_bradycardia	Dose-dependent bradycardia induced by verapamil was potentiated by LNa, LCa, and HCa.
UN	7542793_D016559_1_116_126_Fujimycine_D006984_1_321_332_hypertrophy	Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.
CID	7542793_D016559_6_996_1001_FK506_D007674_6_965_976_nephrotoxic	These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.
CID	7542793_D016559_0_36_41_FK506_D007674_0_0_14_Nephrotoxicity	Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.
UN	7542793_D016572_1_82_95_Cyclosporin A_D006984_1_321_332_hypertrophy	Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.
CID	7542793_D016572_0_18_31_cyclosporin A_D007674_0_0_14_Nephrotoxicity	Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.
CID	7542793_D016572_6_988_991_CsA_D007674_6_965_976_nephrotoxic	These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.
UN	7542793_D018942_1_165_174_macrolide_D006984_1_321_332_hypertrophy	Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.
UN	7542793_D020123_1_193_202_rapamycin_D006984_1_321_332_hypertrophy	Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.
UN	7565311_D016190_2_232_243_carboplatin_D018233_2_273_299_embryonal rhabdomyosarcoma	We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.
CID	7565311_D016190_0_33_44_carboplatin_D058186_0_0_19_Acute renal failure	Acute renal failure in high dose carboplatin chemotherapy.
CID	7565311_D016190_1_59_70_Carboplatin_D058186_1_98_117_acute renal failure	Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.
UN	7582165_D000305_0_29_44_corticosteroids_D004342_0_7_25_allergic reactions	Pseudo-allergic reactions to corticosteroids: diagnosis and alternatives.
UN	7582165_D010248_9_1149_1162_paramethasone_D004342_9_1177_1193_hypersensitivity	Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients; however, a few of them were tolerated.
UN	7582165_D010248_11_1405_1418_paramethasone_D004342_11_1387_1394_allergy	To our knowledge, this is the first report of a pseudo-allergy caused by paramethasone.
CID	7596955_C045645_6_1104_1107_CLZ_D005483_6_1035_1047_facial flush	Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.
CID	7596955_C045645_6_1104_1107_CLZ_D006261_6_993_1001_headache	Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.
CID	7596955_C045645_6_1104_1107_CLZ_D009325_6_1059_1065_nausea	Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.
UN	7596955_D000242_4_845_849_cAMP_D001791_4_789_809_platelet aggregation	At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.
UN	7604176_D008148_8_752_762_lovastatin_D009135_8_811_819_myopathy	While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.
UN	7604176_D017035_4_335_346_pravastatin_D006937_4_370_390_hypercholesterolemia	He assumed pravastatin (20 mg/day) because of hypercholesterolemia.
CID	7604176_D017035_2_116_127_pravastatin_D009220_2_67_88_inflammatory myopathy	A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.
UN	7604176_D019821_8_767_778_simvastatin_D009135_8_811_819_myopathy	While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.
UN	761833_D000641_0_12_19_ammonia_D003128_0_20_24_coma	Reversal of ammonia coma in rats by L-dopa: a peripheral effect.
UN	761833_D000641_1_65_72_Ammonia_D003128_1_73_77_coma	Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.
UN	761833_D000641_4_577_584_ammonia_D003128_4_585_589_coma	Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.
UN	761833_D000641_5_745_752_ammonia_D003128_5_753_757_coma	Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.
UN	761833_D000641_6_846_853_ammonia_D003128_6_854_858_coma	Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.
CID	761833_D000643_1_166_171_NH4CL_D003128_1_73_77_coma	Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.
UN	761833_D004298_4_529_537_dopamine_D003128_4_585_589_coma	Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.
UN	761833_D007980_7_1107_1113_L-dopa_D001927_7_1072_1087_encephalopathic	These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving L-dopa.
UN	761833_D007980_2_212_218_L-dopa_D003128_2_178_182_coma	This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.
UN	761833_D007980_0_36_42_L-dopa_D003128_0_20_24_coma	Reversal of ammonia coma in rats by L-dopa: a peripheral effect.
UN	761833_D007980_5_703_709_L-dopa_D003128_5_753_757_coma	Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.
UN	761833_D007980_6_865_871_L-dopa_D003128_6_854_858_coma	Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.
UN	7619765_D005047_1_125_134_etoposide_D003327_1_170_192_coronary heart disease	The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.
CID	7619765_D005047_0_0_9_Etoposide_D009203_0_18_39_myocardial infarction	Etoposide-related myocardial infarction.
CID	7619765_D005047_1_125_134_etoposide_D009203_1_61_82_myocardial infarction	The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.
UN	7628595_D002955_1_202_214_folinic acid_D001855_1_270_293_bone marrow suppression	A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.
UN	7628595_D002955_2_493_505_folinic acid_D015658_2_308_351_human immunodeficiency virus (HIV)-infected	Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).
UN	7628595_D005492_7_1302_1308_folate_D001855_7_1335_1351_myelosuppression	There was no correlation between vitamin B12 or folate levels and development of myelosuppression.
UN	7628595_D014805_7_1287_1298_vitamin B12_D001855_7_1335_1351_myelosuppression	There was no correlation between vitamin B12 or folate levels and development of myelosuppression.
UN	7628595_D014805_2_538_549_vitamin B12_D015658_2_308_351_human immunodeficiency virus (HIV)-infected	Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).
CID	7628595_D015215_8_1460_1463_ZDV_D001855_8_1472_1485_myelotoxicity	Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.
CID	7628595_D015215_1_257_260_ZDV_D001855_1_270_293_bone marrow suppression	A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.
UN	7628595_D015215_2_427_430_ZDV_D015658_2_308_351_human immunodeficiency virus (HIV)-infected	Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).
UN	7647582_D004737_4_551_560_enflurane_D004342_4_585_601_hypersensitivity	This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.
UN	7647582_D004737_8_1228_1237_enflurane_D004342_8_1272_1288_hypersensitivity	This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.
CID	7647582_D004737_8_1228_1237_enflurane_D056486_8_1328_1337_hepatitis	This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.
CID	7647582_D004737_1_137_146_enflurane_D056486_1_206_220_hepatic injury	Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.
UN	7647582_D006221_4_613_622_halothane_D004342_4_585_601_hypersensitivity	This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.
UN	7647582_D006221_8_1318_1327_halothane_D004342_8_1272_1288_hypersensitivity	This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.
CID	7647582_D006221_1_267_276_halothane_D056486_1_206_220_hepatic injury	Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.
CID	7647582_D006221_3_458_467_halothane_D056486_3_468_477_hepatitis	An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.
CID	7647582_D006221_2_278_287_Halothane_D056486_2_288_297_hepatitis	Halothane hepatitis appears to involve an aberrant immune response.
CID	7647582_D006221_8_1318_1327_halothane_D056486_8_1328_1337_hepatitis	This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.
UN	7647582_D007530_8_1245_1255_isoflurane_D004342_8_1272_1288_hypersensitivity	This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.
UN	7647582_D007530_4_565_575_isoflurane_D004342_4_585_601_hypersensitivity	This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.
CID	7647582_D007530_1_151_161_isoflurane_D056486_1_206_220_hepatic injury	Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.
CID	7647582_D007530_8_1245_1255_isoflurane_D056486_8_1328_1337_hepatitis	This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.
UN	7647582_D014269_3_413_428_trifluoroacetyl_D056486_3_468_477_hepatitis	An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.
UN	7650771_D004456_1_157_177_echothiophate iodide_D009157_1_277_294_myasthenia gravis	A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.
CID	7650771_D004456_1_157_177_echothiophate iodide_D018908_1_220_235_muscle weakness	A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.
UN	7651879_D001569_1_178_193_benzodiazepines_D012131_1_144_166_respiratory depression	Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.
UN	7651879_D005442_1_64_74_Flumazenil_D012131_1_144_166_respiratory depression	Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.
CID	7651879_D005442_0_14_24_flumazenil_D012640_0_0_7_Seizure	Seizure after flumazenil administration in a pediatric patient.
CID	7651879_D005442_5_577_587_flumazenil_D012640_5_501_521_tonic-clonic seizure	We report the occurrence of a generalized tonic-clonic seizure in a pediatric patient following the administration of flumazenil.
CID	7707116_D015474_15_1738_1744_cis-RA_D006934_15_1693_1706_hypercalcemia	The DLT included hypercalcemia, and may be predicted by serum cis-RA levels.
UN	7707116_D015474_3_499_505_cis-RA_D009447_3_564_577_neuroblastoma	This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).
UN	7707116_D015474_1_160_180_13-cis-retinoic acid_D009447_1_130_143_neuroblastoma	PURPOSE: Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation.
UN	7707116_D015474_2_245_251_cis-RA_D009447_2_291_304_neuroblastoma	Since cis-RA has demonstrated clinical responses in neuroblastoma patients, it may be effective in preventing relapse after cytotoxic therapy.
UN	7707116_D015474_0_17_37_13-cis-retinoic acid_D009447_0_55_68_neuroblastoma	Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.
UN	7710775_D001241_6_1101_1117_acetylsalicylate_D007022_6_1211_1222_hypotensive	Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.
UN	7710775_D001241_6_1101_1117_acetylsalicylate_D007511_6_1151_1159_ischemia	Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.
CID	7710775_D008315_0_26_41_malondialdehyde_D002545_0_89_106_cerebral ischemia	Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.
UN	7710775_D008315_6_1341_1356_malondialdehyde_D007022_6_1211_1222_hypotensive	Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.
UN	7710775_D008315_6_1341_1356_malondialdehyde_D007511_6_1301_1309_ischemia	Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.
UN	7710775_D009599_6_1228_1241_nitroprusside_D007022_6_1211_1222_hypotensive	Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.
UN	7710775_D009599_6_1228_1241_nitroprusside_D007511_6_1301_1309_ischemia	Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.
UN	7710775_D009705_0_59_70_nucleosides_D002545_0_89_106_cerebral ischemia	Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.
UN	7710775_D009705_7_1468_1479_nucleosides_D007511_7_1578_1586_ischemic	The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)
UN	7710775_D009705_4_640_651_nucleosides_D007511_4_579_587_ischemia	During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.
UN	7724492_D003487_0_56_69_cyanoacrylate_D007674_0_6_20_renal toxicity	Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.
UN	7724492_D004317_1_91_102_doxorubicin_D005921_1_205_223_glomerulonephritis	Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.
UN	7724492_D004317_6_697_699_DX_D005921_6_662_680_glomerulonephritis	In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.
UN	7724492_D004317_0_24_35_doxorubicin_D007674_0_6_20_renal toxicity	Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.
UN	7724492_D004317_1_91_102_doxorubicin_D007674_1_130_144_renal toxicity	Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.
CID	7724492_D004317_7_897_908_doxorubicin_D011507_7_798_809_Proteinuria	Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.
CID	7724492_D004317_3_487_489_DX_D011507_3_410_421_proteinuria	A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX.
CID	7752389_D015232_0_0_16_Prostaglandin E2_D053201_0_25_46_bladder hyperactivity	Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?
UN	7752389_D015320_8_1469_1480_tachykinins_D053201_8_1510_1531_bladder hyperactivity	Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.
UN	7752389_D015320_0_89_100_tachykinins_D053201_0_25_46_bladder hyperactivity	Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?
UN	7785794_D001285_3_419_427_atropine_D006327_3_367_378_heart block	The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.
UN	7785794_D001285_3_419_427_atropine_D007022_3_341_352_hypotensive	The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.
UN	7785794_D002122_4_547_563_calcium chloride_D006327_4_605_616_heart block	However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.
UN	7785794_D002122_4_547_563_calcium chloride_D007022_4_580_591_hypotension	However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.
UN	7785794_D004280_3_489_499_dobutamine_D006327_3_367_378_heart block	The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.
UN	7785794_D004280_3_489_499_dobutamine_D007022_3_341_352_hypotensive	The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.
UN	7785794_D004298_3_476_484_dopamine_D006327_3_367_378_heart block	The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.
UN	7785794_D004298_3_476_484_dopamine_D007022_3_341_352_hypotensive	The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.
CID	7785794_D008790_0_77_87_metoprolol_D006327_0_42_53_heart block	Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.
CID	7785794_D008790_2_297_307_metoprolol_D007022_2_196_207_hypotension	A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.
UN	7785794_D008790_0_77_87_metoprolol_D012770_0_11_28_cardiogenic shock	Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.
CID	7785794_D014700_0_60_69_verapamil_D006327_0_42_53_heart block	Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.
CID	7785794_D014700_2_263_272_verapamil_D007022_2_196_207_hypotension	A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.
UN	7785794_D014700_0_60_69_verapamil_D012770_0_11_28_cardiogenic shock	Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.
CID	7791169_D007213_8_1487_1499_indomethacin_D007674_8_1508_1525_renal dysfunction	CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction.
CID	7791169_D007213_0_36_48_indomethacin_D007674_0_57_74_renal dysfunction	Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.
UN	7791169_D016595_0_21_32_misoprostol_D007674_0_57_74_renal dysfunction	Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.
UN	7791169_D016595_9_1539_1550_misoprostol_D007674_9_1569_1585_renal impairment	Addition of misoprostol can minimize this renal impairment without affecting pain control.
UN	7791169_D016595_9_1539_1550_misoprostol_D010146_9_1604_1608_pain	Addition of misoprostol can minimize this renal impairment without affecting pain control.
UN	7802851_D000525_3_219_229_alprazolam_D000379_3_265_276_agoraphobia	The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.
UN	7802851_D000525_4_484_494_alprazolam_D000379_4_453_464_agoraphobia	METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.
CID	7802851_D000525_8_731_741_alprazolam_D001259_8_944_950_ataxia	Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.
CID	7802851_D000525_8_731_741_alprazolam_D003866_8_799_809_depression	Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.
CID	7802851_D000525_8_731_741_alprazolam_D004775_8_811_819_enuresis	Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.
CID	7802851_D000525_8_731_741_alprazolam_D008569_8_911_926_impaired memory	Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.
CID	7802851_D000525_8_731_741_alprazolam_D015431_8_928_939_weight loss	Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.
UN	7802851_D000525_3_219_229_alprazolam_D016584_3_245_259_panic disorder	The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.
UN	7802851_D000525_4_484_494_alprazolam_D016584_4_433_447_panic disorder	METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.
CID	7803371_D003915_0_48_64_dextromethorphan_D003072_0_0_23_Cognitive deterioration	Cognitive deterioration from long-term abuse of dextromethorphan: a case report.
CID	7803371_D003915_7_1109_1111_DM_D003072_7_1053_1076_cognitive deterioration	This report describes a case of cognitive deterioration resulting from prolonged use of DM.
UN	783197_D004071_2_205_225_digitalis glycosides_D003324_2_323_346_coronary artery disease	The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.
CID	783197_D010042_10_1898_1905_ouabain_D002303_10_1848_1891_left ventricular end-diastolic volume falls	We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.
UN	783197_D010042_0_11_18_ouabain_D003324_0_83_106_coronary artery disease	Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.
UN	783197_D010042_10_1898_1905_ouabain_D003324_10_1775_1798_coronary artery disease	We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.
UN	783197_D010042_3_421_428_ouabain_D003324_3_543_566_coronary artery disease	We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.
UN	783197_D010042_10_1898_1905_ouabain_D006333_10_1823_1847_congestive heart failure	We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.
UN	783197_D010100_0_33_39_oxygen_D003324_0_83_106_coronary artery disease	Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.
UN	7834920_D007538_2_372_381_isoniazid_D014397_2_386_408_pulmonary tuberculosis	This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.
UN	7834920_D007538_2_372_381_isoniazid_D051437_2_462_475_renal failure	This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.
CID	7834920_D012293_5_922_930_rifampin_D005921_5_877_895_glomerulonephritis	This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.
CID	7834920_D012293_0_70_78_rifampin_D005921_0_22_40_glomerulonephritis	Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.
CID	7834920_D012293_1_239_247_rifampin_D005921_1_194_212_glomerulonephritis	This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease.
UN	7834920_D012293_0_70_78_rifampin_D014397_0_91_113_pulmonary tuberculosis	Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.
UN	7834920_D012293_2_359_367_rifampin_D014397_2_386_408_pulmonary tuberculosis	This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.
CID	7834920_D012293_2_359_367_rifampin_D051437_2_462_475_renal failure	This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.
CID	7843916_D003907_12_2030_2043_dexamethasone_D009798_12_1982_2001_ocular hypertension	CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.
CID	7843916_D003907_10_1347_1360_dexamethasone_D009798_10_1369_1386_hypertensive eyes	In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.
CID	7843916_D003907_0_0_13_Dexamethasone_D009798_0_22_41_ocular hypertension	Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes.
UN	7843916_D013256_13_2058_2065_Steroid_D005901_13_2165_2188_corticosteroid glaucoma	Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.
UN	7843916_D013256_13_2058_2065_Steroid_D005902_13_2193_2212_open angle glaucoma	Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.
UN	7858459_C007419_5_948_961_dihydrouracil_D020258_5_837_850_neurotoxicity	The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.
UN	7858459_C007744_5_909_922_fluorocitrate_D020258_5_837_850_neurotoxicity	The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.
UN	7858459_D002945_1_158_169_cisplatinum_D013274_1_265_287_gastric adenocarcinoma	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.
UN	7858459_D002955_2_503_515_folinic acid_D001523_2_368_380_irritability	He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.
CID	7858459_D002955_2_503_515_folinic acid_D003128_2_410_414_coma	He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.
CID	7858459_D002955_0_70_82_folinic acid_D003221_0_6_15_confusion	Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.
CID	7858459_D002955_2_503_515_folinic acid_D003221_2_349_363_disorientation	He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.
UN	7858459_D002955_6_1013_1025_folinic acid_D009369_6_1093_1100_cancers	High-dose 5-fluorouracil/folinic acid infusion therapy has recently become a popular regimen for various cancers.
UN	7858459_D002955_1_234_246_folinic acid_D013274_1_265_287_gastric adenocarcinoma	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.
UN	7858459_D002955_4_670_682_folinic acid_D020258_4_734_747_neurotoxicity	Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.
UN	7858459_D005047_1_171_180_etoposide_D013274_1_265_287_gastric adenocarcinoma	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.
UN	7858459_D005463_5_891_904_fluoroacetate_D020258_5_837_850_neurotoxicity	The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.
UN	7858459_D005472_2_484_498_5-fluorouracil_D001523_2_368_380_irritability	He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.
CID	7858459_D005472_2_484_498_5-fluorouracil_D003128_2_410_414_coma	He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.
CID	7858459_D005472_0_51_65_5-fluorouracil_D003221_0_6_15_confusion	Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.
UN	7858459_D005472_6_998_1012_5-fluorouracil_D009369_6_1093_1100_cancers	High-dose 5-fluorouracil/folinic acid infusion therapy has recently become a popular regimen for various cancers.
UN	7858459_D005472_1_192_206_5-fluorouracil_D013274_1_265_287_gastric adenocarcinoma	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.
UN	7858459_D005472_5_822_836_5-fluorouracil_D020258_5_837_850_neurotoxicity	The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.
UN	7858459_D005472_4_765_779_5-fluorouracil_D020258_4_734_747_neurotoxicity	Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.
UN	7858459_D013831_5_924_932_thiamine_D020258_5_837_850_neurotoxicity	The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.
UN	7862923_C036006_2_155_168_oxcarbazepine_D012559_2_198_211_schizophrenic	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.
UN	7862923_C036006_2_155_168_oxcarbazepine_D019965_2_215_232_organic psychotic	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.
UN	7862923_D002220_2_104_117_Carbamazepine_D012559_2_198_211_schizophrenic	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.
UN	7862923_D002220_2_104_117_Carbamazepine_D019965_2_215_232_organic psychotic	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.
UN	7862923_D002746_2_275_289_chlorpromazine_D012559_2_198_211_schizophrenic	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.
UN	7862923_D002746_2_275_289_chlorpromazine_D019965_2_215_232_organic psychotic	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.
UN	7862923_D003024_2_293_302_clozapine_D012559_2_198_211_schizophrenic	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.
UN	7862923_D003024_2_293_302_clozapine_D019965_2_215_232_organic psychotic	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.
UN	7862923_D006220_2_262_273_haloperidol_D012559_2_198_211_schizophrenic	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.
UN	7862923_D006220_2_262_273_haloperidol_D019965_2_215_232_organic psychotic	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.
UN	7881871_D010100_1_93_99_oxygen_D007674_1_198_209_nephropathy	Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.
UN	7881871_D010100_1_93_99_oxygen_D011507_1_256_267_proteinuria	Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.
CID	7881871_D011692_1_185_188_PAN_D007674_1_198_209_nephropathy	Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.
CID	7881871_D011692_0_37_62_puromycin aminonucleoside_D007674_0_71_82_nephropathy	Time course of lipid peroxidation in puromycin aminonucleoside-induced nephropathy.
CID	7881871_D011692_9_1127_1130_PAN_D007674_9_1131_1142_nephropathy	This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.
CID	7881871_D011692_9_1127_1130_PAN_D011507_9_1105_1123_proteinuric injury	This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.
UN	7890216_D002118_10_1928_1935_calcium_D042882_10_1905_1916_gall stones	In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.
UN	7890216_D002784_8_1548_1559_cholesterol_D042882_8_1490_1500_gall stone	After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.
UN	7890216_D002784_10_1760_1771_cholesterol_D042882_10_1713_1724_gall stones	In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.
UN	7890216_D002784_10_1760_1771_cholesterol_D042882_10_1814_1832_gall stone disease	In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.
UN	7890216_D014580_0_80_100_ursodeoxycholic acid_D042882_0_15_34_gall bladder stones	Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.
UN	7890216_D015282_2_377_387_octreotide_D000172_2_396_407_acromegalic	Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.
CID	7890216_D015282_2_377_387_octreotide_D042882_2_422_433_gall stones	Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.
CID	7890216_D015282_0_51_61_octreotide_D042882_0_15_34_gall bladder stones	Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.
CID	7890216_D015282_10_1694_1704_octreotide_D042882_10_1713_1724_gall stones	In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.
UN	7905523_C059896_5_792_800_SC-48334_D007153_5_915_931_immunodeficiency	The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).
UN	7905523_C059896_0_65_73_SC-48334_D015658_0_107_122_HIV-1 infection	The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.
UN	7905523_D015215_0_79_89_zidovudine_D015658_0_107_122_HIV-1 infection	The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.
UN	7910951_D000305_0_77_92_corticosteroids_D010243_0_10_19_paralysis	Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.
UN	7910951_D000305_9_1158_1173_corticosteroids_D018908_9_1016_1024_weakness	The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).
CID	7910951_D003473_9_1118_1125_ND-NMBA_D009468_9_1053_1097_pathology at both the neuromuscular junction	The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).
UN	7910951_D003473_0_27_72_nondepolarizing neuromuscular blocking agents_D010243_0_10_19_paralysis	Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.
UN	7910951_D003473_2_463_471_ND-NMBAs_D012131_2_371_396_respiratory insufficiency	We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.
CID	7910951_D003473_2_463_471_ND-NMBAs_D018908_2_421_429_weakness	We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.
CID	7919560_D000667_0_63_73_ampicillin_D004892_0_0_19_Erythema multiforme	Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.
CID	7919560_D000667_1_169_179_ampicillin_D004892_1_106_125_erythema multiforme	OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.
CID	7919560_D000667_0_63_73_ampicillin_D009205_0_24_52_hypersensitivity myocarditis	Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.
CID	7919560_D000667_1_169_179_ampicillin_D009205_1_130_158_hypersensitivity myocarditis	OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.
UN	7919560_D000667_2_230_240_ampicillin_D018805_2_277_287_septicemia	CASE SUMMARY: A 13-year-old boy was treated with ampicillin and gentamicin because of suspected septicemia.
UN	7919560_D005839_2_245_255_gentamicin_D018805_2_277_287_septicemia	CASE SUMMARY: A 13-year-old boy was treated with ampicillin and gentamicin because of suspected septicemia.
CID	7930386_D002997_0_0_12_Clomipramine_D012893_0_21_38_sleep disturbance	Clomipramine-induced sleep disturbance does not impair its prolactin-releasing action.
UN	7988234_D004155_7_727_742_diphenhydramine_D000799_7_663_673_angioedema	The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.
CID	7988234_D008790_0_55_65_metoprolol_D000799_0_0_10_Angioedema	Angioedema following the intravenous administration of metoprolol.
UN	7988234_D013256_7_714_722_steroids_D000799_7_663_673_angioedema	The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.
CID	7988234_D017706_3_357_367_lisinopril_D000799_3_333_343_angioedema	A history of angioedema secondary to lisinopril therapy was elicited.
UN	8012887_D006493_2_297_304_heparin_D001791_2_313_333_platelet aggregation	Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.
CID	8012887_D006493_3_543_550_heparin_D013927_3_559_569_thrombosis	The authors present a case of failure of ancrod treatment in a patient with heparin-induced thrombosis.
CID	8012887_D006493_1_119_126_heparin_D013927_1_135_145_thrombosis	The morbidity and mortality associated with heparin-induced thrombosis remain high despite numerous empirical therapies.
CID	8012887_D006493_2_297_304_heparin_D013927_2_269_279_thrombosis	Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.
CID	8012887_D006493_0_38_45_heparin_D013927_0_63_73_thrombosis	Failure of ancrod in the treatment of heparin-induced arterial thrombosis.
UN	803783_D010121_3_289_297_Oxytocin_D000031_3_341_350_abortions	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.
UN	803783_D010121_1_143_151_oxytocin_D000031_1_189_198_abortions	Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.
UN	803783_D010121_0_35_43_oxytocin_D000031_0_81_89_abortion	Water intoxication associated with oxytocin administration during saline-induced abortion.
UN	803783_D010121_3_289_297_Oxytocin_D001247_3_576_584_asthenia	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.
UN	803783_D010121_3_289_297_Oxytocin_D001523_3_595_607_irritability	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.
UN	803783_D010121_3_289_297_Oxytocin_D006261_3_612_621_headaches	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.
CID	803783_D010121_1_143_151_oxytocin_D014869_1_105_123_water intoxication	Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.
CID	803783_D010121_0_35_43_oxytocin_D014869_0_0_18_Water intoxication	Water intoxication associated with oxytocin administration during saline-induced abortion.
CID	804391_D012293_0_58_66_rifampin_D011507_0_12_23_proteinuria	Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.
UN	804391_D012293_1_183_191_rifampin_D014376_1_148_160_tuberculosis	Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin.
UN	804391_D012293_0_58_66_rifampin_D014376_0_89_101_tuberculosis	Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.
CID	8045270_C061282_2_352_361_CGS 21680_D002375_2_243_253_cataleptic	Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.
UN	8045270_C081198_3_407_414_KF17837_D002375_3_432_441_catalepsy	KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).
UN	8045270_C081198_7_1043_1050_KF17837_D010302_7_1092_1104_parkinsonism	Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism.
UN	8045270_D000241_2_320_329_adenosine_D002375_2_243_253_cataleptic	Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.
CID	8045270_D006220_3_453_464_haloperidol_D002375_3_432_441_catalepsy	KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).
CID	8045270_D012110_3_487_496_reserpine_D002375_3_432_441_catalepsy	KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).
CID	8073369_C007112_12_1591_1598_coniine_D001176_12_1607_1621_arthrogryposis	In summary, the chick embryo provides a reliable and simple experimental animal model of coniine-induced arthrogryposis.
CID	8073369_C007112_3_263_270_coniine_D001176_3_293_307_arthrogryposis	However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.
CID	8073369_D009538_9_1115_1123_nicotine_D002543_9_1080_1098_cranial hemorrhage	No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all nicotine sulfate-treated chicks.
CID	8092427_D000658_2_388_399_amoxicillin_D004342_2_366_374_allergic	A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.
CID	8092427_D000658_13_1495_1497_AX_D004342_13_1474_1491_allergic reaction	Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.
CID	8092427_D000658_15_1642_1644_AX_D004342_15_1645_1653_allergic	We describe the largest group of AX-allergic patients who have tolerated PG reported so far.
CID	8092427_D000658_7_928_930_AX_D004342_7_931_938_allergy	We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.
CID	8092427_D000658_0_32_43_amoxicillin_D004342_0_10_28_allergic reactions	Immediate allergic reactions to amoxicillin.
UN	8092427_D010400_9_1177_1179_PG_D007645_9_1150_1153_MDM	All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.
CID	809711_D005996_1_279_292_nitroglycerin_D007022_1_301_312_hypotension	Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.
UN	809711_D005996_3_494_507_nitroglycerin_D009203_3_450_472_myocardial infarctions	Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.
UN	809711_D005996_0_67_80_nitroglycerin_D009203_0_98_125_acute myocardial infarction	Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction.
UN	809711_D005996_7_1193_1206_nitroglycerin_D009203_7_1259_1286_acute myocardial infarction	Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction.
UN	809711_D010656_0_12_25_phenylephrine_D009203_0_98_125_acute myocardial infarction	Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction.
UN	809711_D010656_7_1176_1189_phenylephrine_D009203_7_1259_1286_acute myocardial infarction	Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction.
UN	8106150_D001285_8_898_906_Atropine_D002819_8_945_951_chorea	Atropine converted the dystonic movements into chorea.
UN	8106150_D001285_8_898_906_Atropine_D020821_8_921_929_dystonic	Atropine converted the dystonic movements into chorea.
UN	8106150_D001418_7_815_823_Baclofen_D004409_7_886_896_dyskinesia	Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.
UN	8106150_D001418_7_815_823_Baclofen_D020821_7_869_877_dystonic	Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.
UN	8106150_D003000_5_558_567_clonidine_D004409_5_652_662_dyskinetic	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
UN	8106150_D003000_5_558_567_clonidine_D020734_5_704_716_parkinsonian	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
UN	8106150_D004298_4_426_434_dopamine_D004409_4_493_503_dyskinetic	A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.
UN	8106150_D007980_4_472_478_L-DOPA_D004409_4_493_503_dyskinetic	A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.
UN	8106150_D007980_0_35_41_L-dopa_D004409_0_50_61_dyskinesias	Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.
UN	8106150_D008614_6_756_766_meperidine_D004409_6_793_803_dyskinetic	However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
UN	8106150_D008784_5_584_596_methysergide_D004409_5_652_662_dyskinetic	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
UN	8106150_D008784_5_584_596_methysergide_D020734_5_704_716_parkinsonian	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
UN	8106150_D010830_5_569_582_physostigmine_D004409_5_652_662_dyskinetic	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
UN	8106150_D010830_5_569_582_physostigmine_D020734_5_704_716_parkinsonian	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
UN	8106150_D011433_5_606_617_propranolol_D004409_5_652_662_dyskinetic	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
UN	8106150_D011433_5_606_617_propranolol_D020734_5_704_716_parkinsonian	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
UN	8106150_D015016_6_742_751_yohimbine_D004409_6_793_803_dyskinetic	However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
UN	8106150_D015632_0_65_69_MPTP_D004409_0_50_61_dyskinesias	Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.
CID	8106150_D015632_1_152_156_MPTP_D020734_1_124_136_parkinsonian	A group of four monkeys was rendered parkinsonian with the toxin MPTP.
UN	8106150_D016291_5_623_629_MK-801_D004409_5_652_662_dyskinetic	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
UN	8106150_D016291_5_623_629_MK-801_D020734_5_704_716_parkinsonian	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
UN	8111719_D006220_12_1302_1313_haloperidol_D011595_12_1243_1252_agitation	If agitation becomes marked, high-potency neuroleptics (i.e., haloperidol) may be effective.
CID	8111719_D007069_9_890_900_ifosfamide_D006212_9_909_923_hallucinations	The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. "Eyes-closed" hallucinatory experiences appear to be an unusual feature of this presentation.
CID	8111719_D007069_3_329_339_ifosfamide_D006212_3_348_362_hallucinations	METHODS: The authors interviewed six persons with ifosfamide-induced hallucinations in the presence of a clear sensorium.
CID	8111719_D007069_2_192_202_ifosfamide_D006212_2_211_225_hallucinations	Most cases of ifosfamide-induced hallucinations have been reported with other mental status changes.
CID	8111719_D007069_0_19_29_ifosfamide_D006212_0_0_14_Hallucinations	Hallucinations and ifosfamide-induced neurotoxicity.
UN	8111719_D007069_0_19_29_ifosfamide_D020258_0_38_51_neurotoxicity	Hallucinations and ifosfamide-induced neurotoxicity.
UN	8111719_D007069_1_166_176_ifosfamide_D020258_1_104_117_neurotoxicity	BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.
CID	8170551_D000086_3_288_301_acetazolamide_D007669_3_318_331_renal calculi	Three patients on acetazolamide (15%) developed renal calculi.
UN	8170551_D000086_0_0_13_Acetazolamide_D009468_0_69_92_neuromuscular disorders	Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.
CID	8231633_D002045_5_887_898_bupivacaine_D012640_5_907_918_convulsions	The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.
UN	8231633_D002118_5_822_829_calcium_D012640_5_907_918_convulsions	The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.
UN	8231633_D015764_5_957_965_bepridil_D012640_5_907_918_convulsions	The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.
CID	8251368_D009543_0_17_27_nifedipine_D013684_0_43_57_telangiectasia	Photodistributed nifedipine-induced facial telangiectasia.
CID	8251368_D017311_4_397_407_amlodipine_D013684_4_442_456_telangiectasia	One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.
UN	8267029_D010396_0_0_13_Penicillamine_D001172_0_79_99_rheumatoid arthritis	Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.
CID	8267029_D010396_6_751_766_D-penicillamine_D005921_6_729_733_RPGN	This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.
CID	8267029_D010396_1_221_236_D-penicillamine_D005921_1_197_201_RPGN	A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.
CID	8267029_D010396_0_0_13_Penicillamine_D005921_0_42_60_glomerulonephritis	Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.
UN	8267029_D010396_6_751_766_D-penicillamine_D011507_6_878_889_proteinuria	This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.
UN	8268147_D010396_2_301_316_D-penicillamine_D003882_2_231_246_dermatomyositis	Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.
UN	8268147_D010396_0_80_95_D-penicillamine_D008105_0_41_66_primary biliary cirrhosis	A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.
UN	8268147_D010396_1_106_121_D-penicillamine_D012216_1_145_167_rheumatologic diseases	Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients.
CID	8268147_D010396_3_467_482_D-penicillamine_D017285_3_438_450_polymyositis	We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.
CID	8268147_D010396_0_80_95_D-penicillamine_D017285_0_10_22_polymyositis	A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.
CID	8278214_D009020_1_200_208_morphine_D006930_1_219_231_hyperalgesia	Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.
CID	8278214_D009020_5_674_682_morphine_D006930_5_633_645_hyperalgesia	Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.
CID	8278214_D009020_0_91_99_morphine_D009207_0_17_26_myoclonus	Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.
CID	8278214_D009020_5_674_682_morphine_D009207_5_646_655_myoclonus	Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.
UN	8278214_D009020_0_91_99_morphine_D009369_0_39_45_cancer	Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.
CID	8302922_D000527_1_125_129_PGE1_D007022_1_161_172_hypotension	To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.
CID	8302922_D000527_0_27_43_prostaglandin E1_D007022_0_68_79_hypotension	Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.
CID	8302922_D000527_4_886_890_PGE1_D007022_4_867_878_hypotension	After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.
CID	8302922_D000527_7_1291_1295_PGE1_D007022_7_1325_1336_hypotensive	These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.
UN	8302922_D007530_1_342_352_isoflurane_D007022_1_161_172_hypotension	To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.
CID	8302922_D014294_0_47_59_trimethaphan_D007022_0_68_79_hypotension	Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.
CID	8302922_D014294_1_148_151_TMP_D007022_1_161_172_hypotension	To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.
CID	8302922_D014294_7_1317_1320_TMP_D007022_7_1325_1336_hypotensive	These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.
UN	8305357_D003630_1_169_181_daunorubicin_D000163_1_214_218_AIDS	We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.
UN	8305357_D003630_1_169_181_daunorubicin_D012514_1_227_243_Kaposi's sarcoma	We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.
UN	8305357_D003630_0_10_22_daunorubicin_D012514_0_35_51_Kaposi's sarcoma	Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.
UN	8319760_D000804_1_350_364_angiotensin II_D006937_1_157_177_hypercholesterolemia	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
UN	8319760_D000804_1_350_364_angiotensin II_D009404_1_99_118_nephrotic syndromes	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
UN	8319760_D000804_1_350_364_angiotensin II_D011507_1_127_138_proteinuria	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
UN	8319760_D000804_1_350_364_angiotensin II_D034141_1_140_155_hypoalbuminemia	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
UN	8319760_D000809_2_477_488_angiotensin_D009401_2_552_561_nephrosis	The results suggest a possible involvement of the renin-angiotensin system in the development of puromycin aminonucleoside-induced nephrosis.
UN	8319760_D001806_1_194_213_blood nitrogen urea_D006937_1_157_177_hypercholesterolemia	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
UN	8319760_D001806_1_194_213_blood nitrogen urea_D009404_1_99_118_nephrotic syndromes	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
UN	8319760_D001806_1_194_213_blood nitrogen urea_D011507_1_127_138_proteinuria	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
UN	8319760_D001806_1_194_213_blood nitrogen urea_D034141_1_140_155_hypoalbuminemia	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
CID	8319760_D011692_1_247_272_puromycin aminonucleoside_D006937_1_157_177_hypercholesterolemia	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
CID	8319760_D011692_1_247_272_puromycin aminonucleoside_D009404_1_99_118_nephrotic syndromes	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
CID	8319760_D011692_1_247_272_puromycin aminonucleoside_D011507_1_127_138_proteinuria	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
CID	8319760_D011692_1_247_272_puromycin aminonucleoside_D034141_1_140_155_hypoalbuminemia	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
UN	8319760_D019808_1_322_329_Dup 753_D006937_1_157_177_hypercholesterolemia	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
UN	8319760_D019808_0_0_7_Dup 753_D009401_0_70_79_nephrosis	Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis.
UN	8319760_D019808_1_322_329_Dup 753_D009404_1_99_118_nephrotic syndromes	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
UN	8319760_D019808_1_322_329_Dup 753_D011507_1_127_138_proteinuria	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
UN	8319760_D019808_1_322_329_Dup 753_D034141_1_140_155_hypoalbuminemia	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
UN	8384253_D014750_1_123_134_vincristine_D008228_1_87_109_Non-Hodgkin's Lymphoma	Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.
UN	8386779_D000527_2_624_640_prostaglandin E1_D007172_2_502_511_impotence	A total of 38 consecutive patients who presented to our clinic with impotence received 0.2 ml. of a combination of 3 drugs: 6 mg. papaverine, 100 micrograms. phentolamine and 10 micrograms. prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).
UN	8386779_D010208_2_564_574_papaverine_D007172_2_502_511_impotence	A total of 38 consecutive patients who presented to our clinic with impotence received 0.2 ml. of a combination of 3 drugs: 6 mg. papaverine, 100 micrograms. phentolamine and 10 micrograms. prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).
UN	8386779_D010646_2_592_604_phentolamine_D007172_2_502_511_impotence	A total of 38 consecutive patients who presented to our clinic with impotence received 0.2 ml. of a combination of 3 drugs: 6 mg. papaverine, 100 micrograms. phentolamine and 10 micrograms. prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).
UN	8386779_D017693_0_0_18_Sodium bicarbonate_D004414_0_30_41_penile pain	Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.
UN	8386779_D017693_1_380_398_sodium bicarbonate_D004414_1_300_311_penile pain	In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.
UN	8386779_D017693_3_898_916_sodium bicarbonate_D004414_3_931_942_penile pain	Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.
UN	8386779_D017693_0_0_18_Sodium bicarbonate_D007172_0_83_103_erectile dysfunction	Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.
UN	8387218_D015215_0_92_102_zidovudine_D015658_0_44_65_HIV antibody-positive	The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)
UN	8387218_D016049_12_1451_1461_didanosine_D003920_12_1361_1369_diabetes	Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing didanosine.
UN	8387218_D016049_0_36_39_ddI_D015658_0_44_65_HIV antibody-positive	The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)
CID	8387218_D016049_12_1451_1461_didanosine_D018149_12_1318_1342_glucose tolerance curves	Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing didanosine.
CID	839274_D003276_1_217_236_oral contraceptives_D000236_1_134_141_adenoma	Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.
CID	839274_D003276_0_78_97_oral contraceptives_D000236_0_8_16_adenomas	Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.
CID	839274_D003276_1_217_236_oral contraceptives_D020518_1_153_178_focal nodular hyperplasia	Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.
CID	839274_D003276_0_78_97_oral contraceptives_D020518_0_21_46_focal nodular hyperplasia	Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.
CID	8410052_D010862_3_526_537_pilocarpine_D002544_3_456_500_Infarcts in substantia nigra pars reticulata	Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.
CID	8410052_D010862_3_526_537_pilocarpine_D013226_3_546_564_status epilepticus	Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.
UN	8410052_D019344_2_398_405_lactate_D001480_2_349_369_injury in the cortex	Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion.
UN	8410199_C028911_4_865_878_cresyl violet_D009410_4_889_910_neuronal degeneration	Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.
CID	8410199_D010862_2_512_523_pilocarpine_D012640_2_532_540_seizures	Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.
CID	8410199_D010862_0_91_102_pilocarpine_D012640_0_111_119_seizures	Loss of glutamate decarboxylase mRNA-containing neurons in the rat dentate gyrus following pilocarpine-induced seizures.
UN	8410199_D018698_1_177_190_glutamic acid_D012640_1_291_298_seizure	In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.
UN	8410199_D018698_0_8_17_glutamate_D012640_0_111_119_seizures	Loss of glutamate decarboxylase mRNA-containing neurons in the rat dentate gyrus following pilocarpine-induced seizures.
CID	84204_D002927_0_54_64_cimetidine_D003221_0_83_92_confusion	Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. 15 cases of cimetidine-associated mental confusion have been reported.
CID	84204_D002927_0_106_116_cimetidine_D003221_0_135_144_confusion	Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. 15 cases of cimetidine-associated mental confusion have been reported.
UN	84204_D002927_2_504_514_cimetidine_D008107_2_445_472_renal and liver dysfunction	These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).
UN	84204_D002927_2_504_514_cimetidine_D051437_2_445_472_renal and liver dysfunction	These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).
UN	8421099_D015282_7_1364_1374_octreotide_D000172_7_1394_1405_acromegalic	Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.
UN	8421099_D015282_8_1510_1520_octreotide_D000172_8_1532_1543_acromegalic	It is therefore very important to follow the changes of gallbladder function during long-term octreotide therapy of acromegalic patients.
UN	8421099_D015282_1_344_354_octreotide_D000172_1_280_290_acromegaly	This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.
UN	8421099_D015282_0_67_77_octreotide_D000172_0_138_149_acromegalic	Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.
CID	8421099_D015282_2_451_461_octreotide_D041881_2_528_547_acute cholecystitis	During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.
CID	8421099_D015282_0_67_77_octreotide_D042882_0_107_116_gallstone	Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.
CID	8421099_D015282_5_809_819_octreotide_D042882_5_843_853_gallstones	After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.
UN	8423889_D000928_2_251_265_antidepressant_D009069_2_159_175_motor disability	We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.
UN	8423889_D000928_2_251_265_antidepressant_D010300_2_198_228_idiopathic Parkinson's disease	We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.
UN	8423889_D004298_3_319_327_dopamine_D010300_3_367_386_Parkinson's disease	The possibility of a clinically relevant dopamine-antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered.
CID	8423889_D005473_0_39_49_fluoxetine_D009069_0_12_32_Parkinson disability	Increase of Parkinson disability after fluoxetine medication.
UN	8423889_D005473_3_353_363_fluoxetine_D010300_3_367_386_Parkinson's disease	The possibility of a clinically relevant dopamine-antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered.
UN	8423889_D005473_2_266_276_fluoxetine_D010300_2_198_228_idiopathic Parkinson's disease	We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.
CID	8424298_D007530_8_1302_1312_isoflurane_D007022_8_1264_1275_hypotension	The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.
CID	8424298_D007530_2_346_356_isoflurane_D007022_2_358_369_hypotensive	Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).
CID	8424298_D007530_0_60_70_isoflurane_D007022_0_22_33_hypotension	Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function.
CID	8424298_D007741_8_1287_1296_labetalol_D007022_8_1264_1275_hypotension	The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.
CID	8424298_D007741_0_45_54_labetalol_D007022_0_22_33_hypotension	Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function.
CID	8424298_D007741_2_331_340_labetalol_D007022_2_308_319_hypotension	Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).
CID	8437969_D002927_1_121_131_cimetidine_D001919_1_183_199_bradyarrhythmias	The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias.
UN	8437969_D002927_2_364_374_cimetidine_D007938_2_224_232_leukemia	A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.
CID	8437969_D002927_2_364_374_cimetidine_D054138_2_315_327_sinus arrest	A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.
CID	8437969_D002927_0_49_59_cimetidine_D054138_0_0_12_Sinus arrest	Sinus arrest associated with continuous-infusion cimetidine.
CID	8437969_D002927_4_619_629_cimetidine_D054138_4_570_582_sinus arrest	This is the first reported case of sinus arrest associated with continuous-infusion cimetidine.
UN	8437969_D011899_3_513_523_ranitidine_D001145_3_391_402_arrhythmias	The arrhythmias were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ranitidine treatment.
CID	8441146_D006046_2_299_303_gold_D000741_2_263_278_aplastic anemia	BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.
CID	8441146_D010396_2_320_335_D-penicillamine_D000741_2_263_278_aplastic anemia	BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.
CID	8473723_D008728_0_29_44_levomepromazine_D012640_0_0_8_Seizures	Seizures induced by combined levomepromazine-fluvoxamine treatment.
CID	8473723_D008728_1_97_112_levomepromazine_D012640_1_143_151_seizures	We report a case of combined levomepromazine-fluvoxamine treatment-induced seizures.
CID	8473723_D016666_0_45_56_fluvoxamine_D012640_0_0_8_Seizures	Seizures induced by combined levomepromazine-fluvoxamine treatment.
CID	8473723_D016666_1_113_124_fluvoxamine_D012640_1_143_151_seizures	We report a case of combined levomepromazine-fluvoxamine treatment-induced seizures.
UN	8475949_D008274_3_340_349_magnesium_C537153_3_361_375_hypomagnesemia	Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.
UN	8475949_D008274_7_732_741_magnesium_D008133_7_687_712_QTc interval prolongation	When QTc interval prolongation is observed, early magnesium supplementation is advocated.
UN	8475949_D008274_3_340_349_magnesium_D016171_3_297_315_torsade de pointes	Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.
UN	8475949_D010419_3_277_288_Pentamidine_C537153_3_361_375_hypomagnesemia	Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.
CID	8475949_D010419_3_277_288_Pentamidine_D016171_3_297_315_torsade de pointes	Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.
UN	8480959_D003401_9_1567_1575_creatine_D009135_9_1525_1533_Myopathy	Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).
UN	8480959_D008148_1_140_150_lovastatin_D006937_1_174_194_hypercholesterolemia	OBJECTIVE: To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia.
UN	8480959_D008148_0_29_39_lovastatin_D006937_0_68_88_hypercholesterolemia	Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia.
CID	8480959_D008148_9_1710_1720_lovastatin_D009135_9_1525_1533_Myopathy	Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).
UN	8492347_D002118_2_328_335_calcium_C537153_2_226_240_hypomagnesemia	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).
UN	8492347_D002118_2_328_335_calcium_D007008_2_180_191_hypokalemia	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).
UN	8492347_D002118_2_328_335_calcium_D013035_2_260_273_muscle spasms	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).
UN	8492347_D002118_2_328_335_calcium_D013746_2_278_284_tetany	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).
UN	8492347_D002118_2_328_335_calcium_D018908_2_202_217_muscle weakness	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).
CID	8492347_D005665_0_47_57_furosemide_D012206_0_11_25_rhabdomyolysis	Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.
CID	8492347_D005665_0_47_57_furosemide_D013746_0_0_6_Tetany	Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.
UN	8492347_D008274_4_617_626_magnesium_D006996_4_567_579_hypocalcemia	Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.
UN	8492347_D008274_4_617_626_magnesium_D007008_4_498_509_hypokalemia	Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.
UN	8492347_D008274_0_73_82_magnesium_D012206_0_11_25_rhabdomyolysis	Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.
UN	8492347_D008274_0_73_82_magnesium_D013746_0_0_6_Tetany	Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.
UN	8492347_D011188_2_314_323_potassium_C537153_2_226_240_hypomagnesemia	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).
UN	8492347_D011188_2_314_323_potassium_D007008_2_180_191_hypokalemia	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).
UN	8492347_D011188_2_314_323_potassium_D013035_2_260_273_muscle spasms	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).
UN	8492347_D011188_2_314_323_potassium_D013746_2_278_284_tetany	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).
UN	8492347_D011188_2_314_323_potassium_D018908_2_202_217_muscle weakness	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).
UN	8494478_D002939_0_0_13_Ciprofloxacin_D009369_0_54_60_cancer	Ciprofloxacin-induced nephrotoxicity in patients with cancer.
UN	8494478_D002939_2_209_222_ciprofloxacin_D009369_2_139_145_cancer	Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.
CID	8494478_D002939_6_771_784_ciprofloxacin_D058186_6_793_812_acute renal failure	An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.
CID	8494478_D002939_2_209_222_ciprofloxacin_D058186_2_160_179_acute renal failure	Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.
UN	8514073_D000431_7_1093_1100_alcohol_D010146_7_1110_1114_pain	Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.
UN	8514073_D000431_7_1093_1100_alcohol_D014652_7_1170_1190_venous complications	Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.
UN	8514073_D003975_5_804_812_diazepam_D010146_5_731_735_Pain	Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).
CID	8514073_D003975_3_490_498_diazepam_D014652_3_445_465_venous complications	Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).
CID	8514073_D003975_1_155_163_diazepam_D014652_1_94_114_venous complications	Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.
CID	8514073_D003975_2_331_339_diazepam_D014652_2_279_299_venous complications	We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.
CID	8514073_D003975_0_41_49_diazepam_D014652_0_0_20_Venous complications	Venous complications of midazolam versus diazepam.
UN	8514073_D008874_5_862_871_midazolam_D010146_5_731_735_Pain	Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).
CID	8514073_D008874_1_135_144_midazolam_D014652_1_94_114_venous complications	Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.
CID	8514073_D008874_0_24_33_midazolam_D014652_0_0_20_Venous complications	Venous complications of midazolam versus diazepam.
CID	8514073_D008874_2_343_352_midazolam_D014652_2_279_299_venous complications	We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.
UN	8546130_D000535_4_644_652_aluminum_D007676_4_570_591_chronic renal failure	The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.
UN	8546130_D000535_4_644_652_aluminum_D020258_4_711_721_neurotoxic	The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.
CID	8546130_D017291_0_0_14_Clarithromycin_D006212_0_26_47_visual hallucinations	Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.
UN	8546130_D017291_0_0_14_Clarithromycin_D007676_0_66_87_chronic renal failure	Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.
UN	8546130_D017291_4_544_558_clarithromycin_D007676_4_570_591_chronic renal failure	The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.
UN	8546130_D017291_4_544_558_clarithromycin_D020258_4_711_721_neurotoxic	The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.
UN	85485_C012282_2_440_478_ethyl-alpha-p-chlorophenoxyisobutyrate_D006528_2_311_320_hepatomas	Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.
UN	85485_C012282_2_440_478_ethyl-alpha-p-chlorophenoxyisobutyrate_D009369_2_409_414_tumor	Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.
CID	85485_D001556_0_78_104_alpha-benzene hexachloride_D006528_0_50_58_hepatoma	Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.
UN	85485_D001556_1_203_229_alpha-benzene hexachloride_D017093_1_162_175_liver lesions	Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.
UN	8558192_C030852_0_18_29_vinorelbine_C562729_0_44_78_squamous cell esophageal carcinoma	Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.
UN	8558192_C030852_15_1573_1576_VNB_C562729_15_1610_1644_esophageal squamous cell carcinoma	CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.
UN	8558192_C030852_2_261_264_VNB_C562729_2_311_345_squamous cell esophageal carcinoma	PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma.
UN	8586822_D002216_1_182_191_captopril_D006973_1_214_226_hypertensive	OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.
UN	8586822_D002216_0_79_88_captopril_D006973_0_111_123_hypertensive	Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.
CID	8586822_D017673_1_324_347_dietary sodium chloride_D006973_1_301_313_hypertensive	OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.
CID	8586822_D017673_5_879_902_dietary sodium chloride_D006973_5_911_926_increase in MAP	Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.
UN	8586822_D018738_5_810_823_hexamethonium_D006973_5_911_926_increase in MAP	Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.
CID	8590259_C016986_3_583_596_apraclonidine_D015814_3_521_539_ocular hypotensive	The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.
UN	8595686_D008012_11_1302_1311_lidocaine_D010146_11_1369_1373_pain	We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.
UN	8595686_D013874_0_0_11_Thiopentone_D010146_0_48_52_pain	Thiopentone pretreatment for propofol injection pain in ambulatory patients.
UN	8595686_D013874_11_1405_1416_thiopentone_D010146_11_1369_1373_pain	We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.
CID	8595686_D015742_1_101_109_propofol_D010146_1_120_124_pain	This study investigated propofol injection pain in patients undergoing ambulatory anaesthesia.
CID	8595686_D015742_0_29_37_propofol_D010146_0_48_52_pain	Thiopentone pretreatment for propofol injection pain in ambulatory patients.
CID	8595686_D015742_11_1350_1358_propofol_D010146_11_1369_1373_pain	We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.
CID	8599504_D004329_0_27_37_droperidol_D000799_0_0_10_Angioedema	Angioedema associated with droperidol administration.
UN	8599504_D004329_2_464_474_droperidol_D004342_2_309_323_drug allergies	We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.
UN	8599504_D004329_2_464_474_droperidol_D004487_2_360_375_tongue swelling	We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.
UN	8599504_D004329_2_464_474_droperidol_D014060_2_360_375_tongue swelling	We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.
UN	8600333_C053519_1_172_198_Rosen's T5 or T10 protocol_D001859_1_130_141_bone tumors	Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.
UN	8600333_D004317_1_215_226_doxorubicin_D001859_1_130_141_bone tumors	Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.
UN	8600333_D004317_9_1241_1252_doxorubicin_D066126_9_1261_1275_cardiotoxicity	The incidence of doxorubicin-induced cardiotoxicity is high and increases with follow-up, irrespective of cumulative dose.
CID	8607407_D002110_1_132_140_caffeine_D006973_1_157_169_hypertensive	Whether the vasoconstrictive actions of caffeine are enhanced in hypertensive persons has not been demonstrated.
CID	8607407_D002110_0_37_45_caffeine_D006973_0_78_90_hypertension	Acute blood pressure elevations with caffeine in men with borderline systemic hypertension.
CID	8607407_D002110_9_1402_1410_caffeine_D006973_9_1373_1385_hypertensive	Consequently, whereas all participants exhibited normotensive levels during the resting predrug baseline, 33% of borderline subjects achieved hypertensive BP levels after caffeine ingestion.
CID	8617710_D006220_5_864_875_haloperidol_D003072_5_781_813_Impairment of cognitive function	RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.
CID	8617710_D006220_11_1522_1533_Haloperidol_D003072_11_1562_1582_cognitive impairment	CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.
CID	8617710_D006220_0_89_100_haloperidol_D003072_0_63_83_cognitive impairment	Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.
UN	8617710_D020280_11_1620_1630_sertraline_D003072_11_1562_1582_cognitive impairment	CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.
UN	8617710_D020280_0_21_31_sertraline_D003072_0_63_83_cognitive impairment	Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.
CID	8638206_D001279_4_646_656_atracurium_D010243_4_665_674_paralysis	We report a case of atracurium-related paralysis persisting for approximately 50 hours in a patient who was not treated with corticosteroids.
CID	8638206_D001279_0_44_54_atracurium_D010243_0_11_20_paralysis	Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.
CID	8638206_D014673_2_330_348_vecuronium bromide_D010243_2_222_231_paralysis	Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.
CID	8638876_D004958_8_840_849_estradiol_D002341_8_965_1012_thrombosis of both the ICA and the venous sinus	In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.
UN	8638876_D004958_8_840_849_estradiol_D003920_8_886_888_DM	In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.
UN	8638876_D004958_2_292_301_estradiol_D006261_2_182_190_headache	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.
UN	8638876_D004958_2_292_301_estradiol_D009325_2_192_198_nausea	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.
UN	8638876_D004958_2_292_301_estradiol_D010291_2_218_229_hemiparesis	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.
UN	8638876_D004958_2_292_301_estradiol_D012640_2_234_241_seizure	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.
CID	8638876_D004958_8_840_849_estradiol_D012851_8_965_1012_thrombosis of both the ICA and the venous sinus	In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.
UN	8638876_D004958_2_292_301_estradiol_D014839_2_203_211_vomiting	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.
CID	8638876_D011374_8_854_866_progesterone_D002341_8_965_1012_thrombosis of both the ICA and the venous sinus	In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.
UN	8638876_D011374_8_854_866_progesterone_D003920_8_886_888_DM	In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.
UN	8638876_D011374_2_275_287_progesterone_D006261_2_182_190_headache	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.
UN	8638876_D011374_2_275_287_progesterone_D009325_2_192_198_nausea	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.
UN	8638876_D011374_2_275_287_progesterone_D010291_2_218_229_hemiparesis	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.
UN	8638876_D011374_2_275_287_progesterone_D012640_2_234_241_seizure	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.
CID	8638876_D011374_8_854_866_progesterone_D012851_8_965_1012_thrombosis of both the ICA and the venous sinus	In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.
UN	8638876_D011374_2_275_287_progesterone_D014839_2_203_211_vomiting	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.
UN	8643966_D017239_1_98_108_Paclitaxel_D001943_1_254_282_ovarian and breast carcinoma	Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.
UN	8643966_D017239_0_68_78_paclitaxel_D002289_0_36_62_non-small cell lung cancer	Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
UN	8643966_D017239_14_1843_1853_paclitaxel_D002289_14_1895_1900_NSCLC	Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.
UN	8643966_D017239_1_98_108_Paclitaxel_D009369_1_233_238_tumor	Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.
UN	8643966_D017239_1_98_108_Paclitaxel_D010051_1_254_282_ovarian and breast carcinoma	Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.
UN	8643971_D002945_0_38_47_cisplatin_D006258_0_74_95_head and neck cancers	A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
UN	8643971_D002945_2_474_483_cisplatin_D010051_2_582_596_ovarian cancer	Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.
UN	8643971_D017239_0_22_32_paclitaxel_D006258_0_74_95_head and neck cancers	A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
UN	8643971_D017239_2_463_473_paclitaxel_D010051_2_582_596_ovarian cancer	Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.
UN	8643973_D016190_0_25_36_carboplatin_D010051_0_77_91_ovarian cancer	Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
UN	8643973_D016190_1_266_277_carboplatin_D010051_1_328_342_ovarian cancer	In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.
UN	8643973_D017239_1_344_354_paclitaxel_D010051_1_328_342_ovarian cancer	In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.
UN	8643973_D017239_0_0_10_Paclitaxel_D010051_0_77_91_ovarian cancer	Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
CID	8649546_D007980_4_540_548_levodopa_D004409_4_579_589_dyskinesia	This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.
CID	8649546_D007980_0_15_23_levodopa_D004409_0_32_42_dyskinesia	Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.
UN	8649546_D007980_0_15_23_levodopa_D010300_0_61_80_Parkinson's disease	Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.
UN	8649546_D007980_4_540_548_levodopa_D010300_4_593_595_PD	This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.
UN	8649546_D011433_0_46_57_propranolol_D004409_0_32_42_dyskinesia	Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.
UN	8649546_D011433_1_190_201_propranolol_D004409_1_161_171_dyskinesia	Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.
UN	8649546_D011433_0_46_57_propranolol_D010300_0_61_80_Parkinson's disease	Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.
UN	8649546_D011433_1_190_201_propranolol_D010300_1_133_135_PD	Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.
UN	8665051_D000305_1_194_209_corticosteroids_D009135_1_133_141_myopathy	Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids.
CID	8665051_D008775_3_353_371_methylprednisolone_D000855_3_489_513_reduction of food intake	Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).
UN	8665051_D008775_8_1129_1130_M_D013746_8_1140_1147_tetanic	Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas tetanic tensions were similar.
UN	8665051_D013256_12_1887_1895_steroids_D001284_12_1927_1934_atrophy	We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.
UN	8665051_D013256_12_2023_2030_steroid_D009336_12_2045_2053_necrosis	We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.
UN	8665051_D013256_8_1072_1079_steroid_D013746_8_1140_1147_tetanic	Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas tetanic tensions were similar.
CID	8665051_D014221_3_380_393_triamcinolone_D000855_3_489_513_reduction of food intake	Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).
CID	8665051_D014221_10_1478_1479_T_D009133_10_1465_1472_atrophy	ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.
CID	8665051_D014221_11_1725_1726_T_D009133_11_1655_1669_muscle atrophy	Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.
UN	8665051_D014221_10_1478_1479_T_D009336_10_1564_1572_necrosis	ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.
UN	8669433_D000082_0_16_29_acetaminophen_D007676_0_51_72_chronic renal failure	Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin.
UN	8669433_D000082_3_592_605_acetaminophen_D007676_3_630_651_chronic renal failure	However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.
UN	8669433_D000082_4_754_767_acetaminophen_D007676_4_800_804_ESRD	These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.
UN	8669433_D000082_8_1352_1365_acetaminophen_D007676_8_1394_1398_ESRD	The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated, but cannot be dismissed.
CID	8669433_D010615_1_192_202_phenacetin_D007676_1_241_262_chronic renal failure	Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.
CID	8669433_D010615_4_739_749_phenacetin_D007676_4_800_804_ESRD	These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.
CID	8677458_D007069_1_154_164_ifosfamide_D003556_1_100_120_Hemorrhagic cystitis	Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.
CID	8677458_D007069_0_59_69_ifosfamide_D003556_0_78_98_hemorrhagic cystitis	Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
CID	8677458_D007069_0_59_69_ifosfamide_D006470_0_78_98_hemorrhagic cystitis	Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
CID	8677458_D007069_1_154_164_ifosfamide_D006470_1_100_120_Hemorrhagic cystitis	Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.
UN	8677458_D007069_4_677_687_ifosfamide_D014839_4_696_702_emesis	In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.
CID	8677458_D015080_0_42_47_mesna_D003556_0_78_98_hemorrhagic cystitis	Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
CID	8677458_D015080_0_42_47_mesna_D006470_0_78_98_hemorrhagic cystitis	Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
UN	8677458_D015080_4_648_653_mesna_D014839_4_696_702_emesis	In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.
UN	8682684_D000082_3_250_263_acetaminophen_D000707_3_309_320_anaphylaxis	However, acetaminophen has been demonstrated to produce symptoms of anaphylaxis, including hypotension, in sensitive individuals.
CID	8682684_D000082_4_511_524_acetaminophen_D007022_4_452_463_hypotension	This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.
CID	8682684_D000082_7_737_750_acetaminophen_D007022_7_768_779_hypotension	The reports illustrate the need for clinicians to consider acetaminophen in patients with hypotension of unknown origin.
CID	8682684_D000082_0_0_13_Acetaminophen_D007022_0_22_33_hypotension	Acetaminophen-induced hypotension.
UN	8682684_D000082_4_511_524_acetaminophen_D016638_4_398_412_critically ill	This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.
UN	8686832_D000431_4_557_564_alcohol_D010146_4_533_537_pain	Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor.
CID	8686832_D008012_0_67_77_lignocaine_D001416_0_0_17_Leg and back pain	Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.
UN	8690168_C015445_1_372_387_cuprolinic blue_D003920_1_276_284_diabetes	Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.
UN	8690168_D006497_1_149_165_Heparan sulphate_D003920_1_276_284_diabetes	Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.
UN	8690168_D006497_9_1876_1892_heparan sulphate_D003920_9_1807_1815_diabetic	We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.
UN	8690168_D006497_0_13_29_heparan sulphate_D003928_0_127_147_diabetic nephropathy	Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.
CID	8690168_D013311_0_104_118_streptozotocin_D003928_0_127_147_diabetic nephropathy	Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.
UN	869641_D004298_0_69_77_dopamine_D001919_0_35_46_bradycardia	Mediation of enhanced reflex vagal bradycardia by L-dopa via central dopamine formation in dogs.
UN	869641_D004298_3_495_503_dopamine_D007022_3_559_570_hypotension	FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.
UN	869641_D005406_3_485_491_FLA-63_D001919_3_572_583_bradycardia	FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.
UN	869641_D005406_3_485_491_FLA-63_D007022_3_559_570_hypotension	FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.
UN	869641_D006916_6_1023_1028_5-HTP_D001919_6_929_940_bradycardia	However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate. 5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.
UN	869641_D007980_3_614_620_L-dopa_D001919_3_572_583_bradycardia	FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.
UN	869641_D007980_2_363_369_L-dopa_D001919_2_287_298_bradycardia	In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.
UN	869641_D007980_0_50_56_L-dopa_D001919_0_35_46_bradycardia	Mediation of enhanced reflex vagal bradycardia by L-dopa via central dopamine formation in dogs.
UN	869641_D007980_7_1161_1167_L-dopa_D001919_7_1184_1195_bradycardia	It is concluded that L-dopa enhances reflex bradycardia through central alpha-receptor stimulation.
UN	869641_D007980_6_909_915_L-dopa_D001919_6_929_940_bradycardia	However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate. 5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.
UN	869641_D007980_3_614_620_L-dopa_D007022_3_559_570_hypotension	FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.
CID	869641_D009638_6_1124_1138_norepinephrine_D001919_6_1109_1120_bradycardia	However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate. 5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.
CID	869641_D009638_2_318_332_norepinephrine_D001919_2_287_298_bradycardia	In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.
UN	869641_D015103_2_371_401_DL-Threo-dihydroxyphenylserine_D001919_2_287_298_bradycardia	In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.
UN	8701950_D000305_2_313_328_corticosteroids_D000743_2_377_381_MAHA	In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.
UN	8701950_D001241_2_330_337_aspirin_D000743_2_377_381_MAHA	In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.
UN	8701950_D004176_2_343_355_dipyridamole_D000743_2_377_381_MAHA	In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.
CID	8701950_D016559_0_47_52_FK506_D000743_0_0_33_Microangiopathic hemolytic anemia	Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.
CID	8701950_D016559_1_176_181_FK506_D000743_1_136_140_MAHA	We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.
CID	8701950_D016559_3_417_422_FK506_D000743_3_450_454_MAHA	In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.
CID	8701950_D016559_4_456_461_FK506_D000743_4_473_477_MAHA	FK506-associated MAHA is probably rare but physicians must be aware of this severe complication.
UN	8701950_D016572_5_644_657_cyclosporin A_D000743_5_716_720_MAHA	In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.
CID	871943_D013390_0_35_50_succinylcholine_D001049_0_51_57_apnoea	The use of serum cholinesterase in succinylcholine apnoea.
CID	871943_D013390_1_146_161_succinylcholine_D001049_1_111_117_apnoea	Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase.
CID	871943_D013390_6_664_679_succinylcholine_D001049_6_680_686_apnoea	The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist.
UN	873132_D003840_0_58_74_deoxycholic acid_D002779_0_104_115_cholestasis	Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.
CID	873132_D004997_0_78_95_ethinyl estradiol_D002779_0_104_115_cholestasis	Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.
CID	8739323_D003520_7_1165_1167_CY_D003556_7_1175_1195_hemorrhagic cystitis	CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.
CID	8739323_D003520_7_1165_1167_CY_D006470_7_1175_1195_hemorrhagic cystitis	CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.
UN	8739323_D003520_9_1537_1539_CY_D007674_9_1506_1520_nephrotoxicity	Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.
UN	8739323_D005472_7_1270_1274_5-FU_D003556_7_1175_1195_hemorrhagic cystitis	CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.
UN	8739323_D005472_7_1270_1274_5-FU_D006470_7_1175_1195_hemorrhagic cystitis	CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.
UN	8739323_D005472_9_1530_1534_5-FU_D007674_9_1506_1520_nephrotoxicity	Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.
UN	8739323_D008466_1_128_143_nitrogranulogen_D007674_1_81_92_nephrotoxic	The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.
UN	8739323_D008727_7_1279_1282_MTX_D003556_7_1175_1195_hemorrhagic cystitis	CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.
UN	8739323_D008727_7_1279_1282_MTX_D006470_7_1175_1195_hemorrhagic cystitis	CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.
UN	8739323_D008727_9_1524_1527_MTX_D007674_9_1506_1520_nephrotoxicity	Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.
CID	8741744_D009538_2_398_406_nicotine_D006948_2_415_428_hyperactivity	Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.
UN	8741744_D009538_2_334_342_nicotine_D009069_2_301_323_locomotor hypoactivity	Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.
CID	8742498_D000082_7_1406_1409_AAP_D056486_7_1418_1427_hepatitis	Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.
CID	8742498_D000082_8_1676_1689_acetaminophen_D056486_8_1708_1722_hepatic damage	We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.
CID	8742498_D000082_2_525_528_AAP_D056486_2_529_538_hepatitis	The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.
CID	8742498_D000082_1_273_276_AAP_D056486_1_278_287_hepatitis	Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.
CID	8742498_D000082_1_309_312_AAP_D056486_1_321_333_liver injury	Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.
CID	8742498_D000082_0_44_57_acetaminophen_D056486_0_58_72_hepatotoxicity	Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.
CID	8742498_D000431_2_583_590_ethanol_D056486_2_529_538_hepatitis	The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.
CID	8742498_D000431_5_1268_1275_ethanol_D056486_5_1231_1243_liver damage	In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.
CID	8742498_D000431_7_1452_1459_ethanol_D056486_7_1418_1427_hepatitis	Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.
UN	8742498_D009243_0_26_29_NAD_D056486_0_58_72_hepatotoxicity	Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.
UN	8742498_D009536_1_140_160_nicotinic acid amide_D056486_1_278_287_hepatitis	Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.
UN	8742498_D009536_8_1609_1612_NAA_D056486_8_1708_1722_hepatic damage	We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.
UN	8742498_D009536_7_1519_1522_NAA_D056486_7_1418_1427_hepatitis	Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.
UN	8742498_D009536_6_1333_1336_NAA_D056486_6_1304_1313_hepatitis	A further 64% reduction of hepatitis was observed, when NAA was given to ethanol/AAP-mice.
UN	8742498_D011064_1_187_203_poly(ADP-ribose)_D056486_1_278_287_hepatitis	Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.
UN	8742498_D018698_3_675_684_glutamate_D056486_3_621_635_Liver injuries	Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).
UN	8742498_D019289_3_731_739_pyruvate_D056486_3_621_635_Liver injuries	Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).
UN	8742498_D062907_3_685_697_oxaloacetate_D056486_3_621_635_Liver injuries	Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).
UN	8752018_D008094_5_881_888_lithium_D001714_5_896_903_bipolar	RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.
UN	8752018_D008094_6_1002_1009_lithium_D001714_6_1013_1020_bipolar	CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.
UN	8752018_D008094_3_552_559_lithium_D001714_3_530_537_bipolar	This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.
CID	8752018_D008094_6_1002_1009_lithium_D003072_6_1043_1061_cognitive deficits	CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.
CID	8752018_D008094_5_881_888_lithium_D003072_5_821_866_cognitive, motivational, or creative deficits	RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.
CID	8752018_D008094_3_552_559_lithium_D003072_3_599_635_cognitive and functional impairments	This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.
CID	8752018_D008094_2_362_369_lithium_D003072_2_391_409_cognitive deficits	Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.
CID	8752018_D008094_0_0_7_Lithium_D003072_0_19_52_cognitive and functional deficits	Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.
UN	8752018_D008094_2_312_319_lithium_D011141_2_329_337_polyuria	Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.
UN	8752018_D008094_2_362_369_lithium_D014202_2_342_348_tremor	Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.
UN	8752018_D014635_6_954_971_divalproex sodium_D001714_6_1013_1020_bipolar	CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.
UN	8752018_D014635_3_563_580_divalproex sodium_D001714_3_530_537_bipolar	This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.
UN	8752018_D014635_0_76_93_divalproex sodium_D003072_0_19_52_cognitive and functional deficits	Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.
UN	8752018_D014635_3_563_580_divalproex sodium_D003072_3_599_635_cognitive and functional impairments	This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.
UN	8752018_D014635_5_765_782_divalproex sodium_D003072_5_821_866_cognitive, motivational, or creative deficits	RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.
UN	8766220_D004308_2_309_333_dosulepine hydrochloride_D059350_2_365_377_chronic pain	This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.
CID	8766220_D014147_0_56_64_tramadol_D006212_0_15_29_hallucinations	Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.
UN	8766220_D014147_1_96_104_Tramadol_D009369_1_206_212_cancer	Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.
UN	8766220_D014147_1_96_104_Tramadol_D010146_1_213_217_pain	Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.
UN	8766220_D017374_2_294_304_paroxetine_D059350_2_365_377_chronic pain	This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.
UN	8800187_D002118_3_320_327_calcium_D007022_3_381_392_hypotension	This study addressed the potential role of calcium channel blockade in tricyclic antidepressant-induced hypotension.
UN	8800187_D002118_4_497_504_calcium_D062787_4_521_529_overdose	METHODS: Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose.
CID	8800187_D002122_11_1096_1101_CaCl2_D001145_11_1029_1052_ventricular arrhythmias	The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.
UN	8800187_D002122_13_1271_1276_CaCl2_D002493_13_1310_1360_cardiovascular and central nervous system toxicity	CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.
UN	8800187_D002122_12_1176_1181_CaCl2_D007022_12_1250_1261_hypotension	CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.
UN	8800187_D002122_11_1096_1101_CaCl2_D012640_11_1069_1077_seizures	The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.
CID	8800187_D003891_6_614_625_desipramine_D001919_6_675_686_bradycardia	Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.
CID	8800187_D003891_6_614_625_desipramine_D007022_6_640_651_hypotension	Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.
UN	8800187_D015761_12_1185_1200_4-aminopyridine_D007022_12_1250_1261_hypotension	CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.
UN	8800187_D017693_9_886_892_NaHCO3_D007022_9_918_929_hypotension	RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.
UN	8829025_D009543_2_394_404_nifedipine_D006973_2_353_365_hypertensive	Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.
UN	8829025_D009543_5_716_726_nifedipine_D007674_5_743_757_nephrotoxicity	The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.
CID	8829025_D016559_2_282_292_tacrolimus_D006973_2_353_365_hypertensive	Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.
CID	8829025_D016559_5_774_784_tacrolimus_D006973_5_877_889_hypertension	The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.
UN	8829025_D016559_5_774_784_tacrolimus_D007674_5_743_757_nephrotoxicity	The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.
UN	88336_D000431_2_251_258_alcohol_D013375_2_259_278_withdrawal symptoms	Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.
UN	88336_D000431_2_251_258_alcohol_D062787_2_304_312_overdose	Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.
CID	88336_D002719_3_387_402_chlormethiazole_D003128_3_452_456_coma	The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.
UN	88336_D002719_2_231_246_chlormethiazole_D013375_2_259_278_withdrawal symptoms	Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.
UN	88336_D002719_3_387_402_chlormethiazole_D062787_3_356_364_overdose	The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.
CID	88336_D009567_3_345_355_nitrazepam_D003128_3_452_456_coma	The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.
UN	88336_D009567_2_316_326_nitrazepam_D013375_2_259_278_withdrawal symptoms	Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.
CID	88336_D009567_3_345_355_nitrazepam_D062787_3_356_364_overdose	The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.
CID	88336_D009567_2_316_326_nitrazepam_D062787_2_304_312_overdose	Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.
CID	8841157_C081489_12_1524_1533_valsartan_D004487_12_1417_1422_edema	The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).
UN	8841157_C081489_13_1661_1670_valsartan_D006973_13_1747_1759_hypertension	CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.
UN	8841157_C081489_2_460_469_valsartan_D006973_2_365_377_hypertension	METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.
UN	8841157_C081489_0_0_9_Valsartan_D006973_0_74_86_hypertension	Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
UN	8841157_D000804_0_17_31_angiotensin II_D006973_0_74_86_hypertension	Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
CID	8841157_D017311_12_1450_1460_amlodipine_D004487_12_1417_1422_edema	The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).
UN	8841157_D017311_13_1699_1709_amlodipine_D006973_13_1747_1759_hypertension	CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.
CID	8854309_D003042_0_50_57_cocaine_D010259_0_66_74_paranoia	A measure of pupillary oscillation as a marker of cocaine-induced paranoia.
CID	8854309_D003042_1_76_83_Cocaine_D010259_1_92_100_paranoia	Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.
CID	8854309_D003042_0_50_57_cocaine_D011681_0_13_34_pupillary oscillation	A measure of pupillary oscillation as a marker of cocaine-induced paranoia.
UN	8854309_D016578_2_319_332_crack cocaine_D010259_2_356_359_CIP	Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).
UN	8854309_D016578_2_319_332_crack cocaine_D011681_2_237_258_pupillary oscillation	Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).
UN	8864707_D010672_10_1317_1326_phenytoin_D002526_10_1274_1292_cerebellar atrophy	We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.
UN	8864707_D010672_1_161_170_phenytoin_D002526_1_186_204_cerebellar atrophy	The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication.
UN	8864707_D010672_0_75_84_phenytoin_D004827_0_50_59_epileptic	Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.
UN	8864707_D010672_8_1010_1019_phenytoin_D012640_8_979_986_seizure	Using linear regression we found that no correlation exists between seizure duration, elevation of phenytoin serum levels and cerebellar volume.
CID	8864707_D010672_10_1222_1231_phenytoin_D062787_10_1232_1242_overdosage	We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.
CID	8864707_D010672_0_75_84_phenytoin_D062787_0_85_96_overdosages	Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.
UN	8888541_C047426_4_511_522_venlafaxine_D003866_4_634_644_depression	We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
CID	8888541_C047426_0_24_35_venlafaxine_D020230_0_0_18_Serotonin syndrome	Serotonin syndrome from venlafaxine-tranylcypromine interaction.
CID	8888541_C047426_4_511_522_venlafaxine_D020230_4_561_579_serotonin syndrome	We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
UN	8888541_D003975_10_1170_1178_diazepam_D009127_10_1211_1226_muscle rigidity	After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.
UN	8888541_D012701_1_137_146_serotonin_D003221_1_211_220_confusion	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.
UN	8888541_D012701_1_137_146_serotonin_D005334_1_236_248_hyperthermia	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.
UN	8888541_D012701_1_137_146_serotonin_D009127_1_182_197_muscle rigidity	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.
UN	8888541_D012701_1_137_146_serotonin_D011595_1_222_231_agitation	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.
UN	8888541_D012701_1_137_146_serotonin_D012798_1_199_209_salivation	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.
UN	8888541_D014191_4_614_629_tranylcypromine_D003866_4_634_644_depression	We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
CID	8888541_D014191_0_36_51_tranylcypromine_D020230_0_0_18_Serotonin syndrome	Serotonin syndrome from venlafaxine-tranylcypromine interaction.
CID	891050_D003276_1_155_174_oral contraceptives_D006463_1_132_135_HUS	A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.
UN	891050_D004176_2_206_218_dipyridamole_D001002_2_343_349_anuria	She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.
UN	891050_D006493_2_197_204_heparin_D001002_2_343_349_anuria	She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.
CID	8911359_D003520_2_305_321_cyclophosphamide_D001749_2_333_347_bladder cancer	MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.
CID	8911359_D003520_0_0_16_Cyclophosphamide_D001749_0_28_42_bladder cancer	Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.
CID	8911359_D003520_7_740_756_Cyclophosphamide_D001749_7_768_781_bladder tumor	CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.
UN	8911359_D003520_1_169_185_cyclophosphamide_D014523_1_197_214_urothelial cancer	PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.
CID	8919272_D014635_0_96_105_valproate_D001927_0_26_40_encephalopathy	Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats.
CID	8919272_D014635_15_2051_2060_valproate_D001927_15_2061_2075_encephalopathy	The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.
CID	8919272_D014635_2_445_454_valproate_D001927_2_455_469_encephalopathy	Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral "Polfa") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage ("valproate encephalopathy").
UN	8919272_D014635_2_445_454_valproate_D002526_2_425_442_cerebellum damage	Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral "Polfa") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage ("valproate encephalopathy").
UN	8919272_D014635_15_2051_2060_valproate_D022124_15_2011_2025_hyperammonemia	The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.
UN	8919272_D014635_15_2051_2060_valproate_D056486_15_1988_2002_hepatic damage	The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.
UN	8953972_D004837_4_468_479_Epinephrine_D004342_4_591_608_allergic reaction	Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.
UN	8953972_D004837_2_376_387_epinephrine_D005076_2_275_279_rash	The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.
CID	8953972_D004837_4_468_479_Epinephrine_D006323_4_501_515_cardiac arrest	Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.
UN	8953972_D004837_4_468_479_Epinephrine_D006973_4_620_632_hypertension	Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.
UN	8953972_D004837_2_376_387_epinephrine_D012128_2_253_273_respiratory distress	The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.
CID	8953972_D004837_0_63_74_epinephrine_D013345_0_6_27_intracranial bleeding	Fatal intracranial bleeding associated with prehospital use of epinephrine.
UN	8955532_C065679_3_597_604_Hoe-140_D006973_3_551_563_hypertension	Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).
UN	8955532_D001920_5_902_912_bradykinin_D006973_5_846_858_hypertension	These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of bradykinin to activate B2 receptors.
UN	8955532_D003911_3_497_504_dextran_D006973_3_551_563_hypertension	Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).
CID	8955532_D010656_3_523_536_phenylephrine_D006973_3_551_563_hypertension	Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).
UN	8958188_C045894_2_314_324_lometrexol_D009369_2_346_353_tumours	Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
UN	8958188_D008727_2_399_411_methotrexate_D009369_2_346_353_tumours	Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
UN	8988571_C005618_5_817_832_benzoylecgonine_D003693_5_778_782_EDDs	EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.
CID	8988571_D003042_6_1044_1051_cocaine_D003645_6_1141_1153_sudden death	The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.
CID	8988571_D003042_0_33_40_cocaine_D003693_0_14_22_delirium	Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.
CID	8988571_D003042_5_805_812_cocaine_D003693_5_778_782_EDDs	EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.
CID	8988571_D003042_2_392_399_cocaine_D003693_2_425_433_delirium	From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.
CID	8988571_D003042_1_165_172_cocaine_D003693_1_189_197_delirium	We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.
UN	8988571_D003042_6_1044_1051_cocaine_D011595_6_1073_1082_agitation	The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.
CID	8988571_D003042_6_1044_1051_cocaine_D012206_6_1121_1135_rhabdomyolysis	The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.
UN	8988571_D003042_2_392_399_cocaine_D062787_2_400_408_overdose	From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.
UN	9022662_C064210_1_109_120_oxazolidine_D001289_1_210_236_attention deficit disorder	BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.
UN	9022662_D000662_1_168_180_amphetamines_D001289_1_210_236_attention deficit disorder	BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.
UN	9022662_D001569_9_1083_1098_benzodiazepines_D001264_9_1128_1142_choreoathetoid	The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements.
UN	9022662_D001569_9_1083_1098_benzodiazepines_D002819_9_1128_1142_choreoathetoid	The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements.
UN	9022662_D008774_5_741_756_methylphenidate_D001289_5_690_716_attention deficit disorder	The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success.
CID	9022662_D010389_3_402_410_pemoline_D001264_3_436_451_choreoathetosis	The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.
CID	9022662_D010389_13_1560_1568_pemoline_D001264_13_1485_1499_choreoathetoid	The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.
CID	9022662_D010389_0_0_8_Pemoline_D001264_0_23_38_choreoathetosis	Pemoline induced acute choreoathetosis: case report and review of the literature.
UN	9022662_D010389_1_94_102_Pemoline_D001289_1_210_236_attention deficit disorder	BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.
CID	9022662_D010389_3_402_410_pemoline_D002819_3_436_451_choreoathetosis	The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.
CID	9022662_D010389_0_0_8_Pemoline_D002819_0_23_38_choreoathetosis	Pemoline induced acute choreoathetosis: case report and review of the literature.
CID	9022662_D010389_13_1560_1568_pemoline_D002819_13_1485_1499_choreoathetoid	The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.
CID	9022662_D010389_13_1560_1568_pemoline_D062787_13_1569_1577_overdose	The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.
UN	9034419_C047426_2_176_187_venlafaxine_D003865_2_139_155_major depression	CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.
CID	9034419_C047426_5_513_524_venlafaxine_D012640_5_565_572_seizure	DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.
CID	9034419_C047426_0_25_36_venlafaxine_D012640_0_0_7_Seizure	Seizure resulting from a venlafaxine overdose.
CID	9034419_C047426_7_753_764_venlafaxine_D062787_7_765_773_overdose	CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.
CID	9034419_C047426_5_513_524_venlafaxine_D062787_5_525_533_overdose	DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.
CID	9034419_C047426_1_78_89_venlafaxine_D062787_1_90_98_overdose	OBJECTIVE: To report a case of venlafaxine overdose.
CID	9034419_C047426_2_176_187_venlafaxine_D062787_2_164_172_overdose	CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.
CID	9034419_C047426_0_25_36_venlafaxine_D062787_0_37_45_overdose	Seizure resulting from a venlafaxine overdose.
CID	9041081_D000305_6_809_823_corticosteroid_D009798_6_753_782_elevated intraocular pressure	During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.
UN	9041081_D013256_6_737_744_steroid_D009798_6_753_782_elevated intraocular pressure	During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.
UN	9041081_D013256_9_1101_1108_steroid_D009798_9_1117_1125_IOP rise	The transient steroid-induced IOP rise did not seem to cause functional impairment.
CID	9061311_D000082_2_332_343_paracetamol_D017114_2_321_324_ALF	In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.
CID	9061311_D000082_8_1172_1183_paracetamol_D017114_8_1161_1164_ALF	These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.
UN	9061311_D000082_8_1172_1183_paracetamol_D062787_8_1184_1192_overdose	These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.
UN	9061311_D000082_2_332_343_paracetamol_D062787_2_344_352_overdose	In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.
UN	9061311_D006861_1_119_136_hydrogen peroxide_D001424_1_191_211_bacterial infections	Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).
UN	9061311_D006861_4_543_560_hydrogen peroxide_D017114_4_575_578_ALF	Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).
UN	9061311_D006861_0_26_43_hydrogen peroxide_D017114_0_72_91_acute liver failure	Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.
UN	9061311_D009240_6_910_914_fMLP_D017114_6_934_937_ALF	Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.
UN	9061311_D010100_2_278_284_oxygen_D017114_2_321_324_ALF	In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.
UN	9061311_D010100_2_278_284_oxygen_D062787_2_344_352_overdose	In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.
UN	9061311_D013481_1_104_114_superoxide_D001424_1_191_211_bacterial infections	Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).
UN	9061311_D013481_0_11_21_superoxide_D017114_0_72_91_acute liver failure	Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.
UN	9061311_D013481_4_528_538_Superoxide_D017114_4_575_578_ALF	Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).
UN	9067481_C013440_1_222_247_cholesteryl hemisuccinate_D056486_1_324_335_hepatotoxic	In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).
CID	9067481_D000082_4_1018_1031_acetaminophen_D056486_4_982_993_hepatotoxic	A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.
UN	9067481_D000082_4_1018_1031_acetaminophen_D066126_4_1089_1100_cardiotoxic	A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.
CID	9067481_D002251_4_1005_1009_CCl4_D056486_4_982_993_hepatotoxic	A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.
CID	9067481_D002251_1_347_367_carbon tetrachloride_D056486_1_324_335_hepatotoxic	In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).
UN	9067481_D002251_4_1005_1009_CCl4_D066126_4_1089_1100_cardiotoxic	A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.
CID	9067481_D002725_4_1011_1016_CHCl3_D056486_4_982_993_hepatotoxic	A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.
UN	9067481_D002725_4_1011_1016_CHCl3_D066126_4_1089_1100_cardiotoxic	A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.
UN	9067481_D004317_4_1112_1122_adriamycin_D056486_4_982_993_hepatotoxic	A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.
CID	9067481_D004317_4_1112_1122_adriamycin_D066126_4_1089_1100_cardiotoxic	A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.
CID	9067481_D005688_7_1559_1572_galactosamine_D056486_7_1573_1587_hepatotoxicity	The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).
UN	9067481_D005688_4_1036_1049_galactosamine_D066126_4_1089_1100_cardiotoxic	A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.
CID	9088814_D000527_4_793_797_PGE1_D007022_4_746_757_hypotension	Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.
CID	9088814_D000527_0_30_46_prostaglandin E1_D007022_0_55_66_hypotension	Combined effects of prolonged prostaglandin E1-induced hypotension and haemodilution on human hepatic function.
CID	9088814_D000527_1_160_164_PGE1_D007022_1_174_185_hypotension	Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.
CID	9088814_D000527_8_1430_1434_PGE1_D007022_8_1443_1454_hypotension	The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.
CID	9088814_D000527_8_1430_1434_PGE1_D008107_8_1494_1524_impairment of hepatic function	The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.
UN	9088814_D000527_8_1430_1434_PGE1_D020141_8_1468_1481_haemodilution	The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.
UN	9088814_D000527_1_160_164_PGE1_D020141_1_190_203_haemodilution	Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.
UN	9088814_D000527_0_30_46_prostaglandin E1_D020141_0_71_84_haemodilution	Combined effects of prolonged prostaglandin E1-induced hypotension and haemodilution on human hepatic function.
UN	9088814_D001663_7_1301_1310_bilirubin_D007022_7_1206_1217_hypotension	In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.
UN	9088814_D003911_3_672_679_dextran_D020141_3_540_553_Haemodilution	Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.
CID	9098464_D005473_0_76_100_fluoxetine hydrochloride_D006966_0_46_64_hyperprolactinemia	A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.
CID	9098464_D005473_1_252_262_fluoxetine_D006966_1_311_329_hyperprolactinemia	OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.
CID	9098464_D005473_8_1255_1265_fluoxetine_D062788_8_1198_1209_adenomyosis	Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving fluoxetine.
CID	9098464_D005473_1_252_262_fluoxetine_D062788_1_362_373_adenomyosis	OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.
CID	9098464_D005473_0_76_100_fluoxetine hydrochloride_D062788_0_18_29_adenomyosis	A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.
UN	9098464_D012701_0_114_123_serotonin_D006966_0_46_64_hyperprolactinemia	A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.
UN	9098464_D012701_0_114_123_serotonin_D062788_0_147_158_adenomyosis	A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.
UN	9100294_D002118_2_335_342_calcium_D018376_2_378_406_cardiovascular malformations	The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.
UN	9100294_D002118_5_871_878_calcium_D018376_5_794_822_cardiovascular malformations	A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.
UN	9100294_D002118_0_53_60_calcium_D018376_0_0_26_Cardiovascular alterations	Cardiovascular alterations in rat fetuses exposed to calcium channel blockers.
CID	9100294_D009543_5_969_979_nifedipine_D018376_5_794_822_cardiovascular malformations	A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.
CID	9100294_D014700_5_955_964_verapamil_D018376_5_794_822_cardiovascular malformations	A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.
CID	9100294_D020748_1_163_173_Ro 40-5967_D018376_1_183_209_cardiovascular alterations	Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.
CID	9105126_D013256_2_277_284_steroid_D018658_2_323_337_septal rupture	A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed.
CID	9105126_D013256_0_67_74_steroid_D018658_0_15_40_ventricular septal defect	Postinfarction ventricular septal defect associated with long-term steroid therapy.
CID	9105126_D013256_1_164_171_steroid_D018658_1_112_138_ventricular septal rupture	Two cases of postinfarction ventricular septal rupture in patients on long-term steroid therapy are presented and the favourable outcome in both cases described.
UN	9121607_D001569_4_916_930_benzodiazepine_D012640_4_976_984_seizures	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.
UN	9121607_D002998_4_1155_1165_clonazepam_D012640_4_1130_1137_seizure	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.
UN	9121607_D003900_1_218_237_deoxycorticosterone_D012640_1_420_428_seizures	Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.
CID	9121607_D007608_6_1590_1601_kainic acid_D012640_6_1617_1625_seizures	However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.
CID	9121607_D007608_5_1391_1402_kainic acid_D012640_5_1371_1379_seizures	Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
CID	9121607_D007608_8_1921_1932_kainic acid_D012640_8_1941_1949_seizures	We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.
CID	9121607_D007608_0_54_65_kainic acid_D012640_0_81_89_seizures	Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.
CID	9121607_D007608_6_1590_1601_kainic acid_D013226_6_1630_1648_status epilepticus	However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.
CID	9121607_D007608_8_1921_1932_kainic acid_D013226_8_1954_1972_status epilepticus	We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.
CID	9121607_D007608_0_54_65_kainic acid_D013226_0_94_112_status epilepticus	Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.
CID	9121607_D010862_4_964_975_pilocarpine_D012640_4_976_984_seizures	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.
CID	9121607_D010862_8_1904_1915_pilocarpine_D012640_8_1941_1949_seizures	We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.
CID	9121607_D010862_0_37_48_pilocarpine_D012640_0_81_89_seizures	Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.
CID	9121607_D010862_8_1904_1915_pilocarpine_D013226_8_1954_1972_status epilepticus	We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.
CID	9121607_D010862_0_37_48_pilocarpine_D013226_0_94_112_status epilepticus	Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.
UN	9121607_D011374_1_166_178_progesterone_D012640_1_420_428_seizures	Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.
UN	9121607_D013256_0_12_20_steroids_D012640_0_81_89_seizures	Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.
UN	9121607_D013256_2_438_446_Steroids_D012640_2_634_642_seizures	Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
UN	9121607_D013256_4_986_994_steroids_D012640_4_976_984_seizures	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.
UN	9121607_D013256_5_1243_1251_Steroids_D012640_5_1371_1379_seizures	Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
UN	9121607_D013256_6_1509_1516_steroid_D012640_6_1617_1625_seizures	However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.
UN	9121607_D013256_7_1667_1675_steroids_D012640_7_1800_1808_seizures	The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.
UN	9121607_D013256_8_1852_1860_steroids_D012640_8_1941_1949_seizures	We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.
UN	9121607_D013256_8_1852_1860_steroids_D013226_8_1954_1972_status epilepticus	We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.
UN	9121607_D013256_6_1509_1516_steroid_D013226_6_1630_1648_status epilepticus	However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.
UN	9121607_D013256_0_12_20_steroids_D013226_0_94_112_status epilepticus	Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.
UN	9121607_D013256_2_438_446_Steroids_D013226_2_647_665_status epilepticus	Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
UN	9121607_D016202_7_1795_1799_NMDA_D012640_7_1800_1808_seizures	The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.
UN	9121607_D016202_1_406_410_NMDA_D012640_1_420_428_seizures	Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.
UN	9154656_D000809_1_150_161_angiotensin_D009404_1_203_221_nephrotic syndrome	Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).
CID	9154656_D011692_6_1060_1063_PAN_D009404_6_1046_1048_NS	These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.
CID	9154656_D011692_3_537_563_puromycin amino-nucleoside_D009404_3_497_499_NS	NS was induced by a single injection of puromycin amino-nucleoside (PAN).
UN	9165568_D004298_1_109_117_dopamine_D009459_1_49_79_Neuroleptic malignant syndrome	Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.
CID	9165568_D018967_0_36_47_risperidone_D009459_0_0_30_Neuroleptic malignant syndrome	Neuroleptic malignant syndrome with risperidone.
CID	9165568_D018967_7_854_865_risperidone_D009459_7_898_928_neuroleptic malignant syndrome	It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.
CID	9165568_D018967_5_651_662_risperidone_D009459_5_597_627_neuroleptic malignant syndrome	A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.
CID	9195768_D018170_1_102_113_sumatriptan_D010292_1_48_67_Atypical sensations	Atypical sensations following the use of subcutaneous sumatriptan are common, but of uncertain origin.
CID	9199746_D000583_2_251_259_amikacin_D012164_2_260_276_retinal toxicity	METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.
UN	9199746_D000583_2_302_310_amikacin_D013290_2_347_376_streptococcal endophthalmitis	METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.
UN	9199746_D000617_1_79_94_aminoglycosides_D007238_1_168_178_infarction	BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.
UN	9199746_D000617_1_79_94_aminoglycosides_D009877_1_143_158_endophthalmitis	BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.
UN	9199746_D014640_2_315_325_vancomycin_D012164_2_260_276_retinal toxicity	METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.
UN	9199746_D014640_2_315_325_vancomycin_D013290_2_347_376_streptococcal endophthalmitis	METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.
UN	9199746_D019793_4_478_489_fluorescein_D013684_4_542_556_telangiectasis	Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.
UN	9201797_D001712_3_767_776_biperiden_D002375_3_680_689_catalepsy	Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.
UN	9201797_D001712_4_850_859_biperiden_D002375_4_895_904_catalepsy	Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.
UN	9201797_D002354_10_1601_1610_carteolol_D002375_10_1640_1649_catalepsy	These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.
UN	9201797_D002354_6_1026_1035_Carteolol_D009069_6_1133_1148_hyperlocomotion	Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
UN	9201797_D002354_10_1601_1610_carteolol_D017109_10_1750_1759_akathisia	These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.
UN	9201797_D004298_10_1846_1854_dopamine_D002375_10_1640_1649_catalepsy	These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.
UN	9201797_D004298_6_1063_1071_dopamine_D009069_6_1133_1148_hyperlocomotion	Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
UN	9201797_D004298_10_1846_1854_dopamine_D017109_10_1750_1759_akathisia	These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.
CID	9201797_D006220_3_660_671_haloperidol_D002375_3_680_689_catalepsy	Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.
CID	9201797_D006220_4_875_886_haloperidol_D002375_4_895_904_catalepsy	Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.
CID	9201797_D006220_10_1620_1631_haloperidol_D002375_10_1640_1649_catalepsy	These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.
UN	9201797_D006220_10_1620_1631_haloperidol_D017109_10_1750_1759_akathisia	These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.
UN	9201797_D011433_3_751_762_propranolol_D002375_3_680_689_catalepsy	Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.
UN	9201797_D011433_4_834_845_propranolol_D002375_4_895_904_catalepsy	Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.
UN	9205462_D004967_3_349_357_estrogen_D001943_3_376_392_breast carcinoma	CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.
CID	9205462_D013629_0_61_70_tamoxifen_C537296_0_0_33_Granulosa cell tumor of the ovary	Granulosa cell tumor of the ovary associated with antecedent tamoxifen use.
UN	9205462_D013629_3_326_335_tamoxifen_D001943_3_376_392_breast carcinoma	CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.
UN	9205462_D013629_6_782_791_tamoxifen_D006106_6_734_755_granulosa cell tumors	CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.
UN	9205462_D013629_2_230_239_tamoxifen_D009369_2_260_266_tumors	Review of the literature reveals an association between tamoxifen use and gynecologic tumors.
CID	9205462_D013629_6_669_678_tamoxifen_D017093_6_687_704_liver dysfunction	CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.
UN	9209318_D015215_1_144_147_AZT_D000163_1_117_121_AIDS	AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.
CID	9209318_D015215_1_78_81_AZT_D000748_1_96_113_macrocytic anemia	AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.
CID	9209318_D015215_0_48_51_AZT_D009190_0_62_76_myelodysplasia	Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.
UN	921394_D007649_2_245_253_ketamine_D003866_2_317_327_depression	Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action.
CID	921394_D007649_4_574_582_ketamine_D013610_4_591_602_tachycardia	Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine-induced tachycardia, while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery.
UN	9214597_D004967_11_2013_2021_estrogen_D009369_11_2030_2035_tumor	These findings suggest that over expression of VEGF and its receptor (VEGFR-2) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary.
UN	9214597_D004967_0_147_155_estrogen_D009369_0_166_171_tumor	Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.
UN	9214597_D004967_3_473_481_estrogen_D009369_3_503_508_tumor	To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.
UN	9214597_D004967_0_147_155_estrogen_D010911_0_118_134_pituitary tumors	Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.
UN	9214597_D004967_2_404_412_estrogen_D063646_2_413_427_carcinogenesis	The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.
CID	9226773_D008094_3_370_377_lithium_D011141_3_340_348_polyuric	He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.
CID	9226773_D008094_4_700_707_lithium_D011141_4_645_653_polyuria	Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.
CID	9226773_D008094_0_52_59_lithium_D018500_0_11_41_nephrogenic diabetes insipidus	Persistent nephrogenic diabetes insipidus following lithium therapy.
CID	9226773_D008094_2_225_232_lithium_D018500_2_241_271_nephrogenic diabetes insipidus	Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.
CID	9226773_D008094_5_815_822_lithium_D018500_5_831_861_nephrogenic diabetes insipidus	We discuss the possible renal mechanisms and the implications for management of patients with lithium-induced nephrogenic diabetes insipidus.
CID	9226773_D008094_4_539_546_Lithium_D018500_4_555_585_nephrogenic diabetes insipidus	Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.
UN	9226773_D014667_3_461_472_vasopressin_D011141_3_340_348_polyuric	He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.
UN	9226773_D014667_3_461_472_vasopressin_D018500_3_507_537_nephrogenic diabetes insipidus	He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.
UN	9228650_C049860_9_1114_1121_NIK-247_D000544_9_1164_1183_Alzheimer's disease	The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.
CID	9228650_C049860_0_11_18_NIK-247_D000647_0_61_68_amnesia	Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.
CID	9228650_C076946_1_259_265_E-2020_D000647_1_132_139_amnesia	The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.
CID	9228650_D012601_1_112_123_scopolamine_D000647_1_132_139_amnesia	The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.
CID	9228650_D012601_0_41_52_scopolamine_D000647_0_61_68_amnesia	Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.
CID	9228650_D012601_6_763_774_scopolamine_D000647_6_744_751_amnesia	All compounds at 0.1-1 mg/kg p.o. significantly improved the amnesia induced by scopolamine (0.5 mg/kg s.c.) in rats performing a passive avoidance task.
CID	9228650_D012601_8_1018_1029_scopolamine_D000647_8_1038_1045_amnesia	These findings suggest that NIK-247 at a low dose (0.1-1 mg/kg p.o.) improves scopolamine-induced amnesia but does not affect spontaneous movement.
CID	9228650_D013619_1_247_254_tacrine_D000647_1_132_139_amnesia	The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.
CID	9245658_D009538_0_12_20_nicotine_D002318_0_40_62_cardiovascular disease	The role of nicotine in smoking-related cardiovascular disease.
UN	9245658_D009538_4_648_656_Nicotine_D013927_4_684_694_thrombosis	Nicotine does not appear to enhance thrombosis among humans.
CID	9245658_D009538_2_227_235_nicotine_D050197_2_270_285_atherosclerosis	Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis, but evidence among humans is too inadequate to be definitive about such an effect.
UN	9249847_D014700_0_80_89_verapamil_D002311_0_165_198_idiopathic dilated cardiomyopathy	Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.
CID	9249847_D014700_0_80_89_verapamil_D013611_0_35_73_atrioventricular reentrant tachycardia	Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.
UN	9249847_D014700_0_80_89_verapamil_D014927_0_130_160_Wolff-Parkinson-White syndrome	Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.
UN	9270571_C095427_5_1411_1418_A-86929_D004409_5_1560_1571_dyskinesias	Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.
UN	9270571_C095427_3_1000_1007_A-86929_D004409_3_924_934_dyskinetic	We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
UN	9270571_C095427_7_1986_1993_A-86929_D010300_7_2073_2075_PD	Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.
UN	9270571_C095427_5_1411_1418_A-86929_D020734_5_1466_1478_parkinsonism	Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.
UN	9270571_C416545_5_1606_1615_LY-171555_D004409_5_1560_1571_dyskinesias	Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.
UN	9270571_C416545_5_1495_1504_LY-171555_D020734_5_1466_1478_parkinsonism	Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.
UN	9270571_D004298_3_1138_1140_DA_D004409_3_924_934_dyskinetic	We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
UN	9270571_D004298_1_172_174_DA_D010300_1_217_236_Parkinson's disease	The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.
UN	9270571_D004298_0_43_51_dopamine_D020734_0_100_112_parkinsonian	Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
CID	9270571_D007980_3_865_873_levodopa_D004409_3_882_893_dyskinesias	We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
CID	9270571_D007980_5_1543_1551_levodopa_D004409_5_1560_1571_dyskinesias	Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.
UN	9270571_D007980_5_1482_1490_levodopa_D020734_5_1466_1478_parkinsonism	Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.
UN	9270571_D007980_0_113_121_levodopa_D020734_0_100_112_parkinsonian	Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
UN	9270571_D015632_3_768_812_1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_D004409_3_882_893_dyskinesias	We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
UN	9270571_D015632_5_1453_1457_MPTP_D004409_5_1560_1571_dyskinesias	Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.
CID	9270571_D015632_5_1453_1457_MPTP_D020734_5_1466_1478_parkinsonism	Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.
CID	9284778_C067411_6_879_896_HCFCs 123 and 124_D008107_6_919_932_liver disease	We aimed to test whether HCFCs 123 and 124 can result in serious liver disease.
UN	9284778_C067411_12_1760_1777_HCFCs 123 and 124_D056486_12_1800_1812_liver injury	INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.
CID	9284778_C072959_6_879_896_HCFCs 123 and 124_D008107_6_919_932_liver disease	We aimed to test whether HCFCs 123 and 124 can result in serious liver disease.
UN	9284778_C072959_12_1760_1777_HCFCs 123 and 124_D056486_12_1800_1812_liver injury	INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.
UN	9284778_D006221_5_843_852_halothane_D056486_5_825_839_hepatotoxicity	Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.
UN	9284778_D010126_0_69_74_ozone_D008107_0_12_25_liver disease	Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.
UN	9284778_D014269_5_753_768_trifluoroacetyl_D056486_5_825_839_hepatotoxicity	Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.
UN	9284778_D017402_0_98_117_chlorofluorocarbons_D008107_0_12_25_liver disease	Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.
CID	9293063_D003613_0_75_82_danazol_D001650_0_0_19_Bile duct hamartoma	Bile duct hamartoma occurring in association with long-term treatment with danazol.
CID	9293063_D003613_0_75_82_danazol_D006222_0_0_19_Bile duct hamartoma	Bile duct hamartoma occurring in association with long-term treatment with danazol.
UN	9305828_D010862_3_415_426_pilocarpine_D001930_3_565_577_brain damage	The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.
CID	9305828_D010862_8_1284_1288_PILO_D004833_8_1298_1301_TLE	The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.
CID	9305828_D010862_0_39_50_pilocarpine_D004833_0_60_82_temporal lobe epilepsy	Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.
UN	9305828_D010862_3_415_426_pilocarpine_D012640_3_544_552_seizures	The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.
UN	9305828_D010862_3_415_426_pilocarpine_D013226_3_491_509_status epilepticus	The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.
CID	9321531_D007980_9_1902_1910_levodopa_D004409_9_1919_1930_dyskinesias	CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.
UN	9321531_D007980_9_1902_1910_levodopa_D010300_9_1847_1866_Parkinson's disease	CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.
CID	9326871_D004917_3_262_274_erythromycin_D005759_3_301_316_gastroenteritis	Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.
UN	9326871_D004917_4_554_566_erythromycin_D066126_4_467_481_Cardiotoxicity	Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.
CID	9326871_D017291_0_0_14_Clarithromycin_D017180_0_23_46_ventricular tachycardia	Clarithromycin-induced ventricular tachycardia.
UN	9326871_D018942_4_610_620_macrolides_D066126_4_467_481_Cardiotoxicity	Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.
UN	9334596_C004648_7_1144_1166_testosterone heptylate_D006966_7_1238_1256_hyperprolactinemia	Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.
UN	9334596_C004648_7_1144_1166_testosterone heptylate_D007006_7_1203_1215_hypogonadism	Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.
UN	9334596_D001971_7_1220_1233_bromocriptine_D006966_7_1238_1256_hyperprolactinemia	Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.
UN	9334596_D001971_7_1220_1233_bromocriptine_D007006_7_1203_1215_hypogonadism	Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.
UN	9334596_D013739_21_3260_3272_testosterone_D006177_21_3240_3252_gynecomastia	Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.
UN	9334596_D013739_3_730_742_testosterone_D006177_3_714_726_gynecomastia	Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.
UN	9334596_D013739_11_1572_1584_testosterone_D007027_11_1625_1649_hypothalamic dysfunction	Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).
UN	9334596_D013739_18_2732_2744_testosterone_D007172_18_2767_2787_erectile dysfunction	CONCLUSIONS: Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination.
UN	9334596_D013739_10_1522_1534_testosterone_D010911_10_1483_1499_pituitary tumors	Two pituitary tumors were discovered after testosterone determination.
CID	9334596_D013739_20_3021_3033_testosterone_D020018_20_3065_3082_low sexual desire	We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years.
CID	9334596_D013739_12_1937_1949_testosterone_D020018_12_1967_1984_low sexual desire	Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.
CID	9351491_D006220_6_1060_1071_haloperidol_D010302_6_974_999_Drug-induced parkinsonism	Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.
CID	9351491_D018967_6_1038_1049_risperidone_D010302_6_974_999_Drug-induced parkinsonism	Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.
UN	9351491_D018967_2_252_263_risperidone_D011618_2_331_349_psychotic symptoms	Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.
UN	9390208_C085788_0_139_142_MFL_D001943_0_43_56_breast cancer	Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
UN	9390208_D002955_3_677_687_leucovorin_D001943_3_568_581_breast cancer	From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.
UN	9390208_D002955_0_127_137_leucovorin_D001943_0_43_56_breast cancer	Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
UN	9390208_D005472_3_645_649_5-FU_D001943_3_568_581_breast cancer	From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.
UN	9390208_D005472_0_118_122_5-FU_D001943_0_43_56_breast cancer	Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
UN	9390208_D008942_0_60_72_mitoxantrone_D001943_0_43_56_breast cancer	Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
UN	9390208_D008942_3_585_597_mitoxantrone_D001943_3_568_581_breast cancer	From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.
CID	9401499_D013988_5_614_625_ticlopidine_D000380_5_558_573_Agranulocytosis	Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.
CID	9401499_D013988_7_838_849_ticlopidine_D000741_7_858_873_aplastic anemia	Treatment for ticlopidine-induced aplastic anemia with colony-stimulating factors seemed to have little effect.
CID	9401499_D013988_1_143_154_ticlopidine_D000741_1_163_178_aplastic anemia	In this study, three Chinese patients with ticlopidine-induced aplastic anemia were reported and another 13 patients in the English literature were reviewed.
CID	9401499_D013988_0_0_11_Ticlopidine_D000741_0_20_35_aplastic anemia	Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature.
UN	9406968_D001127_6_983_986_AVP_D003681_6_879_890_dehydration	These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.
UN	9406968_D001127_6_1011_1014_AVP_D003919_6_1072_1090_diabetes insipidus	These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.
UN	9406968_D001127_1_161_181_arginine vasopressin_D011141_1_301_309_polyuria	The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.
UN	9406968_D008094_6_1061_1063_Li_D003681_6_879_890_dehydration	These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.
UN	9406968_D008094_0_103_110_lithium_D003919_0_119_137_diabetes insipidus	Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.
UN	9406968_D008094_6_1061_1063_Li_D003919_6_1072_1090_diabetes insipidus	These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.
UN	9406968_D008094_1_289_291_Li_D011141_1_301_309_polyuria	The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.
UN	9406968_D014667_0_34_45_vasopressin_D003919_0_119_137_diabetes insipidus	Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.
CID	9406968_D018021_2_429_433_LiCl_D011141_2_476_484_polyuria	The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked polyuria.
UN	9431903_D005996_6_1605_1624_glyceryl trinitrate_D013035_6_1649_1672_sphincter of Oddi spasm	CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.
UN	9431903_D005996_0_10_29_glyceryl trinitrate_D013035_0_37_60_sphincter of Oddi spasm	Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.
UN	9431903_D005996_1_147_166_glyceryl trinitrate_D013035_1_203_226_sphincter of Oddi spasm	OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.
UN	9431903_D005996_1_147_166_glyceryl trinitrate_D046628_1_203_226_sphincter of Oddi spasm	OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.
UN	9431903_D005996_6_1605_1624_glyceryl trinitrate_D046628_6_1649_1672_sphincter of Oddi spasm	CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.
UN	9431903_D005996_0_10_29_glyceryl trinitrate_D046628_0_37_60_sphincter of Oddi spasm	Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.
CID	9431903_D009020_0_83_91_morphine_D013035_0_37_60_sphincter of Oddi spasm	Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.
CID	9431903_D009020_1_186_194_morphine_D013035_1_203_226_sphincter of Oddi spasm	OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.
CID	9431903_D009020_2_359_367_morphine_D013035_2_308_331_Sphincter of Oddi spasm	METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.
CID	9431903_D009020_6_1632_1640_morphine_D013035_6_1649_1672_sphincter of Oddi spasm	CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.
CID	9431903_D009020_2_359_367_morphine_D046628_2_308_331_Sphincter of Oddi spasm	METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.
CID	9431903_D009020_1_186_194_morphine_D046628_1_203_226_sphincter of Oddi spasm	OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.
CID	9431903_D009020_0_83_91_morphine_D046628_0_37_60_sphincter of Oddi spasm	Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.
CID	9431903_D009020_6_1632_1640_morphine_D046628_6_1649_1672_sphincter of Oddi spasm	CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.
CID	9431903_D009388_1_174_185_prostigmine_D013035_1_203_226_sphincter of Oddi spasm	OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.
CID	9431903_D009388_0_71_82_prostigmine_D013035_0_37_60_sphincter of Oddi spasm	Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.
CID	9431903_D009388_2_347_358_prostigmine_D013035_2_308_331_Sphincter of Oddi spasm	METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.
CID	9431903_D009388_2_347_358_prostigmine_D046628_2_308_331_Sphincter of Oddi spasm	METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.
CID	9431903_D009388_0_71_82_prostigmine_D046628_0_37_60_sphincter of Oddi spasm	Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.
CID	9431903_D009388_1_174_185_prostigmine_D046628_1_203_226_sphincter of Oddi spasm	OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.
UN	9495837_C087567_4_1852_1856_PG-9_D000647_4_1820_1827_amnesic	Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.
UN	9495837_D000109_4_1880_1893_acetylcholine_D000647_4_1820_1827_amnesic	Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.
CID	9495837_D004025_3_1418_1429_dicyclomine_D000647_3_1366_1373_amnesia	Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.
CID	9495837_D012601_3_1385_1396_scopolamine_D000647_3_1366_1373_amnesia	Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.
UN	950631_D010396_1_171_186_D-penicillamine_D001172_1_80_100_rheumatoid arthritis	Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.
CID	950631_D010396_0_19_32_penicillamine_D007674_0_41_59_glomerular disease	Immunopathology of penicillamine-induced glomerular disease.
CID	950631_D010396_1_171_186_D-penicillamine_D011507_1_117_128_proteinuria	Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.
CID	9514561_D002211_0_38_47_capsaicin_D010146_0_21_25_pain	Experimental cranial pain elicited by capsaicin: a PET study.
CID	9522143_D002045_5_654_665_bupivacaine_D034381_5_609_621_hearing loss	Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).
CID	9522143_D011318_5_570_580_prilocaine_D034381_5_609_621_hearing loss	Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).
CID	9522143_D011318_6_762_772_prilocaine_D034381_6_704_716_hearing loss	The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.
UN	9523805_D002045_9_1535_1546_bupivacaine_D009422_9_1551_1555_TNSs	RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.
CID	9523805_D008012_1_223_232_lidocaine_D009422_1_199_203_TNSs	BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.
CID	9523805_D008012_9_1414_1423_lidocaine_D009422_9_1436_1440_TNSs	RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.
CID	9523805_D011318_0_78_88_prilocaine_D009422_0_0_29_Transient neurologic symptoms	Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.
CID	9523805_D011318_4_594_604_prilocaine_D009422_4_692_696_TNSs	Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.
CID	9523805_D011318_11_1771_1781_Prilocaine_D009422_11_1912_1916_TNSs	CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.
CID	9523805_D011318_9_1469_1479_prilocaine_D009422_9_1436_1440_TNSs	RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.
CID	9523850_D007505_0_120_132_iron dextran_D018771_0_49_59_arthralgia	Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.
UN	9523850_D007505_0_120_132_iron dextran_D063806_0_60_67_myalgia	Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.
UN	9523850_D008775_0_9_27_methylprednisolone_D018771_0_49_59_arthralgia	Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.
UN	9523850_D008775_0_9_27_methylprednisolone_D063806_0_60_67_myalgia	Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.
CID	9545159_D001393_2_356_361_azole_D008133_2_208_235_Prolongation of QT interval	Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.
CID	9545159_D001393_2_356_361_azole_D016171_2_237_256_torsades de pointes	Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.
CID	9545159_D001393_2_356_361_azole_D016757_2_262_282_sudden cardiac death	Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.
UN	9545159_D004110_3_545_554_diltiazem_D005764_3_508_540_gastroesophageal reflux disorder	A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
UN	9545159_D004110_3_545_554_diltiazem_D006973_3_607_619_hypertension	A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
CID	9545159_D004110_0_53_62_diltiazem_D008133_0_0_31_Prolongation of the QT interval	Prolongation of the QT interval related to cisapride-diltiazem interaction.
CID	9545159_D004917_2_340_352_erythromycin_D008133_2_208_235_Prolongation of QT interval	Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.
CID	9545159_D004917_2_340_352_erythromycin_D016171_2_237_256_torsades de pointes	Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.
CID	9545159_D004917_2_340_352_erythromycin_D016757_2_262_282_sudden cardiac death	Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.
UN	9545159_D020117_3_494_503_cisapride_D005764_3_508_540_gastroesophageal reflux disorder	A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
UN	9545159_D020117_3_494_503_cisapride_D006973_3_607_619_hypertension	A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
CID	9545159_D020117_0_43_52_cisapride_D008133_0_0_31_Prolongation of the QT interval	Prolongation of the QT interval related to cisapride-diltiazem interaction.
UN	9545159_D020117_1_76_85_Cisapride_D015835_1_171_206_gastrointestinal motility disorders	Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.
CID	9549528_D007980_4_977_983_L-dopa_D004409_4_1002_1012_dyskinesia	These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.
CID	9549528_D007980_0_60_66_L-dopa_D004409_0_85_95_dyskinesia	Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.
CID	9549528_D007980_1_358_364_L-dopa_D004409_1_373_383_dyskinesia	We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.
UN	9549528_D007980_4_977_983_L-dopa_D006948_4_928_940_hyperkinetic	These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.
UN	9549528_D007980_0_60_66_L-dopa_D020734_0_33_45_parkinsonian	Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.
UN	9549528_D007980_1_317_323_L-dopa_D020734_1_292_304_parkinsonian	We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.
UN	9564988_D064704_0_25_37_levofloxacin_D012852_0_75_84_sinusitis	Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.
UN	9579567_D013629_13_1897_1906_tamoxifen_D001943_13_1911_1924_breast cancer	Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment.
UN	9579567_D013629_3_433_442_tamoxifen_D001943_3_488_501_breast cancer	We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.
UN	9579567_D013629_2_191_200_tamoxifen_D001943_2_219_232_breast cancer	Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.
UN	9579567_D013629_14_2051_2060_tamoxifen_D001943_14_2091_2104_breast cancer	A long-term evaluation of the risk-benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted.
CID	9579567_D013629_5_755_764_tamoxifen_D016889_5_804_822_endometrial cancer	Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).
CID	9579567_D013629_12_1846_1855_tamoxifen_D016889_12_1794_1813_Endometrial cancers	Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis.
CID	9579567_D013629_3_433_442_tamoxifen_D016889_3_410_428_endometrial cancer	We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.
CID	9579567_D013629_10_1597_1606_tamoxifen_D016889_10_1610_1628_endometrial cancer	Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.
CID	9579567_D013629_9_1431_1440_tamoxifen_D016889_9_1395_1413_endometrial cancer	Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.
UN	9579567_D013629_9_1431_1440_tamoxifen_D020178_9_1450_1466_advanced disease	Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.
CID	9587734_D013390_3_420_433_suxamethonium_D001919_3_435_446_bradycardia	Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.
UN	9587734_D013390_7_891_904_suxamethonium_D003643_7_851_856_death	It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.
UN	9587734_D013390_0_0_13_Suxamethonium_D003643_0_41_46_death	Suxamethonium-induced cardiac arrest and death following 5 days of immobilization.
UN	9587734_D013390_1_208_221_suxamethonium_D003643_1_152_157_death	The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.
CID	9587734_D013390_7_891_904_suxamethonium_D004342_7_871_887_hypersensitivity	It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.
CID	9587734_D013390_0_0_13_Suxamethonium_D006323_0_22_36_cardiac arrest	Suxamethonium-induced cardiac arrest and death following 5 days of immobilization.
CID	9587734_D013390_1_208_221_suxamethonium_D006947_1_173_186_hyperkalaemia	The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.
CID	9587734_D013390_6_810_823_suxamethonium_D006947_6_764_777_hyperkalaemia	Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.
UN	9625142_D001663_2_324_333_bilirubin_D000744_2_390_417_autoimmune hemolytic anemia	Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.
CID	9625142_D002443_0_84_95_ceftriaxone_D000744_0_17_44_autoimmune hemolytic anemia	Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.
CID	9625142_D002443_1_169_180_ceftriaxone_D056486_1_130_139_hepatitis	An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone.
UN	9630698_C066192_3_985_993_5,7-DCKA_D009127_3_912_927_muscle rigidity	Muscle rigidity was induced by haloperidol (2.5 mg/kg i.p.). 5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG). 5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.
UN	9630698_D005998_3_743_750_glycine_D009127_3_631_646_Muscle rigidity	Muscle rigidity was induced by haloperidol (2.5 mg/kg i.p.). 5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG). 5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.
CID	9630698_D006220_3_892_903_haloperidol_D009127_3_912_927_muscle rigidity	Muscle rigidity was induced by haloperidol (2.5 mg/kg i.p.). 5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG). 5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.
UN	9636837_D002945_9_1431_1435_CDDP_D020258_9_1461_1474_neurotoxicity	CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.
UN	9636837_D002945_1_153_157_CDDP_D020258_1_191_201_neurotoxic	BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.
CID	9636837_D016190_5_771_776_CBDCA_D010523_5_815_839_peripheral neurotoxicity	RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.
UN	9636837_D016190_2_231_236_CBDCA_D020258_2_295_305_neurotoxic	However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.
UN	9636837_D016190_9_1307_1312_CBDCA_D020258_9_1316_1326_neurotoxic	CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.
UN	9653867_D013974_4_669_678_thyroxine_D001068_4_583_599_eating disorders	In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.
CID	9653867_D013974_4_669_678_thyroxine_D013971_4_637_651_thyrotoxicosis	In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.
CID	9653867_D013974_0_0_9_Thyroxine_D013971_0_36_50_thyrotoxicosis	Thyroxine abuse: an unusual case of thyrotoxicosis in pregnancy.
UN	9660111_D003000_8_1291_1300_clonidine_D010554_8_1266_1280_aggressiveness	It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor.
CID	9660111_D003913_6_937_950_d-amphetamine_D006948_6_912_925_hyperactivity	TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).
UN	9660111_D004298_6_1005_1013_dopamine_D006948_6_912_925_hyperactivity	TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).
UN	9660111_D006916_5_816_835_5-hydroxytryptophan_D007035_5_768_779_hypothermia	In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.
UN	9660111_D010656_8_1168_1181_phenylephrine_D010554_8_1266_1280_aggressiveness	It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor.
CID	9660111_D012110_5_758_767_reserpine_D007035_5_768_779_hypothermia	In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.
CID	9660111_D014299_6_859_862_TRI_D006948_6_912_925_hyperactivity	TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).
UN	9660111_D014299_5_717_720_TRI_D007035_5_768_779_hypothermia	In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.
CID	9660111_D019257_6_952_962_quinpirole_D006948_6_912_925_hyperactivity	TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).
UN	9669632_D020117_8_1652_1661_cisapride_D003248_8_1670_1682_constipation	Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].
UN	9669632_D020117_5_853_862_cisapride_D003967_5_871_880_diarrhoea	In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.
UN	9669632_D020117_8_1652_1661_cisapride_D043183_8_1695_1698_IBS	Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].
UN	9669632_D020117_9_1877_1886_cisapride_D043183_9_1834_1837_IBS	Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].
UN	9669632_D020117_10_2012_2021_Cisapride_D043183_10_2087_2090_IBS	CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS.
UN	9672273_D013629_13_1543_1552_tamoxifen_D001943_13_1507_1520_breast cancer	There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.
UN	9672273_D013629_12_1436_1445_tamoxifen_D001943_12_1377_1390_breast-cancer	There is no difference in breast-cancer frequency between the placebo (22 cases) and tamoxifen (19) arms.
UN	9672273_D013629_2_176_185_Tamoxifen_D001943_2_226_239_breast cancer	BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.
UN	9672273_D013629_0_33_42_tamoxifen_D001943_0_14_27_breast cancer	Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.
CID	9672273_D013629_14_1906_1915_tamoxifen_D014652_14_1849_1864_vascular events	Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.
CID	9672273_D013629_14_1906_1915_tamoxifen_D015228_14_1869_1890_hypertriglyceridaemia	Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.
UN	9672273_D013629_2_176_185_Tamoxifen_D016889_2_301_319_endometrial cancer	BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.
UN	9672936_D008614_0_63_72_pethidine_D010149_0_77_95_postoperative pain	Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.
CID	9672936_D008614_0_0_9_Pethidine_D012640_0_21_28_seizure	Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.
CID	9698967_D004837_1_373_383_adrenaline_D001281_1_122_141_atrial fibrillation	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.
UN	9698967_D004837_1_373_383_adrenaline_D004387_1_412_435_Dupuytren's contracture	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.
CID	9698967_D004837_1_373_383_adrenaline_D006973_1_79_105_increase in blood pressure	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.
UN	9698967_D004837_1_373_383_adrenaline_D011595_1_143_152_agitation	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.
UN	9698967_D004837_1_373_383_adrenaline_D014474_1_182_203_loss of consciousness	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.
UN	9698967_D004837_1_373_383_adrenaline_D019954_1_154_177_incomprehensible shouts	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.
CID	9698967_D008619_1_343_354_mepivacaine_D001281_1_122_141_atrial fibrillation	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.
UN	9698967_D008619_1_343_354_mepivacaine_D004387_1_412_435_Dupuytren's contracture	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.
CID	9698967_D008619_1_343_354_mepivacaine_D006973_1_79_105_increase in blood pressure	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.
UN	9698967_D008619_1_343_354_mepivacaine_D011595_1_143_152_agitation	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.
UN	9698967_D008619_1_343_354_mepivacaine_D014474_1_182_203_loss of consciousness	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.
UN	9698967_D008619_1_343_354_mepivacaine_D019954_1_154_177_incomprehensible shouts	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.
CID	9721172_D007052_4_730_739_ibuprofen_D013262_4_655_679_Stevens-Johnson syndrome	A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.
UN	9721172_D011241_5_788_798_prednisone_D002779_5_825_844_cholestatic disease	Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.
UN	9721172_D011241_5_788_798_prednisone_D005355_5_867_876_cirrhosis	Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.
UN	9721172_D014580_5_766_786_ursodeoxycholic acid_D002779_5_825_844_cholestatic disease	Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.
UN	9721172_D014580_5_766_786_ursodeoxycholic acid_D005355_5_867_876_cirrhosis	Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.
UN	9721172_D016559_5_809_819_tacrolimus_D002779_5_825_844_cholestatic disease	Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.
UN	9721172_D016559_5_809_819_tacrolimus_D005355_5_867_876_cirrhosis	Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.
CID	9727773_D001067_0_65_86_appetite suppressants_D006976_0_18_48_primary pulmonary hypertension	High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.
CID	9727773_D001067_9_1228_1249_appetite suppressants_D006976_9_1293_1323_primary pulmonary hypertension	A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.
CID	9746003_D002220_1_79_92_Carbamazepine_D004832_1_139_155_absence seizures	Carbamazepine and vigabatrin are contraindicated in typical absence seizures.
CID	9746003_D002220_0_21_34_carbamazepine_D004832_0_61_77_absence seizures	Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.
CID	9746003_D002220_4_445_458_carbamazepine_D009207_4_486_501_myoclonic jerks	Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.
CID	9746003_D020888_0_39_49_vigabatrin_D004832_0_61_77_absence seizures	Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.
CID	9746003_D020888_1_97_107_vigabatrin_D004832_1_139_155_absence seizures	Carbamazepine and vigabatrin are contraindicated in typical absence seizures.
CID	9754849_D003042_2_409_416_cocaine_D002819_2_238_262_choreoathetoid movements	This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.
CID	9754849_D003042_1_175_182_cocaine_D002819_1_72_98_Choreatiform hyperkinesias	Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.
CID	9754849_D003042_1_175_182_cocaine_D006948_1_72_98_Choreatiform hyperkinesias	Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.
UN	9754849_D003932_2_397_404_heroine_D002819_2_238_262_choreoathetoid movements	This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.
CID	9754849_D008691_0_61_70_methadone_D002819_0_0_24_Choreoathetoid movements	Choreoathetoid movements associated with rapid adjustment to methadone.
UN	9758264_D002220_6_848_861_carbamazepine_D004827_6_804_813_epileptic	This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.
UN	9758264_D005492_1_120_130_folic acid_D000014_1_263_276_birth defects	OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.
CID	9758264_D005492_0_61_71_folic acid_D008180_0_56_59_SLE	Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)
CID	9758264_D005492_9_1245_1255_folic acid_D012640_9_1279_1287_seizures	CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.
CID	9766615_D003024_6_1092_1101_clozapine_D000380_6_1075_1090_agranulocytosis	The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).
UN	9766615_D003024_6_1059_1068_clozapine_D001480_6_865_868_EPS	The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).
UN	9766615_D003024_6_1059_1068_clozapine_D012640_6_1030_1037_seizure	The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).
UN	9766615_D003024_6_1059_1068_clozapine_D012735_6_985_1003_sexual dysfunction	The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).
UN	9766615_D003024_6_1059_1068_clozapine_D015430_6_972_983_weight gain	The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).
UN	9799166_D000661_1_70_81_amphetamine_D007511_1_107_115_ischemic	The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.
CID	9799166_D000661_1_70_81_amphetamine_D020521_1_116_122_stroke	The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.
CID	9799166_D000661_2_252_263_amphetamine_D020521_2_219_225_stroke	The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.
CID	9799166_D000661_10_1272_1283_amphetamine_D020521_10_1312_1318_stroke	The use of cocaine and/or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous, insured urban population.
CID	9799166_D000661_0_22_33_amphetamine_D020521_0_0_6_Stroke	Stroke and cocaine or amphetamine use.
UN	9799166_D003042_1_58_65_cocaine_D007511_1_107_115_ischemic	The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.
CID	9799166_D003042_1_58_65_cocaine_D020521_1_116_122_stroke	The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.
CID	9799166_D003042_2_237_244_cocaine_D020521_2_219_225_stroke	The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.
CID	9799166_D003042_0_11_18_cocaine_D020521_0_0_6_Stroke	Stroke and cocaine or amphetamine use.
CID	9799166_D003042_8_1005_1012_cocaine_D020521_8_967_973_stroke	The univariate matched odds ratio for stroke in women who admitted to using cocaine and/or amphetamine was 8.5 (95% confidence interval = 3.6-20.0).
UN	9812111_D006220_11_1858_1869_haloperidol_D000544_11_1915_1934_Alzheimer's disease	The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.
UN	9812111_D006220_0_58_69_haloperidol_D000544_0_112_131_Alzheimer's disease	A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.
CID	9812111_D006220_9_1627_1638_haloperidol_D001480_9_1712_1732_extrapyramidal signs	CONCLUSIONS: The results indicated a favorable therapeutic profile for haloperidol in doses of 2-3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs.
UN	9812111_D006220_4_934_945_haloperidol_D011595_4_1031_1052_psychomotor agitation	RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.
UN	9812111_D006220_0_58_69_haloperidol_D011618_0_74_83_psychosis	A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.
UN	9812111_D006220_1_228_239_haloperidol_D011618_1_272_281_psychosis	OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.
UN	9812111_D006220_0_58_69_haloperidol_D019958_0_88_108_disruptive behaviors	A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.
UN	9812111_D006220_1_228_239_haloperidol_D019958_1_286_306_disruptive behaviors	OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.
CID	982002_D012293_0_56_66_rifampicin_D058186_0_0_19_Acute renal failure	Acute renal failure subsequent to the administration of rifampicin.
UN	983936_D001241_0_11_31_acetylsalicylic acid_D009202_0_89_106_myocardial injury	Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.
UN	983936_D004176_0_33_45_dipyridamole_D009202_0_89_106_myocardial injury	Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.
CID	983936_D004837_0_69_80_epinephrine_D009202_0_89_106_myocardial injury	Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.
CID	983936_D004837_1_178_189_epinephrine_D009202_1_159_176_myocardial injury	A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.
UN	983936_D004837_1_178_189_epinephrine_D009203_1_321_342_myocardial infarction	A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.
UN	983936_D006854_0_51_65_hydrocortisone_D009202_0_89_106_myocardial injury	Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.
UN	9848575_C055866_0_63_70_SM-5887_D009202_0_112_126_cardiomyopathy	Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.
UN	9848575_C055866_8_1326_1333_SM-5887_D009202_8_1374_1388_cardiomyopathy	On the contrary, the SM-5887 treatment did not progress the grade of cardiomyopathy.
UN	9848575_C055866_1_219_226_SM-5887_D066126_1_194_205_cardiotoxic	This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.
UN	9848575_C055866_9_1405_1412_SM-5887_D066126_9_1452_1466_cardiotoxicity	In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.
UN	9848575_C055866_5_980_987_SM-5887_D066126_5_958_969_cardiotoxic	To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).
CID	9848575_D004317_0_92_103_doxorubicin_D009202_0_112_126_cardiomyopathy	Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.
CID	9848575_D004317_5_1053_1064_doxorubicin_D009202_5_999_1013_cardiomyopathy	To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).
UN	9848575_D004317_1_317_328_doxorubicin_D066126_1_287_301_cardiotoxicity	This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.
UN	9848575_D004317_9_1495_1506_doxorubicin_D066126_9_1515_1529_cardiotoxicity	In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.
UN	9848575_D004317_7_1282_1293_doxorubicin_D066126_7_1230_1241_cardiotoxic	The low-grade cardiotoxic changes were enhanced by the additional doxorubicin treatment.
UN	9855119_D003404_7_1344_1354_creatinine_D007674_7_1405_1416_nephropathy	The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).
UN	9855119_D016559_6_1070_1075_FK506_D005355_6_1297_1318_interstitial fibrosis	Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).
UN	9855119_D016559_4_873_878_FK506_D005922_4_804_819_IgA nephropathy	RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).
CID	9855119_D016559_6_1070_1075_FK506_D005923_6_1225_1259_focal segmental glomerulosclerosis	Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).
UN	9862868_D004997_5_725_727_EE_D001651_5_743_767_extrahepatic cholestasis	We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.
CID	9862868_D004997_5_706_723_ethinyl estradiol_D002780_5_678_702_intrahepatic cholestasis	We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.
UN	9867728_D020372_0_64_79_dexfenfluramine_D006349_0_9_31_valvular heart disease	Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.
UN	9867728_D020372_1_257_272_dexfenfluramine_D006349_1_277_293_valvular disease	BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.
UN	9867728_D020372_2_447_462_dexfenfluramine_D006349_2_393_415_valvular abnormalities	OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.
UN	9869257_C087567_2_322_326_PG-9_D000647_2_407_414_amnesia	In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.
UN	9869257_C087567_3_564_568_PG-9_D000647_3_648_655_amnesia	In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced amnesia, demonstrating a central localization of the activity.
CID	9869257_C098725_2_513_525_S-(-)-ET-126_D000647_2_407_414_amnesia	In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.
CID	9869257_D012601_2_469_480_scopolamine_D000647_2_407_414_amnesia	In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.
UN	9875685_D003404_12_1478_1488_creatinine_D007674_12_1577_1591_nephrotoxicity	Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.
UN	9915601_D001262_3_587_595_atenolol_D001919_3_532_543_bradycardia	Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.
UN	9915601_D002217_3_656_665_carbachol_D001919_3_532_543_bradycardia	Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.
UN	9915601_D002698_2_477_487_chloralose_D001919_2_382_393_bradycardia	In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
UN	9915601_D003000_3_614_623_clonidine_D001919_3_532_543_bradycardia	Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.
UN	9915601_D005680_1_287_310_gamma-aminobutyric acid_D001919_1_216_227_bradycardia	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).
UN	9915601_D005680_1_287_310_gamma-aminobutyric acid_D007022_1_130_141_hypotension	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).
UN	9915601_D005680_1_287_310_gamma-aminobutyric acid_D013610_1_201_212_tachycardia	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).
CID	9915601_D007538_2_369_378_isoniazid_D001919_2_382_393_bradycardia	In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
CID	9915601_D007538_3_498_507_Isoniazid_D001919_3_532_543_bradycardia	Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.
CID	9915601_D007538_1_111_120_isoniazid_D007022_1_130_141_hypotension	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).
UN	9915601_D007538_1_111_120_isoniazid_D013610_1_201_212_tachycardia	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).
UN	9915601_D007741_3_573_582_labetalol_D001919_3_532_543_bradycardia	Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.
UN	9915601_D010869_3_563_571_pindolol_D001919_3_532_543_bradycardia	Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.
UN	9915601_D011433_3_550_561_propranolol_D001919_3_532_543_bradycardia	Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.
UN	9915601_D014520_2_488_496_urethane_D001919_2_382_393_bradycardia	In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
UN	9915601_D018738_3_639_652_hexamethonium_D001919_3_532_543_bradycardia	Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.
UN	9931093_C079574_3_657_666_FR 139317_D006973_3_685_697_hypertension	In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.
UN	9931093_D009569_2_446_458_nitric oxide_D006973_2_259_271_hypertension	To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.
CID	9931093_D016559_1_145_151_FK 506_D006973_1_182_194_hypertension	The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.
CID	9931093_D016559_0_14_20_FK 506_D006973_0_29_41_hypertension	Mechanisms of FK 506-induced hypertension in the rat. -Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.
CID	9931093_D016559_3_670_676_FK 506_D006973_3_685_697_hypertension	In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.
CID	9931093_D016559_2_244_250_FK 506_D006973_2_259_271_hypertension	To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.
CID	9931093_D016559_7_1173_1179_FK 506_D006973_7_1188_1200_hypertension	The administration of FR 139317 (10 mg. kg-1. d-1) prevented FK 506-induced hypertension in rats.
UN	9931093_D016559_1_145_151_FK 506_D007674_1_199_213_nephrotoxicity	The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.
CID	9952311_D004317_6_1090_1093_ADR_D001919_6_1145_1156_bradycardia	Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.
UN	9952311_D004317_6_1090_1093_ADR_D004487_6_1332_1340_swelling	Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.
UN	9952311_D004317_0_56_66_adriamycin_D009202_0_75_89_cardiomyopathy	Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.
UN	9952311_D004317_1_178_181_ADR_D009369_1_186_192_cancer	The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.
CID	9952311_D004317_0_56_66_adriamycin_D028361_0_0_52_Structural and functional impairment of mitochondria	Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.
CID	9952311_D004317_8_1799_1802_ADR_D028361_8_1838_1888_mitochondrial structural and functional impairment	Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.
